This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/75279 A2

(51) International Patent Classification[7]: C12N

(21) International Application Number: PCT/US00/15728

(22) International Filing Date: 6 June 2000 (06.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/328,925 9 June 1999 (09.06.1999) US

(71) Applicant *(for all designated States except US)*: **REGENTS OF THE UNIVERSITY OF MICHIGAN** [US/US]; 3003 South State Street, Wolverine Tower, Ann Arbor, MI 48109-1280 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KURACHI, Kotoku** [JP/JP]; 2211 Avalon Place, Ann Arbor, MI 48104 (US). **KURACHI, Sumiko** [JP/JP]; 2211 Avalon Place, Ann Arbor, MI 48104 (US).

(74) Agents: **CARROLL, Peter, G. et al.**; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/75279 A2

(54) Title: NUCLEOTIDE SEQUENCES FOR GENE REGULATION AND METHODS OF USE THEREOF

(57) Abstract: The invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest. In particular, the invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner and/or in a liver-specific manner. The invention further provides methods of using the regulatory nucleic acid sequences provided herein for age-related and/or liver-specific expression of nucleotides sequences of interest. The invention also provides host cells and transgenic non-human animals which harbor the regulatory nucleic acid sequences of the invention. The compositions and methods of the invention are useful in regulating expression of a nucleotide sequence of interest in an age-related and/or liver-specific manner.

NUCLEOTIDE SEQUENCES FOR GENE REGULATION AND METHODS OF USE THEREOF

This work was made, in part, with Government support by the National Institutes of Health grant numbers HL38644 and HL53713. The Government has certain rights in this invention.

FIELD OF THE INVENTION

The invention relates to nucleic acid sequences which regulate expression of a nucleotide sequence of interest. In particular, the invention relates to nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner and/or in a liver-specific manner. The invention further relates to methods of using the regulatory nucleic acid sequences provided herein for age-related and/or liver-specific expression of nucleotides sequences of interest. The invention also relates to host cells and to transgenic non-human animals which harbor the regulatory nucleic acid sequences of the invention. The compositions and methods of the invention are useful in regulating expression of a nucleotide sequence of interest in an age-related and/or liver-specific manner.

BACKGROUND OF THE INVENTION

A multitude of human diseases (*e.g.*, thrombosis, cardiovascular diseases, diabetes, Alzheimer's disease, cancer, osteoporosis, osteoarthritis, Parkinson's disease, dementia) are associated with increasing age and result in serious effects on the quality of life and on the life expectancy of individuals suffering from such diseases. Other diseases (*e.g.*, cirrhosis, primary and metastatic neoplasia, Wilson disease, hepachromatosis, infectious hepatitis, hepatic necrosis, Gilbert disease, Criggler-Najar disease) which afflict the liver also have serious clinical manifestations and are responsible for high morbidity and mortality.

The treatment of age-related diseases (*i.e.*, diseases whose prevalence and/or severity of clinical manifestations increases with the age of the patient) and diseases afflicting the liver focuses on the alleviation of the general symptoms of the disease using one or a combination of two modalities, *i.e.*, non-pharmacological treatment and pharmacological treatment. Non-pharmacological treatment include, for example, periods of bed rest and dietary changes. Non-pharmacological treatment is often used as an adjunct to

pharmacological treatment which involves the use of drugs. Unfortunately, many of the commonly used pharmacological agents have numerous side effects and their use is further exacerbated by the non-responsiveness by many patients with severe disease, who, paradoxically, are in most need of treatment. Both non-pharmacological and pharmacological treatments provide unsatisfactory approaches to treating age-related and liver-associated diseases because these approaches are often ineffective, their effects are inconsistent, and are directed to alleviating the general symptoms of disease, rather than to specifically addressing the source of morbidity and mortality. Moreover, no suitable animal models are currently available to rationally design drugs which target specific biochemical and physiological pathways which are associated with age-related and with liver-associated diseases.

What is needed are methods for age-related and liver-specific gene expression and models for age-related and liver-specific diseases.

SUMMARY OF THE INVENTION

The invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner, as well as nucleic acid sequences which direct liver-specific expression of a gene of interest. Further provided by the invention are transgenic animals which may be used as models for age-related and/or liver specific diseases.

In one embodiment, the invention provides a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3. Without intending to limit the invention to any particular type or source of nucleic acids sequence of interest, in a preferred embodiment, the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, tissue factor pathway inhibitor, LDL-receptor, human α1-antitrypsin, antithrombin III, fibrinolytic pathway factors and inhibitors, PEA-3 protein, PEA-3 related proteins including Ets family transcriptional factors, β-galactosidase, and luciferase. While it is not intended that the invention be restricted to any particular type or source of promoter sequence, in an alternative preferred embodiment, the promoter sequence is selected from human factor IX

promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. It is not contemplated that the invention be limited to any particular age regulatory sequence which is a portion of SEQ ID NO:1. However, in another preferred embodiment, the age regulatory sequence which is a portion of SEQ ID NO:1 is selected from SEQ ID NO:2, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38. Without intending to limit the invention to any particular rage regulatory sequence which s a portion of SEQ ID NO:3, in yet another preferred embodiment, the age regulatory sequence which is a portion of SEQ ID NO:3 is selected from SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:61.

Also provided by the invention is a host cell containing a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3. Without intending to limit the invention to the environment in which the host cell is contained, in one preferred embodiment, the host cell is comprised in a tissue or organ in a living animal. In another preferred embodiment, the host cell is a gamete. In yet another preferred embodiment, the host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

The invention also provides a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a functional homolog of one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3. Without limiting the invention to the type or source of the nucleic acid sequence of interest, in one preferred embodiment, the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, fibrinolytic pathway factors and inhibitors, PEA-3 protein, PEA-3 related proteins including Ets family transcriptional factors, β-galactosidase, and luciferase. While it is not intended that the invention be limited to the type or source of the promoter sequence, in an alternative

preferred embodiment, the promoter sequence is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. Though it is not contemplated that the invention be limited to the portion of SEQ ID NO:1 which has age-related regulatory activity, in another preferred embodiment, the age regulatory sequence which is a portion of SEQ ID NO:1 is selected from SEQ ID NO:2, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38. Without intending to limit the invention the portion of SEQ ID NO:3 which has age-related regulatory activity, in yet another preferred embodiment, the age regulatory sequence which is a portion of SEQ ID NO:3 is selected from SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:61.

Also provided herein is a host cell containing recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a functional homolog of one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3. Without intending to limit the invention to the environment in which the host cell is contained, in one preferred embodiment, the host cell is comprised in a tissue or organ in a living animal. In an alternative preferred embodiment, the host cell is a gamete. In another preferred embodiment, the host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

The invention also provides a method, comprising: a) providing: i) a cell, ii) a nucleic acid sequence of interest, iii) a promoter sequence, and iv) one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the one or more age regulatory sequences to produce a transgene; and c) introducing the transgene into the cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in the treated cell. Without intending to limit the treated cell to any particular environment, in one preferred embodiment, the treated cell is comprised in a tissue or organ in a living animal.

The invention further provides a substantially purified nucleic acid sequence comprising a nucleotide sequence selected from a functional homolog of SEQ ID NO:1 and of the complement thereof.

Also provided herein is a substantially purified nucleic acid sequence comprising a nucleotide sequence selected from a functional homolog of SEQ ID NO:3 and of the complement thereof.

Also provided by the present invention is a substantially purified nucleic acid sequence comprising a portion of a nucleotide sequence selected from a functional homolog of SEQ ID NO:1 and of the complement thereof. In one embodiment, the portion is SEQ ID NO:2. In an alternative embodiment, the portion is selected from SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38.

The invention also provides a substantially purified nucleic acid sequence comprising a portion of a nucleotide sequence selected from a functional homolog of SEQ ID NO:3 and of the complement thereof. In one embodiment, the portion is selected from SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:61.

Also provided herein is a substantially purified nucleic acid sequence which hybridizes under stringent hybridization conditions with SEQ ID NO:1 or with the complement thereof, wherein the nucleic acid sequence is characterized by having age-related regulatory activity, and by having greater than 63% and less than 100% homology to the SEQ ID NO:1.

The invention also provides a substantially purified nucleic acid sequence which hybridizes under stringent hybridization conditions with SEQ ID NO:3 or with the complement thereof, wherein the nucleic acid sequence is characterized by having age-related regulatory activity, and by having greater than 60% and less than 100% homology to the SEQ ID NO:3.

The invention additionally provides a recombinant expression vector comprising at least a portion of a nucleotide sequence selected from a functional homolog of SEQ ID NO:1 and of the complement thereof.

Also provided herein is a recombinant expression vector comprising at least a portion of a nucleotide sequence selected from a functional homolog of SEQ ID NO:3 and of the complement thereof.

The invention also provides a transgenic cell comprising at least a portion of a nucleotide sequence selected from a functional homolog of SEQ ID NO:1 and of the complement thereof. In one embodiment, the nucleotide sequence is operably linked to a promoter and to a nucleic acid sequence of interest. In a preferred embodiment, the transgenic cell is comprised in an animal. In a more preferred embodiment, the nucleic acid sequence of interest is expressed in an age-related manner in the transgenic cell.

The invention additionally provides a transgenic cell comprising at least a portion of a nucleotide sequence selected from a functional homolog of SEQ ID NO:3 and of the complement thereof. In one embodiment, the nucleotide sequence is operably linked to a promoter and to a nucleic acid sequence of interest. In a preferred embodiment, the transgenic cell is comprised in an animal. In a more preferred embodiment, the nucleic acid sequence of interest is expressed in an age-related manner in the transgenic cell.

The invention also provides a method for expressing a nucleic acid sequence of interest in a cell, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; iv) SEQ ID NO:1; and v) SEQ ID NO:3; b) operably linking the nucleic acid sequence of interest, the promoter sequence, the SEQ ID NO:1 and the SEQ ID NO:3 to produce a transgene; and c) introducing the transgene into the cell to produce a transgenic cell under conditions such that the nucleic acid sequence of interest is expressed in the transgenic cell. In one embodiment, the cell expresses a recombinant protein identified as SEQ ID NO:47. In an alternative embodiment, the cell is selected from HepG2 cell, fibroblast cell, myoblast cell, and endothelial cell. In another embodiment, the cell is a fertilized egg cell, and the transgenic cell is a transgenic fertilized egg cell. In a preferred embodiment, the method further comprises d) introducing the transgenic fertilized egg cell into a non-human animal and permitting the animal to deliver progeny containing the transgene. In a more preferred embodiment, the progeny is characterized by age-related expression of the nucleic acid sequence of interest. In an alternative more preferred embodiment, the progeny is characterized by liver-specific expression of the nucleic acid sequence of interest. In another preferred embodiment, the fertilized egg cell is derived from a mammal of the order Rodentia. In a more preferred embodiment, the fertilized egg cell is a mouse fertilized egg cell. In yet another embodiment, the promoter is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK

promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. In a further embodiment, the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, fibrinolytic pathway factors and inhibitors, PEA-3 protein, PEA-3 related proteins including Ets family transcriptional factors, β-galactosidase, and luciferase.

The invention also provides a method for expressing a nucleic acid sequence of interest in a cell, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; iv) a portion of SEQ ID NO:1; and v) a portion of SEQ ID NO:3; b) operably linking the nucleic acid sequence of interest, the promoter sequence, the portion of SEQ ID NO:1 and the portion of SEQ ID NO:3 to produce a transgene; and c) introducing the transgene into the cell to produce a transgenic cell under conditions such that the nucleic acid sequence of interest is expressed in the transgenic cell.

Additionally provided by the invention is a method for expressing a nucleic acid sequence of interest in a cell, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) SEQ ID NO:1; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the SEQ ID NO:1 to produce a transgene; and c) introducing the transgene into the cell to produce a transgenic cell under conditions such that the nucleic acid sequence of interest is expressed in the transgenic cell.

Also provided herein is a method for expressing a nucleic acid sequence of interest in a cell, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) a portion of SEQ ID NO:1; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the portion of SEQ ID NO:1 to produce a transgene; and c) introducing the transgene into the cell to produce a transgenic cell under conditions such that the nucleic acid sequence of interest is expressed in the transgenic cell.

The invention further provides a method for expressing a nucleic acid sequence of interest in a cell, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) SEQ ID NO:3; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the SEQ ID NO:3 to produce a transgene; and c) introducing the transgene into the cell to produce a transgenic cell under conditions such that the nucleic acid sequence of interest is expressed in the transgenic cell.

Further provided by the invention is a method for expressing a nucleic acid sequence of interest in a cell, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) a portion of SEQ ID NO:3; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the portion of SEQ ID NO:3 to produce a transgene; and c) introducing the transgene into the cell to produce a transgenic cell under conditions such that the nucleic acid sequence of interest is expressed in the transgenic cell.

The invention further also provides additional sequences derived from the hFIX gene. In particular, the invention provides a substantially purified nucleic acid sequence comprising at least a portion of SEQ ID NO:93. In one embodiment, the portion has age-related regulatory activity. In an alternative embodiment, the portion is selected from SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95; SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, and SEQ ID NO:144. In a preferred embodiment, the portion is SEQ ID NO:91.

Also provided herein is a substantially purified nucleic acid sequence which hybridizes under high stringency hybridization conditions with a nucleotide sequence selected from SEQ ID NO:91, the complement of SEQ ID NO:91, SEQ ID NO:93, and the complement of SEQ ID NO:93. In one embodiment, the nucleic acid sequence has age-related regulatory activity.

The invention also provides a substantially purified nucleic acid sequence comprising a functional homolog of an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof.

The invention further provides expression vectors containing hFIX sequences. In one embodiment, the invention provides a recombinant expression vector comprising in operable

combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof. In a preferred embodiment, the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, tissue factor pathway inhibitor, LDL-receptor, human α1-antitrypsin, antithrombin III, PEA-3 protein, β-galactosidase, and luciferase. In an alternative embodimnt, the promoter sequence is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. In yet another alternative embodiment, the portion of SEQ ID NO:93 is selected from SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95; SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, and SEQ ID NO:144. In a more preferred embodiment, the portion is SEQ ID NO:91. In another embodiment, the expression vector further comprises in operable combination an age-related regulatory sequence selected from SEQ ID NO:1 and portions thereof.

The invention further provides cells containing hFIX-derived sequences. In particular, the invention provides a host cell containing a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof. In one embodiment, the host cell is comprised in a tissue or organ in a living animal. In an alternative embodiment, the host cell is a gamete. In another alternative embodiment, the host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

The invention additionally provides a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a functional homolog of an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof. In one embodiment, the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, tissue factor pathway inhibitor, LDL-receptor, human α1-antitrypsin, antithrombin III, PEA-3 protein, β-galactosidase, and luciferase. In an alternative embodiment, the promoter sequence is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. In yet another embodiment, the portion of SEQ ID NO:93 is selected from SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95; SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, and SEQ ID NO:144. In yet a further embodiment, the portion is SEQ ID NO:91. In another embodiment, the expression vector further comprises in operable combination an age-related regulatory sequence selected from SEQ ID NO:1 and portions thereof.

Also provided herein is host cell containing a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a functional homolog of an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof. In one embodiment, the host cell is comprised in a tissue or organ in a living animal. In another embodiment, the host cell is a gamete. In yet

another embodiment, the host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

Also provided herein are methods for using hFIX-derived sequences. For example, the invention provides a method for expressing a nucleic acid sequence of interest, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the age-related regulatory sequence to produce a transgene; and c) introducing the transgene into the cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in the treated cell. In one embodiment, the treated cell is comprised in a tissue or organ in a living animal.

The invention also provides a method for expressing a nucleic acid sequence of interest, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) a functional homolog of an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the functional homolog to produce a transgene; and c) introducing the transgene into the cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in the treated cell.

In addition to sequences from the hFIX gene, the invention provides sequences derived from the hPC gene. In particular, the invention provides substantially purified nucleic acid sequence comprising a nucleotide sequence selected from at least a portion of SEQ ID NO:85, and at least a portion of SEQ ID NO:92. In one embodiment, the portion has activity selected from age-related regulatory activity and regulatory activity. In an alternative embodiment, the portion is selected from SEQ ID NO:88, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162; SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:87, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID

NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:89, and SEQ ID NO:90. In another alternative embodiment, the portion is selected from SEQ ID NO:89 and SEQ ID NO:90.

Also provided herein is a substantially purified nucleic acid sequence which hybridizes under stringent hybridization conditions with a nucleotide sequence selected from SEQ ID NO:92, the complement of SEQ ID NO:92, SEQ ID NO:85, the complement of SEQ ID NO:85, SEQ ID NO:89, the complement of SEQ ID NO:89, SEQ ID NO:90, and the complement of SEQ ID NO:90. In one embodiment, the nucleic acid sequence has activity selected from age-related regulatory activity and regulatory activity.

The invention additionally provides a substantially purified nucleic acid sequence comprising a functional homolog of a sequence having activity selected from age-related regulatory activity and regulatory activity, the sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90.

Also provided by the invention is a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, the nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90. In one embodiment, the expression vector of Claim 38, wherein the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, tissue factor pathway inhibitor, LDL-receptor, human α1-antitrypsin, antithrombin III, PEA-3 protein, β-galactosidase, and luciferase. In another embodiment, the promoter sequence is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. In yet another embodiment, the portion is

selected from SEQ ID NO:88, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:87, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:89, and SEQ ID NO:90. In a further embodiment, the portion is selected from SEQ ID NO:89 and SEQ ID NO:90.

The invention also provides a host cell containing a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, the nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90. In one embodiment, the host cell is comprised in a tissue or organ in a living animal. In another embodiment, the host cell is a gamete. In a further embodiment, the host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

The invention also provides a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a functional homolog of a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, the nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90. In one embodiment, the nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin,

protein C, antithrombin III, tissue factor pathway inhibitor, LDL-receptor, human α1-antitrypsin, antithrombin III, PEA-3 protein, β-galactosidase, and luciferase. In another embodiment, the promoter sequence is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter. In a further embodiment, the portion is selected from SEQ ID NO:88, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:87, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:89, and SEQ ID NO:90. In an alternative embodiment, the portion is selected from SEQ ID NO:89 and SEQ ID NO:90.

Further provided herein is a host cell containing a recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) a functional homolog of a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, the nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90. In one embodiment, the host cell is comprised in a tissue or organ in a living animal. In an alternative embodiment, the host cell is a gamete. In yet another embodiment, the host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

Also provided herein are methods for using hPC sequences. In particular, the invention discloses a method for expressing a nucleic acid sequence of interest, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, the nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the nucleotide sequence to produce a transgene; and c) introducing the transgene into the cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in the treated cell. In one embodiment, the treated cell is comprised in a tissue or organ in a living animal.

Also provided herein is a method for expressing a nucleic acid sequence of interest, comprising: a) providing: i) a cell; ii) a nucleic acid sequence of interest; iii) a promoter sequence; and iv) a functional homolog of a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, the nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90; b) operably linking the nucleic acid sequence of interest, the promoter sequence, and the functional homolog to produce a transgene; and c) introducing the transgene into the cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in the treated cell.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the structure of eleven exemplary human FIX minigene expression constructs and relative *in vitro* transient expression activities (ng hFIX/10^6 cells/48 hr).

Figure 2 shows graphs of longitudinal analyses of transgenic mice which carry -416FIXm1 (A), -416FIXm1/1.4 (B), -590FIXm1 (C), -679FIXm1 (D), and -770FIXm1 (E) expression vectors and which produce high initial prepubertal, but rapidly decreasing, hFIX expression levels with age.

Figure 3 shows a Northern blot of human FIX mRNA levels (A) and a gel showing hFIX transgene DNA levels as determined by multiplex PCR analysis (B) in the livers and tails of animals carrying -416FIXm1.

Figure 4 shows graphs of longitudinal analysis of transgenic mice which carry -802FIXm1 (A), -802FIXm1/1.4 (B), -2231FIXm1 (C), -2231FIXm1/1.4 (D) and -416FIXm1/AE5' (E) expression vectors and which produce hFIX at stable and increasing levels with age.

Figure 5 shows a Northern blot of transgenic mice carrying -802FIXm1 and -802FIXm1/1.4 expression vectors.

Figure 6 is a gel of a gel electrophoretic mobility shift assay using mouse liver nuclear extract (NEs) from three different age groups, and using double-stranded oligonucleotides containing a PEA-3 element nucleotide sequence spanning from nt -797 to -776 of the hFIX gene (A), and using a competition assay for ^{32}P-labelled double stranded oligonucleotides containing the PEA-3 nucleotide sequence (B).

Figure 7 is a Northern blot showing tissue specificity of hFIX expression in transgenic mice carrying -416FIXm1 (A) and -802 FIXm1 (B) expression vectors.

Figure 8A-E shows the nucleotide sequence (SEQ ID NO:4) of, and eight amino acid sequences (SEQ ID NOs:5 to 12) which together form, the human factor IX (GenBank accession number K02402). The initiation transcription site (nucleotide 1) and the poly-A addition site (nucleotide 32,757) are identified by solid circles. The solid vertical arrows indicate the intron-exon splice junction. The five Alu repetitive sequences have been underlined, while the 5-base insert in intron A and the AATAAA sequence in exon VIII are boxed. The cleavage or termination site at the 3' end of the gene (CATTG) is underlined with a dashed line.

Figure 9 shows the cDNA sequence (SEQ ID NO:13) (A) and encoded polypeptide sequence (SEQ ID NO:47) (B) of mouse PEA-3 (GenBank accession number X63190).

Figure 10 A-D shows the cDNA sequence (SEQ ID NO:42) of the human α1-antitrypsin gene (GenBank accession number K02212).

Figure 11 shows the DNA sequence (SEQ ID NO:43) of human antithrombin III (GenBank accession number A06100).

Figure 12 shows the cDNA sequence (A) (SEQ ID NO:49) (GenBank accession number X02750) and genomic DNA sequence (B) (SEQ ID NO:50) (GenBank accession number M11228) of human protein C.

Figure 13 (A-E) shows the nucleic acid sequences (SEQ ID NOs:76-83) of exemplary homologs of AE3' (SEQ ID NO:3).

Figure 14 shows the nucleotide sequence (from nt -1462 to nt +1; SEQ ID NO:85) which is located at the 5'-end of the human protein C gene.

Figure 15 shows the structure of eight exemplary human protein C minigene expression constructs.

Figure 16 shows the relative *in vitro* transient expression activities for five exemplary human protein C minigene expression constructs.

Figure 17 shows graphs of longitudinal analyses of transgenic mice which carry -1462hPCm1 (A), -82hPCm1 (B), and AE5'/-1462hPCm1/AE3' (C) expression vectors.

DEFINITIONS

To facilitate understanding of the invention, a number of terms are defined below.

The term "isolated" when used in relation to a nucleic acid, as in "an isolated nucleic acid sequence" refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural state, or when obtained from its actual source. Isolated nucleic acid is nucleic acid present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA which are found in the state they exist in nature. For example, a given DNA sequence (*e.g.*, a gene) is found on the host cell chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, are found in the cell as a mixture with numerous other mRNAs which encode a multitude of proteins. However, an isolated nucleic acid sequence comprising SEQ ID NO:1 includes, by way of example, such nucleic acid sequences in cells which ordinarily contain SEQ ID NO:1 where the nucleic acid sequence is in a chromosomal or extrachromosomal location different from that of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid sequence may be present in single-stranded or double-stranded form. When an isolated nucleic acid sequence is to be utilized to express a protein, the nucleic acid sequence will contain (at a minimum) at least a portion of the sense or coding strand (*i.e.*, the nucleic acid sequence may be single-stranded). Alternatively, it may contain both the sense and anti-sense strands (*i.e.*, the nucleic acid sequence may be double-stranded).

As used herein, the term "purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated. An

"isolated nucleic acid sequence" is therefore a purified nucleic acid sequence. "Substantially purified" molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated.

The term "recombinant" when made in reference to a DNA sequence refers to a DNA sequence which is comprised of segments of DNA joined together by means of molecular biological techniques. The term "recombinant" when made in reference to a polypeptide sequence refers to a polypeptide sequence which is expressed using a recombinant DNA sequence.

As used herein, the terms "vector" and "vehicle" are used interchangeably in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.

The term "expression vector" as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism. Nucleic acid sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.

The term "transgenic" when used in reference to a cell refers to a cell which contains a transgene, or whose genome has been altered by the introduction of a transgene. The term "transgenic" when used in reference to a tissue or animal refers to a tissue or animal, respectively, which comprises one or more cells that contain a transgene, or whose genome has been altered by the introduction of a transgene. Transgenic cells, tissues and animals may be produced by several methods including the introduction of a "transgene" comprising nucleic acid (usually DNA) into a target cell or integration of the transgene into a chromosome of a target cell by way of human intervention, such as by the methods described herein.

A "non-human animal" refers to any animal which is not a human and includes vertebrates such as rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc. Preferred non-human animals are selected from the order Rodentia. The term "order Rodentia" refers to rodents *i.e.*, placental mammals (class Euthria) which include the family Muridae (*e.g.*, rats and mice), most preferably mice.

The term "nucleotide sequence of interest" refers to any nucleotide sequence, the manipulation of which may be deemed desirable for any reason (*e.g.*, treat disease, confer improved qualities, *etc.*), by one of ordinary skill in the art. Such nucleotide sequences include, but are not limited to, coding sequences of structural genes (*e.g.*, reporter genes, selection marker genes, oncogenes, drug resistance genes, growth factors, *etc.*), and non-coding regulatory sequences which do not encode an mRNA or protein product (*e.g.*, promoter sequence, polyadenylation sequence, termination sequence, enhancer sequence, *etc.*).

As used herein, the terms "complementarity," or "complementary" are used in reference to nucleotide sequences related by the base-pairing rules. For example, the sequence 5'-AGT-3' is complementary to the sequence 5'-ACT-3'. Complementarity can be "partial" or "total." "Partial" complementarity is where one or more nucleic acid bases is not matched according to the base pairing rules. "Total" or "complete" complementarity between nucleic acids is where each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands.

A "complement" of a nucleic acid sequence as used herein refers to a nucleotide sequence whose nucleic acids show total complementarity to the nucleic acids of the nucleic acid sequence.

The term "homology" when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology (*i.e.*, partial identity) or complete homology (*i.e.*, complete identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid sequence and is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe (*i.e.*, an oligonucleotide which is capable of hybridizing to another oligonucleotide of interest) will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous sequence to a target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific

binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.

When used in reference to a double-stranded nucleic acid sequence such as a cDNA or genomic clone, the term "substantially homologous" refers to any probe which can hybridize to either or both strands of the double-stranded nucleic acid sequence under conditions of low stringency as described *infra*.

When used in reference to a single-stranded nucleic acid sequence, the term "substantially homologous" refers to any probe which can hybridize to the single-stranded nucleic acid sequence under conditions of low stringency as described *infra*.

The term "hybridization" as used herein includes "any process by which a strand of nucleic acid joins with a complementary strand through base pairing." [Coombs J (1994) *Dictionary of Biotechnology*, Stockton Press, New York NY]. Hybridization and the strength of hybridization (*i.e.*, the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the T_m of the formed hybrid, and the G:C ratio within the nucleic acids.

As used herein, the term "T_m" is used in reference to the "melting temperature." The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. The equation for calculating the T_m of nucleic acids is well known in the art. As indicated by standard references, a simple estimate of the T_m value may be calculated by the equation: $T_m = 81.5 + 0.41(\% G + C)$, when a nucleic acid is in aqueous solution at 1 M NaCl [*see e.g.*, Anderson and Young, Quantitative Filter Hybridization, *in Nucleic Acid Hybridization* (1985)]. Other references include more sophisticated computations which take structural as well as sequence characteristics into account for the calculation of T_m.

Low stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 68°C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l $NaH_2PO_4 \cdot H_2O$ and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 1% SDS, 5X Denhardt's reagent [50X Denhardt's contains the following per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 µg/ml

denatured salmon sperm DNA followed by washing in a solution comprising 0.2X SSPE, and 0.1% SDS at room temperature when a DNA probe of about 100 to about 1000 nucleotides in length is employed.

High stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 68°C in a solution consisting of 5X SSPE, 1% SDS, 5X Denhardt's reagent and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, and 0.1% SDS at 68°C when a probe of about 100 to about 1000 nucleotides in length is employed.

The term "equivalent" when made in reference to a hybridization condition as it relates to a hybridization condition of interest means that the hybridization condition and the hybridization condition of interest result in hybridization of nucleic acid sequences which have the same range of percent (%) homology. For example, if a hybridization condition of interest results in hybridization of a first nucleic acid sequence with other nucleic acid sequences that have from 50% to 70% homology to the first nucleic acid sequence, then another hybridization condition is said to be equivalent to the hybridization condition of interest if this other hybridization condition also results in hybridization of the first nucleic acid sequence with other nucleic acid sequences that have from 50% to 70% homology to the first nucleic acid sequence.

When used in reference to nucleic acid hybridization the art knows well that numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency hybridization different from, but equivalent to, the above-listed conditions.

Those skilled in the art know that whereas higher stringencies may be preferred to reduce or eliminate non-specific binding of the nucleotide sequence of SEQ ID NOs:1 or 3 with other nucleic acid sequences, lower stringencies may be preferred to detect a larger number of nucleic acid sequences having different homologies to the nucleotide sequence of SEQ ID NOs:1 and 3.

As used herein, the terms "regulatory element" and "regulatory sequence" interchangeably refer to a nucleotide sequence which does not encode RNA or a protein and which controls some aspect of the expression of nucleic acid sequences. For example, a promoter is a regulatory element which facilitates the initiation of transcription of an operably linked coding region. Other regulatory elements are splicing signals, polyadenylation signals, termination signals, *etc.* In contrast, the term "regulatory gene" refers to a DNA sequence which encodes RNA or a protein (*e.g.*, transcription factor) that controls the expression of other genes.

Regulatory elements may be tissue specific or cell specific. The term "tissue specific" as it applies to a regulatory element refers to a regulatory element that is capable of directing selective expression of a nucleotide sequence of interest to a specific type of tissue (*e.g.*, liver) in the relative absence of expression of the same nucleotide sequence of interest in a different type of tissue (*e.g.*, lung).

Tissue specificity of a regulatory element may be evaluated by, for example, operably linking a reporter gene to a promoter sequence (which is not tissue-specific) and to the regulatory element to generate a reporter construct, introducing the reporter construct into the genome of an animal such that the reporter construct is integrated into every tissue of the resulting transgenic animal, and detecting the expression of the reporter gene (*e.g.*, detecting mRNA, protein, or the activity of a protein encoded by the reporter gene) in different tissues of the transgenic animal. The detection of a greater level of expression of the reporter gene in one or more tissues relative to the level of expression of the reporter gene in other tissues shows that the regulatory element is "specific" for the tissues in which greater levels of expression are detected. Thus, the term "tissue-specific" (*e.g.*, liver-specific) as used herein is a relative term that does not require absolute specificity of expression. In other words, the term "tissue-specific" does not require that one tissue have extremely high levels of expression and another tissue have no expression. It is sufficient that expression is greater in one tissue than another. By contrast, "strict" or "absolute" tissue-specific expression is meant to indicate expression in a single tissue type (*e.g.*, liver) with no detectable expression in other tissues.

The term "cell type specific" as applied to a regulatory element refers to a regulatory element which is capable of directing selective expression of a nucleotide sequence of interest in a specific type of cell in the relative absence of expression of the same nucleotide

sequence of interest in a different type of cell within the same tissue. The term "cell type specific" when applied to a regulatory element also means a regulatory element capable of promoting selective expression of a nucleotide sequence of interest in a region within a single tissue.

Cell type specificity of a regulatory element may be assessed using methods well known in the art, *e.g.*, immunohistochemical staining and/or Northern blot analysis. Briefly, for immunohistochemical staining, tissue sections are embedded in paraffin, and paraffin sections are reacted with a primary antibody which is specific for the polypeptide product encoded by the nucleotide sequence of interest whose expression is regulated by the regulatory element. A labeled (*e.g.*, peroxidase conjugated) secondary antibody which is specific for the primary antibody is allowed to bind to the sectioned tissue and specific binding detected (*e.g.*, with avidin/biotin) by microscopy. Briefly, for Northern blot analysis, RNA is isolated from cells and electrophoresed on agarose gels to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled oligo-deoxyribonucleotide probe or DNA probe to detect RNA species complementary to the probe used. Northern blots are a standard tool of molecular biologists.

The term "promoter," "promoter element," or "promoter sequence" as used herein, refers to a DNA sequence which when ligated to a nucleotide sequence of interest is capable of controlling the transcription of the nucleotide sequence of interest into mRNA. A promoter is typically, though not necessarily, located 5' (*i.e.*, upstream) of a nucleotide sequence of interest whose transcription into mRNA it controls, and provides a site for specific binding by RNA polymerase and other transcription factors for initiation of transcription.

Promoters may be constitutive or regulatable. The term "constitutive" when made in reference to a promoter means that the promoter is capable of directing transcription of an operably linked nucleic acid sequence in the absence of a stimulus (*e.g.*, heat shock, chemicals, *etc.*). In contrast, a "regulatable" promoter is one which is capable of directing a level of transcription of an operably linked nucleic acid sequence in the presence of a stimulus (*e.g.*, heat shock, chemicals, *etc.*) which is different from the level of transcription of the operably linked nucleic acid sequence in the absence of the stimulus.

The terms "essentially consisting of" and "consisting essentially of" are equivalent terms, and when in reference to a nucleic acid sequence they are intended to refer to nucleotide sequences which contain from 50% to 100% of the nucleic acid bases which are present in the nucleic acid sequence, in which the arrangement of these nucleic acid bases with respect to each other in the nucleotide sequences is the same as their arrangement in the nucleic acid sequence, and in which the biological activity of the nucleotide sequences is from 50% to 100%, more preferably from 75% to 100%, and most preferably from 90% to 100%, of the biological activity of the nucleic acid sequence. To illustrate, the term "a nucleic acid sequence consisting essentially of SEQ ID NO:1" refers to nucleotide sequences which contain from 50% to 100% of the nucleic acid bases which are present in SEQ ID NO:1, in which the arrangement of these nucleic acid bases with respect to each other in the nucleotide sequences is the same as their arrangement in SEQ ID NO:1, and in which the nucleotide sequences exhibit from 50% to 100%, more preferably from 75% to 100%, and most preferably from 90% to 100%, of the age-related regulatory activity, and/or of the liver-specific activity of SEQ ID NO:1.

A "functional homolog" of a nucleotide sequence which is derived from the hFIX gene shown in Figure 8 is defined as a nucleic acid sequence which has more than 50% identity and less than 100% identity with the hFIX-derived nucleotide sequence (*i.e.*, with the entire, or a portion of the, hFIX sequence of Figure 8), and which has age-related regulatory activity and/or liver-specific activity. For example, a functional homolog of SEQ ID NO:33 includes nucleic acid sequences which have more than 50% identity and less than 100% identity with SEQ ID NO:33, and which have age-related regulatory activity and/or liver-specific activity.

A "functional homolog" of a nucleotide sequence which is derived from the hPC sequence shown in Figure 14 is defined as a nucleic acid sequence which has more than 50% identity and less than 100% identity with the hPC-derived nucleotide sequence (*i.e.*, with the entire, or a portion of the, hPC sequence of Figure 14), and which has age-related regulatory activity and/or regulatory activity. For example, a functional homolog of SEQ ID NO:93 includes nucleic acid sequences which have more than 50% identity and less than 100% identity with SEQ ID NO:93, and which have age-related regulatory activity and/or regulatory activity.

DESCRIPTION OF THE INVENTION

The invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest. In on embodiment, the invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner. Yet more particularly, the exemplary age-regulatory element 5' (AE5') has been discovered to regulate stable gene expression over time *in vivo*, while the exemplary age-regulatory element 3' (AE3') has been discovered to regulate increased gene expression over time *in vivo*. In another embodiment, the invention provides nucleic acid sequences (*e.g.*, AE5') which direct liver-specific expression of a gene of interest. In yet another embodiment, the invention provides transgenic animals which harbor the nucleic acid sequences provided herein and which expres a nucleotide sequence of interest in an age-related and/or liver-specific manner. The nucleic acid sequences provided herein are useful in, for example, identifying and isolating functional homologs of AE5' and AE3', and amplifying at least a portion of AE5' and AE3'. Importantly, the nucleic acid sequences of the invention are also useful in age-related expression and/or liver-specific expression of a nucleotide sequence of interest in an animal, in gene therapy, and in reducing expression of factor IX in an animal.

In addition to regulatory sequences which are derived from the human factor IX gene (*e.g.*, AE5', AE3', and AE3''), the invention further provides sequences which are derived from the human protein C (hPC) gene and which are characterized by age-related regulatory activity and regulatory activity.

The invention is further discussed under (A) Regulatory Nucleic Acid Sequences, (B) Using Probes To Identify And Isolate Homologs Of AE5', AE3', and Of hPC-Derived Regulatory Sequences, (C) Using Primers to Amplify At Least A Portion Of AE5', AE3', and Of hPC-Derived Regulatory Sequences, (D) Methods For Regulating Gene Expression, (E) Gene Therapy, and (F) Reducing Expression Of Factor IX In An Animal.

A. Regulatory Nucleic Acid Sequences

The invention provides regulatory sequences which are derived from the hFIX and hPC genes.

i. Regulatory Nucleic Acid Sequences From The hFIX Gene

The regulatory nucleic acid sequences of the invention and their surprising properties in regulating gene expression were discovered during the inventor's investigation of the mechanisms underlying age-associated regulation of the human factor IX, which is involved in blood coagulation. Blood coagulation plays a critical role not only in homeostasis, but also in many physiological and pathological conditions [Saito in *Disorders of Hemostasis*, O.D. Ratnoff and C.D. Forbes, Eds., Sauders, Philadelphia, ed. 2 (1991), pp. 18-47; Kurachi *et al.* (1993) Blood Coagul. Fibrinol. 4:953-974]. Blood coagulation potential in humans as well as in other mammals reaches the young adult level around the age of weaning [Yao *et al.* (1991) Thromb. Haemost. 65:52-58; Andrew *et al.* (1992) Blood 80:1998-2005; Andrew *et al.* Blood (1987) 70:165-172; Andrew *et al.* (1988) Blood 72:1651-1657]. This is followed by a gradual increase in coagulation potential during young adulthood, and an almost two-fold increase by old age [Sweeney and Hoernig (1993) Am. J. Clin. Pathol. 99:687-688; Kurachi *et al.* (1996) Thromb. Haemost. 76:965-969]. This age-associated increase in coagulation potential takes place in healthy centenarians [Marie *et al.* (1995) Blood 85:3144-3149], indicating that the increase is a normal phenomenon associated with aging.

It is the inventors' consideration that this increase in coagulation potential may make a crucial contribution to the development and progression of age-associated diseases such as cardiovascular and thrombotic disorders [Conlan *et al.* (1993) The Atherosclerosis Risk in Communities (ARIC) Study 70:380-385; Balleisen *et al.* (1985) Thromb. Haemost. 54:475-479; Rode *et al.* (1996) Nat. Med. 2:293-298; Woodward *et al.* (1997) Brit. J. Haemat. 97:785-797]. The inventors' consideration was based on the observation that this increase in blood coagulation potential coincides with plasma level increases of pro-coagulant factors such as factor IX, whereas plasma levels of anti-coagulation factors (such as antithrombin III and protein C) or of factors involved in fibrinolysis are only marginally affected [Conlan *et al.* (1994) The Atherosclerosis Risk in Committees (ARIC) Study 72:551-556; Lowe *et al.* (1997) Brit. J. Haemat. 97:775-784]. These facts strongly suggested to the inventors that the

observed increase in blood coagulation activity with advancing age is due to regulated events. Plasma levels of each protein factor involved in blood coagulation, fibrinolysis and their regulatory systems are presumably determined by the balance of the many processes involved. At present, little is known about why an advancing age-associated increase in blood coagulation activity exists, or what molecular mechanisms are involved in age-dependent regulation (homeostasis) of blood coagulation [Finch in *Longevity, Senescence, and the Genome*, The University of Chicago Press, Chicago, 1990].

Blood coagulation factor IX (FIX) occupies a key position in the blood coagulation cascade where the intrinsic and extrinsic pathways merge [Saito in *Disorders of Hemostasis*, O.D. Ratnoff and C.D. Forbes, Eds., Sauders, Philadelphia, ed. 2 (1991), pp. 18-47; Kurachi *et al.* (1993) Blood Coagul. Fibrinol. 4:953-974]. FIX is synthesized in the liver with strict tissue-specificity, and its deficiency results in the bleeding disorder hemophilia B. In normal humans the plasma activity and protein concentration levels of human FIX (hFIX) increase with advancing age [Sweeney and Hoernig (1993) Am. J. Clin. Pathol. 99:687-688; Kurachi *et al.* (1996) Thromb. Haemost. 76:965-969]. Mouse FIX (mFIX) plasma activity also increases with age in a manner similar to hFIX, and is directly correlated with an increase in liver mFIX messenger RNA (mRNA) level [Sweeney and Hoernig (1993) Am. J. Clin. Pathol. 99:687-688; Kurachi *et al.* (1996) Thromb. Haemost. 76:965-969]. However, nothing else is known about the molecular mechanisms underlying such an increase. In investigating the basic molecular mechanisms responsible for age-associated regulation of hFIX, the inventors discovered the nucleotide sequences which regulate age-associated expression, and which direct liver-specific expression, of the exemplary hFIX gene.

The discovery of the invention sequences was made possible, in part, by the inventors' use of the hFIX promoter in combination with the coding sequence for hFIX instead of with the coding sequence for commonly used reporter proteins. The discovery of the surprising functions of the nucleotide sequences provided herein was also made possible by the inventors' use of longitudinal *in vivo* analyses, rather than of *in vitro* analyses. In particular, the inventors' earlier studies used reporter genes (including bacterial β-galactosidase and chloramphenicol acetyltransferase [CAT]) which are heterologous to the factor IX promoter. In these earlier studies, the factor IX promoter showed only very weak expression activity *in vitro* [Kurachi et al. (1995) J. Biol. Chem. 270:5276-5281]. Use of such heterologous reporter genes made it impossible to reliably and quantitatively perform

longitudinal analyses of transgene expression in animals. The inventors unexpectedly observed that the use of hFIX minigene expression vectors which contained the hFIX promoter and its homologous hFIX gene were capable of producing high level plasma hFIX *in vivo*. This unexpected observation not only solved the problems associated with the use of genes which are heterologous to the hFIX promoter by providing a reliable animal assay system, but also provided multiple unexpected critical insights into the regulatory mechanisms of the hFIX gene, including the determination of nucleotide sequences which regulate the stability and age-related increased expression of the exemplary hFIX gene.

The present invention provides the 32-nucleotide nucleic acid sequence 5'-agccatt cagtcgagga aggatagggt ggtat-3' (SEQ ID NO:1) of AE5' which corresponds to the sequence from 2164 to 2195 of the hFIX gene deposited in GenBank as accession number K02402, and which corresponds to the sequence from -802 to -771 of Figure 8 when in relation to the hFIX start codon (ATG) in which the adenine is designated as position +30.

The present invention also provides the 1273-nucleotide nucleic acid sequence (SEQ ID NO:3) (Figure 13) of AE3' which corresponds to the sequence from 34,383 to 35,655 of GenBank accession number K02402, and which corresponds to the sequence from 31,418 to 32,690 of Figure 8 when in relation to the hFIX start codon (ATG) in which the adenine is designated as position +30.

The terms "age-related regulatory activity" and "age-related activity" when made in reference to a nucleic acid sequence refer to the ability of the nucleic acid sequence to alter in an age-related manner (*e.g.*, increase over a period of time) the level of transcription into mRNA and/or the synthesis of a polypeptide encoded by a nucleotide sequence of interest which is operably linked to a promoter sequence as compared to the level of transcription into mRNA of the nucleotide sequence of interest which is operably linked to the promoter sequence in the absence of the nucleic acid sequence which has age-related regulatory activity. An "age regulatory sequence" is herein used to refer to a nucleic acid sequence which has age-related regulatory activity.

To illustrate, where expression levels of a gene of interest decrease over a period of time, a nucleic acid sequence is said to have age-related regulatory activity if (when operably linked to the gene of interest) it results in (a) a smaller decrease in expression levels of the gene over the same period of time as compared to the decrease in expression levels in the absence of the nucleic acid sequence, (b) relatively constant (*i.e.*, unchanged) expression

levels over the same period of time, or (c) increased expression levels over the same period of time.

The terms "operably linked," "in operable combination," and "in operable order" as used herein refer to the linkage of nucleic acid sequences such that they perform their intended function. For example, operably linking a promoter sequence to a nucleotide sequence of interest refers to linking the promoter sequence and the nucleotide sequence of interest in a manner such that the promoter sequence is capable of directing the transcription of the nucleotide sequence of interest and/or the synthesis of a polypeptide encoded by the nucleotide sequence of interest. Similarly, operably linking a nucleic acid sequence having age-related regulatory activity to a promoter sequence and to a nucleotide sequence of interest means linking the nucleic acid sequence having age-related regulatory activity, the promoter sequence and the nucleotide sequence of interest in a manner such that the nucleic acid sequence having age-related regulatory activity is capable of altering over a period of time the level of transcription into mRNA of the nucleotide sequence of interest and/or the synthesis of a polypeptide encoded by the nucleotide sequence of interest.

Methods for determining age-related regulatory activity of a candidate nucleic acid sequence, given the teachings of the present specification, are within the ordinary skill in the art and are exemplified by the methods disclosed herein. For example, a test vector is constructed in which the candidate nucleic acid sequence is linked upstream or downstream of a promoter sequence which is operably linked to a nucleotide sequence of interest (*e.g.*, Example 1). A control vector which is similar to the test vector but which lacks the candidate nucleic acid sequence is also constructed. The test vector and control vector are separately introduced into a host cell. It is preferred that the host cell (*e.g.*, fertilized egg) be capable of generating a transgenic multicellular organism, *e.g.*, a transgenic mouse (*e.g.*, Example 3) and that transgenic multicellular organisms are generated. Longitudinal analyses of the expression of mRNA which is encoded by the nucleotide sequence of interest (*e.g.*, by Northern blot hybridization) over a period of time in, and preferably over the entire life span of, founders and successive generations of the transgenic multicellular organism are carried out (*e.g.*, Example 3). The detection in any tissue of mRNA and/or protein levels which are encoded by the nucleotide sequence of interest and which are greater in transgenic animals harboring the test vector as compared to the mRNA and/or protein levels in transgenic

animals harboring the control vector at least one point in time indicates that the candidate nucleic acid sequence has age-related regulatory activity.

For example, evidence provided herein shows the surprising result that AE5' (SEQ ID NO:1) alone has age-related regulatory activity in that AE5' stabilizes hFIX mRNA whereby hFIX mRNA levels are essentially unchanged at different time points over the entire life span of transgenic animals (Figure 4, A, C and E) as compared to the declining hFIX mRNA levels in transgenic animals which harbor vectors that lack AE5' (Figures 2A and 2E). The age-related regulatory activity of AE5' was observed regardless whether AE5' was placed upstream (Figure 4A) or downstream (Figure 4E) of the promoter sequence in the expression construct.

Furthermore, data provided herein demonstrates the unexpected result that AE3' (SEQ ID NO:3) alone has age-related regulatory activity in that AE3' increases hFIX mRNA at several time points during the life of transgenic animals (Figure 2B) relative to the hFIX mRNA levels at the same time points in transgenic animals harboring vectors that lack AE3' (Figure 2A). AE3' substantially increased the steady state hFIX mRNA levels (Figure 5). This result which was observed *in vivo* was surprising in part because AE3' exhibited weak down regulatory effects on hFIX production *in vitro*. Without limiting the invention to any particular mechanism, these results suggest that AE3' functions by increasing hFIX mRNA stability which directly correlates with an increase in the hFIX protein level in the circulation. Also without intending to limit the invention to any particular theory, it is the inventors' consideration that the age-related regulatory activity of AE3′ is due to the s1 structure-forming dinucleotide repeats present in the 3′UTR; the s1 region is the 103 bp sequence (SEQ ID NO:61) from nt 32,141 through nt 32,243 of Figure 8. This consideration is based on the inventors' observation that dinucleotide repeats, such as $(AT)_n$ of the 3′ UTR of various genes, can form sl structures in mRNA, which upon binding specific proteins are known to modulate mRNA stability, mostly to a less stable state [Ross (1995) Microbiol. Rev. 59:423-450].

Importantly, the invention demonstrates the surprising synergistic action of AE5' and AE3' which together result in hFIX mRNA levels which not only are greater at each time point tested over the life span of transgenic animals (Figures 4 B and D) as compared to hFIX mRNA levels in transgenic animals harboring vectors that lack both AE5' and AE3', but also that the profile of increased human FIX mRNA levels over the life span of

transgenic mouse recapitulates the profile of increased mouse FIX mRNA levels as a wild-type mouse ages.

Data presented herein further demonstrate that the age-related regulatory activity of AE5' alone, of AE3' alone, and of the combination of AE5' and AE3' is independent of the level of expression of the transgenes harboring them, sex, generation or zygosity status of the transgenic animals.

The present invention is not limited to SEQ ID NOs:1 and 3 but specifically contemplates portions thereof. As used herein the term "portion" when made in reference to a nucleic acid sequence refers to a fragment of that sequence. The fragment may range in size from five (5) contiguous nucleotide residues to the entire nucleic acid sequence minus one nucleic acid residue. Thus, a nucleic acid sequence comprising "at least a portion of" a nucleotide sequence comprises from five (5) contiguous nucleotide residues of the nucleotide sequence to the entire nucleotide sequence.

In a preferred embodiment, portions of SEQ ID NO:1 contemplated to be within the scope of the invention include, but are not limited to, the 7-nucleotide nucleic acid sequence of the polyomavirus enhance activator 3 (PEA-3) (5'-GAGGAAG-3') (SEQ ID NO:2) which corresponds to the sequence from 2176 to 2182 of GenBank accession number K02402, and which corresponds to the sequence from -790 to -784 of GenBank accession number K02402 when in relation to the hFIX start codon (ATG) in which the adenine is designated as position +30. A nucleotide sequence [5'-CAGGAAG-3' (SEQ ID NO:40)] which is homologous to the invention's PEA-3 nucleotide sequence was initially reported in the art as a polyoma virus enhancer, and was reported to be involved in the regulation of expression of various genes (*e.g.*, collagen gene and *c-fos*) in several tissues [Martin *et al.* (1988) Proc. Natl. Acad. Sci. 85:5839-5843; Xin *et al.* (1992) Genes & Develop. 6:481-496; Chotteau-Lelievre *et al.*(1997) Oncogene 15:937-952; Gutman and Wasylyk (1990) EMBO J. 9:2241-2246]. However, the PEA-3 protein sequence [or PEA-3 related protein(s)] which binds to nucleotide sequences which are homologous to the invention's PEA-3 nucleotide sequence has not been reported to be either liver-specific or enriched in the liver.

Other portions of SEQ ID NO:1 included within the scope of the invention include, for example, SEQ ID NO:33 [5'-tcgaggaagga-3'], SEQ ID NO:34 [5'-agtcgaggaaggata-3'], SEQ ID NO:35 [5'-tcagtcgaggaaggatagg-3'], SEQ ID NO:36 [5'-attcagtcgaggaaggatagggt-3'], SEQ ID NO:37 [5'-ccattcagtcgaggaaggatagggtgg-3'], and

SEQ ID NO:38 [5'-gccattcagtcgaggaaggatagggtggta-3'], all of which include the PEA-3 nucleotide sequence.

In a preferred embodiment, portions of SEQ ID NO:3 contemplated to be within the scope of the invention include, but are not limited to, SEQ ID NO:51 [5'-TTATTTTATATATATAATATATATATAAAATA-3'], SEQ ID NO:52 [5'-TAT AATATA-3'], SEQ ID NO:53 [5'-CAATATAAATATATAG-3'], SEQ ID NO:54 [5'-TGTGTGTGTATGCGTGTGTGTAGACACACACGCATACACACATA-3'], the combination of SEQ ID NOs:51 and 52, *i.e.*, SEQ ID NO:55 [5'-TTATTTTATA TATATAATATATATATAAAATATATAATATA-3'], the combination of SEQ ID NOs:52 and 53, *i.e.*, SEQ ID NO:56 [5'-TATAATATACAATATAAATATATAG-3'], the combination of SEQ ID NOs:53 and 54, *i.e.*, SEQ ID NO:57 [5'-CAATATAAAT ATATAGTGTGTGTGTATGCGTGTGTGTAGACACACACGCATACACACATA-3'], the combination of SEQ ID NOs:51, 52, 53, and 54, *i.e.*, SEQ ID NO:58 [5'-TTAT TTTATATATATAATATATATATAAAATATATAATATACAATATAAATATATAGTGT GTGTGTATGCGTGTGTGTAGACACACACGCATACACACATA-3'], the 723 bp sequence (SEQ ID NO:59) from nt 31,418 through nt 32,140 of Figure 8, the 447 bp sequence (SEQ ID NO:60) from nt 32,244 through nt 32,690 of Figure 8, and the 103 bp sequence (SEQ ID NO:61) (*i.e.*, the s1 region of the 3' UTR) from nt 32,141 through nt 32,243 of Figure 8.

The nucleotide sequence of portions of SEQ ID NOs:1 and 3 which exhibit age-related regulatory activity may be determined using methods known in the art, *e.g.*, using deletion constructs (*e.g.*, see Yang *et al.* (1998) J. Biol. Chem. 273:891-897). Briefly, several expression plasmids are constructed to contain a reporter gene under the control of a promoter and of different candidate nucleotide sequences which are obtained either by restriction enzyme deletion of internal sequences in SEQ ID NOs:1 and 3, restriction enzyme truncation of sequences at the 5' and/or 3' end of SEQ ID NOs:1 and 3, by the introduction of single nucleic acid base changes by PCR into SEQ ID NOs:1 and 3, or by chemical synthesis. The gene-related regulatory activity of the different constructs is determined as described *supra* in order to determine whether the candidate nucleotide sequence exhibits age-related regulatory activity.

The sequences of the present invention are not limited to SEQ ID NOs:1 and 3 and portions thereof, but also include homologs of SEQ ID NOs:1 and 3, and homologs of portions thereof. Homologs of SEQ ID NOs:1 and 3, and of portions thereof, include, but

are not limited to, nucleotide sequences having deletions, insertions or substitutions of different nucleotides or nucleotide analogs as compared to SEQ ID NOs:1 and 3, and of portions thereof, respectively. Such homologs may be produced using methods well known in the art.

A "homolog" of SEQ ID NO:1 is defined as a nucleotide sequence having more than 63% identity and less than 100% identity with SEQ ID NO:1. Homologs of SEQ ID NO:1 are exemplified, but not limited to, SEQ ID NO:66 (5'-acccatt cagtcgagga aggatagggt ggtat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that the G at nt 2,165 is replaced with a C; SEQ ID NO:67 (5'-agccatt gagtcgagga aggatagggt ggtat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that the C at nt 2,171 is replaced with a G; SEQ ID NO:68 (5'-agccatt cagacgagga aggatagggt ggtat-3') is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that the T at nt 2,174 is replaced with a A; SEQ ID NO:69 (5'-agccatt cagtcgagga aggatagggt ggttt-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that the A at nt 2,194 is replaced with a T; SEQ ID NO:70 (5'-agccatt cagtcgagga tcccaagggt ggtat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that AGGGT beginning at nt 2,186 is replaced with TCCCA; SEQ ID NO:71 (5'-agccatt cagtcgagga aggatagggcctaat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that TGGT beginnining at nt 2,190 is replaced with CCTA; SEQ ID NO:72 (5'-agaccatt cagtcgagga aggatagggt ggtat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that a A is inserted after nt 2,165; SEQ ID NO:73 (5'-agccatt cagtcgagga aggatagcggt ggtat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that a C is inserted after nt 2,187; SEQ ID NO:74 (5'-agccatt cagtcgagga aggataat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that GGGTGGT beginning at nt 12,187 is deleted; and SEQ ID NO:75 (5'-agccatt cgagga aggatagggt ggtat-3') which is the sequence from nt 2,164 to nt 2,195 of GenBank accession number k02402, except that CAGT beginning at nt 2,171 is deleted.

A "homolog" of SEQ ID NO:2 is defined as a nucleotide sequence having more than 75% identity and less than 100% identity with SEQ ID NO:2. Homologs of SEQ ID NO:2 include, for example, GAGGATG (SEQ ID NO:39), CAGGAAG (SEQ ID NO:40),

CAGGATG (SEQ ID NO:41), GTGGAAG (SEQ ID NO:62), GTGGATG (SEQ ID NO:63), CTGGAAG (SEQ ID NO:64), CTGGATG (SEQ ID NO:65), and CAGGAAG (SEQ ID NO:84).

A "homolog" of SEQ ID NO:3 is defined as a nucleotide sequence having less than 100% and more than 60% identity with SEQ ID NO:3. Homologs of SEQ ID NO:3 are exemplified, but not limited to, SEQ ID NOs:76-83 shown in Figure 13. Specifically, SEQ ID NO:76 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that the C at nt 34,390 has been replaced with a G. SEQ ID NO:77 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that the T at nt 34,649 has been replaced with a A. SEQ ID NO:78 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that the GC beginning at nt 34,959 has been replaced with a CG. SEQ ID NO:79 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that the CATG beginning at nt 35,501 has been replaced with a GTAC. SEQ ID NO:80 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that TT is inserted after the A at nt 34,681. SEQ ID NO:81 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that TGC is inserted after the C at nt 35,581. SEQ ID NO:82 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that A at nt 35,636 is deleted. SEQ ID NO:83 is the sequence from nt 34,383 to nt 35,655 of GenBank accession number k02402, except that the G at nt 34,383 is deleted.

A "homolog" of SEQ ID NO:59 is defined as a nucleotide sequence having less than 100% and more than 62% identity with SEQ ID NO:59.

A "homolog" of SEQ ID NO:60 is defined as a nucleotide sequence having less than 100% and more than 60% identity with SEQ ID NO:60.

A "homolog" of SEQ ID NO:61 is defined as a nucleotide sequence having less than 100% and more than 60% identity with SEQ ID NO:61.

Homologs of a portion of SEQ ID NO:1 are exemplified by homologs of the PEA-3 nucleotide sequence (SEQ ID NO:2), which include, for example, GAGGATG (SEQ ID NO:39), CAGGAAG (SEQ ID NO:40), CAGGATG (SEQ ID NO:41), GTGGAAG (SEQ ID NO:62), GTGGATG (SEQ ID NO:63), CTGGAAG (SEQ ID NO:64), CTGGATG (SEQ ID NO:65), and CAGGAAG (SEQ ID NO:84).

The present invention also contemplates functioning or functional homologs of SEQ ID NO:1, of portions of SEQ ID NO:1 (*e.g.*, functional portions of SEQ ID NOs:2, and 33-38), of SEQ ID NO:3, and of portions of SEQ ID NO:3 (*e.g.*, functional portions of SEQ ID NOs:51-61).

A "functional homolog" of SEQ ID NO:1 is defined as a nucleotide sequence having more than 63% identity and less than 100% identity with SEQ ID NO:1, and which has age-related regulatory activity. Alternatively, a functional homolog of SEQ ID NO:1 is a nucleotide sequence having more than 63% identity and less than 100% identity with SEQ ID NO:1, and having liver-specific activity.

A "functional homolog" of SEQ ID NO:2 is defined as a nucleotide sequence having more than 75% identity and less than 100% identity with SEQ ID NO:2, and which has age-related regulatory activity. Alternatively, a functional homolog of SEQ ID NO:2 is a nucleotide sequence having more than 75% identity and less than 100% identity with SEQ ID NO:2, and having liver-specific activity.

A "functional homolog" of SEQ ID NO:3 is defined as a nucleotide sequence having less than 100% and more than 60% identity with SEQ ID NO:3, and which has age-related regulatory activity.

A "functional homolog" of SEQ ID NO:59 is defined as a nucleotide sequence having less than 100% and more than 62% identity with SEQ ID NO:59, and which has age-related regulatory activity.

A "functional homolog" of SEQ ID NO:60 is defined as a nucleotide sequence having less than 100% and more than 60% identity with SEQ ID NO:60, and which has age-related regulatory activity.

A "functional homolog" of SEQ ID NO:61 is defined as a nucleotide sequence having less than 100% and more than 60% identity with SEQ ID NO:61, and which has age-related regulatory activity.

The present invention is not limited to sense molecules of SEQ ID NOs:1 and 3 but contemplates within its scope antisense molecules comprising a nucleic acid sequence complementary to at least a portion (*e.g.*, a portion greater than 10 nucleotide bases in length and more preferably greater than 100 nucleotide bases in length) of the nucleotide sequence of SEQ ID NOs:1 and 3. These antisense molecules find use in, for example, reducing or

preventing expression of a gene (*e.g.* hFIX) whose expression is regulated by SEQ ID NOs:1 and 3.

The invention further provides the nucleotide sequence AE3'' which is a preferred portion of AE3'. AE3'' [5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; (SEQ ID NO:93)] is the 154-nucleotide nucleic acid sequence from 35,075 to 35,228 of GenBank accession number K02402, which corresponds to the sequence from 32,110 to 32,263 of Figure 8 when in relation to the hFIX start codon (ATG) in which the adenine is designated as position +30. AE3'' contains a 102-bp stem-loop forming sequence (SEQ ID NO:91).

Data presented herein demonstrates the universality of the regulatory function of portions of AE3' in that AE3'' has been successfully used to regulate expression of the heterologous hPC gene in an age-related manner. In particular, transgenic animals containing the -1462hPCm1 construct expressed age-stable levels of human protein C, *i.e.*, expressed relatively constant levels of human protein C at different time points during the life span of the transgenic animals (Example 12, Figure 17A). In direct contrast, the presence of AE5' and AE3'' sequences resulted in increased expression levels of human protein C over time (Figure 17C). These results confirm the universality of the function of the AE3'' portion of AE3' in regulating expression of operably linked genes in an age-related manner.

The invention also contemplates portions of AE3''. These portions include, but are not limited to, SEQ ID NOs:94-144 wherein SEQ ID NO:94 is 5'-tgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:95 is 5'-gggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:96 is 5'-ggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:97 is 5'-gg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:98 is 5'-g gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:99 is 5'-

gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:100 is 5'-aaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:101 is 5'-aaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:102 is 5'-aagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:103 is 5'-agtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:104 is 5'-gtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:105 is 5'-tttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:106 is 5'-ttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:107 is 5'-tc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:108 is 5'-c tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:109 is 5'-tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:110 is 5'-ttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:111 is 5'-tcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:112 is 5'-cagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:113 is 5'-agagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:114 is 5'-gagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:115 is 5'-agag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata

cacacatata atggaagcaa taagccat-3'; SEQ ID NO:116 is 5'-gag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:117 is 5'-ag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:118 is 5'-g ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:119 is 5'-ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:120 is 5'-taagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:121 is 5'-aagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:122 is 5'-agttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:123 is 5'-gttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:124 is 5'-ttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagccat-3'; SEQ ID NO:125 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagcca-3'; SEQ ID NO:126 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagcc-3'; SEQ ID NO:127 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taagc-3'; SEQ ID NO:128 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taag-3'; SEQ ID NO:129 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa taa-3'; SEQ ID NO:130 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa ta-3'; SEQ ID NO:131 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa t-3'; SEQ ID NO:132 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata

atggaagcaa -3'; SEQ ID NO:133 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagca-3'; SEQ ID NO:134 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagc-3'; SEQ ID NO:135 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaag-3'; SEQ ID NO:136 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaa-3'; SEQ ID NO:137 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atgga-3'; SEQ ID NO:138 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atgg-3'; SEQ ID NO:139 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atg-3'; SEQ ID NO:140 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata at-3'; SEQ ID NO:141 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata a-3'; SEQ ID NO:142 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata-3'; SEQ ID NO:143 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatat-3'; and SEQ ID NO:144 is 5'-ttgggg gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacata-3'.

In a particularly preferred embodiment, the portion of AE3' and of AE3'' is the 102-nucleotide nucleic acid stem-loop forming sequence 5'-tatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacata-3' (SEQ ID NO:91). The stem-loop sequence is located from nt 32,142 to 32,243 of Figure 8, which corresponds to the sequence from nt 35,107 to 35,208 of GenBank accession number K02402. It is the inventors' belief that the 102-nt stem-loop forming sequence exhibits the age-regulatory functions, described herein, of the AE3' and AE3'' sequences.

The nucleotide sequence of SEQ ID NOs:1 and 3, portions, homologs and antisense sequences thereof may be synthesized by synthetic chemistry techniques which are commercially available and well known in the art [see Caruthers MH *et al.*, (1980) Nuc. Acids Res. Symp. Ser. 215-223; Horn T. *et al.*, (1980) Nuc. Acids Res. Symp. Ser. 225-232]. Additionally, fragments of SEQ ID NOs:1 and 3 can be made by treatment of SEQ ID NOs:1 and 3 with restriction enzymes followed by purification of the fragments by gel electrophoresis. Alternatively, sequences may also be produced using the polymerase chain reaction (PCR) as described by Mullis [U.S. Patent Nos. 4,683,195, 4,683,202 and 4,965,188, all of which are hereby incorporated by reference]. SEQ ID NOs:1 and 3, portions, homologs and antisense sequences thereof may be ligated to each other or to heterologous nucleic acid sequences using methods well known in the art.

The nucleotide sequence of synthesized sequences may be confirmed using commercially available kits as well as using methods well known in the art which utilize enzymes such as the Klenow fragment of DNA polymerase I, Sequenase®, *Taq* DNA polymerase, or thermostable T7 polymerase. Capillary electrophoresis may also be used to analyze the size and confirm the nucleotide sequence of the products of nucleic acid synthesis, restriction enzyme digestion or PCR amplification.

It is readily appreciated by those in the art that the sequences of the present invention may be used in a variety of ways. For example, the nucleic acid sequences of the invention and portions thereof can be used as probes for the detection and isolation of functional homologs of AE5' and AE3', amplification of homologous nucleotide sequences, age-related and/or liver-specific expression of a nucleotide sequence of interest in an animal, gene therapy, and reducing factor IX levels in an animal.

ii. Regulatory Nucleic Acid Sequences From The hPC Gene

The invention provides regulatory nucleic acid sequences which are derived from the hPC gene. The presence of these sequences and their surprising properties was fortuitously discovered by the inventors during their investigation of the universality of the function of regulatory sequences from the hFIX gene. In particular, when using what they believed would be "control" constructs which contained different portions of the sequence upstream of nt +1 in the hPC gene, the inventors discovered that whereas transgenic animals containing the -1462hPCm1 construct exhibited relatively constant and relatively high levels (from

about 100 to about 3000 ng/ml) of human protein C over time (Figure 17A), in dramatic contrast, transgenic animals containing the -82hPCm1 construct exhibited relatively low levels (from about 5 to about 40 ng/ml at 1 month of age) (Figure 17B) of human protein C which declined at a precipitous rate over time (Example 12). Indeed, by the age of 5 months, human protein C levels were undetectable in all transgenic animals harboring the -82hPCm1 construct. These results demonstrated to the inventors that the nucleotide sequence from nt -1462 to nt -83 of the human protein C gene exhibits age-related regulatory activity (as evidenced by age-stable expression over time) and regulatory activity (as evidenced by the relatively higher levels of expression as compared to the levels in the absence of the nucleotide sequence from nt -1462 to nt -83) of operably linked sequences of interest.

The term "regulatory activity" when made herein in reference to a nucleic acid sequence refers to the ability of the nucleic acid sequence to alter the level of transcription into mRNA and/or the synthesis of a polypeptide encoded by a nucleotide sequence of interest which is operably linked to a promoter sequence, as compared to the level of transcription into mRNA and/or synthesis of the polypeptide encoded by the nucleotide sequence of interest which is operably linked to the promoter sequence in the absence of the nucleic acid sequence which has regulatory activity. In contrast to "age-related regulatory activity," the term "regulatory activity" relates to alteration in the level of transcription or protein synthesis at a single time point (rather than over a period of time) in the life cycle of a cell, tissue, or organism. In a preferred embodiment, the level of transcription into mRNA and/or synthesis of polypeptide is increased from 2-fold to at least 10,000-fold, preferably from 2-fold to 10,000 fold, more preferably from 2-fold to 1,000-fold, and most preferably, from 2-fold to 500-fold, when compared to the level of transcription into mRNA and/or synthesis of the polypeptide encoded by the nucleotide sequence of interest which is operably linked to the promoter sequence in the absence of the nucleic acid sequence which has regulatory activity. Data presented herein demonstrates that the inclusion of the human protein C (hPC) nucleotide sequence from nt -1462 to nt -83 resulted in expression of from about 100 to about 3000 ng/ml of human protein C (Figure 17A) as compared to expression of from about 5 to about 40 ng/ml of human protein C (Figure 17B) in transgenic mice at one-month of age. The increased level of expression was even more dramatic when the transgenic animals were 5 months-old; while the levels of hPC were undetectable in the

absence of the sequence from nt -1462 to nt -83, they were from about 100 to about 3000 ng/ml in the presence of this sequence.

In one embodiment, the invention provides the nucleic acid sequence (SEQ ID NO:85) from -1462 to +1 of the hPC gene (Figure 14; 5'-GAATTCTGTA AGCATTTCCT ATGTGTACCT GCCCCTGGGC AAGGTGGGCC TGACTTGTTA GAGTGTTAGA GTTTTACCCT GTTCCTCTAG GAGGGCCTGG TACCACCACA GCCCAGCATG GTGTGGTGCC TCAGCAGGAG GCATCTGGTT ACAATCAACA CAAGCTGTTC CAGCCAATTT AAAGAAACTT CAGGAGGAAT AGGGTTTTAG GAGGGCATGG GGACCCTCCT GCACCCGAAG CCAGGATGTG CCACCAATCA TAAGGAGGCA GGGGCCTCCT TCCGCTGCTC CCTGGGACTC TCTAGGTGTC CGTGGCCTCA GCCCCCCTCT GCACACCTGC ATCTTCCTTC TCATCAGCTT CCTCTGCTTT AAGCGTAAAC ATGGATGCCC AGGACCTGGC CTCAATCTTC CGAGTCTGGT ACTTATGGTG TACTGACAGT GTGAGACCCT ACTCCTCTGA TCAATCCCCT GGGTTGGTGA CTTCCCTGTG CAATCAATGG AAGCCAGCGA GGCAGGGTCA CATGCCCCGT TTAGAGGTGC AGACTTGGAG AAGGAACGTG GGCAAGTCTT CCCAGGAACA GGTAGGGCAG GGAGGAAAGG GGGGCATCTC TGGTGCAGCC CGGTTCGGAG CAGGAAGACG CTTAATAAAT GCTGATAGAC TGCAGGACAC AGGCAAAGGT GCTGAGCTGG ACCCTTTATT TCTGCCCTTC TCCCTTCTGG CACCCCGGCC AGGAAATTGC TGCAGCCTTT CTGGAATCCC GTTCATTTTT CTTACTGGTC CACAAAAGGG GCCAAATGGA AGCAGCAAGA CCTGAGTTCA AATTAAATCT GCCAACTACC AGCTCAGTGA ATCTGGGCGA GTAACACAAA ACTTGAGTGT CCTTACCTGA AAAATAGAGG TTAGAGGGAT GCTATGTGCC ATTGTGTGTG TGTGTTGGGG GTGGGGATTG GGGGTGATTT GTGAGCAATT GGAGGTGAGG GTGGAGCCCA GTGCCCAGCA CCTATGCACT GGGGACCCAA AAAGGAGCAT CTTCTCATGA TTTTATGTAT CAGAAATTGG GATGGCATGT CATTGGGACA GCGTCTTTTT TCTTGTATGG TGGCACATAA ATACATGTGT CTTATAATTA ATGGTATTTT AGATTTGACG AAATATGGAA TATTACCTGT TGTGCTGATC TTGGGCAAAC TATAATATCT CTGGGCAAAA ATGTCCCCAT CTGAAAAACA GGGACAACGT TCCTCCCTCA GCCAGCCACT ATGGGGCTAA AATGAGACCA CATCTGTCAA GGGTTTTGCC CTCACCTCCC TCCCTGCTGG ATGGCATCCT TGGTAGGCAG AGGTGGGCTT CGGGCAGAAC AAGCCGTGCT GAGCTAGGAC CAGGAGTGCT AGTGCCACTG TTTGTCTATG GAGAGGGAGG

CCTCAGTGCT GAGGGCCAAG CAAATATTTG TGGTTATGGA TTA-3'). This sequence was successfully used to express hPC in transgenic mice in an age-related manner (*i.e.*, at relatively constant levels over time; Figure 17A), and at relatively high levels (*e.g.*, as compared to expression levels in the presence of sequences from nt -1462 to nt -82; Figure 17B).

The invention also provides the nucleotide sequence (SEQ ID NO:92) from -1462 to -83 of the hPC gene (Figure 14). The finding that SEQ ID NO:92 exhibited age-related regulatory activity and regulatory activity as discussed in Example 11, *infra*, was surprising because it was contrary to the results which had previously been reported by Miao et al. [Miao et al. (1996) J. Biol. Chem. 16:9587-9594] when using a heterologous reporter gene, chloramphenicol acetyltranferase (CAT), under the transcriptional control of varying lengths of the protein C 5'-end sequences. In particular, Miao et al. found that construct pPC-1528 which contained nucleotides -1462 to +1 resulted in substantially reduced CAT *in vitro* activity as compared to construct pPC-82-66 which contained nucleotides -82 to +1. From this, Miao et al: concluded that there is an element with silencer activity in the region between -1462 and -82. In contrast, data presented herein demonstrates that nucleotides -1462 to +1 and -82 to +1 resulted in similar *in vitro* activities of hPC (Example 11, Figure 16). Indeed, the inventors' data disclosed in relation to hPC's age-related regulatory sequences which are upstream of the hPC coding sequences when used to regulate expression of hPC is consistent with the inventor's observation (Figure 1) in relation to hFIX's age-related regulatory AE5' sequences when used to regulate expression of hFIX. In particular, the inventors have observed that hFIX's AE3' and AE3'' sequences resulted in moderate suppression in *in vitro* transient expression assays when using hFIX and hPC, respectively (Figures 1 and 16).

Further contemplated to be within the scope of this invention are portions of the SEQ ID NOS:85 and 92. In a particularly preferred embodiment, these portions contain one or both of the first PEA-3 element (SEQ ID NO:89) [7-bp long; 5'-GAGGAAA-3', from -871 to -865 of the hPC gene of Figure 14] and the second PEA-3 element (SEQ ID NO:90) [7-bp long; 5'-CAGGAAG-3', from -832 to -826 of the hPC gene of Figure 14].

Exemplary portions of SEQ ID NOs:85 and 92 which contain both the first and second PEA-3 elements include, but are not limited to, the nucleotide sequence (SEQ ID NO:88) from -1462 to -802 of the hPC gene, which is embodied in plasmid -849hPCm1

(Figure 15, Example 10). Further examples include the nucleotide sequence (SEQ ID NO:145) from -1462 to -804, (SEQ ID NO:146) from -1462 to -805, (SEQ ID NO:147) from -1462 to -806, (SEQ ID NO:148) from -1462 to -807, (SEQ ID NO:149) from -1462 to -808, (SEQ ID NO:150) from -1462 to -809, (SEQ ID NO:151) from -1462 to -810, (SEQ ID NO:152) from -1462 to -811, (SEQ ID NO:153) from -1462 to -812, (SEQ ID NO:154) from -1462 to -813, (SEQ ID NO:155) from -1462 to -814, (SEQ ID NO:156) from -1462 to -815, (SEQ ID NO:157) from -1462 to -816, (SEQ ID NO:158) from -1462 to -817, (SEQ ID NO:159) from -1462 to -818, (SEQ ID NO:160) from -1462 to -819, (SEQ ID NO:161) from -1462 to -820, (SEQ ID NO:162) from -1462 to -821, (SEQ ID NO:163) from -1462 to -822, (SEQ ID NO:164) from -1462 to -823, (SEQ ID NO:165) from -1462 to -824, (SEQ ID NO:166) from -1462 to -825, (SEQ ID NO:167) from -1462 to -826, (SEQ ID NO:168) from -1452 to -803, (SEQ ID NO:169) from -1442 to -803, (SEQ ID NO:170) from -1412 to -803, (SEQ ID NO:171) from -1102 to -803, (SEQ ID NO:172) from -902 to -803, and (SEQ ID NO:173) from -873 to -803.

Portions of SEQ ID NOs:85 and 92 which contain only the first PEA-3 element include the nucleotide sequence (SEQ ID NO:87) from -1462 to -849 of the hPC gene, which is embodied in plasmid -802hPCm1 (Figure 15, Example 10). Additional exemplary portions include, but are not limited to the nucleotide sequence (SEQ ID NO:174) from -1462 to -850, (SEQ ID NO:175) from -1462 to -851, (SEQ ID NO:176) from -1462 to -852, (SEQ ID NO:177) from -1462 to -853, (SEQ ID NO:178) from -1462 to -854, (SEQ ID NO:179) from -1462 to -855, (SEQ ID NO:180) from -1462 to -856, (SEQ ID NO:181) from -1462 to -857, (SEQ ID NO:182) from -1462 to -858, (SEQ ID NO:183) from -1462 to -859, (SEQ ID NO:184) from -1462 to -860, (SEQ ID NO:185) from -1462 to -861, (SEQ ID NO:186) from -1462 to -862, (SEQ ID NO:187) from -1462 to -863, (SEQ ID NO:188) from -1462 to -864, (SEQ ID NO:189) from -1462 to -865, (SEQ ID NO:190) from -1362 to -865, (SEQ ID NO:191) from -1262 to -865, (SEQ ID NO:192) from -1162 to -865, (SEQ ID NO:193) from -1062 to -865, (SEQ ID NO:194) from -962 to -865, and (SEQ ID NO:195) from -872 to -865.

Examples of portions of SEQ ID NOs:85 and 92 which contain only the second PEA-3 element include, but are not limited to, the nucleotide sequence (SEQ ID NO:196) from -863 to -83, (SEQ ID NO:197) from -853 to -83, (SEQ ID NO:198) from -843 to -83, (SEQ ID NO:199) from -833 to -83, (SEQ ID NO:200) from -832 to -83, (SEQ ID NO:201) from

-863 to -183, (SEQ ID NO:202) from -863 to -283, (SEQ ID NO:203) from -863 to -383, (SEQ ID NO:204) from -863 to -483, (SEQ ID NO:205) from -863 to -583, (SEQ ID NO:206) from -863 to -683, (SEQ ID NO:207) from -863 to -783, and (SEQ ID NO:208) from -863 to -826.

In a particularly preferred embodiment, the portion of SEQ ID NOs:85 and 92 is selected from the first PEA-3 element (SEQ ID NO:89) and the second PEA-3 element (SEQ ID NO:90). It is the inventor's view that the first and/or second PEA-3 elements within SEQ ID NOs:85 and 92 are responsible for the observed age-related regulatory activity and regulatory activity of SEQ ID NOs:85 and 92.

B. Using Probes To Identify And Isolate Homologs Of AE5', AE3', and Of hPC-Derived Regulatory Sequences

The invention provided herein is not limited to SEQ ID NO:1, 3, 85 and 92, homologs and portions thereof having age-related regulatory activity, but includes sequences having no age-related regulatory activity (*i.e.*, non-functional homologs and non-functional portions of homologs). The use of such sequences may be desirable, for example, where a portion of SEQ ID NOs:1, 3, 85, and 92 is used as a probe to detect the presence of SEQ ID NOs:1, 3, 85 and 92, respectively, or of portions thereof in a sample.

As used herein, the term "probe" refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is capable of hybridizing to a nucleotide sequence of interest. A probe may be single-stranded or double-stranded. It is contemplated that any probe used in the present invention will be labelled with any "reporter molecule," so that it is detectable in any detection system including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, calorimetric, gravimetric, magnetic, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.

The probes provided herein are useful in the detection, identification and isolation of, for example, sequences such as those listed as SEQ ID NOs:1, 3, 85 and 92 as well as of homologs thereof. Preferred probes are of sufficient length (*e.g.*, from about 9 nucleotides to about 20 nucleotides or more in length) such that high stringency hybridization may be

employed. In one embodiment, probes from 20 to 50 nucleotide bases in length are employed.

C. Using Primers to Amplify At Least A Portion Of AE5', AE3', and Of hPC-Derived Regulatory Sequences

The invention provided herein is not limited to SEQ ID NOs:1 and 3, homologs and portions thereof having age-related regulatory activity, but includes sequences having no age-related regulatory activity. This may be desirable, for example, where a portion of the nucleic acid sequences set forth as SEQ ID NOs:1 and 3 is used as a primer for the amplification of nucleic acid sequences by, for example, polymerase chain reactions (PCR) or reverse transcription-polymerase chain reactions (RT-PCR). The term "amplification" is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction technologies well known in the art [Dieffenbach CW and GS Dveksler (1995) *PCR Primer, a Laboratory Manual*, Cold Spring Harbor Press, Plainview NY]. As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis disclosed in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,965,188, all of which are hereby incorporated by reference, which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the "polymerase chain reaction" (hereinafter

"PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are the to be "PCR amplified."

With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; and/or incorporation of ^{32}P-labeled deoxyribonucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any nucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications. Amplified target sequences may be used to obtain segments of DNA (*e.g.*, genes) for the construction of targeting vectors, transgenes, *etc.*

As used herein, the term "primer" refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (*i.e.*, in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long (*e.g.*, from about 9 nucleotides to about 20 nucleotides or more in length) to prime the synthesis of extension products in the presence of the inducing agent. Suitable lengths of the primers may be empirically determined and depend on factors such as temperature, source of primer and the use of the method. In one embodiment, the present invention employs primers from 20 to 50 nucleotide bases in length.

The primers contemplated by the invention are useful in, for example, identifying sequences which are homologous to AE5', AE3', and regulatory sequences derived from hPC, in mammals, yeast, bacteria, and in other organisms.

D. Methods For Regulating Gene Expression

The present invention provides methods for regulating expression of a nucleotide sequence of interest over a period of time in a cell or multicellular organism. Specifically, gene expression is preferably regulated in a multicellular organism. In one embodiment, expression of a nucleotide sequence of interest is stabilized such that the level of mRNA and/or protein encoded by the nucleotide sequence of interest remains relatively unchanged at different times during the life of the organism. In an alternative embodiment, expression of a nucleotide sequence of interest is increased. Increased expression means that the level of mRNA and/or protein encoded by the nucleotide sequence of interest at a given time point is greater than the level of mRNA and/or protein, respectively, at an earlier time point during the life of the organism or cell. Alternatively, increased expression means that the level of mRNA and/or protein encoded by the nucleotide sequence of interest is greater than the level of mRNA and/or protein, respectively, at the same time point in the life of the organism or cell as compared to the level of mRNA and/or protein when expressed in the absence of the sequences of the invention.

In one embodiment, regulating expression of a nucleotide sequence of interest over a period of time is accomplished by introducing into a host cell a vector that contains a nucleotide sequence of interest operably linked to a promoter sequence and to sequences provided herein which have age-related regulatory activity. The transfected host cell is allowed to develop into a transgenic animal in which the nucleotide sequence of interest is expressed in at least one tissue. These steps are further described below for specific embodiments.

1. Expression Constructs

In one embodiment of the methods of the invention for regulating expression of a nucleotide sequence of interest in an age-related manner and/or to liver tissue, a vector is constructed in which the nucleic acid sequences of the invention (*e.g.*, AE5' alone, AE3' alone, or a combination of AE5' and AE3') are operably linked to a promoter sequence and to a nucleotide sequence of interest. In one embodiment, the nucleotide sequence of interest is the coding region of the hFIX gene (Example 1). In another embodiment the nucleotide sequence of interest is the coding region of the protein C gene (Example 7).

The invention is not limited to coding sequences of the hFIX gene or protein C gene. Rather, any nucleotide acid sequence whose expression is desired to be regulated by sequences provided herein are contemplated to be within the scope of this invention. Such nucleotide sequences include, but are not limited to, coding sequences of structural genes which encode a protein [*e.g.*, reporter genes, selection marker genes, oncogenes, drug resistance genes, growth factor genes, activator protein 1 gene, activator protein 2 gene, Sp1 gene, *etc.*]. In one preferred embodiment, the structural gene is the human α1-antitrypsin gene (Figure 10) (SEQ ID NO:42) which encodes a plasma proteinase inhibitor used for treating emphysema. In another preferred embodiment, the structural gene is one encoding the human antithrombin III (Figure 11) (SEQ ID NO:43) which is a plasma proteinase inhibitor for activated blood coagulation factors and whose activity is increased by heparin. In yet another preferred embodiment, the structural gene is the gene encoding the PEA-3 protein (Figure 9) (SEQ ID NO:47) and/or its related protein, which has been shown to bind specifically to homologs of the PEA-3 nucleotide sequence (SEQ ID NO:2) disclosed herein.

The invention is not limited to using a single nucleotide sequence of interest in operable combination with the sequences of the invention. Rather, a plurality (*i.e.*, more than one) of nucleotide sequences of interest may be ligated in tandem such that their expression is regulated by the regulatory sequences of the invention. A plurality of coding sequences may be desirable, for example, where it is useful to express a transcription product of more than one gene to permit interaction of these transcriptional products. Alternatively, a plurality of coding sequences may be desirable where one of the gene sequences is a reporter gene sequence. For example, it may be advantageous to place a coding sequence of a reporter gene in tandem with the coding sequence of a gene of interest such that expression of the coding region of both the reporter gene and the gene of interest is regulated by the sequences of the invention. Expression of the reporter gene usually correlates with expression of the gene of interest. Examples of reporter gene sequences include the sequences encoding the enzymes β-galactosidase and luciferase. Fusion genes may also be desirable to facilitate purification of the expressed protein. For example, the heterologous sequence which encodes protein A allows purification of the fusion protein on immobilized immunoglobulin. Other affinity traps are well known in the art and can be utilized to advantage in purifying the expressed fusion protein. For example, pGEX vectors (Promega, Madison WI) may be used to express the polypeptides of interest as a fusion protein with

glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Other fusion polypeptides useful in the purification of proteins of interest are commercially available, including histidine tails (which bind to Ni^{2+}), biotin (which binds to streptavidin), and maltose-binding protein (MBP) (which binds to amylose). Proteins made in such systems may be designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released at will from the heterologous polypeptide moiety to which it is fused.

One of skill in the art would understand that where a plurality of nucleotide sequences of interest is operably linked to sequences of the present invention, the nucleotide sequences of interest may be either contiguous or separated by intervening polynucleotide sequences, so long as the nucleic acid sequences of interest are operably linked to the promoter sequence, and so long as the sequences of the invention are operably linked to the promoter sequence.

While specific preferred embodiments used herein disclose the use of the hFIX promoter and the CMV promoter, it is not intended that the invention be limited to the type or source of the promoter sequence which is operably linked to the sequences of the invention. Any promoter whose activity is desired to be regulated by the sequences provided herein is contemplated to be within the scope of the invention. Exemplary promoters include the tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter (can be isolated from vector plasmid pRc/RSV from Invitrogen), retrovirus LTR promoter (can be isolated from vector plasmid pLXSN from Clontech) SV40 promoter (located between positions +3530 to +3192 in vector plasmid pCR3 from Invitrogen), PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter having the 23-bp sequence (SEQ ID NO:44) 5'-TAATACGACTCACTATAGGGCGA-3', T_3 promoter having the 24-bp sequence (SEQ ID NO:45) 5'-TTATTAACCCTCACTAAAGGGAAG -3', SP6 promoter having the 23-bp sequence (SEQ ID NO:46) 5'-ATTTAGGTGACACTATAGAATAC -3', and K11 promoter. The T_7 promoter, T_3 promoter, SP6 promoter and K11 promoter have been described in U.S Patent No. 5,591,601, the entire contents of which are incorporated by reference.

Nor is the invention intended to be limited to the use of a single promoter. For example, chimeric promoters (*i.e.*, two or more promoters which are derived from at least

one gene) are expressly contemplated to be within the scope of the invention. Such chimeric promoters may be desirable where, for example, chimeric promoters result in increased levels of expression of an operably linked downstream coding sequence. Chimeric promoters are known in the art and include, for example, the double *Tet* promoter [Kistner et al. (1996) Proc. Natl. Acad. Sci. USA 93:10933-10938], and the U1 snRNA promoter-CMV promoter/enhancer [Bartlett et al. (1996) Proc. Natl. Acad. Sci. USA 93:8852-8857].

Expression vectors in which expression of a nucleic acid sequence of interest is regulated by sequences of the invention may be constructed using the teachings of the present invention in conjunction with techniques well known in the art. [Sambrook *et al.* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview NY; Ausubel *et al.* (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York NY]. Briefly, the nucleic acid sequence of interest is placed in operable combination with a promoter sequence and sequences of the invention in the presence of transcription and translation regulatory sequences, including initiation signals such as a start codon (*i.e.*, ATG), enhancers, and transcription termination signals. The ATG initiation codon must be in the correct reading frame to ensure translation of the entire heterologous nucleotide sequence. Transcription termination signals are placed downstream of the heterologous nucleic acid sequence and include polyadenylation sequences which are exemplified by, but not limited to, SV40 poly-A sequence, hINV poly-A sequence, or bovine growth hormone poly-A sequence, *etc.*

Other regulatory sequences which may affect RNA stability as well as enhancers (*i.e.*, a sequence which when activated results in an increase in the basal rate of transcription of a gene) and silencers (*i.e.*, a sequence involved in reducing expression of a gene) may also be included. These regulatory sequences may be relatively position-insensitive, *i.e.*, the regulatory element will function correctly even if positioned differently in relation to the heterologous nucleotide sequence in the construct as compared to its position in relation to the corresponding heterologous nucleotide sequence in the genome. For example, an enhancer may be located at different distances from the promoter sequence, in a different orientation, and/or in a different linear order. Thus, an enhancer that is located 3' to a promoter sequence in germline configuration might be located 5' to the promoter sequence in the construct.

2. Host Cells

Host cells are transformed with expression vectors which contain the sequences of the invention in operable combination with a nucleic acid sequence of interest using methods known in the art. The term "transformation" as used herein refers to the introduction of a transgene into a cell. The term "transgene" as used herein refers to any nucleic acid sequence which is introduced into the genome of a cell by experimental manipulations.

The term "transgene" as used herein refers to any nucleic acid sequence which is introduced into the genome of a cell by experimental manipulations. A transgene may be an "endogenous DNA sequence," or a "heterologous DNA sequence." The term "endogenous DNA sequence" refers to a nucleotide sequence which is naturally found in the cell into which it is introduced so long as it does not contain some modification (*e.g.*, a point mutation, the presence of a selectable marker gene, *etc.*) relative to the naturally-occurring sequence. The terms "heterologous DNA sequence" and "foreign DNA sequence" refer to a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Heterologous DNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell. Heterologous DNA also includes an endogenous DNA sequence which contains some modification (*e.g.*, a point mutation, the presence of a selectable marker gene, *etc.*) relative to the naturally-occurring gene. Generally, although not necessarily, heterologous DNA encodes RNA and proteins that are not normally produced by the cell into which it is expressed. Examples of heterologous DNA include reporter genes, transcriptional and translational regulatory sequences, selectable marker proteins (*e.g.*, proteins which confer drug resistance), *etc.*

Transformation may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, biolistics (*i.e.*, particle bombardment) and the like.

Transformation of a cell may be stable or transient. The term "transient transformation" or "transiently transformed" refers to the introduction of one or more transgenes into a cell in the absence of integration of the transgene into the host cell's genome. Transient transformation may be detected by, for example, enzyme-linked immunosorbent assay (ELISA) which detects the presence of a polypeptide encoded by one

or more of the transgenes. Alternatively, transient transformation may be detected by detecting the activity of the protein encoded by the transgene. For example, the activity of β-glucuronidase (GUS) which is encoded by the *uid A* gene may be detected using either a histochemical assay of GUS enzyme activity by staining with X-gluc which gives a blue precipitate in the presence of the GUS enzyme, or a chemiluminescent assay using the GUS-Light kit (Tropix). The term "transient transformant" refers to a cell which has transiently incorporated one or more transgenes. In contrast, the term "stable transformation" or "stably transformed" refers to the introduction and integration of one or more transgenes into the genome of a cell. Stable transformation of a cell may be detected by Southern blot hybridization of genomic DNA of the cell with nucleic acid sequences which are capable of binding to one or more of the transgenes. Alternatively, stable transformation of a cell may also be detected by the polymerase chain reaction (PCR) of genomic DNA of the cell to amplify transgene sequences. The term "stable transformant" refers to a cell which has stably integrated one or more transgenes into the genomic DNA. Thus, a stable transformant is distinguished from a transient transformant in that, whereas genomic DNA from the stable transformant contains one or more transgenes, genomic DNA from the transient transformant does not contain a transgene.

Suitable host cells include bacterial, yeast, plant, insect, and mammalian cells. In one embodiment the host cell is mammalian. In a preferred embodiment, the mammalian host cell is a mouse fertilized egg cell. In an alternative embodiment, the mammalian host cell is a HepG2 cell (ATCC number HB8065), a fibroblast cell (*e.g.*, ATCC number CCL 110), a myoblast cell (*e.g.*, Clonetics, catalog # SkMC), and an endothelial cell (*e.g.*, human umbilical cord endothelial cells; ATCC number CRL 1730).

In one embodiment, the host cell is transformed both with an expression vector which contains the sequences of the invention in operable combination with the nucleic acid sequences of interest, as well as with an expression vector which expresses the PEA-3 protein (Example 6). Such co-transformation may be desirable, for example, where expression of the nucleotide sequence of interest is regulated by AE5' or portions or homologs thereof which contain homologs of the PEA-3 nucleotide sequence to which the PEA-3 protein binds. In one embodiment, expression of the PEA-3 protein is under the control of the LTR promoter of the Moloney murine leukemia virus (MoLV) which is capable of driving expression of operably linked genes in several cell types. Transient

expression assays are suitable for determining the relative promoter activities in expressing desirable PEA-3 protein levels.

Any number of selection systems may be used to recover transfected cells. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M *et al.* (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy I *et al.* (1980) Cell 22:817-23) genes which can be employed in tk$^-$ or aprt$^-$ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate [Wigler M *et al.*, (1980) Proc Natl Acad Sci 77:3567-70]; *npt*, which confers resistance to the aminoglycosides neomycin and G-418 [Colbere-Garapin F *et al.*, (1981) J. Mol. Biol. 150:1-14] and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine [Hartman SC and RC Mulligan (1988) Proc Natl Acad Sci 85:8047-51]. Recently, the use of a reporter gene system which expresses visible markers has gained popularity with such markers as β-glucuronidase and its substrate (GUS), luciferase and its substrate (luciferin), and β-galactosidase and its substrate (X-Gal) being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system [Rhodes CA *et al.* (1995) Methods Mol Biol 55:121-131].

The presence or expression of the reporter gene usually indicates the presence or expression, respectively, of the tandem heterologous nucleic acid sequence as well. However, it is preferred that the presence and expression of the desired heterologous nucleic acid sequence be confirmed. This is accomplished by procedures known in the art which include DNA-DNA or DNA-RNA hybridization or amplification using probes, or fragments of the heterologous nucleic acid sequence. For example, Fluorescent In Situ Hybridization (FISH) can be used to detect the heterologous nucleic acid sequence in cells. Several guides to FISH techniques are available, *e.g.*, Gall *et al.* Meth. Enzymol. 21:470-480 (1981); Angerer *et al.*, in "Genetic Engineering: Principles and Methods," Setlow & Hollaender, Eds. Vol. 7 pp. 43-65, Plenum Press, New York (1985). Alternatively, DNA or RNA can be isolated from cells for detection of the transgene by Southern or Northern hybridization or by amplification based assays. Nucleic acid amplification based assays involve the use of

oligonucleotides or oligomers based on the nucleotide sequence of interest in order to detect cells and tissues which contain the DNA or RNA encoding the transgene of interest. As used herein, the terms "oligonucleotides" and "oligomers" refer to a nucleic acid sequence of at least about five (5) contiguous nucleotide residues and as many as about sixty (60) nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplimer. Standard PCR methods useful in the present invention are described by Innis *et al.* (Eds.), "PCR Protocols: A Guide to Methods and Applications," Academic Press, San Diego (1990).

Yet another alternative for the detection of heterologous nucleic acid sequences includes detecting the polypeptide product of transcription of the heterologous nucleotide sequence. A variety of protocols which employ polyclonal or monoclonal antibodies specific for the protein product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A competitive binding assay may also be used. Alternatively, a two-site, monoclonal-based immunoassay which utilizes monoclonal antibodies that are reactive to two non-interfering epitopes on the protein of interest may be employed. These and other assays are described in, among other places, Hampton R *et al.* (1990), *Serological Methods a Laboratory Manual*, APS Press, St Paul MN), and Maddox DE *et al.* (1983), J. Exp. Med. 158:1211.

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the nucleotide sequence of interest, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides. A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like.

Host cells transformed with expression vectors containing the sequences provided herein are useful for age-related expression of recombinant proteins of interest. Host cells transformed with expression vectors containing the invention's sequences may be part of a tissue or organ of a living animal. A "living animal" as used herein refers to any multicellular animal (*e.g.*, humans, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.) into whose cells the sequences provided herein may be introduced. Where the host cells (*e.g.*, fertilized egg cells) are capable of generating a multicellular organism, these cells when transformed with expression vectors containing the sequences of the invention are useful in generating transgenic animals which exhibit age-related and/or liver-specific expression of nucleotide sequences of interest.

3. Transgenic Animals

The present invention provides transgenic non-human animals which express a nucleotide sequence of interest in an age-related manner. These animals provide useful models for diseases (*e.g.*, thrombosis, cardiovascular diseases, diabetes, Alzheimer's disease, cancer, osteoporosis, osteoarthritis, Parkinson's disease, dementia) which are associated with increasing age, as well a for screening candidate therapeutic agents against such diseases. These transgenic animals are also useful in studies of normal phenomena, such as ageing, gene regulation, *etc.* In one embodiment, the invention discloses transgenic mice which express in an age-related manner the exemplary hFIX coding sequence under the control of AE5' and/or AE3' (Example 3).

The term "age-related manner" when made in reference to the expression of a nucleotide sequence of interest is a relative term which refers to an increase over a period of time in the quantity of mRNA and/or protein encoded by the nucleotide sequence of interest when the nucleotide sequence of interest is operably linked to a promoter and to a nucleic acid sequence which has age-related regulatory activity, as compared to the quantity of mRNA and/or protein, respectively, encoded by the nucleotide sequence of interest when the nucleotide sequence of interest is operably linked to the promoter in the absence of the nucleic acid sequence which has age-related regulatory activity. Thus, the term "age-related" when made in reference to expression of a nucleotide sequence of interest by a transgenic

animal means that the transgenic animal expresses the nucleotide sequence of interest in an age-related manner.

For example, in one embodiment, the invention demonstrates that hFIX is expressed in an age-related manner in transgenic mice which harbor a transgene (-416FIXm1/1.4) (Figure 2B) which contains hFIX under the control of the hFIX promoter and the regulatory control of AE3' as compared to expression of hFIX in transgenic mice which harbor a transgene (-416FIXm1) (Figure 2A) in which hFIX is under the control of the hFIX promoter in the absence of AE3'. While transgenic mice harboring the -416FIXm1/1.4 construct showed decreasing hFIX activity levels over a period of time (*e.g.*, from 1 to 9 months of age), this decrease was less than the decrease in hFIX activity levels which was observed in transgenic mice harboring the -416FIXm1 construct over the same period of time.

In another embodiment, the invention discloses that hFIX is expressed in an age-related manner in transgenic mice which harbor transgenes (-802FIXm1, -2231FIXm1, and -416FIXm1/AE5') (Figures 4A, C and E) each of which contains hFIX under the control of the hFIX promoter and the regulatory control of AE5' as compared to expression of hFIX in transgenic mice which harbor a transgenes (-416FIXm1 and -770FIXm1) (Figures 2A and E) in which hFIX is under the control of the hFIX promoter in the absence of AE5'. Transgenic mice harboring each of the -802FIXm1, -2231FIXm1, and -416FIXm1/AE5' constructs showed relatively unchanged hFIX activity levels over a period of time (*e.g.*, from 1 to 7 months of age) while transgenic mice harboring either the -416FIXm1 or -770FIXm1 construct showed decreasing hFIX activity levels over the same time period.

In an additional embodiment, the invention shows that hFIX is expressed in an age-related manner in transgenic mice which harbor transgenes (-802FIXm1/1.4 and -2231FIXm1/1.4) (Figures 4B and D) each of which contains hFIX under the control of the hFIX promoter and the regulatory control of both AE3' and AE5' as compared to expression of hFIX in transgenic mice which harbor a transgene (-770FIXm1) (Figure 2E) in which hFIX is under the control of the hFIX promoter in the absence of both AE3' and AE5'. Transgenic mice harboring either the -802FIXm1/1.4 or the -2231FIXm1/1.4 construct showed increasing levels of hFIX activity over a period of time (*e.g.*, 1 to 3 months of age) as compared to decreasing hFIX activity levels over the same period of time in transgenic mice harboring the -770FIXm1 construct.

The present invention also provides transgenic non-human animals which express a nucleotide sequence of interest in a liver-specific manner. These animals are useful for targeting expression of a nucleotide sequence of interest to the liver. Examples of nucleotide sequences of interest are those which encode blood coagulation factors (*e.g.*, factor VIII, factor VII, factor X and prothrombin) whose deficiency is known to play a role in abnormal bleeding disorders. Other examples of nucleotide sequences of interest include those which encode blood coagulation regulators and/or inhibitors (*e.g.*, protein C, antithrombin III, and tissue factor pathway inhibitor [TFPI]) whose deficiency results in thrombosis, α1-antitrypsin whose deficiency results in emhysima, and LDL-receptor whose deficiency results in hypercholestrolemia.

Yet other examples of a nucleotide sequence of interest include those encoding enzymes involved in specific metabolic defects (*e.g.*, urea cycle enzymes, especially ornithine transcarbamylase, argininosuccinate synthase, and carbamyl phosphate synthase); receptors (*e.g.*, LDL receptor); toxins; thymidine kinase to ablate specific cells or tissues; ion channels (*e.g.*, chloride channel of cystic fibrosis); membrane transporters (*e.g.*, glucose transporter); and cytoskeletal proteins (*e.g.*, dystrophin). The nucleotide sequence of interest may be of synthetic, cDNA, or genomic origin, or a combination thereof. The nucleotide sequence of interest may be one which occurs in nature, a non-naturally occurring gene which nonetheless encodes a naturally occurring polypeptide, or a gene which encodes a recognizable mutant of such a polypeptide. It may also encode an mRNA which will be "antisense" to a DNA found or to an mRNA normally transcribed in the host cell, but which antisense RNA is not itself translatable into a protein. In one embodiment, the invention discloses transgenic mice which express in a liver-specific manner the exemplary hFIX coding sequence under the control of AE5' (Example 3).

The term "liver-specific manner" as used herein in reference to the expression of a nucleotide sequence of interest in a transgenic animal is a relative term which means that the quantity of mRNA and/or protein encoded in liver tissue by the nucleotide sequence of interest is greater than, preferably two times greater, more preferably five times greater, and most preferably ten times greater, than the quantity of mRNA and/or protein encoded by the nucleotide sequence of interest in tissues other than liver tissue of the same transgenic animal as detected by Northern blot hybridization and/or by the activity of the encoded protein as described herein. Thus, the term "liver-specific" when made in reference to expression of a

nucleotide sequence of interest by a transgenic animal means that the transgenic animal expresses the nucleotide sequence of interest in an liver-specific manner.

A first step in the generation of the transgenic animals of the invention is the introduction of a construct containing nucleic acid sequences of interest under the expression regulatory control of sequences of the invention into target cells. Several methods are available for accomplishing this, including microinjection, retroviral infection, and implantation of embryonic stem cells. These methods are discussed as follows.

i. Microinjection Methods

Direct microinjection of expression vectors into pronuclei of fertilized eggs is the preferred, and most prevalent, technique for introducing heterologous nucleic acid sequences into the germ line. Technical aspects of the microinjection procedure and important parameters for optimizing integration of nucleic acid sequences have been previously described [Hogan *et al.*, (1986) Manipulation of the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Lab.].

Once the expression vector has been injected into the fertilized egg cell, the cell is implanted into the uterus of a pseudopregnant female and allowed to develop into an animal. Of the founder transgenic animals born, 70% carry the expression vector sequence in all of their cells, including the germ cells. The remaining 30% of the transgenic animals are chimeric in somatic and germ cells because integration of the expression vector sequence occurs after one or more rounds of replication. Heterozygous and homozygous animals can then be produced by interbreeding founder transgenics. This method has been successful in producing transgenic mice, sheep, pigs, rabbits and cattle [Hammer *et al.*, (1986) J. Animal Sci.:63:269; Hammer *et al.*, (1985) Nature 315:680-683].

ii. Retroviral Methods

Retroviral infection of pre-implantation embryos with genetically engineered retroviruses may also be used to introduce transgenes into an animal cell. For example, blastomeres have been used as targets for retroviral infection [Jaenisch, (1976) Proc. Natl. Acad. Sci USA 73:1260-1264]. Transfection is typically achieved using a replication-defective retrovirus carrying the transgene [Jahner *et al.*, (1985) Proc. Natl. Acad. Sci. USA 82:6927-6931; Van der Putten *et al.*, (1985) Proc. Natl. Acad Sci USA 82:6148-6152].

Transfection is obtained, for example, by culturing eight-cell embryos, from which the zona pellucida has been removed with fibroblasts which produce the virus [Van der Putten (1985), *supra*; Stewart *et al.*, (1987) EMBO J. 6:383-388]. The transfected embryos are then transferred to foster mothers for continued development. Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele [Jahner *et al.*, (1982) Nature 298:623-628]. Yet another alternative method involves intrauterine retroviral infection of the midgestation embryos [Jahner *et al.* (1982), *supra*].

The advantages of retroviral infection methods include the ease of transfection and the insertion of a single copy of the transgene, which is flanked by the retroviral long terminal repeats (LTRs), into the chromosome. However, this method is not a preferred method because most of the founders will show mosaicism since infection occurs after cell division has begun. This necessitates outbreeding to establish homozygous and heterozygous lines suitable for analysis of gene expression. More importantly, the retroviral LTR sequences may interfere with the activity of the hINV upstream sequences in directing expression of the heterologous nucleic aid sequences.

iii. Embryonic Stem Cell Implantation

Another method of introducing transgenes into the germ line involves using embryonic stem (ES) cells as recipients of the expression vector. ES cells are pluripotent cells directly derived from the inner cell mass of blastocysts [Doetchman *et al.*, (1988) Dev. Biol. 127:224-227], from inner cell masses [Tokunaga *et al.*, (1989) Jpn. J. Anim. Reprod. 35:173-178], from disaggregated morulae [Eistetter, (1989) Dev. Gro. Differ. 31:275-282] or from primordial germ cells [Matsui *et al.*, (1992) Cell 70:841-847]. Expression vectors can be introduced into ES cells using any method which is suitable for gene transfer into cells, *e.g.*, by transfection, cell fusion, electroporation, microinjection, DNA viruses, and RNA viruses [Johnson *et al.*, (1989) Fetal Ther. 4 (Suppl. 1):28-39].

The advantages of using ES cells include their ability to form permanent cell lines *in vitro*, thus providing an unlimited source of genetic material. Additionally ES cells are the most pluripotent cultured animal cells known. For example, when ES cells are injected into an intact blastocyst cavity or under the zona pellucida, at the morula stage embryo, ES cells are capable of contributing to all somatic tissues including the germ line in the resulting chimeras.

Once the expression vector has been introduced into an ES cell, the modified ES cell is then introduced back into the embryonic environment for expression and subsequent transmission to progeny animals. The most commonly used method is the injection of several ES cells into the blastocoel cavity of intact blastocysts [Bradley *et al.*, (1984) Nature 309:225-256]. Alternatively, a clump of ES cells may be sandwiched between two eight-cell embryos [Bradley *et al.*, (1987) in "Teratocarcinomas and Embryonic Stem Cells: A Practical Approach," Ed. Robertson E.J. (IRL, Oxford, U.K.), pp. 113-151; Nagy *et al.*, (1990) Development 110:815-821]. Both methods result in germ line transmission at high frequency.

Target cells which contain the heterologous nucleic acid sequences are recovered, and the presence of the heterologous nucleic acid sequence in the target cells as well as in the animal is accomplished as described *supra*.

E. Gene Therapy

The regulatory nucleic acid sequences provided herein may be used for gene therapy applications in both non-human animals as well as in humans. For example, the regulatory nucleic acid sequences of the invention may be introduced into cells using an expression vector which encodes a polypeptide sequence of interest using a variety of means known in the art to be useful both for delivery *in vivo* and *ex vivo*, including (1) recombinant retroviral transduction, (2) recombinant adenoviral vectors, (3) targeted cationic liposomes, and (4) gene transfer using biolistics, as described in the following sections.

1. Recombinant Retroviral Transduction

Retroviral vectors encoding polypeptides of interest may be used for the expression of the polypeptides in any desired cell, such as primary tumor cells. The transfer of polypeptides of interest using retroviruses may be made more efficient by increasing the titer of the virus encoding the polypeptides of interest and increasing the transduction efficiency. To increase the virus titer, the retroviral construct may be designed to include a selectable marker (*e.g.*, *neo* gene), and cells harboring the retroviral construct are selected by growth in the presence of a suitable selective agent (e.g., G418) followed by expansion of clones producing the highest titers of virus. To improve the transduction efficiency, retrovirus are

used in combination with liposomes or poly-L-ornithine or polylysine to enhance virus uptake.

Another way to improve gene transfer efficiency using retroviruses is to increase the targeting efficiency. Many tumor cells including glioblastomas and melanomas express excess levels of the transferrin receptor. Transferrin has been used to increase the transduction efficiency of adenovirus in combination with polylysine. Several recent reports demonstrated that replacing the SU (surface) domain of the *env* gene of a retrovirus can increase receptor-mediated transduction efficiency. The human transferrin gene is 2097 bp long and its insertion into the SU domain of the *env* gene of MLV vector may not produce a stable Env product. However, since earlier studies have suggested that the modified Env fusion protein requires the native Env for stable assembly and efficient entry, co-transfection of the transferrin-*env* fusion gene with the native *env* gene may be used to produce retrovirus particles bearing a mixture of wild type and recombinant Env. The gene transfer efficiency of the new vector may be examined by transducing tumor cells expressing high levels of transferrin receptor.

2. Recombinant Adenoviral Vectors

Recombinant adenoviruses can accommodate relatively large segments of foreign DNA (~7 kb), and have the advantage of a broad host cell range and high titer virus production. Adenoviruses have been used *in vivo* in rats to efficiently deliver genes to the liver and the pancreatic islets [reviewed in Becker *et al.* (1994) In *Protein Expression in Animal Cells*, Roth *et al.* eds.] and to the central nervous system [Davidson *et al.* (1993) Nature Genet. 3:219]. Rat livers have also been efficiently transduced *ex vivo* and then re-implanted [Shaked *et al.* (1994) Transplantation 57:1508]. Thus, the present invention contemplates *ex vivo* transfection followed by transplantation of the transfected cells or organ.

The replication defective recombinant adenoviruses are preferably employed; these viruses contain a deletion of the key immediate early genes E1a and E1b. To generate and propagate recombinant viruses, a packaging cell line such as 293 cells which supply the E1a and E2a proteins *in trans* is employed. Recombinant adenoviruses are created by making use of intracellular recombination between a much larger plasmid encoding most of the viral genome and a small plasmid containing the nucleotide sequence of interest flanked by

regions of homology with the viral integration site. Standard methods may be used to construct the recombinant adenoviruses [Graham and Prevec (1991) Meth. Mol. Biol. 7:109-128; Becker *et al.* (1994) In *Protein Expression in Animal Cells*, Roth *et al.* eds.]. Briefly, each plasmid is co-transfected together with pJM17 (Microbix Systems, Toronto) into sub-confluent monolayers of 293 cells (ATCC CRL 1573) using calcium phosphate precipitation and a glycerol shock. Initial recombinant viral stocks are titered on monolayers of 293 cells, and isolated single plaques are obtained and tested for expression of the polypeptide of interest using ELISA. Viral stocks are amplified and titered on 293 cells, and stored in aliquots at -70°C; if necessary, stocks are concentrated by centrifugation on density gradients. To infect tumor cells with recombinant adenoviruses, freshly isolated tumor cells are mixed with adenoviral stocks in a minimal volume. Titers of stocks are typically 10^5-10^8/ml. Medium is replaced after several hours and the cells are followed for expression of the recombinant adenoviral-encoded polypeptide of interest (*e.g.*, reporter genes).

A potential drawback of using an adenoviral delivery system is that the transduced cells may retain or express small quantities of adenoviral antigens on their surface. "Second generation" adenoviral vectors which contain deletions in the E2a gene are available and are associated with less inflammation in the recipient and a longer period of expression of the gene of interest [Engelhardt *et al.* (1994) Proc. Natl. Acad. Sci. USA 91:6196]. If necessary, nucleic acid sequences encoding polypeptides of interest are inserted into second generation adenoviral vectors.

Recently, adenoassociated virus (AAV) vectors and chimeric lentivirus vectors have also been shown promise in the expression of polypeptide sequences of interest.

3. Targeted Cationic Liposomes

Cationic liposomes have proven to be a safe and effective means for inducing the transient expression of DNA in target cells [Ledley (1995) Human Gene Ther. 6:1129]. Clinical trials are underway using cationic liposomes to introduce the CFTR gene into the lungs of cystic fibrosis patients [Caplen *et al.* (1994) Gene Ther. 1:139 and Alton *et al.* (1993) Nature Genet. 5:135] or to introduce, by direct intra-tumor injection, the T cell costimulator B7-1 into malignant melanoma lesions in order to induce a cell-mediated immune response [Nabel *et al.* (1993) Proc. Natl. Acad. Sci. USA 90:11307].

Cationic liposomes (*e.g.*, DOTAP/DOPE) and ligand-targeted cationic liposomes may be employed for the delivery of polypeptides of interest to tumor cells. Recently, in addition to cationic liposomes, neutral liposomes have also been reproted to also be useful in targeing ligands to cells. Ligand-targeted liposomes are made by covalently attaching ligands or antibodies to the surface of the cationic liposome. For example, when glioblastoma cells are to be targeted, transferrin is used as the ligand as glioblastoma cells express high levels of the transferrin receptor on their surface. When melanoma cells are to be targeted, internalizing receptors, monoclonal antibodies directed against melanoma-specific surface antigens (*e.g.*, mAb HMSA5) may be employed as the ligand.

Plasmid DNA encoding polypeptides of interest is formed into a complex with preformed cationic liposomes using standard methodology or alternatively the DNA is encapsulated into the liposome interior. The DNA-containing liposomes are then used to transfer the DNA to tumor cells *in vivo* by direct intra-tumor injection or *in vitro* (using freshly explanted tumor cells) followed by return of the transduced cells to the recipient (*e.g.*, a human patient or non-human animal).

4. Gene Transfer Using Biolistics

Biolistics (microballistics) is a method of delivering DNA into cells by projection of DNA-coated particles into cells or tissues. DNA is coated onto the surface of gold or tungsten microparticles (~1-3 μm diameter) and these particles are accelerated to high velocity and are impacted onto the target cells. The particles burst through the cell membrane and lodge within the target cell. The cell membrane quickly reseals and the passenger DNA elutes off of the particle and is expressed. The biolistic method has been used to transfect mammalian cells [Sanford *et al.* (1993) Methods Enzymol. 217:483].

A hand-held biolistic apparatus (BioRad) is used to transfer DNA into tumor cells or isolated tumor fragments. This device uses compressed helium to drive a disc-shaped macroprojectile which carries on its surface microparticles (1-5 μm) of gold which have been coated with purified plasmid DNA (coprecipitated with spermine) (Williams *et al.*, *supra*). This apparatus has been used to successfully transfect primary tissues.

Plasmid DNA encoding the polypeptides of interest may be coated onto the surface of gold microparticles according to the manufacturer's instructions (BioRad) and the biolistic apparatus is used to transfer the DNA into freshly explanted tumor cells or directly into

exposed tumors (*e.g.*, metastatic nodules on the surface of the liver, melanoma lesions on the skin).

Regardless of the method of delivery of the expression vector into a cell, it is preferred, though not required, that the expression vector contain a selection marker (*e.g.*, *neo* gene) to facilitate selection of transfected cells. Transfected cells are selected by growth in the presence of G418 (*e.g.*, 200 μg/ml), followed by culture in growth medium containing reduced concentrations of G418 (*e.g.*, 100 μg/ml) and growth to confluence. Expression of the polypeptides of interest is evaluated using, for example, immunoblot analysis or flow cytometry using monoclonal antibodies which are specific for the polypeptides of interest. It is preferred, though not necessary, that expression of the polypeptides of interest in the transfected tumor cells is both constitutive and stable. Constitutive expression refers to expression in the absence of a triggering event or condition, and can be achieved by the selection of a promoter which drives expression of the nucleic acid sequence encoding the polypeptides of interest. Examples of promoters which drive constitutive expression of a structural nucleic acid sequence which is operably linked to the promoter include the SRα promoter, CMV promoter, and HIV promoter.

Regardless of the type of expression vector used for delivery of the nucleic acid sequences of interest into a cell, the expression vector may be introduced to the cell by direct injection into tumor and/or preneoplastic tissue, systemic (*e.g.*, intravenous) administration, aerosol administration (e.g., for delivery to the bronchial tree and other lung tissues), injection into breast ducts (*e.g.*, for delivery to breast tissue), and topical administration (*e.g.*, for delivery to cervical tissue).

F. Reducing Expression Of Factor IX In An Animal

The regulatory sequences of the invention may also be used to reduce expression of a polypeptide sequence of interest which is encoded by a nucleic acid sequence whose transcription is under the regulatory control of the regulatory sequences provided herein. For example, the regulatory sequences of the invention may be used to reduce the rate of age-related increase of FIX activity in an animal as a means of treating diseases (*e.g.*, thrombosis, cardiovascular disease, *etc.*) which are associated with age-related increases in FIX activity. Since the inventors have discovered that the exemplary nucleic acid sequences AE5' and AE3' regulate stable and increased expression levels, respectively, of hFIX, the

increase in the level of hFIX activity over time may be reduced by inhibiting the function of AE3' which regulates increased expression of hFIX. This approach has the advantage that expression of hFIX remains under the control of AE5' thus providing hFIX activities which are stable over time and which continue to play an important role in normal blood coagulation processes.

The function of AE3' in age-related expression of FIX may be inhibited by, for example, inhibiting the activity of the protein which specifically binds to AE3'. The protein(s) which bind to AE3' may be identified by using the AE3' (or the minimum portion of AE3' which has age-related regulatory activity) to screen protein libraries for specific binding to AE3' or its portion. Once the protein which binds to AE3' is identified, the function of this protein may be inhibited using antibodies which are specific for this protein. Antibodies which are specific for the protein which binds to AE3' are expected to disrupt the interaction between AE3' and this protein.

Antibodies (polyclonal and monoclonal) which are specific for the protein that binds to AE3' or portions thereof may be generated using methods known in the art. The term "antibody" refers to immunoglobulin evoked in animals by an immunogen (antigen). It is desired that the antibody demonstrates specificity to epitopes contained in the immunogen. The term "polyclonal antibody" refers to immunoglobulin produced from more than a single clone of plasma cells; in contrast "monoclonal antibody" refers to immunoglobulin produced from a single clone of plasma cells. The terms "specific binding," "specifically binding" and grammatical equivalents thereof when used in reference to the interaction of an antibody and an immunogen mean that the interaction is dependent upon the presence of a particular structure (*i.e.*, the antigenic determinant or epitope) on the immunogen; in other words the antibody is recognizing and binding to a specific immunogen structure rather than to immunogens in general. For example, if an antibody is specific for epitope "A", the presence of an immunogen containing epitope A (or free, unlabelled A) in a reaction containing labelled "A" and the antibody will reduce the amount of labelled A bound to the antibody.

Polyclonal and monoclonal antibodies which are specific to a desirable polypeptide, given the teachings herein, may readily be prepared by one of skill in the art. For example, monoclonal antibodies may be generated by immunizing an animal (*e.g.*, mouse, rabbit, *etc.*) with a desired antigen and the spleen cells from the immunized animal are immortalized,

commonly by fusion with a myeloma cell. Immunization with antigen may be accomplished in the presence or absence of an adjuvant, *e.g.*, Freund's adjuvant. Typically, for a mouse, 10 μg antigen in 50-200 μl adjuvant or aqueous solution is administered per mouse by subcutaneous, intraperitoneal or intra-muscular routes. Booster immunization may be given at intervals, *e.g.*, 2-8 weeks. The final boost is given approximately 2-4 days prior to fusion and is generally given in aqueous form rather than in adjuvant.

Spleen cells from the immunized animals may be prepared by teasing the spleen through a sterile sieve into culture medium at room temperature, or by gently releasing the spleen cells into medium by pressure between the frosted ends of two sterile glass microscope slides. The cells are harvested by centrifugation (400 x g for 5 min.), washed and counted. Spleen cells are fused with myeloma cells to generate hybridoma cell lines. Several mouse myeloma cell lines which have been selected for sensitivity to hypoxanthine-aminopterin-thymidine (HAT) are commercially available and may be grown in, for example, Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL) containing 10-15% fetal calf serum. Fusion of myeloma cells and spleen cells may be accomplished using polyethylene glycol (PEG) or by electrofusion using protocols which are routine in the art. Fused cells are distributed into 96-well plates followed by selection of fused cells by culture for 1-2 weeks in 0.1 ml DMEM containing 10-15% fetal calf serum and HAT. The supernatants are screened for antibody production using methods well known in the art. Hybridoma clones from wells containing cells which produce antibody are obtained, *e.g.*, by limiting dilution. Cloned hybridoma cells (4-5 x 10^6) are implanted intraperitoneally in recipient mice, preferably of a BALB/c genetic background. Sera and ascites fluids are collected from mice after 10-14 days.

The invention also contemplates humanized antibodies which may be generated using methods known in the art, such as those described in U.S. Patent Numbers 5,545,806; 5,569,825 and 5,625,126, the entire contents os which are incorporated by reference. Such methods include, for example, generation of transgenic non-human animals which contain human immunoglobulin chain genes and which are capable of expressing these genes to produce a repertoire of antibodies of various isotypes encoded by the human immunoglobulin genes.

Alternatively, the function of AE3' in age-related expression of FIX may be inhibited by, for example, inhibiting the activity of AE3' using antisense sequences which are directed to AE3'. The term "antisense" as used herein refers to a deoxyribonucleotide sequence whose sequence of deoxyribonucleotide residues is in reverse 5' to 3' orientation in relation to the sequence of deoxyribonucleotide residues in a strand of a DNA duplex. AE3' antisense sequences may be used to turn off genes under the expression regulation of AE3' by transfecting a cell or tissue with expression vectors which express high levels of a desired AE3' antisense oligomer (*e.g.*, 15-20 nucleotides) or larger fragment. Such constructs can flood cells with antisense sequences which inhibit expression of FIX. Antisense sequences can be designed from various locations along the AE3' sequence. Animals (*e.g.*, mice) treated with vectors expressing AE3' antisense sequences are monitored for changes in the age-related symptoms associated with FIX expression. The alleviation or treatment of one or more of these symptoms in animal by an antisense sequence suggests that the antisense sequence may be useful in the treatment and/or prevention of age-related FIX expression in humans.

EXPERIMENTAL

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. Unless otherwise mentioned, all reference to nucleotide numbers with respect to the factor IX nucleotide sequence, refers to the nucleotide numbers of the hFIX gene sequence shown in Figure 8.

EXAMPLE 1

Construction Of A Series of Twelve Exemplary Human Factor IX (hFIX) Minigene Expression Vectors

To explore the molecular mechanisms underlying age-related regulation of Factor IX, a series of twelve hFIX minigene expression vectors were constructed. These vectors were first analyzed *in vitro* in HepG2 cells, a human hepatoma cell line (see Example 2, *infra*). Transgenic mice harboring the hFIX minigene vectors were generated and longitudinal analyses of hFIX expression for the entire life spans of founders and successive generations of transgenic mice were carried out (See Example 3, *infra*).

The twelve exemplary minigenes contained sequences derived entirely from the hFIX gene sequence, including (a) promoter sequences of various lengths spanning up to nucleotide (nt) -2231 in the 5′ flanking region, (b) the coding region containing a first intron in which the first intron's middle portion is truncated. *i.e.*, nt +1098 through nt +5882 of Figure 8, and (c) either the complete 3' UTR sequence or the 3' UTR sequence in which the middle portion was deleted. Figure 1 shows the structure of eleven out of the twelve human FIX minigene expression constructs. The name of each construct is shown at left. The structure is depicted with the promoter-containing regions (solid thick line on left) with the 5′ terminal nucleotide number. Transcribed hFIX regions (open rectangles connected with thin lines representing the shortened first intron) are followed by 3′ flanking sequence regions (solid thick line at right). Arrow: transcription start site; asterisk: translation stop codon; pA: polyadenylation; sl: potential stem-loop forming dinucleotide repeats.

Construction of hFIX minigene expression vectors was carried out using -416FIXm1 as the starting construct (Kurachi *et al.* (1995) J. Biol. Chem. 270:5276-5281). The nucleotide (nt) numbering system used in this study was based on the complete hFIX gene sequence previously reported (Yoshitake *et al.* (1985) Biochem. 24:3736-3750). Minigene -416FIXm1/1.4 was constructed from -416FIXm1 by inserting the middle portion of the 3′ UTR (1.2 kb in size) which was generated by PCR using the following primer set with BamH I linkers: 5′ primer, TAACAGGATCCGGCCTCTCACTAACTAATCAC (nt +31418 through +31438) (SEQ ID NO:14) and 3′ primer, CAACTGGATCCAAGATTCAAGATAGAAGGAT (nt +32690 through +32671) (SEQ ID NO:15), and human genomic DNA as an amplification template. The PCR product was digested with BamH I, and the generated fragment was inserted into the 3′ UTR BamH I site of -416FIXm1, thus producing -416FIXm1/1.4 which contained the entire 3′ UTR. -416FIX m1/0.7 was constructed by inserting the PCR-amplified 700 bp fragment with BamH I linker, containing the 3′ contiguous sequence to nt +32117. The primers used were, 5′ primer: same as that for -416FIXm1/1.4, 3′primer: GGACAGGATCCCC CAAACTTTTCAGGCAC (nt +32117 through +32097) (SEQ ID NO:16). Minigenes -590FIXm1, -679FIXm1, -770FIXm1, -802FIXm1 and -2231FIXm1 were produced by replacing the 5′ end 433 bp sequence of -416FIXm1 released by Sph I/Nhe I digestion with 607, 696, 787, 819 and 2248 bp fragments containing the 5′ end hFIX region extended up to nt -590, -679, -770, -802 and -2231, respectively. These latter fragments were generated by

Sph I/Nhe I digestion of the PCR product obtained with 5′ primers: CAAGCATGCATCTAGTGTTAGTGGAAGAG (nt -590 through -571) (SEQ ID NO:17), CAAGCATGCAAATATTAACTCAAAATGGA (nt -679 through -660) (SEQ ID NO:18), CAAGCATGCTGTTGTTTTTTGTTTTAAC (nt -770 through -752) (SEQ ID NO:19), CAAGCATGCAGCCATTCAGTCGAGGAAGG (nt -802 through -783) (SEQ ID NO:20), CAAGCATGCGATCCCTTCCTTATACCT (nt -2231 through -2214) (SEQ ID NO:21) with Sph I linker and the common 3′ primer TAAGCTTAACCTTTGCTAGCAGATTGT (nt +30 through +10) (SEQ ID NO:22) and human genomic DNA as the amplification template. Minigene -802FIXm1/0.7 (whose structure is not shown in Figure 1) contains the 3' UTR region through nt 32,140, which is then connected to nt 32,690 through its downstream poly (A) signal sequence that is common to each of the other eleven constructs.

-416FIXm1/AE5′ depicts a construct with the AE5′ region moved to the 3′-end position and shown as an open box at right. -416FIX m1/AE5′ was constructed by inserting the Kpn I fragment generated by PCR (nt -802 through nt -417) into the -416FIXm1 vector (the Kpn I site is outside of the FIX gene, Figure1). The 5′ and 3′ primers used for PCR were CTTGGTACCAGCCATTCAGTCGAGGAAGG (nt -802 through -783) (SEQ ID NO:23) and CTTGGTACCATATGAATCCTTTCATAGAT, (nt -417 through -436) (SEQ ID NO:24) respectively. All constructs were sequenced through PCR amplified regions as well as fragment ligation sites to confirm the correct sequences and orientations.

EXAMPLE 2

Transient Expression of Eleven hFIX Minigene Expression Vectors *In Vitro* In Human Hepatoma HepG2 Cell Line

Transient *in vitro* expression activities of hFIX minigene constructs were assayed using HepG2 cells and hFIX specific enzyme linked immunosorbent assay (ELISA) as previously described (Kurachi *et al.* (1995) J. Biol. Chem. 270:5276-5281) with some modifications. Cell transfection was carried out by the calcium phosphate-DNA conjugate method or later, using FuGene 6 (Boehringer Manheim). The latter, improved transfection method consistently increased transfection efficiency to >20% (Kurachi *et al.* (1998) Biochemica 3:43-44), and all earlier assays were reexamined using FuGene 6. Four to five independent assays of factor IX activity were carried out and the averages were shown with

standard errors. With FuGene 6 transfection, the control minigene -416FIXm1 typically produced hFIX at a level of ~50 ng/10^6 cells/48 hr.

Figure 1 shows the relative *in vitro* transient expression activities of the human FIX minigene expression constructs (transient expression activity of minigene -802FIXm1/0.7 which is not shown in Figure 1 was 81.5% of the acitity of minigene -416FIXm1). Transient expression activities relative to the activity of -416FIXm1 (~50 ng/10^6 cells/48 hour, and defined as 100% activity) are shown on the right side with standard deviations (from 4-5 independent assays). Activities were normalized to the size of minigenes used.

The relative transient expression activities shown in Figure 1 show that all constructs showed comparable high transient hFIX expression in HepG2 cells (~50 ng/10^6 cells/48 hours). However, all the constructs containing the complete 3′ UTR, including a 102 base pair (bp) stretch of inverted AT, GT and GC dinucleotide repeats [Yoshitake *et al.* (1985) Biochem. 24:3736-3750], reproducibly showed expression activity levels which were 25-30% lower than corresponding minigenes without the repeat sequences. Dinucleotide repeats similar to those seen in the hFIX 3′ UTR, which can form stable stem-loop (sl) structures in mRNA, have been implicated in controlling mRNA stability in mammals as well as yeast and plants, thus providing an important layer of protein biosynthesis regulation [Ross (1995) Microbiol. Rev. 59:423-450]. Together, these results suggest a similar negative regulatory activity for this structure of the hFIX gene in the HepG2 assay system on expression of the hFIX gene. As described below (*e.g.*, Example 3), however, the 3′ UTR structure of the hFIX gene containing the dinucleotide repeat region showed unexpected functions *in vivo* which are critical for advancing age-related regulation of the hFIX gene.

Another important and surprising finding with the HepG2 cell assay system is that expression by these hFIX minigenes (which contained sequences which are positioned upstream and downstream of the hFIX gene, and which are derived from the homologous hFIX gene instead of from heterologous reporter genes) does not show any down-regulation in the presence of the 5′ upstream region (nt -802 up through nt -1900) [Salier *et al.* (1990) J. Biol. Chem. 265:7062-7068] (Figure 1). In contrast, when a CAT reporter gene was used, negative regulatory elements were identified in this region [Salier *et al.* (1990) J. Biol. Chem. 265:7062-7068].

EXAMPLE 3

Generation And Analysis Of Transgenic Mice Harboring hFIX Minigene Expression Vectors

Transgenic animals were constructed using the expression plasmids described above in Example 2 according to standard methods [Hogan et al. (1994) in "Manipulating the Mouse Embryo, a Laboratory Manual" (Cold Spring Harbor Press, New York, 2nd Edition). All animal experiments were carried out in accordance with the institutional guidelines of the University of Michigan (OPRR No. A3114-01).

Briefly, Factor IX minigene expression plasmids were double-digested with Sph I/Kpn I and the factor IX minigene-containing fragments released were isolated by 0.8% agarose gel electrophoresis, followed by purification with SpinBind DNA extraction units (FMC). Fertilized eggs of C57B/6 X SJL mice were microinjected with the DNA (1-2 ng/egg), and implanted into foster mother animals (CD-1).

A. Multiplex PCR Analysis

Offspring produced were screened for founder animals with high transgene copy numbers (5 -10 copies per genome) using quantitative multiplex PCR analyses of tail tissue DNA samples. Two pairs of primers were used, one specific to the hFIX transgenes and the other specific to mouse β-globin gene (endogenous control); 5' primer: CTGTGGGAACACACAGATTTTGG (nt +6172 through +6195) (SEQ ID NO:25) and 3' primer: GGAATAATTCGAATCACAT (nt +30885 through +30867) (SEQ ID NO:26), and 5' primer: CCAATCTGCTCACACAGGAT (nt +2590 through +2609) (SEQ ID NO:27) and 3' primer: CCTTGAGGCTGTCCAAGTGA (nt +3083 through +3064) (SEQ ID NO:28), respectively. These primers were designed to amplify a unique 966 bp fragment from the hFIX transgenes and a 494 bp fragment from the mouse β-globin gene, respectively. PCR was initiated with 3 min incubation at 94° C, followed by 25 cycles of 94° C for 30 sec, 65° C annealing for 1 min and 72° C extension for 2 min.

Founders were back-crossed with non-transgenic mice (C57B/6 X SJL) to generate F1 progeny animals. Homozygous F2 animals were generated by crossing among heterozygous F1 littermates and the following generations were similarly generated. Zygosity status of animals was determined by quantitative multiplex PCR analysis as described above.

Minimally, three founder lines for each minigene construct were subjected to longitudinal analysis for their entire life spans up to two years.

Figure 3B shows the results of quantitative multiplex PCR analysis to determine the relative transgene levels in tail and liver tissues. Genomic DNA was extracted from snipped tail tissue of a transgenic -416FIXm1 animal (PA112) at 3 weeks and at 19 months of age. Liver DNA was extracted from the same animal (PA112) sacrificed at 19 months of age and a -416FIXm1 animal (PA412) sacrificed at 1 month of age. Positions of hFIX specific fragment (966 bp) and mouse β-globin specific fragment (494 bp, internal copy number control) are shown on the right. Lane 1: kb size ladder ; lane 2: fragment size control amplified from -416FIXm1 plasmid; lane 3: non-transgenic mouse tail DNA as template; lane 4: tail DNA of PA112 at 3 weeks of age; lane 5: tail DNA of PA112 at 19 months of age; lane 6: liver DNA of PA412 at 1 month of age; lane 7: liver DNA of PA112 at 19 month of age. The relative transgene copy numbers for the 1 month-old versus the 19 month-old animals, normalized to the endogenous mouse β-globin gene, were 1.0-1.1 for both tail as well as liver genomic DNA preparations, showing no sign of loss of the hFIX transgene in the genome with age (Multi Analyst program from BioRad used for quantitation and calculation of ratios).

B. Immunoassay of hFIX Levels In Transgenic Mice

Circulatory hFIX levels were monitored during longitudinal analyses of transgenic mice from the representative founder lines carrying various hFIX minigene transgenes. At various ages, starting at one month of age, transgenic mice were individually subjected to blood sample collection (aliquot of ~100 μl) via tail-tip snipping, and the obtained serum was routinely used to quantify hFIX levels in the circulation using duplicated hFIX-specific ELISA for each age point. Pooled human plasma (George King Bio-Medical) was used to prepare a hFIX standard curve for each assay. In order to minimize experimental fluctuations from assay to assay in the longitudinal analysis, overlapped serum samples from the previous assay group were included in each assay. To ensure reproducibility, three to six independent founder lines were generated for each minigene construct, and animals from at least three representative lines were subjected to longitudinal analyses for their entire life spans. The duplicated ELISA values varied less than 11% from the averages. The results are shown in Figures 2 and 4.

In all panels in Figures 2 and 4, labeling of animals is based on the tag numbers plus additional information. The first letters of the label F or P represent founder or progeny, respectively. Information on progeny generation (F1 or F2) and sex are in parenthesis (m: male; f: female), followed by status (+: alive in good health; d: died; s: sacrificed for various examinations; mo: age of death or sacrifice). To avoid overcrowding of the panels, the results from representative animals are shown for each minigene construct. Importantly, age-regulation patterns were remarkably similar among all animals for each specific construct and different founder lines. Panels A-E of Figure 2 show representative founder line animals with -416FIXm1 (A); -416FIXm1/1.4 (B), -590 FIXm1 (C), -679FIXm1 (D) and -770FIXm1 (E). Panels A-D of Figure 4 show representative founder line animals with -802FIXm1, -802FIXm1/1.4, -2231 FIXm1 and -2231FIXm1/1.4, respectively. Panel E shows representative founder line animals with -416FIXm1/AE5'.

Figure 2 shows that at one month of age, the mice carrying the -416FIXm1 minigene produced hFIX at varying levels, from as high as that of natural hFIX gene expression (~4 μg/ml) to much lower levels (~50 ng/ml) (Figure 2A). Such variations are primarily due to the transgene positional effects in the genome. Circulatory hFIX levels of animals from the representative founder lines carrying the minigene, however, declined drastically through puberty and during the subsequent two to three month period to much lower levels, which then remained stable for the remaining life span. This rapid age-dependent characteristic decline in the circulatory hFIX level was observed in all animals analyzed (n=69), regardless of founder line, differences in initial hFIX level at pre-pubertal age (one month) due to transgene positional effects, generation (founders and F1 or F2 progeny), sex, or zygosity status (homozygous / heterozygous) of the transgenes.

C. Northern Blot Analysis of hFIX mRNA in Transgenic Mice

Northern blot analyses of the liver RNA samples from animals (15 μg per lane) were carried out as previously described [Kurachi *et al.* (1995) *supra*] using the ^{32}P-labeled Ssp I/BamH I fragment (the 3′ half of the hFIX coding region of the cDNA) as a probe, and employing stringent washing conditions. Under these conditions, the probe preferentially hybridized strongly with hFIX minigene mRNA bands (~1.7 kb) with little cross-hybridization with the mouse FIX mRNA bands (3.2 kb and 2.2 kb) [Yao *et al.* (1994) Gene Therapy 1:99-107]. To confirm the presence of equivalent amounts of RNA in each lane, the filters

previously hybridized with hFIX probe were stripped of probe and re-probed with the RNR18 cDNA (ribosomal RNA 18S). After completion of longitudinal analyses of animals from key founder lines for their entire life spans, the representative lines were subjected to embryo-freezing for preservation.

The results of Northern analysis of human FIX mRNA and transgene DNA levels in the livers of animals carrying -416FIXm1 are shown in Figure 3A. hFIX mRNA levels in the liver of young (PA412: F1/f, 1 month of age) and old (PA112; F1/f, 19 months of age) transgenic animals were analyzed by Northern blot analysis of total liver RNA. PA412 and PA112 animals were from the same litter produced by the founder FA661, and expressed 1252 and 1675 ng/ml circulatory hFIX at one month of age, respectively. PA112 was expressing 63.8 ng/ml serum hFIX at the time of sacrifice. Lane 1: non-transgenic mouse liver RNA; lane 2: transgenic PA412 liver RNA; lane 3: transgenic PA112 liver RNA. FIX and 18S on the left or right sides indicate the band position of hFIXm1 mRNA (~1.7 kb) and RNR18 (1.9 kb, ribosomal RNA), respectively.

Figure 3A shows that the decline in blood hFIX level observed in Figure 2 was correlated with a similar decline in the steady-state liver hFIX mRNA, which was not due to a loss of the hFIX transgene with age (Figure 3B). This was further supported by the fact that when 4-5 month old mice with much decreased hFIX levels had progeny, their pups depicted pre-pubertal high hFIX expression levels equivalent to those of their parents at the same time point (one-month of age).

Minigene vector -416FIXm1/1.4 is identical to -416FIXm1 except that -416FIXm1/1.4 contains the complete 3'UTR, including the dinucleotide repeat structure (102 bp in length) in its middle region [Yoshitake *et al.* (1985) Biochem. 24:3736-3750] (Figure 1). Transgenic mice with -416FIXm1/1.4 (n=48) (Figure 2B) showed pre-pubertal high and subsequent age-dependent decline in hFIX levels similar to those of -416FIXm1 (Figure 2A), although the decline was less steep and expression levels were stabilized at significantly higher levels than those observed for -416FIXm1 (Figure 2B).

These results indicate that, while the 102-bp sequence containing the dinucleotide repeat structure of hFIX 3' UTR reduces the age-related decline in expression of hFIX, the presence of the complete 3' UTR containing the extensive dinucleotide repeat structure nonetheless does not completely rescue hFIX expression from the age-decline observed in all

of these animals, regardless of founder line, initial pre-pubertal hFIX level, generation, sex, or zygosity status of the transgenes.

All animals carrying minigenes -590FIXm1and -679FIXm1 (a total of 25 and 26 animals subjected to longitudinal analysis, respectively) also showed an age-associated rapid decline in hFIX expression similar to that seen in animals carrying -416FIXm1 (Figure 2, C and D). Furthermore, hFIX expression levels in three independent founder animals generated to date carrying -770 FIXm1 also rapidly decreased over the puberty period in a similar pattern as the above minigenes (Figure 2E). These observations indicated that minigenes with the promoter region up to nt -770 contain the basic structural elements necessary for hFIX expression, but lack a structural element(s) which functions in age-associated stability of hFIX gene expression.

In contrast, striking and unexpected differences in hFIX expression patterns were observed with animals carrying the minigene -802FIXm1 (Figure 4A) as comp[ared to those carrying the minigene -416FIXm1 (Figure 2A). -802FIXm1 is composed of a vector frame identical to -416FIXm1, except that the 5′ end flanking sequence included was extended to nt -802 (Figure 1).

All animals with -802FIXm1, -2231FIXm1 and -416FIXm1/AE5' (panels A, C, E) exhibited stable expression throughout their life spans. Animals with -802FIXm1/1.4 and -2231FIXm1/1.4 (Figure 4 B, D) exhibited age-associated increases in hFIX expression levels. All animals maintained or increased stable circulatory hFIX levels regardless of founder line, initial expression levels at one month of age, sex, generation or zygosity status. Mice which died at much younger ages than their normal life expectancies are marked with d. The above results show that all animals from three independent founder lines obtained with -802FIXm1 (Figure 4A) showed characteristic differences in hFIX expression pattern from animals with -416FIXm1 (Figure 2A) and -416FIXm1/1.4 (Figure 2B).

The -802FIXm1 transgenic animals (n = 62) subjected to longitudinal analysis invariably showed age-stable plasma hFIX levels for their entire life spans, mostly up to 20-24 months of age. Age-stable circulatory hFIX levels were correlated with age-stable mRNA levels (Figure 5). These observations with -802FIXm1 were further supported by age-stable hFIX expression by mice carrying -2231FIXm1 (Figure 4C). Together, these results suggest that the structural element which is responsible for age-stable expression of the hFIX gene resides in the small region spanning nt -770 through -802. We designated

this small region "age-regulatory element in the 5′ end" (AE5′). This region contains a transcription factor PEA-3 nucleotide sequence (GAGGAAG: nt -784 through -790), which completely matches the consensus motif (C/G)AGGA(A/T)G [Martin *et al.* (1988) Proc. Natl. Acad. Sci. 85:5839-5843; Xin *et al.* (1992) Genes & Develop. 6:481-496; Chotteau-Lelievre *et al.*(1997) Oncogene 15:937-952; Gutman and Wasylyk (1990) EMBO J. 9:2241-2246]. The function of AE5′ nucleotide sequence is position-independent as shown by age-stable hFIX expression by animals containing -416FIXm1/AE5′, in which AE5′ was moved to the 3′ end outside of the hFIX minigene (Figure 4E).

Since transgenes of -416FIXm1, -590FIXm1, -679FIXm1 and -770FIXm1 differ from the minigenes -802FIXm1 and -2231FIXm1 only by their promoters, the hFIX mRNA produced from all of these minigenes (an intron spliced form of FIXm1 RNA) was expected to produce identical hFIX protein. Thus, it was hypothesized that the age-dependent decline in the circulatory hFIX level observed in animals with -416FIXm1, -590FIXm1, -679FIXm1 and -770FIXm1, but not with -802FIXm1 and -2231 FIXm1, must be due to an age-dependent decline in the transcriptional activity of the transgenes. This agrees with the facts that no significant changes with age in hFIX mRNA levels in the liver were observed for animals carrying -802FIXm1 (Figure 5, lanes 2 and 3), while advancing age-dependent declines in steady-state mRNA level were observed for -416FIXm1 (Figure 3A, lanes 2 and 3).

To further determine whether the age-dependent decline in the circulatory hFIX levels was due to an age-dependent decline in transcriptional activity of the transgenes, the effects of age on hFIX clearance from the circulation were tested as follows. Aliquots of plasma-derived hFIX preparation (5 μg/0.1 ml of PBS) were injected via tail vein into normal animals at 2, 9-10 and 19-23 months of age (n=3 per age group), which have the same genetic background as the transgenic mice (C57B/6 X SJL). The hFIX level in circulation was monitored by ELISA of collected blood samples (~50 μl aliquot) at 10 min, 2, 6, 12, 18, 24, 30, 36 and 48 hrs after protein injection. As expected, all animals of different age groups showed a typical bi-phasic clearance kinetics (two compartment distribution and clearance) with an initial rapid clearance phase (α-phase), followed by a slower clearance phase (β-phase). The results are shown in Table 1.

Table 1

Clearance Time of Human Factor IX in Mice

Age (months)	Clearance Time ($T_{1/2}$ of Human Factor IX)
2	16.8 ± 0.21
9-10	17.4 ± 0.55
19-23	16.9 ± 0.35

As shown in Table 1, very similar half clearance times were observed for all age groups tested. This agreed with our previous results (17.8 hours) for hFIX clearance in a different strain, BALB/c mice (2 months of age) (Yao *et al.* (1994) *supra*].

Furthermore, the results in Table 1 demonstrate that the hFIX turnover time from the circulation does not change significantly *in vivo* with increasing age, from youth (2 months), to middle age (9-10 months) to old age (19-23 months). These results further confirm that the age-dependent decline in the circulatory hFIX levels was due to an age-dependent decline in transcriptional activity of the transgenes.

It is important to note that in the *in vitro* HepG2 cell assay system, the presence or absence of AE5′ in the minigenes did not make any significant difference in hFIX expression from the hFIX minigenes (Figure 1, and Example 2, *supra*). In contrast, as mentioned above in this Example, the presence or absence *in vivo* of AE5′ makes a dramatic age-dependent difference in hFIX gene expression. This further demonstrates that *in vivo* longitudinal analysis is important for studying age-regulation of a gene.

Unlike the animals with -802FIXm1, mice with -802FIXm1/1.4 (which contains the complete 3′UTR) showed an advancing age-associated increase in the hFIX level in the circulation (n=48) (Figure 4 A and B). Thus, to determine whether this unexpected age-dependent increase in the circulatory hFIX level was directly correlated with an increased level of liver hFIX mRNA, Northern blot analyses of transgenic mice carrying -802FIXm1 and -802FIXm1/1.4 were conducted. The hFIX mRNA levels in the liver of 1-month (young) or 15-month (aged) mice carrying -802FIXm1 (mouse P327 or P552, respectively) and -802FIXm1/1.4 (mouse P32 and P697, respectively) are shown in Figure 5. These

animals were from the same litter produced by the founder F17549 for -802FIX m1 and F229 for -802FIXm1/1.4 (Figure 4 A and B). At the time of sacrifice, P552 and P697 were expressing 2200 and 1658 ng/ml of hFIX, respectively. The total liver RNA (15 μg from each animal was used for the Northern blot analysis performed as described in Figure 3A. Upper panel: probed with the Ssp I/BamH I fragment of hFIX cDNA; lower panel: rehybridized with RNR18 (ribosomal RNA) probe. Lane 1: non-transgenic mouse liver; lane 2: transgenic P327 liver RNA; lane 3: transgenic P552 liver RNA; lane 4: transgenic P32 liver RNA; lane 5: transgenic P697 liver RNA. PhosphorImager (Molecular Dynamics) was used for quantitation of mRNA levels (counts) and ratios of young versus old were calculated. Young and old animals carrying -802FIXm1 showed no significant differences in the mRNA level (the ratio of old over young: 0.92). In contrast, -802FIXm1/1.4 animals showed a substantial elevation in the mRNA level with older age (the ratio of old over young: 1.54).

These results (Figure 5, lanes 4 and 5) indicated the presence of another important age-regulatory nucleotide sequence, designated AE3′, which is located approximately in the middle of the 3′ UTR where an extensive stretch of dinucleotide repeating structures were contained. In the presence of AE5′, AE3′ clearly confers a crucial age-associated increase in hFIX expression. This conclusion was further supported by results obtained with -2231FIXm1 /1.4 (n=42) (Figure 4D). The unique concerted function conferred by the combination of AE5′ and AE3′ was again independent of founder line, initial expression levels at one month of age, sex, generation, or zygosity status of animals.

Interestingly, animals with sustained high hFIX levels in the circulation (approximately 1,500 ng/ml or higher) tended to die at a much earlier age than the expected life span (~2 years) (Figure 4 A, B, D). This happened to both males and females, but appears to be more frequent in males. Without limiting the invention to any particular mechanism, it is believed that since these transgenic mice have hFIX in addition to their own mFIX, they may be at an increased risk of lethal thrombosis compared to wild type mice which do not express the transgenes.

The above-described characterization of transgenic mice harboring hFIX transgenes demonstrates that (a) while the presence of AE5' *in vitro* in HepG2 cells did not affect hFIX gene expression, the presence of AE5' *in vivo* resulted in a dramatic age-dependent increased stability in hFIX gene expression, (b) the age-dependent decline in the circulatory hFIX level

observed in animals with -416FIXm1, -590FIXm1, -679FIXm1 and -770FIXm1 is directly correlated with the decrease in the steady-state mRNA level, which the inventors believe to be due to an age-dependent decline in the transcriptional activity of the transgenes, and (c) animals carrying -802FIXm1/1.4 shwoed a substantial elevation in the liver mRNA levels of hFIX with older age.

EXAMPLE 4

Footprint And Gel Electrophoretic Mobility Shift Analysis Of The Region From Nucleotides -665 To -805 of Human Factor IX

In order to make a preliminary determination of the region within AE5' which is involved in the function of AE5', footprint analysis and gel electrophoretic mobility shift assays were performed as follows.

A. Footprint Analysis

For footprint analysis of the region spanning from nt -665 through nt -805, the fragments used were amplified by PCR with the ^{32}P-labeled 5′ primer ATGGTTAACTGACTTACGAA (nt -833 through -814) (SEQ ID NO:29) and 3′ unlabeled primer GCTCCATTTTGAGTTAATATTTGTGT (nt -657 through -682) (SEQ ID NO:30). The nuclear extracts (NEs) from HepG2 human hepatoma cells and livers of young (1 month of age) and old (19 months of age) mice were prepared as previously reported [Kurachi et al. (1986) Biochemistry 33:1580-1591]. Various amounts of NEs (0, 100 and 150 μg) were incubated with the labeled fragments (30,000 CPM) for 1 hour on ice and subjected to DNase 1 digestion (0.5 unit) for 2 min at room temperature. The samples tested included those without NEs, with 100 μg and 150 μg of HepG2 cell NEs, with 100 μg and 150 μg NEs from old mice, and with 100 μg and 150 μg NEs from young mice. Major and minor footprints and apparent DNase hypersensitivity sites were observed.

Footprint analysis of the region nt -665 through -805 with aged mouse liver nuclear extracts showed a major footprint (nt -784 through -802), a minor foot print (nt -721 through -728) and an interesting DNase hypersensitive region (nt -670 through -714). With nuclear extracts from one month-old animals or HepG2 cells, no such clear footprints were observed.

B. Gel Electrophoretic Mobility Shift Assay

Gel electrophoretic mobility shift assay using mouse liver nuclear extracts from three different age groups was used. Nuclear extracts were prepared from 1, 5 or 19 month-old mouse livers (as described *supra*). Double stranded oligonucleotides containing a PEA-3 nucleotide sequence spanning from nt -797 to -776 of the hFIX gene (TTCAGTCGAGGAAGGATAGGGT) (SEQ ID NO:31) were ^{32}P-labeled at the 5′ end to a specific activity of 1.9×10^9 cpm. Aliquots of the radio-labeled oligonucleotide (20,000 cpm) were incubated with 10 μg of NEs in the presence of 1 μg of poly dI-dC in DNA binding buffer for 20 min at room temperature and subjected to polyacrylamide gel electrophoresis (Kurachi et al. (1986) *supra*). In Figure 6A, Lane 1: without NEs; lane 2: with NEs of 1 month-old mice; lane 3: with NEs of 5 month-old mice; land 4: with NEs of 19 month-old mice; lane 5: with mouse brain NEs (positive control for PEA-3, showing a slightly higher size of shifted band).

Figure 6B shows the results of the competition assay for ^{32}P-labeled double stranded oligonucleotides containing the PEA-3 nucleotide sequence. A 100-fold excess unlabeled oligonucleotide described in the preceding paragraph or mutant oligonucleotide [TTCAGTCGGTTGGTGATAGGGT (SEQ ID NO:32) with mutated sequences underlined] was incubated with 10 μg of 19 month-old mouse liver NEs for 5 min followed by addition of ^{32}P-labeled oligonucleotides as described *supra*. Lane 1: without NEs; lane 2: with NEs; lane 3: with NEs and wildtype competitor; lane 4: with NEs and mutant competitor.

In agreement with the above results of footprinting, gel electrophoretic mobility-shift (bandshift) assays showed an increase in protein binding with the nuclear extracts of aged mice (19 months of age) (Figure 6A). Bandshifts were competitively reduced with excess amounts of oligonucleotides harboring the PEA-3 motif, but not with oligonucleotides harboring a mutant PEA-3 motif sequence (Figure 6B), thus confirming the presence of the PEA-3 motif in AE5'. This is the first time that the PEA-3 protein, which is a member of the Ets family of transcription factors and which has been shown to bind to nucleotide sequences [SEQ ID NO:40; SEQ ID NO:48; and SEQ ID NO:84] that are homologous to the PEA-3 nucleotide sequence within the AE5' region [Karim *et al.* (1990) Genes & Develop. 4:1451-1453; Nelsen *et al.* (1993) Science 261:82-86; Fisher *et al.* (1991) Oncogene 6:2249-2254], has been implicated in such a unique role in age-stable regulation of a gene.

Without limiting the invention to any particular mechanism, the PEA-3 nucleotide sequence in the hFIX gene appears to have been generated through evolutionary drift of a L1 sequence originally recruited presumably via its retrotransposition into the 5′ specific location. Modern retrotransposable L1 [Kazazian *et al.* (1988) Nature 332:164-166; Dombroski *et al.* (1993) Proc. Natl. Acad. Sci. USA 90:6513-6517; Minakami *et al.* (1992) Nucl. Acids Res. 20:3139-3145; Dombroskiet *et al.* (1994) Mol. Cell. Biol. 14:4485-4492] does not have the corresponding PEA-3 nucleotide sequence. The PEA-3 nucleotide sequence of AE5′ nucleotide sequence resides within the L1-derived sequence retaining a 63-70% similarity with the ORF2 corresponding region of the modern retrotransposable L1 in the 5′ to 3′ orientation. Interestingly, the murine FIX gene also has the L1-derived nucleotide sequence in its 5′ end region in an almost identical position as in the hFIX gene, and has multiple PEA-3 consensus nucleotide elements [Kawarura *et al.*in *Organization of L1 Sequence in the 5' Flanking Region of Factor IX Gene* [in preparation]. Age-regulation of the murine FIX gene is indeed very similar to that of the hFIX gene [Sweeney and Hoernig (1993) Am. J. Clin. Pathol. 99:687-688; Kurachi *et al.* (1996) Thromb. Haemost. 76:965-969], thus providing further insights into the evolutionary origin of the molecular mechanisms underlying age-associated regulation of the FIX gene.

EXAMPLE 5

Liver-Specific Expression Of The Exemplary hFIX Gene Under Control Of The hFIX Promoter

Expression of the natural FIX gene is virtually restricted to the liver [Salier *et al.* (1990) J. Biol. Chem. 265:7062-7068]. In order to determine whether any of the upstream and/or downstream sequences in the hFIX minigenes directed liver-specific expression of the hFIX transgene, Northern blot analysis was carried out as described *supra* (Example 3) in transgenic mice carrying -416FIXm1 and -802 FIXm1 expression vectors. Animals expressing hFIX at high level (PA412 and P580 carrying -416FIXm1 and -802FIXm1, respectively) were sacrificed at one month of age and total RNA was extracted from liver, lung, intestine, muscle, kidney, brain and heart and from untransfected HepG2 cells (negative control). The results in transgenic mice carrying -416FIXm1 and -802 FIXm1 are shown in Figure 7A and B, respectively.

In Figure 7, the positions of hFIX mRNA, RNR18 (control for RNA loading in wells), and ribosomal 28S and 18S RNA bands are shown on the left and right sides, respectively. Animals with -416FIXm/1.4 and -679FIXm1 showed tissue specific expression patterns similar to that of -416FIXm1 (A) (data not shown). Interestingly, liver expression of hFIX observed for minigenes lacking the region containing AE5′ (except -770FIXm1, which remains to be tested as sufficient progeny animals become available) was high, but not as robust, as that seen with the natural gene. In addition, these minigenes expressed not only in the liver, but also in other tissues, such as kidney, lung and muscle, at various levels as high as ~20% of the liver level (Figure 7A). In clear contrast, animals with -802FIXm1 showed substantially liver-specific hFIX expression similar to that for the natural FIX gene (Figure 7B). These results suggest that the AE5' region controls liver specific expression of hFIX.

An apolipoprotein(a) transcription cotnrol region (ACR) whcih contains an ETS family target sequence 5'-CCCGGAAG-3' (SEQ ID NO:48) has been shown to exhibit enahncer activity *in vitro* in liver-derived HepG2 cells. However, the ACR does not appear to be liver-specific [Yang *et al.* (1998), *supra*].

EXAMPLE 6

Expression Of PEA-3 Protein In HepG2 Liver Cells

Expression of the transgene FIX was observed *in vivo*, but not *in vitro* in HepG2 cells, when expression vectors containing AE5' were used (See, Examples 2 and 3, *supra*). This observation, together with the absence of a footprint in HepG2 cell NEs (See, Example 4, *supra*) suggested to the inventors that HepG2 cells' lack of expression of the FIX transgene may be a result of the cells' expression of low levels of the PEA-3 protein (and/or the PEA-3 related protein) which binds to homologs of the invention's PEA-3 nucleotide sequence. The complete human PEA-3 cDNA has not yet been cloned (the human PEA-3 cDNA sequence of GenBank accession number U18018 lacks 8 amino acids at the N-terminal region when compared to the mouse PEA-3 cDNA sequence). In order to determine the role of the PEA-3 nucleotide sequence in gene expression *in vitro*, HepG2 cells which overexpress mouse PEA-3 protein were constructed as follows.

Expression constructs containing the mouse PEA-3 cDNA sequence (GenBank Accession Number X63190; Figure 9) were constructed as follows. Using the reported mouse PEA-3 cDNA sequence three sets of PCR primers were synthesized such that the entire coding region and parts of the flanking sequences would be amplified. Reverse transcription PCR (RT-PCR) was carried out, and the amplified mouse PEA-3 cDNA sequence was inserted into an expression vector under the control of the SV40 promoter, which does not interfere with the factor IX promoter (data not shown).

The PEA-3 expression vector is used to transfect HepG2 cells using the FuGene 6 (Boehringer Manheim) since this method was shown to improve transfection efficiency (See, Example 2, *supra*). Transfected HepG2 cells are screened for expression of PEA-3 by Northern blot analysis and/or Western blot analysis using commercially available antibody. Transfected HepG2 cell lines which stably express PEA-3 protein are selected for further use, *e.g.*, to analyze the underlying mechanism of PEA-3 action.

EXAMPLE 7

In vitro And *In Vivo* Expression Of Exemplary Human Protein C Minigene Expression Vectors Containing AE5' And AE3'

Protein C is a factor which plays a critical role in the anti-blood coagulation mechanism. Unlike factor IX, whose level in the circulation substantially increases with advancing age, protein C levels in the circulation do not increase with advancing age, but rather show a slight decrease over time. This decrease in circulating protein C levels is believed by the inventors to be the result of regulation at the gene transcription level. For this reason, the protein C gene provides an interesting exemplary gene for demonstrating the universality of the AE5' and AE3' function in gene expression both *in vitro* and *in vivo* as follows. In this Example, bases are numbered relative to the major transcription start site (+1) as previously described [Miao et al. (1996) J. Biol. Chem. 16:9587-9594].

A. Construction of Human Protein C Minigene Expression Vectors

The human protein C genomic sequence has been previously reported (GenBank accession number M11228; Figure 12B]. Using this sequence, three protein C minigene expression vectors were prepared. The first human protein C minigene vector (-1426PCm1)

contained the human protein C promoter region of the protein C gene (GenBank accession number M11228; Figure 12 B) ligated to the human protein C cDNA (GenBank accession number X02750; Figure 12 A) which contains the first entire intron and poly-A sequence. The second human protein C minigene (AE5'/-1426PCm1) was the same as the first vector except that it additionally contained the nucleotide sequence AE5' at the 5' end of the human protein C cDNA. The third human protein C minigene (AE5'/-1426PCm1/AE3') was the same as the first vector vector except that it additionally contained the nucleotide sequences AE5' and AE3' at the 5' and 3' ends, respectively, of the human protein C cDNA.

B. Transient Expression Of human Protein C *in vitro* In HepG2 Cells

Each of the protein C minigene expression vectors was transfected into HepG2 cells using the FuGene 6 (Boehringer Mannheim). Four to five independent assays of human protein C activity were carried out as previously described [Turkey et al (1999) Throm. Haemost. 81:727-732]. HepG2 cells transfected with the -1426PCm1 vector showed *in vitro* transient protein C activities which were comperable to the activities shown by HepG2 cells transfected with the AE5'/-1426PCm1 vector (*i.e.*, (60-70 ng/10E6 cells/24 hrs).

C. Generation Of Transgenic Mice Harboring The protein C Minigene Expression Vectors

In order to determine whether AE5' in combination with AE3' is capable of increasing human protein C expression with advancing age, as observed for factor IX expression (Example 3, *supra*), transgenic mice which harbor the protein C minigene expression vectors are generated according to standard methods [Hogan et al. (1994), *supra*]. Briefly, protein C minigene vector plasmids are injected into fertilized eggs of C57B/6 X SJL mice and implanted into foster mother animals (CD-1). Offspring produced are screened for founder animals with high transgene copy numbers (5 -10 copies per genome) using quantitative multiplex PCR analyses of tail tissue DNA samples using two pairs of primers which are designed to amplify a unique fragment from the protein C transgenes and a 494 bp fragment from the mouse β-globin gene, respectively.

Founders are back-crossed with non-transgenic mice (C57B/6 X SJL) to generate F1 progeny animals. Homozygous F2 animals are generated by crossing among heterozygous

F1 littermates and the following generations are similarly generated. Zygosity status of animals is determined by quantitative multiplex PCR analysis as described above. Founder lines for each minigene construct are subjected to longitudinal analysis for their entire life spans up to two years.

Circulatory human protein C levels are monitored during longitudinal analyses of transgenic mice from the representative founder lines carrying the protein C minigene transgenes. Age-regulation patterns of circulatory human protein C levels are compared among all animals for each specific construct, different founder lines, different initial human protein C level at pre-pubertal age (one month) due to transgene positional effects, generation (founders and F1 or F2 progeny), sex, and zygosity (homozygous / heterozygous) status of the transgenes.

Northern blot analyses of the liver RNA samples from animals is carried out using stringent washing conditions to determine whether any changes in circulatory human protein C levels are correlated with similar changes in the steady-state liver human protein C mRNA, rather than with loss of the human protein C transgene with age or with changes in human protein C turnover time. Observation of transgenic animals which contain the human protein C sequence as well as AE5' and AE3' and which increase stable circulatory human protein C levels with increasing animal age, as compared to the levels in transgenic animals which express the human protein C sequence in the absence of AE5' and AE3', demonstrates that the combination of AE5' and AE3' functions in age-stable expression of the exemplary human protein C gene. This observation will confirm that these results may ba achieved for genes other than the exempary hFIX and protein C genes.

EXAMPLE 8

In Vivo Expression Of Exemplary Expression Vectors Containing The Cytomegalovirus (CMV) Promoter And The AE5' And AE3'

This Example is carried out to demonstrate the universality of the age-related gene expression regulatory function of AE5' and AE3' with viral promoters. The CMV promoter is currently used in several gene therapy constructs but its activity decreases with time in the Liver. Furthermore, the activity of the CMVpromoter in the liver of transgenic mice is known to be lower than the activity in other tissues, such as muscle. Thus, this Example

investigates whether the combination of AE5' and AE3' halts or reverses the decline in the activity of the CMVpromoter in the liver.

The above-described -416FIXm1 expression vector (Example 1, and Figure 1) is used to construct a control vector to determine the effect of AE5' and AE3' on liver and circulatory levels of expression of human factor IX in transgenic animals. The control vector in which expression of the hFIX gene is under the control of the CMV promoter in the absence of both AE5' and AE3' is constructed by replacing the human factor IX promoter sequence with the CMV promoter sequence (National Vector Core for Non-Viral Vectors at the University of Michigan) (the CMV promoter is also located between positions +1 to +596 in vector plasmid pCR3 from Invitrogen). The resultant expression vector in which the human factor IX gene is under the control of the CMV promoter is transfected into HepG2 cells. Transfected cells are expected to show human factor IX activity.

The -802FIXm1/1.4 vector of Figure 1 is used to construct a test vector in which the human factor IX promoter sequence of -802FIXm1/1.4 vector (which contains both AE5' and AE3') is replaced with the CMV promoter sequence.

In order to determine whether the combination of AE5' and AE3' is capable of increasing human factor IX expression with advancing age under the control of the CMV promoter, as observed for factor IX expression under the control of the factor IX promoter (Example 3, *supra*), transgenic mice which harbor either the control vector or the test vector are generated according to standard methods as described supra (Examples 3 and 7). The mRNA levels of human factor IX in the blood, liver and other tissues are monitored during longitudinal analyses of the transgenic mice. Age-regulation patterns of human factor IX mRNA levels in the different tissues are compared among all animals as described *supra* for each specific construct, different founder lines, different initial human factor IX levels at pre-pubertal age due to transgene positional effects, generation, sex, and zygosity status of the transgenes.

The observation of transgenic animals which contain the test vector and which increase stable circulatory human factor IX mRNA levels, as compared to the circulatory mRNA levels in transgenic animals which contain the control vector, demonstrates that the combination of AE5' and AE3' functions in increasing the activity of the exemplary CMV promoter.

EXAMPLE 9

Liver-Specific Expression Of The Exmplary Human Factor IX Gene Under The Control Of The CMV Promoter

This Example investigates whether the presence of AE5' imparts liver specific activity to the CMV promoter, which otherwise drives gene expression in several tissues in addition to the liver.

The -802FIXm1 vector which contains AE5' and lacks AE3' (Figure 1) is used to construct a test vector in which the human factor IX promoter sequence of the -802FIXm1 vector is replaced with the CMV promoter sequence. This test vector is used in parallel experiments with the control vector of Example 8 in which expression of the hFIX gene is under the control of the CMV promoter in the absence of both AE5' and AE3'. Northern blot analysis is carried out as described *supra* (Example 3) in transgenic mice carrying the control vector or test vector. Animals expressing hFIX at high level are sacrificed at one month of age and total RNA is extracted from liver, lung, intestine, muscle, kidney, brain and heart and from untransfected HepG2 cells (negative control). The levels of hFIX mRNA in the different tissues are compared. It is expected that transgenic animals harboring the control vector will express hFIX mRNA in liver as well as in at least one other tissue. In contrast, the observation that transgenic animals which harbor the test vector express hFIX mRNA in the liver and not in other tissues indicates that AE5' confers liver-specific activity to the exemplary CMV promoter.

From the above, it is clear that the invention provides methods for age-related and liver-specific gene expression and models for age-related and liver-specific diseases.

EXAMPLE 10

Construction Of A Series of Exemplary Human Protein C Minigene Expression Vectors

This Example and the following Examples 11-12 were carried out to further demonstrate the universality of the function of AE5' and AE3'' sequences with respect to regulating expression of the exemplary human protein C as described in Example 7, *supra*. The human protein C genomic sequence has been previously reported (GenBank accession

number M11228; Figure 12B]. In particular, Figure 14 shows the nucleotide sequence (SEQ ID NO:85) of the 5'-end of the human protein C gene [Miao et al. (1996) J. Biol. Chem. 16:9587-9594]. In Figure 14, bases are numbered relative to the major transcription start site (+1) as previously described [Miao et al. (1996) J. Biol. Chem. 16:9587-9594]. Two minor start sites are marked with double asterisks. Exons are underlined. The translation start codon (ATG) is shown in boldface.

Using this sequence, eight protein C minigene expression vectors were prepared as shown in Figure 15. Fat lines at 5' and 3' ends represent flanking sequences. Introns are shown by blank rectangles. Exons are shown by shaded rectangles (corresponding to the 3' UTR part of the last exon). Arrows indicate transcriptional start sites. The vectors contained the human FIX AE5' sequence (SEQ ID NO:1; nt -802 through -771 of Figure 8; 32 bp in size) linked to Sph I linker sequences and/or the human FIX AE3'' sequence (SEQ ID NO:93; nt 32,110 through nt 32,263 of Figure 8, 154-bp long) linked to Sse8387 I linker sequences. All the amplified sequences of the human protein C minigene vectors were verified by dideoxy sequencing.

The first human protein C (hPC) minigene vector (-1462hPCm1) was composed of the 5' flanking sequence of human protein C up to nt -1462, exon I sequence, the complete first intron at the natural site (1431 bp in length) and the contiguous following sequence containing exons 2-9 (derived from the hPC cDNA) and the 3' immediate flanking genomic sequence through nt 11,108 (325 bp in length). As shown in Figure 15, nucleotide 67 was the first base of intron I, nucleotide 1,497 was the first base of exon 2 (the first base of the Met codon is nucleotide 1,514), and nucleotide 10,488 was the last base of the stop codon.

To construct -1462hPCm1, a region spanning nt -1462 through 1,560 (3,022 bp in length) of the hPC gene was amplified by PCR (Expand High Fidelity PCR System, Boehringer Mannheim) using 5' and 3' primers containing Sph I linker and the unique internal Msc I site in the exon 2, respectively, and human genomic DNA as the template. The generated fragment, containing the 5' flanking sequence, exon I, intron I and a short 5' portion of exon 2 to the internal Msc I site, was then inserted into a hPC cDNA plasmid, PUC119-hPC, in between Sph I and Msc I sites by replacing its 5' portion of the hPC cDNA sequence. The 3' end of the resulting minigene, -1462hPCm', contained the entire 3' UTR, but only up to poly(A) attachment site (nt 10,783). Its 3' end region (the 3' sequence beyond the internal Sse8387 I site in the 3' UTR) was then freed by Sse8387 I/EcoR I

double digestion, and replaced with a Sse8387 I/EcoR I fragment (612 bp in the length, spanning nt 10,497 through 11,108 of hPC gene), which was generated by PCR. The hPC minigene, thus constructed was named -1462hPCm1, (approximately 4981 bp in length) and served as a parent construct for generating other hPC minigene constructs for generating other hPC minigene constructs as described below. This hPC minigene vector was used to construct the first transgenic mouse colony, which was used as a positive control for hPC expression.

The second human protein C minigene vector (-82hPCm1) was another control human hPC minigene. It was the same as -1462hPCm1, except that its promoter region was extended only up to nt -82 instead of to nt -1462, and thus contained the hPC upstream sequence (SEQ ID NO:86) from nt -82 to nt +1. Minigene -1462hPCm1 was subjected to Sph I digestion, followed by partial MscI digestion, releasing the 5' half region spanning nt -1462 in the 5' upstream through nt 1,547 at the internal Msc I site in exon 2. Due to another Msc I site in the first intron, partial digestion was needed to get the needed 5' end half fragment. This region was then replaced by smaller Sph I/Msc I fragments generated by PCR, spanning nt -82 in the 5' upstream through the internal Msc I site, thus generating -82hPCm1.

The third human protein C minigene vector (AE5'/-1462hPCm1) was the same as -1462hPCm1, except that it had an AE5' sequence (32 bp in length) inserted at the 5' end at an Sph I site.

The fourth human protein C minigene vector (-1462hPCm1/AE3'') was the same as -1462hPCm1, except it had an AE3'' sequence inserted at the Sse8387 I site within the 3' untranslated region (UTR) of the hPC minigene.

The fifth human protein C minigene vector (AE5'/-1462hPCm1/AE3'') was the same as -1462hPCm1, except it had both AE5' and AE3''. The AE5' fragment (32 bp in length, spanning nt -802 through -771 of hFIX gene) was amplified by PCR (Expand High Fidelity PCR System, Boehringer Mannheim) with human genomic DNA as template and PCR primers containing Sph I linker sequences. The AE3'' fragment spanning nt 32,110 through nt 32,263, and containing the potential stem-loop structure forming region (nt 32,142 through 32,243) was produced by PCR using primers containing the internal Sse8387 I site sequences. AE5' and AE3'' fragments with Sph I or Sse8387 I sticky ends, respectively, were then inserted into -1462hPCm1 at Sph I site at the 5' end and Sse8387 I site in the 3'

UTR, respectively, thus generating minigene AE5'/-1462hPCm1/AE3''. Therefore, AE5'/-1462hPCm1/AE3'' is the same as -1462hPCm1 except it has both AE5' and AE3' sequences of the hFIX gene at the 5' end Sph I site and Sse8387 I site in the 3' UTR, respectively.

The sixth and seventh human protein C minigene vectors (-849hPCm1 and -802hPCm1) were the same as -1462hPCm1, except that their 5' end sequences extended to nt -849 and -802, respectively, instead of to -1462. Construction of these minigenes was essentially the same as construction of the second human protein C minigene (-82hPCm1); minigene -1462hPCm1 was subjected to Sph I digestion, followed by partial MscI digestion, releasing the 5' half region spanning nt -1462 in the 5' upstream region through nt 1,547 at the internal Msc I site in exon 2. Due to another Msc I site in the first intron, partial digestion was needed to get the needed 5' end half fragment. This region was then replaced by smaller Sph I/Msc I fragments generated by PCR, spanning nt -849, or -802 in the 5' upstream through the internal Msc I site, thus generating -849hPCm1 and -802hPCm1, respectively.

The eighth human protein C minigene vector (AE5'/-82hPCm1) was generated by inserting the AE5' sequence with Sph I sticky ends into the second vector, -82hPCm1, at the 5' end Sph I site.

EXAMPLE 11

Transient Expression of Exemplary Human Protein C Minigene Expression Vectors *In Vitro* In Human Hepatoma HepG2 Cell Line

Transient expression activities of the hPC minigenes of Example 10 were tested with HepG2 cells as described in Example 2, *supra*. Figure 16 shows the relative *in vitro* transient expression activities and standard deviations of the human protein C minigene expression constructs relative to the activity (approximately 70 ng/10^6 cells/48 hr, defined as 100% activity) of the control -1462hPCm1 construct.

The relative transient expression activities in Figure 16 show that the results obtained with AE3'' when in tandem with the hPC gene are fully consistent with what the inventors previously observed with AE3'' when in tandem with the hFIX gene (Figure 1); the presence of AE3'' showed approximately a 30% suppression in transient expression in comparison to the minigenes which lacked AE3'' (*i.e.*, -1462hPCm1/AE3'' compared with

-1462hPCm1, and AE5'/-1462hPCm1/AE3'' compared with AE5'/-1462hPCm1). The control constructs -1462hPCm1 and -82hPCm1 showed similar transient expression activities to each other.

As discussed above, these results were surprising because they were contrary to those previously reported by Miao et al. (1996), *supra*, when using a heterologous reporter gene, chloramphenicol acetyltranferase (CAT), under the transcriptional control of varying lengths of the protein C 5'-end sequences.

EXAMPLE 12

Generation And Analysis Of Transgenic Mice Harboring Human Protein C Minigene Expression Vectors

Transgenic animals were constructed using each of the eight expression plasmids described above in Example 10 according to standard methods [Hogan et al. (1994) in "Manipulating the Mouse Embryo, a Laboratory Manual" (Cold Spring Harbor Press, New York, 2nd Edition) as described in Example 3, *supra*. Fertilized eggs of mice were microinjected with the minigene transgene DNA and implanted into foster mother animals.

Circulatory hPC levels were monitored during longitudinal analyses of transgenic mice harboring the -1462hPCm1, -82hPCm1, and AE5'/-1462hPCm1/AE3'' minigene transgenes. At various ages, starting at one month of age, transgenic mice were individually subjected to blood sample collection via tail-tip snipping, and the obtained serum was routinely used to quantify hPC levels in the circulation using ELISA for each age point. The ELISA assay employed a mouse monoclonal anti-hPC antibody (Celsus Laboratories) as a first antibody and a rabbit polyclonal anti-hPC antibody (Celsus Laboratories) as a second antibody. Pooled human plasma (George King Bio-Medical) was used to prepare a hPC standard curve for each assay. The results are shown in Figure 17. The labeling in Figure 17 reflects the tag numbers of animals containing each minigene construct. Figure 17 shows representative animals with -1462hPCm1 (A), -82hPCm1 (B), and AE5'/-1462hPCm1/AE3'' (C) expression vectors.

Importantly, Figure 17 shows that age-regulation patterns were remarkably similar among all animals for each specific construct. In particular, the results show that transgenic animals containing the -1462hPC m1 construct contained age-stable levels of human protein C, *i.e.*, the animals expressed relatively constant levels of human protein C at different time

points during the life span of the transgenic animals (Figure 17A). In direct contrast, the presence of AE5' and AE3' sequences resulted in increased expression levels of human protein C over time (Figure 17C). These results confirm the universality of the function of AE5' and AE3'' sequences in regulating expression of operably linked genes in an age-related manner.

The data also shows that, whereas transgenic animals containing the -1462hPC m1 construct exhibited relatively constant and relatively high levels (from about 100 to about 3000 ng/ml) of human protein C over time (Figure 17A), in dramatic contrast, transgenic animals containing the -82hPCm1 construct exhibited relatively low levels (from about 5 to about 40 ng/ml at 1 month of age) of human protein C which declined at a precipitous rate over time. Indeed, by the age of 5 months, human protein C levels were undetectable in all transgenic animals harboring the -82hPCm1 construct. These results demonstrate that the nucleotide sequence from nt -1462 to nt -83 of the human protein C gene directs age-stable expression as well as relatively higher levels of expression (as compared to the levels in the absence of the nucleotide sequence from nt -1462 to nt -83) of operably linked sequences of interest.

CLAIMS

1. A recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3.

2. A method, comprising:

a) providing: i) a cell, ii) a nucleic acid sequence of interest, iii) a promoter sequence, and iv) one or more age regulatory sequences selected from SEQ ID NO:1, SEQ ID NO:3, a portion of SEQ ID NO:1, and a portion of SEQ ID NO:3;

b) operably linking said nucleic acid sequence of interest, said promoter sequence, and said one or more age regulatory sequences to produce a transgene; and

c) introducing said transgene into said cell to create a treated cell under conditions such that said nucleic acid sequence of interest is expressed in said treated cell.

3. A substantially purified nucleic acid sequence comprising at least a portion of SEQ ID NO:93.

4. The nucleic acid sequence of Claim 1, wherein said portion has age-related regulatory activity.

5. The nucleic acid sequence of Claim 1, wherein said portion is selected from SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95; SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID

NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, and SEQ ID NO:144.

6. The nucleic acid sequence of Claim 3, wherein said portion is SEQ ID NO:91.

7. A recombinant expression vector comprising in operable combination i) a nucleic acid sequence of interest, ii) a promoter sequence, and iii) an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof.

8. The expression vector of Claim 7, , wherein said nucleic acid sequence of interest encodes a protein selected from factor VIII, factor VII, factor IX, factor X, prothrombin, protein C, antithrombin III, tissue factor pathway inhibitor, LDL-receptor, human α1-antitrypsin, antithrombin III, PEA-3 protein, β-galactosidase, and luciferase.

9. The expression vector of Claim 7, wherein said promoter sequence is selected from human factor IX promoter, cytomegalovirus promoter, tRNA promoter, 5S rRNA promoters, histone gene promoters, RSV promoter, retrovirus LTR promoter, SV40 promoter, PEPCK promoter, MT promoter, SRα promoter, P450 family promoters, GAL7 promoter, T_7 promoter, T_3 promoter, SP6 promoter, K11 promoter, and HIV promoter.

10. The expression vector of Claim 7, , wherein said portion of SEQ ID NO:93 is selected from SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95; SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, and SEQ ID NO:144.

11. The expression vector of Claim 10, , wherein said portion is SEQ ID NO:91.

12. The expression vector of Claim 7, further comprising in operable combination an age-related regulatory sequence selected from SEQ ID NO:1 and portions thereof.

13. A host cell containing the recombinant expression vector of Claim 7.

14. The host cell of Claim 13, wherein said host cell is comprised in a tissue or organ in a living animal.

15. The host cell of Claim 13, wherein said host cell is a gamete.

16. The host cell of Claim 13, wherein said host cell is selected from bacterial cell, yeast cell, plant cell, insect cell, and mammalian cell.

17. A method for expressing a nucleic acid sequence of interest, comprising:

a) providing:

i) a cell;

ii) a nucleic acid sequence of interest;

iii) a promoter sequence; and

iv) an age-related regulatory sequence selected from SEQ ID NO:93 and portions thereof;

b) operably linking said nucleic acid sequence of interest, said promoter sequence, and said age-related regulatory sequence to produce a transgene; and

c) introducing said transgene into said cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in said treated cell.

18. The method of Claim 17, wherein said treated cell is comprised in a tissue or organ in a living animal.

19. A substantially purified nucleic acid sequence comprising a nucleotide sequence selected from at least a portion of SEQ ID NO:85, and at least a portion of SEQ ID NO:92.

20. A method for expressing a nucleic acid sequence of interest, comprising:

a) providing:

i) a cell;

ii) a nucleic acid sequence of interest;

iii) a promoter sequence; and

iv) a nucleotide sequence having activity selected from age-related regulatory activity and regulatory activity, said nucleotide sequence selected from SEQ ID NO:92, a portion of SEQ ID NO:92, SEQ ID NO:85, a portion of SEQ ID NO:85, SEQ ID NO:89, and SEQ ID NO:90;

b) operably linking said nucleic acid sequence of interest, said promoter sequence, and said nucleotide sequence to produce a transgene; and

c) introducing said transgene into said cell to create a treated cell under conditions such that the nucleic acid sequence of interest is expressed in said treated cell.

Figure 1


-416FIXm1
-416
* pA
100
-416FIXm1/0.7
-416
* pA
119 ± 11
-416FIXm1/1.4
-416
* sl pA
68 ± 8
-590FIXm1
-590
* pA
107 ± 13
-679FIXm1
-679
* pA
98 ± 12
-770FIXm1
-770
* pA
104 ± 6
-802FIXm1
-802
* pA
115 ± 13
-802FIXm1/1.4
-802
* sl pA
77 ± 11
-2231FIXm1
-2231
* pA
109 ± 17
-2231FIXm1/1.4
-2231
* sl pA
82 ± 10
-416FIXm1/AE5'
-416
* pA
AE5'
86 ± 7


A
hFIX Level in Circulation (ng/ml)
Age (month)
FA661(m)s21mo
PA558(F1/f)d23mo
PA112(F1/f)s19mo
PA454(F1/m)d22mo
PA477(F2/m)d19mo
PA479(F2/m)d19mo
B
hFIX Level in Circulation (ng/ml)
Age (month)
F17933(m)d18mo
P656(F1/f)+
P814(F1/f)+
P815(F1/f)+
P981(F2/f)+
P982(F2/m)d22mo
C
hFIX Level in Circulation (ng/ml)
Age (month)
F1985(f)+
F1987(f)+
F22969(f)+
F22976(m)+
F22978(f)+
D
hFIX Level in Circulation (ng/ml)
Age (month)
F846(f)+
F886(f)+
F898(f)+
F905(m)+
F1060(m)+
F1068(f)+
E
hFIX Level in Circulation (ng/ml)
Age (month)
F562(f)+
F567(f)+
F568(f)+

Figure 2

Figure 3




A
hFIX Level In Circulation (ng/ml)
Age (month)
F17549(m)d14mo
P579 (F1/f)d19mo
P595(F1/f)k18mo
P746(F1m)d17mo
P774(F1/m)d21mo
P923(F2/m)d7mo
P928(F2/m)+
P949(F2/m)d6mo
B
hFIX Level In Circulation (ng/ml)
Age (month)
F229(m)+
P538(F1/m)d11mo
P540(F1/f)+
P680(F1/f)+
P681(F1/m)+
P20(F2/f)+
P22(F2/m)d8mo
P23(F2/m)d11mo
C
hFIX Level In Circuration (ng/ml)
Age (month)
F19679(f)+
P435(F1/m)+
P438(F1/f)+
P933(F1/f)+
P130(F2/m)+
P131(F2/m)+
P192(F2/m)+
P193(F2/m)+
D
hFIX Level In Circulation (ng/ml)
Age (month)
F1785(f)d22mo
P184(F1/m)d7mo
P186(F1/m)+
P187(F1/f)+
P189(F1/f)s16mo
P272(F1/m)d16mo
P812(F2/m)+
P814(F2/f)+
E
hFIX Level In Circulation (ng/ml)
Age (month)
F1654(f)+
F1659(f)+
F1912(m)+
F1959(m)+
F1993(m)+

Figure 4

Figure 5



Figure 6



Figure 7


HepG2
liver
lung
intestine
muscle
kidney
brain
heart
A
-28S
FIX→
-18S
RNR18→
B
-28S
FIX→
-18S
RNR18→

Figure 8A



Figure 8B



Figure 8C



Figure 8D



Figure 8E



Figure 9A

```
   1 gaattccgtg gatgtgcttt aaaaccacac ctaacgtttg agcacaagtc tcacgaactg
  61 gcgctacaac ttcatcagaa acgaagtctc caaatctgtc caacgcaaaa acacaaagga
 121 gtctaatgac taagtcttcc aaccacaact gtctgctgcg cccggaaaac aagccggggc
 181 tctggggacc cggggctcag gccgcctcgc tccggcctag ccccgccacc ttagttgtgt
 241 catccccccgg gcatgctgag catccccccg cggctccggc acagacgccc ggacctcagg
 301 tctctgcctc cgcgcggggg cccggccctg tggccggagg gagcggccgg atggagcgga
 361 ggatgaaagg cggatacttg gaccagcgag tgccctacac cttctgcagc aaatctcccg
 421 gaaatgggag cttgggcgaa gcgctgatgg tcccgcaggg aaagctcatg gacccgggct
 481 ccctgccgcc ttccgactca gaagatctct tccaggacct cagtcacttc caagagacgt
 541 ggctcgcaga agctcaggta ccggacagtg atgagcagtt tgttcctgat ttccattcag
 601 aaaacttagc tttccatagc cccaccacca ggatcaagaa ggaaccccag agtccccgca
 661 cagaccccgc cctgtcctgc agcaggaagc caccactccc ctaccaccat ggagagcagt
 721 gcctttactc cagacaaatc gccatcaagt cccccgctcc cggtgcccct ggacagtcgc
 781 ccctgcagcc cttttccagg gcagaacagc agcagagcct cctgagagcc tccagctctt
 841 cccagtccca ccctggccac gggtaccttg gtgagcacag ctccgtcttc cagcagcccg
 901 tggacatgtg ccactccttc acatctcctc agggaggggg ccgggaacct ctcccagccc
 961 cctatcaaca ccaactgtcg gagccctgcc caccctaccc ccagcagaac ttcaagcagg
1021 agtaccatga ccccctgtac gaacaggctg gccagcccgc ttcaagccag ggtggggtca
1081 gtgggcacag gtacccaggg gcgggggtgg tgatcaaaca ggagcgcaca gacttcgcct
1141 acgactcaga tgtccctgga tgtgcatcaa tgtacctcca cccagagggc ttctctggac
1201 cctctccagg tgatggagtg atgggttatg gctatgaaaa atcccttcga ccattcccag
1261 atgatgtctg cattgtccct aaaaaatttg aaggagacat caagcaggaa gggattggag
1321 ctttccggga ggggccaccc taccagcgcc ggggtgcctt acaactgtgg cagtttctgg
1381 tggccctgct ggatgaccca acaaatgctc atttcattgc ttggacaggc cggggaatgg
1441 agtttaaact aattgaacct gaagaggttg ccaggctctg gggtatccag aagaaccggc
1501 cagccatgaa ttatgacaag ctgagccgct cgctgcgata ctattatgag aaaggcatca
1561 tgcagaaggt ggctggcgaa cgctacgtgt acaagtttgt gtgcgagccg gaggccctgt
1621 tctctctggc cttcccagat aatcaacgtc cagctctgaa ggctgagttt gaccggccag
1681 tcagtgagga ggacacagtc cctttgtccc acttggatga gagtcctgcc tacctcccag
1741 aactcactgg ccccgctccg cccttcggcc acagaggtgg atattcttac taggcaccag
1801 tggcttcccc ttgacatggt ggggttgctc agtgtatata tcaactgatt tggtattggt
1861 gaaggccctc tttctgatgc ctgtagaagt ctctggggtc agagctccac tatcccatct
1921 gatactcctg gccagactca gctgctaacc agagtctgcg ggaaagacag tggaggcagg
1981 ccaaatctaa aggcagtagc tgaagttcgc tgtggctcac ctgtaccttc agttcagctt
2041 ggcctctgcc taggtcttgc tcagaggcca agttcctcac ccccaccaca gagatccagt
2101 gttctattct ggggacatac agggacttcc cttgtttatt atggcaacag ggccaagggg
2161 attctcagaa caccctgtgt ctccccctctc ccaacccccc atgggagaca aagttctgcc
2221 tggcttctgc cctgaacagg ggggtcctgt gttcttggtg ctgtgctctg ggaggcagga
2281 gcatgtgggc ggcagctggg gggggtgtgg gaagtagaga tggctctctg ccctaggcct
2341 acccaggcct aattccacct ttgcctctta tgccagacct taataaagcc tctgcttctc
2401 cccggaattc
```

Figure 9B

MTKSSNHNCLLRPENKPGLWGPGAQAASLRPSPATLVVSSPGHA

EHPPAAPAQTPGPQVSASARGPGPVAGGSGRMERRMKGGYLDQRVPYTFCSKSPGNGS

LGEALMVPQGKLMDPGSLPPSDSEDLFQDLSHFQETWLAEAQVPDSDEQFVPDFHSEN

LAFHSPTTRIKKEPQSPRTDPALSCSRKPPLPYHHGEQCLYSRQIAIKSPAPGAPGQS

PLQPFSRAEQQQSLLRASSSSQSHPGHGYLGEHSSVFQQPVDMCHSFTSPQGGGREPL

PAPYQHQLSEPCPPYPQQNFKQEYHDPLYEQAGQPASSQGGVSGHRYPGAGVVIKQER

TDFAYDSDVPGCASMYLHPEGFSGPSPGDGVMGYGYEKSLRPFPDDVCIVPKKFEGDI

KQEGIGAFREGPPYQRRGALQLWQFLVALLDDPTNAHFIAWTGRGMEFKLIEPEEVAR

LWGIQKNRPAMNYDKLSRSLRYYYEKGIMQKVAGERYVYKFVCEPEALFSLAFPDNQR

PALKAEFDRPVSEEDTVPLSHLDESPAYLPELTGPAPPFGHRGGYSY

Figure 10 (A)

```
   1 gaattccagg ttggaggggc ggcaacctcc tgccagcctt caggccactc tcctgtgcct
  61 gccagaagag acagagcttg aggagagctt gaggagagca ggaaaggtgg aacattgctg
 121 ctgctgctca ctcagttcca caggtgggag gaacagcagg gcttagagtg ggggtcattg
 181 tgcagatggg aaaacaaagg cccagaggagg ggaagaaatg cctaggagct accgagggca
 241 ggcgacctca accacagccc agtgctggag ctgtgagtgg atgtagagca gcggaatatc
 301 cattcagcca gctcagggga aggacagggg ccctgaagcc aggggatgga gctgcaggga
 361 agggagctca gagagaaggg gaggggagtc tgagctcagt ttcccgctgc ctgaaaggag
 421 ggtggtacct actcccttca cagggtaact gaatgagaga ctgcctggag gaaagctctt
 481 caagtgtggc ccaccccacc ccagtgacac cagcccctga cacgggggag ggagggcagc
 541 atcaggaggg gctttctggg cacacccagt acccgtctct gagctttcct tgaactgttg
 601 cattttaatc ctcacagcag ctcaacaagg tacataccgt caccatcccc attttacaga
 661 tagggaaatt gaggctcgga gcggttaaac aactcacctg aggcctcaca gccagtaagt
 721 gggttccctg gtctgaatgt gtgtgctgga ggatcctgtg ggtcactcgc ctggtagagc
 781 cccaaggtgg aggcataaat gggactggtg aatgacagaa ggggcaaaaa tgcactcatc
 841 cattcactct gcaagtatct acggcacgta cgccagctcc caagcaggtt tgcgggttgc
 901 acagcggagc gatgcaatct gatttaggct tttaaaggat tgcaatcaag tgggacccac
 961 tagcctcaac cctgtacctc ccctcccctc caccccagc agtctccaaa ggcctccaac
1021 aaccccagag tgggggccat gtatccaaag aaactccaag ctgtatacgg atcacactgg
1081 ttttccagga gcaaaaacag aaacagcctg aggctggtca aaattgaacc tcctcctgct
1141 ctgagcagcc taggggggcag actaagcaga gggctgtgca gacccacata aagagcctac
1201 tgtgtgccag gcacttcacc cgaggcactt cacaagcatg cttgggaatg aaacttccaa
1261 ctctttggga tgcaggtgaa acagttcctg gttcagagag gtgaagcggc ctgcctgagg
1321 cagcacagct cttctttaca gatgtgcttc cccacctcta ccctgtctca cggccccca
1381 tgccagcctg acggttgtgt ctgcctcagt catgctccat ttttccatcg ggaccatcaa
1441 gagggtgttt gtgtctaagg ctgactgggt aactttggat gagcggtctc tccgctccga
1501 gcctgtttcc tcatctgtca aacgggctct aacccactct gatctcccag ggcggcagta
1561 agtcttcagc atcaggcatt ttggggtgac tcagtaaatg gtagatcttg ctaccagtgg
1621 aacagccact aaggattctg cagtgagagc agagggccag ctaagtggta ctctcccaga
1681 gactgtctga ctcacgccac cccctccacc ttggacacag gacgctgtgg tttctgagcc
1741 aggtacaatg actcctttcg gtaagtgcag tggaagctgt acactgccca ggcaaagcgt
1801 ccgggcagcg taggcgggcg actcagatcc cagccagtgg acttagcccc tgtttgctcc
1861 tccgataact ggggtgacct tggttaatat tcaccagcag cctccccccgt tgcccctctg
1921 gatccactgc ttaaatacgg acgaggacag ggccctgtct cctcagcttc aggcaccacc
1981 actgacctgg gacagtgaat cgtaagtatg cctttcactg cgaggggttc tggagaggct
2041 tccgagctcc ccatggccca ggcaggcagc aggtctgggg caggaggggg gttgtggagt
2101 gggtatccgc ctgctgaggt gcagggcaga tggagaggct gcagctgagc tcctattttc
2161 ataataacag cagccatgag ggttgtgtcc tgtttcccag tcctgcccgg tccccctcg
2221 gtacctcctg gtggatacac tggttcctgt aagcagaagt ggatgagggt gtctaggtct
2281 gcagtcctgg caccccagga tgggggacac cagccaagat acagcaacag caacaaagcg
2341 cagccatttc tttctgtttg cacagctcct ctgtctgtcg ggggctcctg tctgttgtct
2401 cctataagcc tcaccacctc tcctactgct tgggcatgca tctttctccc cttctataga
2461 tgaggaggtt aaggttcaga gaggggtggg gaggaacgcc ggctcacatt ctccatcccc
2521 tccagatatg accaggaaca gacctgtgcc agcctcagcc ttacatcaaa atgggcctcc
2581 ccatgcaccg tggacctctg ggccctcctg tcccagtgga ggacaggaag ctgtgagggg
2641 cactgtcacc cagggctcaa gctggcattc ctgaataatc gctctgcacc aggccacggc
2701 taagctcagt gcgtgattaa gcctcataac cctccaaggc agttactagt gtgattccca
2761 ttttacagat gaggaagatg gggacagaga ggtgaataac tggccccaaa tcacacacca
2821 tccataattc gggctcaggc acctggctcc agtccccaaa ctcttgaacc tggccctagt
2881 gtcactgttt ctcttgggtc tcaggcgctg gatggggaac aggaaacctg ggctgaactt
2941 gaggcctctc tgatgctcgg tgacttcaga cagttgctca acctctctgt tctcttgggc
3001 aaaacatgat aacctttgac ttctgtcccc tcccctcacc ccacccgacc ttgatctctg
3061 aagtgttgga aggatttaat ttttcctgca ctgagttttg gagacaggtc aaaaagatga
3121 ccaaggccaa ggtggccagt ttcctataga acgcctctaa aagacctgca gcaatagcag
3181 caagaactgg tattctcgag aacttgctgc gcagcaggca cttcttggca ttttatgtgt
3241 atttaatttc acaatagctc tatgacaaag tccacctttc tcatctccag gaaactgagg
3301 ttcagagagg ttaagtaact tgtccaaggt cacacagcta atagcaagtt gacgtggagc
3361 aatctggcct cagagccttt aattttagcc acagactgat gctcccctct tcatttagcc
3421 aggctgcctc tgaagttttc tgattcaaga cttctggctt cagctttgta cacagagatg
```

Figure 10 (B)

```
3481 attcaatgtc aggttttgga gcgaaatctg tttaatccca gacaaaacat ttaggattac
3541 atctcagttt tgtaagcaag tagctctgtg atttttagtg agttatttaa tgctctttgg
3601 ggctcaattt ttctatctat aaaatagggc taataatttg caccttatag ggtaagcttt
3661 gaggacagat tagatgatac ggtgcctgta aaacaccagg tgttagtaag tgtggcaatg
3721 atggtgacgc tgaggctgtg tttgcttagc atagggttag gcagctggca ggcagtaaac
3781 agttggataa tttaatggaa aatttgccaa actcagatgc tgttcactgc tgagcaggag
3841 ccccttcctg ctgaaatggt cctggggagt gcagcaggct ctccgggaag aaatctacca
3901 tctctcgggc aggagctcaa cctgtgtgca ggtacaggga gggcttcctc acctggtgcc
3961 cactcatgca ttacgtcagt tattcctcat ccctgtccaa aggattcttt tctccattgt
4021 acagctatga agctagtgct caaagaagtg aagtcattta ccccaggccc cctgccagta
4081 agtgacaggg cctggtcaca cttgggttta tttattgccc agttcaacag gttgtttgac
4141 cataggcgag attctcttcc ctgcaccctg ccgggttgct cttggtccct tattttatgc
4201 tcctgggtag aaatggtgcg agattaggca gggagtggac gcttccctgt ccctggcccc
4261 gcaaagagtg ctcccacctg ccccgatccc agaaatgtca ccatgaagcc ttcattcttt
4321 tggtttaaag cttggcctca gtgtccgtac accatggggt ccttggccag atggcgactt
4381 tctcctctcc agtcgccctc ccaggcacta gcttttagga gtgcagggtg ctgcctctga
4441 tagaagggcc aggagagagc aggttttgga gacctgatgt tataaggaac agcttgggag
4501 gcataatgaa cccaacatga tgcttgagac caatgtcaca gcccaattct gacattcatc
4561 atctgagatc tgaggacaca gctgtctcag ttcatgatct gagtgctggg aaagccaaga
4621 cttgttccag ctttgtcact gacttgctgt atagcctcaa caaggccctg accctctctg
4681 ggcttcaaac tcttcactgt gaaaggagga aaccagagta ggtgatgtga caccaggaaa
4741 gatggatggg tgtgggggaa tgtgctcctc ccagctgtca ccccctcgcc accctccctg
4801 caccagcctc tccacctcct ttgagcccag aattcccctg tctaggaggg cacctgtctc
4861 gtgcctagcc atgggaattc tccatctgtt ttgctacatt gaacccagat gccattctaa
4921 ccaagaatcc tggctgggtg caggggctct cgcctgtaac cccagcactt tgggaggcca
4981 aggcaggcgg atcaagaggt caggagttca agacctgcct ggccaacacg gtgaaacctc
5041 agctctacta aaaatacaaa aattagccag gcgtggtggc acacgcctgt aatcccagct
5101 atttgggaag ctgagacaga agaatttctt gaacccggga ggtggaggtt tcagtgagcc
5161 gagatcacgc cactgcactc caccctggcg gataaagcga gactctgtct caaaaaaaac
5221 ccaaaaacct atgttagtgt acagagggcc ccagtgaagt cttctcccag ccccactttg
5281 cacaactggg gagagtgagg ccccaggacc agaggattct tgctaaaggc caagtggata
5341 gtgatggccc tgccaggcta gaagccacaa cctctggccc tgaggccact cagcatattt
5401 agtgtcccca ccctgcagag gcccaactcc ctcctgacca ctgagccctg taatgatggg
5461 ggaatttcca taagccatga aggactgcac aaagttcagt tgggagtgaa agagaaatta
5521 aagggagatg gaaatataca gcactaattt tagcaccgtc ttcagttcta acaacactag
5581 ctagctgaag aaaatacaaa catgtattat gtaatgtgtg gtctgttcca tttggattac
5641 ttagaggcac gagggccaag gagaaaggtg gtggagagaa accagctttg cacttcattt
5701 gttgctttat tggaaggaaa cttttaaaag tccaaggggg ttgaagaatc tcaatatttg
5761 ttatttccag ctttttttct ccagtttttc atttcccaaa ttcaaggaca ccttttttctt
5821 tgtattttgt taagatgatg gttttggttt tgtgactagt agttaacaat gtggctgccg
5881 ggcatattct cctcagctag gacctcagtt ttcccatctg tgaagacggc aggttctacc
5941 taggggggctg caggcaggtg gtccgaagcc tgggcatatc tggagtagaa ggatcactgt
6001 ggggcagggc aggttctgtg ttgctgtgga tgacgttgac tttgaccatt gctcggcaga
6061 gcctgctctc gctggttcag ccacaggccc caccactccc tattgtctca gccccgggta
6121 tgaaacatgt attcctcact ggcctatcac ctgaagcctt tgaatttgca acacctgcca
6181 acccctcccc caaaagagtt gccctctcta gatccttttg atgtaaggtt tggtgttgag
6241 acttatttca ctaaattctc atacataaac atcactttat gtatgaggca aaatgaggac
6301 cagggagatg aatgacttgt cctggctcat acacctggaa agtgacagag tcagattaga
6361 tcctaggtct atctgaagtt aaaagaggtg tcttttcact tcccacctcc tccatctact
6421 ttaaagcagc acaaacccct gctttcaagg agagatgagc gtctctaaag cccctgacag
6481 caagagccca gaactgggac accattagtg acccagacgg caggtaagct gactgcagga
6541 gcatcagcct attcttgtgt ctgggaccac agagcattgt ggggacagcc ccgtctcttg
6601 ggaaaaaaac cctaagggct gaggatcctt gtgagtgttg ggtgggaaca gctcccagga
6661 ggtttaatca cagcccctcc atgctctcta gctgttgcca ttgtgcaaga tgcatttccc
6721 ttctgtgcag cagtttccct ggccactaaa tagtgggatt agatagaagc cctccaaggg
6781 ctccagcttg acatgattct tgattctgat ctgacccgat tctgataatc gtgggcaggc
6841 ccattcctct tcttgtgcct cattttcttc ttttgtaaaa caatggctgt accatttgca
6901 tcttagggtc attgcagatg aaagtgttgc tgtccagagc ctgggtgcag gacctagatg
6961 taggattctg gttctgctac ttcctcagtg acattgaata gctgacctaa tctctctggc
7021 tttggtttct tcatctgtaa aagaaggata ttagcattag cacctcacgg gattgttaca
```

Figure 10 (C)

```
7081 agaaagcaat gaattaacac atgtgagcac ggagaacagt gcttggcata tggtaagcac
7141 tacgtacatt ttgctattct tctgattctt tcagtgttac tgatgtcggc aagtacttgg
7201 cacaggctgg tttaataatc cctaggcact ttcacgtggt gtcaatccct gatcactggg
7261 agtcatcatg tgccttgact cgggcctggc ccccccatct ctgtcttgca ggacaatgcc
7321 gtcttctgtc tcgtggggca tcctcctgct ggcaggcctg tgctgcctgg tccctgtctc
7381 cctggctgag gatccccagg gagatgctgc ccagaagaca gatacatccc accatgatca
7441 ggatcaccca accttcaaca agatcacccc caacctggct gagttcgcct tcagcctata
7501 ccgccagctg gcacaccagt ccaacagcac caatatcttc ttctccccag tgagcatcgc
7561 tacagccttt gcaatgctct ccctggggac caaggctgac actcacgatg aaatcctgga
7621 gggcctgaat ttcaacctca cggagattcc ggaggctcag atccatgaag gcttccagga
7681 actcctccgt accctcaacc agccagacag ccagctccag ctgaccaccg gcaatggcct
7741 gttcctcagc gagggcctga agctagtgga taagtttttg gaggatgtta aaaagttgta
7801 ccactcagaa gccttcactg tcaacttcgg ggacaccgaa gaggccaaga aacagatcaa
7861 cgattacgtg gagaagggta ctcaagggaa aattgtggat ttggtcaagg agcttgacag
7921 agacacagtt tttgctctgg tgaattacat cttctttaaa ggtaaggttg ctcaaccagc
7981 ctgagctgtt tcccatagaa acaagcaaaa atatttctca aaccatcagt tcttgaactc
8041 tccttggcaa tgcattatgg gccatagcaa tgcttttcag cgtggattct tcagttttct
8101 acacacaaac actaaaatgt tttccatcat tgagtaattt gaggaaataa tagattaaac
8161 tgtcaaaact actgacgctc tgcagaactt ttcagagcct ttaatgtcct tgtgtatact
8221 gtatatgtag aatatataat gcttagaact atagaacaaa ttgtaataca ctgcataaag
8281 ggatagtttc atggaacata ctttacacga ctctagtgtc ccagaatcag tatcagtttt
8341 gcaatctgaa agacctgggt tcaaatcctg cctctaacac aattagcttt tgacaaaaac
8401 aatgcattct acctctttga ggtgctaatt tctcatctta gcatggacaa aataccattc
8461 ttgctgtcag gttttttag gattaaacaa atgacaaaga ctgtggggat ggtgtgtggc
8521 atacagcagg tgatggactc ttctgtatct caggctgcct tcctgcccct gaggggttaa
8581 aatgccaggg tcctgggggc cccagggcat tctaagccag ctcccactgt cccaggaaaa
8641 cagcataggg gaggggaggt gggaggcaag gccaggggct gcttcctcca ctctgaggct
8701 cccttgctct tgaggcaaag gagggcagtg gaggcaagcc aggctgcagt cagcacagct
8761 aaagtcctgg ctctgctgtg gccttagtgg gggcccaggt ccctctccag ccccagtctc
8821 ctccttctgt ccaatgagaa agctgggatc aggggtccct gaggcccctg tccactctgc
8881 atgcctcgat ggtgaagctc tgttggtatg gcagagggga ggctgctcag gcatctgcat
8941 ttcccctgcc aatctagagg atgaggaaag ctctcaggaa tagtaagcag aatgtttgcc
9001 ctggatgaat aactgagctg ccaattaaca aggggcaggg agccttagac agaaggtacc
9061 aaatatgcct gatgctccaa cattttattt gtaatatcca agacaccctc aaataaacat
9121 atgattccaa taaaaatgca cagccacgat ggcatctctt agcctgacat cgccacgatg
9181 tagaaattct gcatcttcct ctagttttga attatcccca cacaatcttt ttcggcagct
9241 tggatggtca gtttcagcac cttttacaga tgatgaagct gagcctcgag ggatgtgtgt
9301 cgtcaagggg gctcagggct tctcagggag gggactcatg gtttcttatt ctgctacact
9361 cttccaaacc ttcactcacc cctggtgatg cccaccttcc cctctctcca ggcaaatggg
9421 agagaccctt tgaagtcaag gacaccgagg aagaggactt ccacgtggac caggtgacca
9481 ccgtgaaggt gcctatgatg aagcgtttag gcatgtttaa catccagcac tgtaagaagc
9541 tgtccagctg ggtgctgctg atgaaatacc tgggcaatgc caccgccatc ttcttcctgc
9601 ctgatgaggg gaaactacag cacctggtaa atgaactcac ccacgatatc atcaccaagt
9661 tcctggaaaa tgaagacaga aggtgattcc ccaacctgag ggtgaccaag aagctgccca
9721 cacctcttag ccatgttggg actgaggccc atcaggactg gccagagggc tgaggagggt
9781 gaaccccaca tccctgggtc actgctactc tgtataaact tggcttccag aatgaggcca
9841 ccactgagtt caggcagcgc cgtccatgct ccatgaggag aacagtaccc agggtgagga
9901 ggtaaaggtc tcgtccctgg gaacttccca ctccagtgtg gacactgtcc cttcccaata
9961 tccagtgccc aaggcaggga cagcagcacc accacacgtt ctggcagaac caaaaaggaa
10021 cagatgggct tcctggcaaa ggcagcagtg gagtgtggag ttcaagggta gaatgtccct
10081 ggggggacgg gggaagagcc tgtgtggcaa ggcccagaaa agcaaggttc ggaattggaa
10141 cagccaggcc atgttcgcag aaggcttgcg tttctctgtc actttatcgg tgctgttaga
10201 ttgggtgtcc tgtagtaagt gatacttaaa catgagccac acattagtgt atgtgtgtgc
10261 attcgtgatt atgcccatgc cctgctgatc tagttcgttt tgtacactgt aaaaccaaga
10321 tgaaaataca aaaggtgtcg ggttcataat aggaatcgag gctggaattt ctctgttcca
10381 tgccagcacc tcctgaggtc tctgctccag gggttgagaa agaacaaaga ggctgagagg
10441 gtaacggatc agagagccca gagccagctg ccgctcacac cagaccctgc tcagggtggc
10501 attgtctccc catggaaaac cagagaggag cactcagcct ggtgtggtca ctcttctctt
10561 atccactaaa cggttgtcac tgggcactgc caccagcccc gtgtttctct gggtgtaggg
10621 ccctggggat gttacaggct gggggccagg tgacccaaca ctacagggca agatgagaca
```

Figure 10 (D)

```
10681 ggcttccagg acacctagaa tatcagagga ggtggcattt caagcttttg tgattcattc
10741 gatgttaaca ttctttgact caatgtagaa gagctaaaag tagaacaaac caaagccgag
10801 ttcccatctt agtgtgggtg gaggacacag gagtaagtgg cagaaataat cagaaaagaa
10861 aacacttgca ctgtggtggg tcccagaaga acaagaggaa tgctgtgcca tgccttgaat
10921 ttcttttctg cacgacaggt ctgccagctt acatttaccc aaactgtcca ttactggaac
10981 ctatgatctg aagagcgtcc tgggtcaact gggcatcact aaggtcttca gcaatggggc
11041 tgacctctcc ggggtcacag aggaggcacc cctgaagctc tccaaggtga gatcaccctg
11101 acgaccttgt tgcaccatgg tatctgtagg gaagaatgtg tgggggctgc agcactgtcc
11161 tgaggctgag gaaggggccg agggaaacaa atgaagaccc aggctgagct cctgaagatg
11221 cccgtgattc actgacacgg gacggtgggc aaacagcaaa gccaggcagg ggctgctgtg
11281 cagctggcac tttcggggcc tcccttgagg ttgtgtcact gaccctgaat ttcaactttg
11341 cccaagacct tctagacatt gggccttgat ttatccatac tgacacagaa aggtttgggc
11401 taagttgttt caaaggaatt tctgactcct tcgatctgtg agatttggtg tctgaattaa
11461 tgaatgattt cagctaaagt gacacttatt ttggaaaact aaaggcgacc aatgaacaac
11521 ctgcagttcc atgaatggct gcattatctt ggggtctggg cactgtgaag gtcactgcca
11581 gggtccgtgt cctcaaggag cttcaagccg tgtactagaa aggagagagc cctggaggca
11641 gacgtggagt gacgatgctc ttccctgttc tgagttgtgg gtgcacctga gcaggggaag
11701 aggcgcttgt caggaagatg gacagagggg agccagcccc atcagccaaa gccttgagga
11761 ggagcaaggc ctatgtgaca gggagggaga ggatgtgcag ggccagggcc gtccaggggg
11821 agtgagcgct tcctgggagg tgtccacgtg agccttgctc gaggcctggg atcagcctta
11881 caacgtgtct ctgcttctct cccctccagg ccgtgcataa ggctgtgctg accatcgacg
11941 agaaagggac tgaagctgct ggggccatgt ttttagaggc catacccatg tctatccccc
12001 ccgaggtcaa gttcaacaaa ccctttgtct tcttaatgat tgaacaaaat accaagtctc
12061 ccctcttcat gggaaaagtg gtgaatccca cccaaaaata actgcctctc gctcctcaac
12121 ccctcccctc catccctggc cccctccctg gatgacatta aagaagggtt gagctggtcc
12181 ctgcctgcat gtgatctgta aatccctggg atgttttctc tg
```

Figure 11

```
   1 caccagcatc atctcctcca attcatccag ctactctgcc catgaagata atagttttca
  61 ggcggattgc ctcagatcac actatctcca cttgcccagc cctgtggaag attagcggcc
 121 atgtattcca atgtgatagg aactgtaacc tctggaaaaa ggaaggttta tcttttgtcc
 181 ttgctgctca ttggcttctg ggactgcgtg acctgtcacg ggagccctgt ggacatctgc
 241 acagccaagc cgcgggacat tcccatgaat cccatgtgca tttaccgctc cccggagaag
 301 aaggcaactg aggatgaggg ctcagaacag aagatcccgg aggccaccaa ccggcgtgtc
 361 tgggaactgt ccaaggccaa ttcccgcttt gctaccactt tctatcagca cctggcagat
 421 tccaagaatg acaatgataa cattttcctg tcacccctga gtatctccac ggcttttgct
 481 atgaccaagc tgggtgcctg taatgacacc ctccagcaac tgatggaggt atttaagttt
 541 gacaccatat ctgagaaaac atctgatcag atccacttct tctttgccaa actgaactgc
 601 cgactctatc gaaaagccaa caaatcctcc aagttagtat cagccaatcg ccttttgga
 661 gacaaatccc ttaccttcaa tgagacctac caggacatca gtgagttggt atatggagcc
 721 aagctccagc ccctggactt caaggaaaat gcagagcaat ccagagcggc catcaacaaa
 781 tgggtgtcca ataagaccga aggccgaatc accgatgtca ttccctcgga agccatcaat
 841 gagctcactg ttctggtgct ggttaacacc atttacttca agggcctgtg gaagtcaaag
 901 ttcagccctg agaacacaag gaaggaactg ttctacaagg ctgatggaga gtcgtgttca
 961 gcatctatga tgtaccagga aggcaagttc cgttatcggc gcgtggctga aggcacccag
1021 gtgcttgagt tgcccttcaa aggtgatgac atcaccatgg tcctcatctt gcccaagcct
1081 gagaagagcc tggccaaggt ggagaaggaa ctcaccccag aggtgctgca ggagtggctg
1141 gatgaattgg aggagatgat gctggtggtt cacatgcccc gcttccgcat tgaggacggc
1201 ttcagtttga aggagcagct gcaagacatg ggccttgtcg atctgttcag ccctgaaaag
1261 tccaaactcc caggtattgt tgcagaaggc cgagatgacc tctatgtctc agatgcattc
1321 cataaggcat ttcttgaggt aaatgaagaa ggcagtgaag cagctgcaag taccgctgtt
1381 gtgattgctg gccgttcgct aaaccccaac agggtgactt tcaaggccaa caggcccttc
1441 ctggttttta taagagaagt tcctctgaac actattatct tcatgggcag agtagccaac
1501 ccttgtgtta agtaaaatgt tcttattctt tgcacctctt cctatttttg gtttgtgaac
1561 agaagtaaaa ataaatacaa actacttcca tctcacatt
```

Figure 12 A

```
   1 ctgcaggggg gggggggggg gggggctgtc atggcggcag gacggcgaac ttgcagtatc
  61 tccacgaccc gcccctacag gtgccagtgc ctccagaatg tggcagctca caagcctcct
 121 gctgttcgtg gccacctggg gaatttccgg cacaccagct cctcttgact cagtgttctc
 181 cagcagcgag cgtgcccacc aggtgctgcg gatccgcaaa cgtgccaact ccttcctgga
 241 ggagctccgt cacagcagcc tggagcggga gtgcatagag gagatctgtg acttcgagga
 301 ggccaaggaa attttccaaa atgtggatga cacactggcc ttctggtcca agcacgtcga
 361 cggtgaccag tgcttggtct tgcccttgga gcacccgtgc gccagcctgt gctgcgggca
 421 cggcacgtgc atcgacggca tcggcagctt cagctgcgac tgccgcagcg gctgggaggg
 481 ccgcttctgc cagcgcgagg tgagcttcct caattgctcg ctggacaacg gcggctgcac
 541 gcattactgc ctagaggagg tgggctggcg gcgctgtagc tgtgcgcctg gctacaagct
 601 gggggacgac ctcctgcagt gtcaccccgc agtgaagttc ccttgtggga ggccctggaa
 661 gcggatggag aagaagcgca gtcacctgaa acgagacaca gaagaccaag aagaccaagt
 721 agatccgcgg ctcattgatg ggaagatgac caggcgggga gacagcccct ggcaggtggt
 781 cctgctggac tcaaagaaga agctggcctg cggggcagtg ctcatccacc cctcctgggt
 841 gctgacagcg gcccactgca tggatgagtc caagaagctc cttgtcaggc ttggagagta
 901 tgacctgcgg cgctgggaga agtgggagct ggacctggac atcaaggagg tcttcgtcca
 961 ccccaactac agcaagagca ccaccgacaa tgacatcgca ctgctgcacc tggcccagcc
1021 cgccaccctc tcgcagacca tagtgcccat ctgcctcccg gacagcggcc ttgcagagcg
1081 cgagctcaat caggccggcc aggagaccct cgtgacgggc tggggctacc acagcagccg
1141 agagaaggag gccaagagaa accgcacctt cgtcctcaac ttcatcaaga ttcccgtggt
1201 cccgcacaat gagtgcagcg aggtcatgag caacatggtg tctgagaaca tgctgtgtgc
1261 gggcatcctc ggggaccggc aggatgcctg cgagggcgac agtggggggc ccatggtcgc
1321 ctccttccac ggcacctggt tcctggtggg cctggtgagc tggggtgagg gctgtgggct
1381 ccttcacaac tacggcgttt acaccaaagt cagccgctac ctcgactgga tccatgggca
1441 catcagagac aaggaagccc cccagaagag ctgggcacct tagcgaccct ccctgcaggg
1501 ctgggctttt gcatggcaat ggatgggaca ttaaagggac atgtaacaag cacaccggcc
1561 tgctgttctg tccttccatc cctcttttgg gctcttctgg agggaagtaa catttactga
1621 gcacctgttg tatgtcacat gccttatgaa tagaatctta actcctagag caactctgtg
1681 gggtggggag gagcagatcc aagttttgcg gggtctaaag ctgtgtgtgt tgaggggat
1741 actctgttta tgaaaaagaa taaaaaacac aaccacgaaa aaaaaaaaaa aaaaaaaaaa
1801 aaaaaaaaaa aaaaaaaccc ccccccgccc ccccccccctg cag
```

Figure 12 B

```
   1 agtgaatctg ggcgagtaac acaaaacttg agtgtcctta cctgaaaaat agaggttaga
  61 gggatgctat gtgccattgt gtgtgtgtgt tgggggtggg gattgggggt gatttgtgag
 121 caattggagg tgagggtgga gcccagtgcc cagcacctat gcactgggga cccaaaaagg
 181 agcatcttct catgatttta tgtatcagaa attgggatgg catgtcattg ggacagcgtc
 241 ttttttcttg tatggtggca cataaataca tgtgtcttat aattaatggt attttagatt
 301 tgacgaaata tggaatatta cctgttgtgc tgatcttggg caaactataa tatctctggg
 361 caaaaatgtc cccatctgaa aaacagggac aacgttcctc cctcagccag ccactatggg
 421 gctaaaatga gaccacatct gtcaagggtt ttgccctcac ctccctccct gctggatggc
 481 atccttggta ggcagaggtg ggcttcgggc agaacaagcc gtgctgagct aggaccagga
 541 gtgctagtgc cactgtttgt ctatggagag ggaggcctca gtgctgaggg ccaagcaaat
 601 atttgtggtt atggattaac tcgaactcca ggctgtcatg gcggcaggac ggcgaacttg
 661 cagtatctcc acgacccgcc cctgtgagtc cccctccagg caggtctatg aggggtgtgg
 721 agggagggct gcccccggga gaagagagct aggtggtgat gagggctgaa tcctccagcc
 781 agggtgctca acaagcctga gcttggggta aaaggacaca aggccctcca caggccaggc
 841 ctggcagcca cagtctcagg tccctttgcc atgcgcctcc ctctttccag gccaagggtc
 901 cccaggccca gggccattcc aacagacagt ttggagccca ggaccctcca ttctccccac
 961 cccacttcca cctttggggg tgtcggattt gaacaaatct cagaagcggc ctcagaggga
1021 gtcggcaaga atggagagca gggtccggta gggtgtgcag aggccacgtg gcctatccac
1081 tggggagggt tccttgatct ctggccacca gggctatctc tgtggccttt tggagcaacc
1141 tggtggtttg gggcaggggt tgaatttcca ggcctaaaac cacacaggcc tggccttgag
1201 tcctggctct gcgagtaatg catggatgta aacatggaga cccaggacct tgcctcagtc
1261 ttccgagtct ggtgcctgca gtgtactgat ggtgtgagac cctactcctg gaggatgggg
1321 gacagaatct gatcgatccc ctgggttggt gacttccctg tgcaatcaac ggagaccagc
1381 aagggttgga tttttaataa accacttaac tcctccgagt ctcagtttcc ccctctatga
1441 aatggggttg acagcattaa taactacctc ttgggtggtt gtgagcctta actgaagtca
1501 taatatctca tgtttactga gcatgagcta tgtgcaaagc ctgttttgag agctttatgt
1561 ggactaactc ctttaattct cacaacaccc tttaaggcac agatacacca cgttattcca
1621 tccattttac aaatgaggaa actgaggcat ggagcagtta agcatcttgc ccaacattgc
1681 cctccagtaa gtgctggagc tggaatttgc accgtgcagt ctggcttcat ggcctgccct
1741 gtgaatcctg taaaaattgt ttgaaagaca ccatgagtgt ccaatcaacg ttagctaata
1801 ttctcagccc agtcatcaga ccggcagagg cagccacccc actgtcccca gggaggacac
1861 aaacatcctg gcaccctctc cactgcattc tggagctgct ttctaggcag gcagtgtgag
1921 ctcagcccca cgtagagcgg gcagccgagg ccttctgagg ctatgtctct agcgaacaag
1981 gaccctcaat tccagcttcc gcctgacggc cagcacacag ggacagccct ttcattccgc
2041 ttccacctgg gggtgcaggc agagcagcag cgggggtagc actgcccgga gctcagaagt
2101 cctcctcaga caggtgccag tgcctccaga atgtggcagc tcacaagcct cctgctgttc
2161 gtggccacct ggggaatttc cggcacacca gctcctcttg gtaaggccac cccacccctа
2221 ccccgggacc cttgtggcct ctacaaggcc ctggtggcat ctgcccaggc cttcacagct
2281 tccaccatct ctctgagccc tgggtgaggt gaggggcaga tgggaatggc aggaatcaac
2341 tgacaagtcc caggtaggcc agctgccaga gtgccacaca ggggctgcca gggcaggcat
2401 gcgtgatggc agggagcccc gcgatgacct cctaaagctc cctcctccac acggggatgg
2461 tcacagagtc ccctgggcct tccctctcca cccactcact ccctcaactg tgaagacccc
2521 aggcccaggc taccgtccac actatccagc acagcctccc ctactcaaat gcacactggc
2581 ctcatggctg ccctgcccca acccctttcc tggtctccac agccaacggg aggaggccat
2641 gattcttggg gaggtccgca ggcacatggg cccctaaagc cacaccaggc tgttggtttc
2701 atttgtgcct ttatagagct gtttatctgc ttgggacctg cacctccacc ctttcccaag
2761 gtgccctcag ctcaggcata ccctcctcta ggatgccttt tcccccatcc cttcttgctc
2821 acacccccaa cttgatctct ccctcctaac tgtgccctgc accaagacag acacttcaca
2881 gagcccagga cacacctggg gacccttcct gggtgatagg tctgtctatc ctccaggtgt
2941 ccctgcccaa ggggagaagc atggggaata cttggttggg ggaggaaagg aagactgggg
3001 ggatgtgtca agatggggct gcatgtggtg tactggcaga agagtgagag gatttaactt
3061 ggcagccttt acagcagcag ccagggcttg agtacttatc tctgggccag gctgtattgg
3121 atgttttaca tgacggtctc atccccatgt ttttggatga gtaaattgaa ccttagaaag
3181 gtaaagacac tggctcaagg tcacacagag atcggggtgg ggttcacagg gaggcctgtc
3241 catctcagag caaggcttcg tcctccaact gccatctgct tcctggggag gaaaagagca
3301 gaggacccct gcgccaagcc atgacctaga attagaatga gtcttgaggg ggcggagaca
3361 agaccttccc aggctctccc agctctgctt cctcagaccc cctcatggcc ccagccctc
3421 ttaggcccct caccaaggtg agctcccctc cctccaaaac cagactcagt gttctccagc
3481 agcgagcgtg cccaccaggt gctgcggatc cgcaaacgtg ccaactcctt cctggaggag
3541 ctccgtcaca gcagcctgga gcgggagtgc atagaggaga tctgtgactt cgaggaggcc
```

Figure 12 B (continued)

3601 aaggaaattt tccaaaatgt ggatgacaca gtaaggccac catgggtcca gaggatgagg
3661 ctcaggggcg agctggtaac cagcaggggc ctcgaggagc aggtggggac tcaatgctga
3721 ggccctctta ggagttgtgg gggtggctga gtggagcgat taggatgctg gccctatgat
3781 gtcggccagg cacatgtgac tgcaagaaac agaattcagg aagaagctcc aggaaagagt
3841 gtggggtgac cctaggtggg gactcccaca gccacagtgt aggtggttca gtccaccctc
3901 cagccactgc tgagcaccac tgcctccccg tcccacctca caaagagggg acctaaagac
3961 caccctgctt ccacccatgc ctctgctgat cagggtgtgt gtgtgaccga aactcacttc
4021 tgtccacata aaatcgctca ctctgtgcct cacatcaaag ggagaaaatc tgattgttca
4081 gggggtcgga agacagggtc tgtgtcctat ttgtctaagg gtcagagtcc tttggagccc
4141 ccagagtcct gtggacgtgg ccctaggtag tagggtgagc ttggtaacgg ggctggcttc
4201 ctgagacaag gctcagaccc gctctgtccc tggggatcgc ttcagccacc aggacctgaa
4261 aattgtgcac gcctgggccc ccttccaagg catccaggga tgctttccag tggaggcttt
4321 cagggcagga gaccctctgg cctgcaccct ctcttgccct cagcctccac ctccttgact
4381 ggacccccat ctggacctcc atccccacca cctctttccc cagtggcctc cctggcagac
4441 accacagtga ctttctgcag gcacatatct gatcacatca agtccccacc gtgctcccac
4501 ctcacccatg gtctctcagc cccagcagcc ttggctggcc tctctgatgg agcaggcatc
4561 aggcacaggc cgtgggtctc aacgtgggct gggtggtcct ggaccagcag cagccgccgc
4621 agcagcaacc ctggtacctg gttaggaacg cagaccctct gcccccatcc tcccaactct
4681 gaaaaacact ggcttaggga aaggcgcgat gctcaggggt cccccaaagc ccgcaggcag
4741 agggagtgat gggactggaa ggaggccgag tgacttggtg agggattcgg gtcccttgca
4801 tgcagaggct gctgtgggag cggacagtcg cgagagcagc actgcagctg catggggaga
4861 gggtgttgct ccagggacgt gggatggagg ctgggcgcgg gcgggtggcg ctggagggcg
4921 ggggaggggc agggagcacc agctcctagc agccaacgac catcgggcgt cgatccctgt
4981 ttgtctggaa gccctcccct cccctgcccg ctcacccgct gccctgcccc acccgggcgc
5041 gcccctccgc acaccggctg caggagcctg acgctgcccg ctctctccgc agctggcctt
5101 ctggtccaag cacgtcggtg agtgcgttct agatccccgg ctggactacc ggcgcccgcg
5161 cccctcggga tctctggccg ctgacccccc accccgcctt gtgtcgcaga cggtgaccag
5221 tgcttggtct tgcccttgga gcacccgtgc gccagcctgt gctgcgggca cggcacgtgc
5281 atcgacggca tcggcagctt cagctgcgac tgccgcagcg gctgggaggg ccgcttctgc
5341 cagcgcggtg aggggagag gtggatgctg gcgggcggcg gggcggggct ggggccgggt
5401 tgggggcgcg gcaccagcac cagctgcccg cgccctcccc tgcccgcaga ggtgagcttc
5461 ctcaattgct ctctggacaa cggcggctgc acgcattact gcctagagga ggtgggctgg
5521 cggcgctgta gctgtgcgcc tggctacaag ctgggggacg acctcctgca gtgtcacccc
5581 gcaggtgaga agcccccaat acatcgccca ggaatcacgc tgggtgcggg gtgggcaggc
5641 ccctgacggg cgcggcgcgg ggggctcagg agggtttcta gggagggagc gaggaacaga
5701 gttgagcctt ggggcagcgg cagacgcgcc caacaccggg gccactgtta gcgcaatcag
5761 cccgggagct gggcgcgccc tccgctttcc ctgcttcctt tcttcctggc gtccccgctt
5821 cctccgggcg cccctgcgac ctggggccac ctcctggagc gcaagcccag tggtggctcc
5881 gctccccagt ctgagcgtat ctggggcgag gcgtgcagcg tcctcctcca tgtagcctgg
5941 ctgcgttttt ctctgacgtt gtccggcgtg catcgcattt ccctctttac ccccttgctt
6001 ccttgaggag agaacagaat cccgattctg ccttcttcta tattttcctt tttatgcatt
6061 ttaatcaaat ttatatatgt atgaaacttt aaaaatcaga gttttacaac tcttacactt
6121 tcagcatgct gttccttggc atgggtcctt ttttcattca ttttcataaa aggtggaccc
6181 ttttaatgtg gaaattccta tcttctgcct ctagggcatt tatcacttat ttcttctaca
6241 atctcccctt tacttcctct attttctctt tctggacctc ccattattca gacctctttc
6301 ctctagtttt attgtctctt ctatttccca tctctttgac tttgtgtttt ctttcaggga
6361 actttctttt ttttcttttt ttttgagatg gagtttcact cttgttgtcc caggctggag
6421 tgcaatgacg tgatctcagc tcaccacaac ctccgcctcc tggattcaag cgattctcct
6481 gccgcagcct cccgagtagc tgggattaca ggcatgcgcc accacgccca gctaattttg
6541 tgtttttagt agagaagggg tttctccgtg ttggtcaagc tggtcttgaa ctcctgacct
6601 caggtgatcc acctgccttg gcctcctaaa gtgctgggat tacaggcgtg agccaccgcg
6661 cccagcctct ttcagggaac tttctacaac tttataattc aattcttctg cagaaaaaaa
6721 tttttggcca ggctcagtag ctcagaccaa taattccagc actttgagag gctgaggtgg
6781 gaggattgct tgagcttggg agtttgagac tagcctgggc aacacagtga gaccctgtct
6841 ctatttttaa aaaaagtaaa aaaagatcta aaaatttaac tttttatttt gaaataatta
6901 gatatttcca ggaagctgca aagaaatgcc tggtgggcct gttggctgtg ggtttcctgc
6961 aaggccgtgg gaaggccctg tcattggcag aaccccagat cgtgagggct ttccttttag
7021 gctgctttct aagaggactc ctccaagctc ttggaggatg gaagacgctc acccatggtg
7081 ttcggcccct cagagcaggg tggggcaggg gagctggtgc ctgtgcaggc tgtggacatt
7141 tgcatgactc cctgtggtca gctaagagca ccactccttc ctgaagcggg gcctgaagtc

Figure 12 B (continued)

7201 cctagtcaga gcctctggtt caccttctgc aggcagggag aggggagtca agtcagtgag
7261 gagggctttc gcagtttctc ttacaaactc tcaacatgcc ctcccacctg cactgccttc
7321 ctggaagccc cacagcctcc tatggttccg tggtccagtc cttcagcttc tgggcgcccc
7381 catcacgggc tgagattttt gctttccagt ctgccaagtc agttactgtg tccatccatc
7441 tgctgtcagc ttctggaatt gttgctgttg tgccctttcc attcttttgt tatgatgcag
7501 ctcccctgct gacgacgtcc cattgctctt ttaagtctag atatctggac tgggcattca
7561 aggcccattt tgagcagagt cgggctgacc tttcagccct cagttctcca tggagtatgc
7621 gctctcttct tggcagggag gcctcacaaa catgccatgc ctattgtagc agctctccaa
7681 gaatgctcac ctccttctcc ctgtaattcc tttcctctgt gaggagctca gcagcatccc
7741 attatgagac cttactaatc ccagggatca cccccaacag ccctggggta caatgagctt
7801 ttaagaagtt taaccaccta tgtaaggaga cacaggcagt gggcgatgct gcctggcctg
7861 actcttgcca ttgggtggta ctgtttgttg actgactgac tgactgactg gaggggttt
7921 gtaatttgta tctcagggat taccccccaac agccctgggg tacaatgagc cttcaagaag
7981 tttaacaacc tatgtaagga cacacagcca gtgggtgatg ctgcctggtc tgactcttgc
8041 cattcagtgg cactgtttgt tgactgactg actgactgac tggctgactg gaggggttc
8101 atagctaata ttaatggagt ggtctaagta tcattggttc cttgaaccct gcactgtggc
8161 aaagtggccc acaggctgga ggaggaccaa gacaggaggg cagtctcggg aggagtgcct
8221 ggcaggcccc tcaccacctc tgcctacctc agtgaagttc ccttgtggga ggccctggaa
8281 gcggatggag aagaagcgca gtcacctgaa acgagacaca gaagaccaag aagaccaagt
8341 agatccgcgg ctcattgatg ggaagatgac caggcgggga gacagcccct ggcaggtggg
8401 aggcgaggca gcaccggctc gtcacgtgct gggtccggga tcactgagtc catcctggca
8461 gctatgctca gggtgcagaa accgagaggg aagcgctgcc attgcgtttg ggggatgatg
8521 aaggtggggg atgcttcagg gaaagatgga cgcaacctga ggggagagga gcagccaggg
8581 tgggtgaggg gaggggcatg ggggcatgga ggggtctgca ggagggaggg ttacagtttc
8641 taaaaagagc tggaaagaca ctgctctgct ggcgggattt taggcagaag ccctgctgat
8701 gggagagggc taggagggag ggccgggcct gagtacccct ccagcctcca catgggaact
8761 gacacttact gggttcccct ctctgccagg catgggggag ataggaacca acaagtggga
8821 gtatttgccc tggggactca gactctgcaa gggtcaggac cccaaagacc cggcagccca
8881 gtgggaccac agccaggacg gcccttcaag ataggggctg agggaggcca aggggaacat
8941 ccaggcagcc tgggggccac aaagtcttcc tggaagacac aaggcctgcc aagcctctaa
9001 ggatgagagg agctcgctgg gcgatgttgg tgtggctgag ggtgactgaa acagtatgaa
9061 cagtgcagga acagcatggg caaaggcagg aagacaccct gggacaggct gacactgtaa
9121 aatgggcaaa aatagaaaac gccagaaagg cctaagccta tgcccatatg accagggaac
9181 ccaggaaagt gcatatgaaa cccaggtgcc ctggactgga ggctgtcagg aggcagccct
9241 gtgatgtcat catcccaccc cattccaggt ggtcctgctg gactcaaaga agaagctggc
9301 ctgcggggca gtgctcatcc acccctcctg ggtgctgaca gcggcccact gcatggatga
9361 gtccaagaag ctccttgtca ggcttggtat gggctggagc caggcagaag ggggctgcca
9421 gaggcctggg taggggacc aggcaggctg ttcaggtttg ggggaccccg ctccccaggt
9481 gcttaagcaa gaggcttctt gagctccaca gaaggtgttt ggggggaaga ggcctatgtg
9541 cccccaccct gcccacccat gtacacccag tattttgcag taggggggttc tctggtgccc
9601 tcttcgaatc tgggcacagg tacctgcaca cacatgtttg tgaggggcta cacagacctt
9661 cacctctcca ctcccactca tgaggagcag gctgtgtggg cctcagcacc cttgggtgca
9721 gagaccagca aggcctggcc tcagggctgt gcctcccaca gactgacagg gatggagctg
9781 tacagaggga gccctagcat ctgccaaagc cacaagctgc ttccctagca ggctgggggc
9841 tcctatgcat tggccccgat ctatggcaat ttctggaggg ggggtctggc tcaactcttt
9901 atgccaaaaa gaaggcaaag catattgaga aaggccaaat tcacatttcc tacagcataa
9961 tctatgccag tggccccgtg gggcttggct tagaattccc aggtgctctt cccagggaac
10021 catcagtctg gactgagagg accttctctc tcaggtggga cccggccctg tcctccctgg
10081 cagtgccgtg ttctgggggt cctcctctct gggtctcact gcccctgggg tctctccagc
10141 tacctttgct ccatgttcct ttgtggctct ggtctgtgtc tggggtttcc aggggtctcg
10201 ggcttccctg ctgcccattc cttctctggt ctcacggctc cgtgactcct gaaaaccaac
10261 cagcatccta ccccttttgga ttgacacctg ttggccactc cttctggcag gaaaagtcac
10321 cgttgatagg gttccacggc atagacaggt ggctccgcgc cagtgcctgg gacgtgtggg
10381 tgcacagtct ccgggtgaac cttcttcagg ccctctccca ggcctgcagg ggcacagcag
10441 tgggtgggcc tcaggaaagt gccactgggg agaggctccc cgcagcccac tctgactgtg
10501 ccctctgccc tgcaggagag tatgacctgc ggcgctggga gaagtgggag ctggacctgg
10561 acatcaagga ggtcttcgtc caccccaact acagcaagag caccaccgac aatgacatcg
10621 cactgctgca cctggcccag cccgccaccc tctcgcagac catagtgccc atctgcctcc
10681 cggacagcgg ccttgcagag cgcgagctca atcaggccgg ccaggagacc ctcgtgacgg
10741 gctggggcta ccacagcagc cgagagaagg aggccaagag aaaccgcacc ttcgtcctca
10801 acttcatcaa gattcccgtg gtcccgcaca atgagtgcag cgaggtcatg agcaacatgg

Figure 12 B (continued)

```
10861 tgtctgagaa catgctgtgt gcgggcatcc tcggggaccg gcaggatgcc tgcgagggcg
10921 acagtggggg gcccatggtc gcctccttcc acggcacctg gttcctggtg ggcctggtga
10981 gctggggtga gggctgtggg ctccttcaca actacggcgt ttacaccaaa gtcagccgct
11041 acctcgactg gatccatggg cacatcagag acaaggaagc cccccagaag agctgggcac
11101 cttagcgacc ctcccctgcag ggctgggctt ttgcatggca atggatggga cattaaaggg
11161 acatgtaaca agcacaccgg cctgctgttc tgtccttcca tccctctttt gggctcttct
11221 ggagggaagt aacatttact gagcacctgt tgtatgtcac atgccttatg aatagaatct
11281 taactcctag agcaactctg tggggtgggg aggagcagat ccaagttttg cggggtctaa
11341 agctgtgtgt gttgaggggg atactctgtt tatgaaaaag aataaaaaac acaaccacga
11401 agccactaga gccttttcca gggctttggg aagagcctgt gcaagccggg gatgctgaag
11461 gtgaggcttg accagctttc cagctagccc agctatgagg tagacatgtt tagctcatat
11521 cacagaggag gaaactgagg ggtctgaaag gtttacatgg tggagccagg attcaaatct
11581 aggtctgact ccaaaaccca ggtgcttttt tctgttctcc actgtcctgg aggacagctg
11641 tttcgacggt gctcagtgtg gaggccacta ttagctctgt agggaagcag ccagagaccc
11701 agaaagtgtt ggttcagccc agaat
```

Figure 13 (A)

SEQ ID NO:3

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

SEQ ID NO:76

ggcctctg actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

Figure 13 (B)

SEQ ID NO:77

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaaat ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

SEQ ID NO:78

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggacg atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

Figure 13 (C)

SEQ ID NO:79

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat gtactctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

SEQ ID NO:80

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atttcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

Figure 13 (D)

SEQ ID NO:81

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctgctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

SEQ ID NO:82

ggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttatcct
tctatcttga atctt

Figure 13 (E)

SEQ ID NO:83

gcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct
tctatcttga atctt

Figure 14


GAATTCTGTA AGCATTTCCT ATGTGTACCT GCCCCTGGGC AAGGTGGGCC TGACTTGTTA -1403
GAGTGTTAGA GTTTTACCCT GTTCCTCTAG GAGGGCCTGG TACCACCACA GCCCAGCATG -1343
GTGTGGTGCC TCAGCAGGAG GCATCTGGTT ACAATCAACA CAAGCTGTTC CAGCCAATTT -1283
AAAGAAACTT CAGGAGGAAT AGGGTTTTAG GAGGGCATGG GGACCCTCCT GCACCCGAAG -1223
CCAGGATGTG CCACCAATCA TAAGGAGGCA GGGGCCTCCT TCCGCTGCTC CCTGGGACTC -1163
TCTAGGTGTC CGTGGCCTCA GCCCCCCTCT GCACACCTGC ATCTTCCTTC TCATCAGCTT -1103
CCTCTGCTTT AAGCGTAAAC ATGGATGCCC AGGACCTGGC CTCAATCTTC CGAGTCTGGT -1043
ACTTATGGTG TACTGACAGT GTGAGACCCT ACTCCTCTGA TCAATCCCCT GGGTTGGTGA -983
CTTCCCTGTG CAATCAATGG AAGCCAGCGA GGCAGGGTCA CATGCCCCGT TTAGAGGTGC -923
AGACTTGGAG AAGGAACGTG GGCAAGTCTT CCCAGGAACA GGTAGGGCAG GGAGGAAAGG -863
GGGGCATCTC TGGTGCAGCC CGGTTCGGAG CAGGAAGACG CTTAATAAAT GCTGATAGAC -803
TGCAGGACAC AGGCAAAGGT GCTGAGCTGG ACCCTTTATT TCTGCCCTTC TCCCTTCTGG -743
CACCCCGGCC AGGAAATTGC TGCAGCCTTT CTGGAATCCC GTTCATTTTT CTTACTGGTC -683
CACAAAAGGG GCCAAATGGA AGCAGCAAGA CCTGAGTTCA AATTAAATCT GCCAACTACC -623
AGCTCAGTGA ATCTGGGCGA GTAACACAAA ACTTGAGTGT CCTTACCTGA AAAATAGAGG -563
TTAGAGGGAT GCTATGTGCC ATTGTGTGTG TGTGTTGGGG GTGGGGATTG GGGGTGATTT -503
GTGAGCAATT GGAGGTGAGG GTGGAGCCCA GTGCCCAGCA CCTATGCACT GGGGACCCAA -443
AAAGGAGCAT CTTCTCATGA TTTTATGTAT CAGAAATTGG GATGGCATGT CATTGGGACA -383
GCGTCTTTTT TCTTGTATGG TGGCACATAA ATACATGTGT CTTATAATTA ATGGTATTTT -323
AGATTTGACG AAATATGGAA TATTACCTGT TGTGCTGATC TTGGGCAAAC TATAATATCT -263
CTGGGCAAAA ATGTCCCCAT CTGAAAAACA GGGACAACGT TCCTCCCTCA GCCAGCCACT -203
ATGGGGCTAA AATGAGACCA CATCTGTCAA GGGTTTTGCC CTCACCTCCC TCCCTGCTGG -143
ATGGCATCCT TGGTAGGCAG AGGTGGGCTT CGGGCAGAAC AAGCCGTGCT GAGCTAGGAC -83
CAGGAGTGCT AGTGCCACTG TTTGTCTATG GAGAGGGAGG CCTCAGTGCT GAGGGCCAAG -23
CAAATATTTG TGGTTATGGA TTAACTCGAA CTCCAGGCTG TCATGGCGGC AGGACGGCGA +38
ACTTGCAGTC TCTCCACGAC CCGCCCCTGT GAGTCCCCCT CCAGGCAGGT CTATGAGGGG +98
TGTGGAGGGA GGGCTGCCCC CGGGAGAAGA ----------
----------1350 bp----------
MET TRP GLN LEU -39
---------- AAGAAGTCCT CCTCAGACAG GTGCCAGTGC CTCCAGAATG TGG CAG CTC +1527

Figure 15


-1462hPCm1
+1
SphI
+67
+1497
stop(+10488)
3'UTR
EcoR I
-1462
exon 1
intron 1
Msc I
exon 2-9
+11108
+10783 (polyA site)
SSc8387 I
-82hPCm1
SphI
stop
-82
exon1
intron1
exon2-9
3'UTR
+11108
AE5'/-1462hPCm1
+1
SphI
+67
+1497
stop(+10488)
3'UTR
EcoR I
-1462
exon 1
intron 1
Msc I
exon 2-9
+11108
+10783 (polyA site)
SSc8387 I
-1462hPCm1/AE3"
SphI
stop AE3'
-1462
exon1
intron1
exon2-9
3'UTR
+11108
AE5'/-1462hPCm1/AE3"
stop
AE5' SphI
AE3' Sse8387I
-1462
exon1
intron1
exon2-9
3'UTR
+11108
-849hPCm1
+1
SphI
+67
+1497
stop(+10488)
-849
exon 1
intron 1
exon 2-9
3'UTR
+11108
-802hPCm1
SphI
stop
-802
exon 1
intron 1
exon 2-9
3'UTR
+11108
AE5'/-82hPCm1
AE5' SphI
stop
exon1
intron1
exon2-9
3'UTR
+11108

Figure 16

hPC Minigene Constructs	Expression Activity (%±SD)
-1464hPCm1	100
-82hPCm1 	98.7±11.8
AE5'/-1464hPCm1	101.9±12.5
-1464hPCm1/AE3" 	70.1±7.5
AE5'/-1464hPCm1/AE3" 	74.0±3.8

Figure 17A


4000
3000
2000
1000
0
hPC levels in serum (ng/ml)
0
2
4
6
8
10
12
Age (Months)
Animal Number
#763
#743
#758
#319
#320
#322

Figure 17B


Animal Number
#358
#334
#330
#331
#384
#346
#372
hPC levels in serum (ng/ml)
Age (Months)
0
10
20
30
40
0
1
2
3
4
5
6
7

Figure 17C


3000
2000
1000
0
hPC levels in serum (ng/ml)
0
2
4
6
8
Age (Months)
Animal Number
#358
#385
#389
#371
#407

SEQUENCE LISTING

<110> Kurachi, Kotoku
Kurachi, Sumiko

<120> Nucleotide Sequences for Gene Regulation and Methods of Use Thereof

<130> UM-04305

<140> xx
<141> 2000-06-06

<150> 09/328,925
<151> 1999-06-09

<160> 208

<170> PatentIn Ver. 2.0

<210> 1
<211> 32
<212> DNA
<213> Homo sapiens

<400> 1
agccattcag tcgaggaagg atagggtggt at 32

<210> 2
<211> 7
<212> DNA
<213> Homo sapiens

<400> 2
gaggaag 7

<210> 3
<211> 1273
<212> DNA
<213> Homo sapiens

<400> 3

ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttacctttc caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggagcat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660
aacataggga tgaagtaagg tgcctgaaaa gtttggggga aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatca tgtctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
aagttgtcct tttctggttt cgtgttcacc atggaacatt ttgattatag ttaatccttc 1260
tatcttgaat ctt 1273

<210> 4
<211> 38059
<212> DNA
<213> Homo sapiens

<400> 4

gtatatctag aaaaccccat tgtctcattc caaaatcacc ttaagatgga taggcaactt 60
cagcaaagtc tcaggataac aaaatcaatg tgcaaaaatc acaggcattc ttatacacca 120
atagcagaca aacagacagc caaatcatga gtgaactccc attcacaatt gcttcaaaga 180
gaataaaata cctaggaatc ctacttacaa gggatgtgaa ggacctcttc aaggagaact 240
acaaaccact gctcaatgaa ataaaagagg atacaaacaa atggaagaac attacatgct 300
catgggtagg aagaatcaat atcatgaaaa tggccataat gcccaaggta atttatagat 360
tcaatgccat ccccatcaag ctaccaatga ctttcttcac agaattggaa aaaactactt 420
taaagttcat atggaaccaa aaaagagccc gcatcgccaa gtcaatccta agccaaaaga 480
acaaagctgg aggcatcatg ctacctgact tcaaactata ctacaaggct acagtaacca 540
aaacagcatg gtactggtac caaaacagag atacagacca atggaacaga acagagccct 600
cagaaataat gccacatatc tacaactatc tgatctttga aaaacctgac aaaaacaaga 660
aatggggaaa ggaatcccta attaataaat ggtgctggga aaactggcta gccatatgta 720
gaaagctgaa actggatccc ttccttatac cttatacaaa aattaattca agatggatta 780
aagacttcat tgttagacct aaaaccataa aaaccctaga agaaaaccta ggcaatacca 840
ttcaggacat aggcatgggc ttggacttca tgtctaaaac accaaaagca atggcaacaa 900

aagccaaaat tgacaaatgg gatcaaatga aactaaagag cttctgcaca gcaaaagaaa 960
ctaccatcag agtgaacagg caacctaaag aatgggagaa aatttttgca atctactcat 1020
ctgtccaagg gctaatatct agaatctaaa atgaactcaa acaaatttac agaaaaaaac 1080
aaacaacccc atcaacaagt gggtgaagga tatgaacaga cacttctcaa aagaagacat 1140
ttatgcagcc aacagacaca tgaaaaaatg ctcagcatca ccggccatca gagaaatgca 1200
aatcaaaacc acaatgagat accatctcac acaagttaga atggcgatca tcaaaaactc 1260
aggaagcaac aggtgctgga gaggatgtgg agaaatagga acactttgac actgttggtg 1320
ggactgtaaa ctagttcaac cattgtggaa gtcagtgtgg cgattcctca gggatctaga 1380
cctagaaata ccatctgacc cagccatccc attattgggt atataccaaa gtattataaa 1440
tcatgctgct ataaagacac atgcacacgt atgtttattg cggcactttt cacaatagca 1500
atgacttgga accaacccaa atgtccaaca atgatagact ggattaagaa aatgtggcac 1560
atatacacct aggaatacta ggcagccata aaaagaaaat gagttcatgt cctttgtagg 1620
gcatggatga agctagaaac catcattctc agcaaactat cgcaaggaca aaaaaccaaa 1680
caccgcatgt tctcactcat aggtgggaac tgaacaatga gaacacttgg acacaggaag 1740
gggaacatca cacaccgggg cctgttgtgg ggtgggggggc gaggggaggg atagcattag 1800
gggatatacc taatgctaaa tgacgagtta atgggtacag cacaccaaca tggcacatgt 1860
atacatatgt aacaaacctg ctcgttgtgc acatgtaccc taaaacttaa agtataataa 1920
taaaaaaaag atcattctaa aatttataca agcccttaga acagttaaaa atatcttacc 1980
aaaagaagaa taaagttgga ggaatcactc tacctaatat aaagtcttac tacatagcta 2040
cagtaattat gacagtgtta tattggcaga gggataaata catcaatggc acaaagaata 2100
gatagagaaa ctggaagtag acccaaaaca atatggttaa ctgacttacg aaaaaatttc 2160
agaagccatt cagtcgagga aggatagggt ggtattgttg ttttttgttt taacaaattg 2220
tgctggataa attggacata cctatggaaa aaaaaatgaa gtttgaccta aacatcatac 2280
tttacacaaa tattaactca aaatggagca tgggcataaa tctaaaactt caaactgtaa 2340
aacatttaga aaaaaatagg aaaaaaacta tcaggatcta gtgttagtgg aagagttcta 2400
aatgtgatcc ataaaacaaa aacaaataaa ctggactaca tcaaaactaa aaaattctac 2460
tctgtgaaag acctaattaa gaggacaaaa gacaagctac aggctggaga caatatattt 2520
aatccacgta tctatgaaag gattcatatc tagaatatat aaacaacctt aagaatctga 2580
cagtaaaaaa aaaaaatcag actaactgga ccactcatac attgctgatg gaaatgtaaa 2640
gtggtacagc cattttggta aacatcattg ctctctgaca aagatacggt gggtcccact 2700
gatgaactgt gctgccacag taaatgtagc cactatgcct atctccattc tgaagatgtg 2760
tcacttcctg tttcagactc aaatcagcca cagtggcaga agcccacgaa atcagaggtg 2820
aaatttaata atgaccactg cccattctct tcacttgtcc caagaggcca ttggaaatag 2880
tccaaagacc cattgaggga gatggacatt atttcccaga agtaaataca gctcagcttg 2940
tactttggta caactaatcg accttaccac tttcacaatc tgctagcaaa ggttatgcag 3000
cgcgtgaaca tgatcatggc agaatcacca ggcctcatca ccatctgcct tttaggatat 3060
ctactcagtg ctgaatgtac aggtttgttt ccttttttaa aatacattga gtatgcttgc 3120
cttttagata tagaaatatc tgatgctgtc ttcttcacta aattttgatt acatgatttg 3180
acagcaatat tgaagagtct aacagccagc acgcaggttg gtaagtactg gttctttgtt 3240
agctaggttt tcttcttctt catttttaaa actaaataga tcgacaatgc ttatgatgca 3300
tttatgttta ataaacactg ttcagttcat gatttggtca tgtaattcct gttagaaaac 3360
attcatctcc ttggtttaaa aaaattaaaa gtgggaaaac aaagaaatag cagaatatag 3420
tgaaaaaaaa taaccacatt atttttgttt ggacttacca ctttgaaatc aaaatgggaa 3480
acaaaagcac aaacaatggc cttatttaca caaaaagtct gattttaaga tatatgacat 3540
ttcaaggttt cagaagtatg taatgaggtg tgtctctaat tttttaaatt atatatcttc 3600

aatttaaagt tttagttaaa acataaagat taacctttca ttagcaagct gttagttatc 3660
accaaagctt ttcatggatt aggaaaaaat cattttgtct ctatgtcaaa catcttggag 3720
tttgattatt tggggaaaca caatactcag ttgagttccc taggggagaa aagcaagctt 3780
aagaattgac ataaagagta ggaagttagc taatgcaaca tatatcactt tgtttttca 3840
caactacagt gactttatgt atttcccaga ggaaggcata cagggaagaa attatcccat 3900
ttggacaaac agcatgttct cacaggaagc atttatcaca cttacttgtc aactttctag 3960
aatcaaatct agtagctgac agtaccagga tcaggggtgc caaccctaag caccccaga 4020
aagctgactg gccctgtggt tcccactcca gacatgatgt cagctgtgaa atcagactga 4080
aatgctgaaa taacgataaa aaaaaataca gaggttaaac tagcaaagtg agtaaagtca 4140
agggataaag aaaatttgtt ggaaaactca caaagcagga cataaagcaa ggccattaga 4200
tatatctcat tagtgtgaca tctgggagga caaagcatcc aaacctttc ttctatataa 4260
gtggtgagat gatgaaggtt gtaagaggct tctgcccct tgaagacttc agatgctggg 4320
gaaaggatag ataagaataa ggatgaacct ggcttttgga gcctgggaaa taatgactag 4380
cgataaacct gaagggaagt taagtatacg atccccagat aatactaagg agaaaggcaa 4440
tgtgattctg cagccattgt agccagagat aataagccct tgaggaaggg gccaggggaa 4500
tttttctaag gatagacagt attaatgcag cactctcttc tgctattaaa ctctcattgg 4560
cttctaaaag gagtttcggt gagtgatttg ctgagatgtt tgcattttca tgctgctgcc 4620
tttaggttat tattgcaaca gtttggaatt ttgaaattaa aacagttctg taaaaccagt 4680
ttagttttgt aaagtgtatg catcaaagat gtccttcatt cagacattac tgagttacaa 4740
ctacggtgcc aggtactgtg tcagggtact aggggtatgg ggataaacca gactccctct 4800
ttgatctaaa gcagcatgag gccaggtgag aggtttcaat atatgtgata aaatgtgcac 4860
taggtactaa gggatcatag agaaaggaac acattaaatg gggaaacaat tgatagagag 4920
agaatatttt catctgggtc ttaaaagatg agtaggcgtt ctctctcttt aaatgtctga 4980
tataagggca ttttatgcaa agaaggatca ctcgtgcaaa gactcagctt tgcaagaacg 5040
tgaggtattt caggagtttt gtatggttcc atatggacta tgacaagtga gacaggtaaa 5100
ctaggcagag ctggtcatca gataatgaag tcattaacct aaggagattg gacaataaaa 5160
tgcaatatgg aggtatcgaa gtataaacat aaggagtacc actgatggct gatttaggat 5220
gcccagtctg gcaacacgct aatgaaatga tagtggggga gggggccgta ccaagactag 5280
gagagagcag tcctgagact attgcaatta tctgcgggag acataaaggc tagaacctga 5340
acagtagcag tacaaaaaaa gaggggagtt caaatgatat taaggaagta gaagtggtat 5400
gacttaacca tctgggtatg gaaggggaaa tggctagagt cttggggact ttgtgtttga 5460
tgtgattatg gaccacagaa taatgtctaa gagaactggc tctttagtct gactgccaga 5520
gtctgaatcc tgaatgtttt agtatgttac cttgcaaagc ccttagcctc tatgaatcta 5580
tcttcctcat ttataaaaat aagatgacag tgcctatctc gtgggacttt tgtgaggatg 5640
aagtgagata atggatgcaa agttactgag cacagtgtcc aacacagcag aagcattaca 5700
tatacattag ctattactgg ctacattatg atatacagtt agggagttgg aaagataatc 5760
tgaaattcag gagacgtatc tgactatagg tgagtatttg gaactcattg ttctgtaaac 5820
agtagttaca gcacgtgtgt gggcatctgg agagtgagca tggatattgt gatacctagt 5880
acagtgcctg gcagtagtgg ttgtatgctc agtaaatttt gttgacaggg tcagggccgg 5940
actagactgt ggtaagcaag gcctgtaggg cataaatata cttgtatgcc ccgagaagtg 6000
aggacctctt aaatattgtg ccctacatgc cttgtttggt tcactcttgt cccagcccta 6060
gcaagtatat ataaggtgaa aaaggaaaaa gctgaggctg gagcctggga gaaccctgga 6120
catttaaggg ccatggagag gaacaggagt taatcaattc aagtgctgga tggataacag 6180
gagttagagc aaagcgggga accagaatag agtgattatt ataaaaagag tttcctaaaa 6240
agggagagat caacaattag aaattattta gagcagccag taaatacata aactcaaaat 6300

tattctttag gtcattcctg attgtgacaa tagtcatttc attatataaa tgtgattaag 6360
gaaggaaaag agctacacag aagttattaa agagctaaag agaattgaga aatttaaaac 6420
agaagaaagt agggccaaca tgaaaggagt agggagaaaa agagataacc agcatattgt 6480
ctcactgatc ctgccaacac ctgtgagata gatattctta ttatactact gttaaaccta 6540
atttacattt gacaaagtta aggttcagag cttgtgtgac ttgtccaagg tcacaggtct 6600
agaggaggca gatacttgat tcaaacctat ttctgtctga tctgattcta aagtctgttt 6660
tttcactcaa ccacactgta cagtcagctc tccttgtgag ttccacagcc acagattcaa 6720
ttaactgcag atcaaaaata ttcaagaaaa aaatggatgg ttcgatctct actgaacatg 6780
tacagactct tttatctttc attattccct aaacaataca gcataacaac tatttacata 6840
gcatttacat tgtattagct attaagagaa acctagagat gatttaaagt acaaaggagg 6900
atgtgtttag gttatatgca aatagtaagc catttttata tcggagactt gagcatccac 6960
agatcttgat atttgcaggg ggtcttgcca ccaattttcc atggatactg aggaacgact 7020
gtaaatggat gcaggcatgg atgctattta ggagtgtcca gggccaagta aatgagttgc 7080
tgagcagaga ggtgggtgga ggctgtgagg catcaatatg tggtggcatc catctgcatt 7140
ttggtgattt ttttccttca cagtcctcgg ctgtctggga agagaaggat gaaggcagat 7200
ggctgctcca atttaggggc taggattgca gggtgggcac agcattgcaa acgagtgaag 7260
gaaattgaga aatatggcca atgaagagtt gaagagaggc ctggcatggt ggctcacacc 7320
tataatccca gcactttcag aggcccaggc aggcagatca cttgaggtca ggagttcgac 7380
accagcctgg ccaacaaggt gaaatggtga aaccccggct ttactaaaaa tacaaaaatt 7440
agctgggcat ggtggcgggt gcctgtaatc ccagctactt gggaggctga ggcaggagaa 7500
tagcttgaac ctgggagatg gaggttgcag tgagctgaga tcgcaccact gcactccagc 7560
ctgggcgaca gagcaagact ctgtcaaaaa aaaaagagtt gaagagaaaa agtctaggct 7620
aaattcaaag aaaaaaagtg agcccaaaag gaacttgcag agcaagggaa aagcagggat 7680
gtcaagggac tagaacactc cataaagtga acagctgcaa tgaaaataag ggaagaaagt 7740
ttagttcatc tccgtttctt tcctttcctt tttactttcc tttctcttcc tttttggagt 7800
tagtcaggaa gtagtcccaa ataccccaga aagttcatct tataagccct tggtcctctt 7860
gagatggtat cagatatatt gctagaccct tgaagaaagg aacaactcca ggcaacttct 7920
tgagtccctg ttattaattt tatacataca cacacatata tgtatataca tgaaaacaca 7980
caaacacatg tgtgtgtata cagccatgca ttccttaaca atggggatat attctgagaa 8040
atgtgtcatt aagcaatttc atcattgtgc gaacataata gagtgtactt acctaaacct 8100
aaatggtata gcttactaca tacctaggtt gtattgatgt ggcctattgc tcctaggctc 8160
ctgggctgca aacctgtaca gcatgtgact gtactgaaca ctgtaggcaa tggtaacagt 8220
ggtatttgtg tatctaaaca tagaaaaggt acagtgaaaa tacagtatta taaccttatg 8280
ggaccactgt cgtataatgt ggtccatcat tgaccaaaat gtcattgtgc agcaaatgat 8340
tatctcatat atatatatat atgatatgat atatatgata tatatgtgtg tgtatatatg 8400
tatacatata tatgtgtaca tatatgtata catatataca cacacatata tatgtacaca 8460
catatatgta tatatatgta cacacatata tgtatatata tgtacacaca tatatgtata 8520
tatatatgta cacacatata tgtatatata tatgtacaca cacacacata gagagagaga 8580
gagaggagag gagaggaagg agggagggaa ggagaaatat gattcagata gagacatcta 8640
tcctccagag ttcaggagtg tctcttcaga ctaggtagat gtagcttaaa aaaaacatat 8700
cctggaattc tagagagatg cttaaatcac tgcaattcct ataacacttg ccaaccaaag 8760
gtgctgttga tctgaaattg ctttttttaaa ttaatgcagt gatttttctt taacatctag 8820
tgacagacac tggggtcaca tttgcagctg gaccataatt aggcttctgt tcttcaggag 8880
acatttgttc aaagtcattt gggcaaccat attctgaaaa cagcccagcc agggtgatgg 8940
atcactttgc aaagatcctc aatgagctat tttcaagtga tgacaaagtg tgaagttaac 9000

cgctcaattt gagttctttc tttttcatcc aaagtaaatt caaatatgat tagaaatctg 9060
accttttatt actggaattc tcttgactaa aagtaaaatt gaattttaat tcctaaatct 9120
ccatgtgtat acagtactgt gggaacatca cagattttgg ctccatgccc taaagagaaa 9180
ttggctttca gattatttgg attaaaaaca aagactttct taagagatgt aaaattttca 9240
tgatgttttc ttttttgcta aaactaaaga attattcttt tacatttcag tttttcttga 9300
tcatgaaaac gccaacaaaa ttctgaatcg gccaaagagg tataattcag gtaaattgga 9360
agagtttgtt caagggaacc ttgagagaga atgtatggaa gaaaagtgta gttttgaaga 9420
agcacgagaa gtttttgaaa acactgaaag aacagtgagt atttccacat aataccttc 9480
agatgcagag catagaatag aaaatcttta aaaagacact tctctttaaa attttaaagc 9540
atccatatat atttatgtat gttaaatgtt ataaaagata ggaaatcaat accaaaacac 9600
tttagatatt accgttaatt tgtcttcttt tattctttat agactgaatt ttggaagcag 9660
tatgttggta agcaattcat tttatcctct agctaatata tgaaacatat gagaattatg 9720
tgggtttttt ctctgcataa atagataata tattaaactt tgtcaaaagg actcagaaag 9780
atcagtccaa ccctctaacc catattggat ggtgatatac tacagggtta tgccagtgtg 9840
ggaactatcg ctggtaaata agtttaatcc tccctagggc ttcacaaaga acattgttcc 9900
accccaggag ggtggaagga agaaactgaa atgattgtgt cttagaacct aatgaaagtt 9960
tgcattcctc agtaaaatca gagactgctg attgacttaa atgtttatag cttcaaagtc 10020
ctcctcatta tcatggccca gaagcccttc catgattgtc cttccccacc ctccccatta 10080
cccttcttgc ctcctctgct acttctctcc tcgcacactg ggctccagcc accctggcct 10140
tcctgtcact tcttgcacac tctaggaatg ctcccacttt ggaggcttta tctggctgtt 10200
tctcttattt ggctgttccc aacttcctgt gggctgactc cctcacctcc ttcgggtctt 10260
tgcccaaatg ttaccatctt aatgaggcct accttcacca tctattaata cttcaacctg 10320
ccccagtagc cttaccactc tagacacctg tacagaactc cactctactt tttaacagag 10380
cttttcacca tctaatgtat catataattt cttactcata ctatttatca tttatttttct 10440
cctactccac taaaatgcaa gtttcatgtt ggcagggata ttcaattgtt ttgtttattg 10500
atatattcct agcacctaga acagtatctg gaaaagaggt actcagtaaa tatttatcaa 10560
atgaattgac caaaagaagg aaaactcaaa actttaatga caactaactt taaagctaca 10620
ataacttaaa attcagagta ggattttgag ggagggtaag tttcaaagat tgacttacct 10680
aagactatct gcataaataa aaagaaatta atccagacaa caaattcacc aacttccatc 10740
aattggaaat ccaattctat tttctacagt ttatgttctg gagacactac tggacactct 10800
tttactctca taactcataa ctcctccact tttgttttta aatcatgaga gaaaaagagt 10860
tgactctgtt atattgtttt atctaccttt ccttgatctt agaaacgaat actaccatac 10920
cagcttctac tgaggtgccc cctaaagtta gtccaaatag gtctttgcaa tctccattcc 10980
cgcagaattt agaactttga atcacatgat ttatttctaa aagtaaatcc atgccgattt 11040
tccccaccaa aaaattcctg actattaaac tcctacaatc ccttcattgc tcactcccca 11100
cccccaggat catattttaa agttgggccc ttgccttttg ggtcacatag gtacactgtt 11160
tgctatacca caggtatagc tatctggaaa acatggaggg tattattctg ttactactgc 11220
ttcgtcaacc aaaaaataaa acaaaacaag aacaaaaaag aaacaaactc cctgcctctt 11280
ttcacttgca gtcaaggttc ctaaccacta caaaattagc ctatgtttct tcttgcacat 11340
agtagaaacc caagcttctc actgctgtgc tattctgtac catcaactca tcacataaag 11400
agcctggttg aagaatgatt gtccaaccac attactagca tctgtcaaga ctttccagtt 11460
tacaaaaggc ctatcacatt taaccctcac accatccttg tgaccaaagc attattaact 11520
ccattttaca ggagagtaaa ctgaagctta gggaagttaa aagaactgcc aaaggtctcc 11580
cagttgggga gtcatgaagc ccagaagaga agccaaattc tctgctgctc aacccccttgc 11640
tttcactatt acacctcagg gccttcaaat ctaaatgcag ttattcatta aacaggaacc 11700

tggtagtctt aaacaggaat ctctcacttg gtaagatctt gtctcttgtt gtatttgacc 11760
ccaactgtct atggctttgc ctgaacccaa agtacacaca gcctagaaac caaaggagaa 11820
ccaaatgtgg gataaaatga cactcatttt aacgacatgt ctcagcaaat gagttcctgt 11880
gtagctggct gaaagcccag acccttttcag taaaacatcc tgaataattc acatttgttg 11940
gtctataata taaagggcaa atgtagctca tttttagacc agttctgaac atcaatagta 12000
acaaaccaga gataaccgat tttgttttca tagaattgga acaaattaga gtatctgtgc 12060
aaaagcatat cagatctagg agcagagggg acaaggtcta atttttaaat aagcaaattt 12120
tccagggagg gactacttat gataaaggga tattagtctc ttagtcaacg gaacctggat 12180
acacgcttct gacagagaag agggagaata ggcaggaatc tacacaccag atgtcaagga 12240
gatttgcttt aaaatacgac tgataattag aaatttctca gtttcccccc tttccctcat 12300
tctttgattc ttattgttat ctttatctct tactcctttg tttctcatat attgagtctt 12360
acagatcaag ctcccatttt tttcttcagg ggtatttttc tagttcaaag tgcctaccat 12420
ctcccttctg gttctattca tccttctctc ccaaagctcc tttagaagtg tggattaagg 12480
cagagcacta agaaaccaga cttaaagatt cccttctcat tctgactttt ctcctttcac 12540
ctattccttc ctcctgtttt cttaccatca gtgtcttcaa aggctttcaa gtacacggta 12600
aatgcagaaa cttcaagaaa ggcagaatgg aaacataacc aatgcataca taaataaagc 12660
acactgtaga atctttttaa attctgtatg atatatcgaa tgctgtctct cacattacct 12720
agaccatttg aaaccgaatt tgtaaaacat agactatctt taagtagtaa cagatgcttc 12780
tgacatgttt tctattgtct tgaaccatta ctgcatatga tacatcaaag ttaagtgaca 12840
atacaagaaa gcagattcat ttgctccctg cctaggccgt cagttcctaa agtggaaacg 12900
ccatatatta tctagctcag tttgctctac aagacctgca atagagcctt gtgtgacata 12960
gagataatat ttgttgaagc aattaaattt gacttggaat taactctgcc atcattctat 13020
aaggaaggat tgaaaatcct tctcaccctg tgctgatata gtacctttct atacaaaaac 13080
gtccttctcc ctcttccctt ggattgcata aactatgtac atgccttcct caggggcact 13140
tttctaggac agtgtcagcc taaggatctt tgtttgggtg gcttttagaa actcaggaag 13200
acaggagcat catatgccta taggcagctg gcttccaggt cagtagtttt gctctgaccc 13260
taaaatcaga ctcccatccc aatgagtatc tacaggggag gaccgggcat tctaagcagt 13320
ttacgtgcca attcaatttc ttaacctatc tcaaagatgg agatcagtgt gagtccaatc 13380
catgtttaaa tggcggcagt tgcaaggatg acattaattc ctatgaatgt tggtgtccct 13440
ttggatttga aggaaagaac tgtgaattag gtaagtaact atttttgaa tactcatggt 13500
tcaaagtttc cctctgaaac aagttgaaac tggaaaatgc aatattggtg tatcataatt 13560
tttcttaaaa acataccttt gatgcttata aacatttcat ttgtagtgat agttttcagg 13620
atatgagttc aagaagctac attaaaatca ataacaatat ttggtaacta atattaagta 13680
ataatgatgt tccgactcac cttattaatc tttaatacaa ccgtatgtgg ttagtactat 13740
cattatgcgc attctatgca gatgagaaaa ccgcaactcc aacggccaaa aattacagag 13800
gcataaatgg tttagacagg acttaaactt cagtgtgacc aaaacccatg cttctaacta 13860
ctatattcaa aactcagaga aaactgaacc cagaaaattg aaatcatgac taaattgcta 13920
tcaacatagg tgaaagtcaa ttaagtacag aactggagta tgactggcca attatcccat 13980
ataatgggaa ttctccacat gtacaaacca cttcatatgc taaacttgtt gacaacattc 14040
aaagctcatc cctgaatttg actatattga ttacatcgaa aatgttacat agcaacctta 14100
gaatccttgt gtacctttc ttctcaaagc ctagattatt tctttttccg acgttttcag 14160
taattggagc agtaaacccc agtgtccctt acctacttgt ttattacctc cagatgcaat 14220
attactggta ctgtgattga gaaacgcaca cagtgctaat gaggaattca ctttctactc 14280
tgacactctg gaagaataga gatgcaatcc taaggaagaa tttaacacca caggctacat 14340
gactaaggat aaagagtaga aaattagcag gactctatta accgattaca gcaatccacc 14400

tgacagatga aaaaggcatg aaatgaaatg aaatgtagca gctacactcg tcctattgag 14460
aaaggaaaaa agtcacctgt aatgttgttc agaaatcctt tcagtactaa aaaattcatt 14520
gaccatcttc ctttagtctc gaaaatttct tagaaggtaa aaaaaggaaa aggtgacagg 14580
gcaaagacat ttgaaaagaa agaaaagagt gaatgaactt gcacacctgg cttggactcc 14640
ccattcccct taggtttcca ttgtggggga caaactaatg cctgggttac ctttcttgag 14700
agtgtgttaa ttgattcaat atctctgaag tgctactttc atctgaaagg ttataatttg 14760
aaattcagat ttacctggat aaatttgatc ttgctattat ggaaacctct agaaatcctt 14820
ggagtagtta ctcattatca gcttaaataa tatagccggt ggagctgagg gaatgagtaa 14880
ctcaattagt ctcagttaca actgaagggc acattgttgt aaactataat tgaaaacata 14940
aatatcttta cctagtttaa aaaataaaga tgctttaaaa ggaggaaggg aatagccctg 15000
aggaatgtaa atataagcac aaaacttcta caacagagtt tgctacgtgt gtggctgtgt 15060
tccacccagc aaaaatgcta agtctacaac tgacacaact tggatactct catgttccca 15120
cattttggtt tggtcaaggc tgtgcagttg tactgcaggc caccaccact cctggcctct 15180
acagtatatt gatctgaccc accaatctga tcaaggttta gaaaaatatt ttcagcccag 15240
ttagctcaca aacaaaatga gaattcccac aaattgctct ttatctcaga caacagagga 15300
aagctacagc aaaagcataa acaaattacc atttaagttt gttgcttcaa attaaagact 15360
aattgcaaca gctactagat agcacagttt atggggcatc tcggccccaa gtcttttgtc 15420
ttataaggtc ttgaaaaaaa gaaaggagat tttcatcaat aagagttttt tgttatcttt 15480
ttcccttgtt catcaggccc ttcactgcga gagagaggtg taaacgttca gggcatgcat 15540
tctagttaaa gaatattaat tggctattgg gtccctttgg ttagaataaa gacctctgta 15600
tgatgtccct agctgtacat caaacccaaa tatctctcag ataaatgaag gtctgtaaga 15660
atttggtcat tcctgtctct tctaaagagt aacagaggca ttttcccgca gtaaagtaga 15720
atggaaagaa aacaaaaatc acaagcctat aaacaccttc ttcaattttc ccagcatgtc 15780
acagacacta ctgtcttatt tactacgtat ttctgaggag taaaaaaagg aaatatgttg 15840
agtttagctg aagcacagca tattttgtgg taaacttgtt aaataaaaca tcttttgtcc 15900
aagctttggt tgtcacacaa gtggatatat caggaaatat aaaggcagaa taaactaaag 15960
cagaacatac taacatttgt agtaggcatg aagggaatta gaaagtgttt gtgttaacat 16020
ggagggaggg agaacagatg ctttgagatg ttcttcaaca gatattctag gcactgagac 16080
ccccttcggg accagagaga gcccatatcc accacagtac ctgacacata aatgctcagt 16140
aattgataaa tgagtcccat tctaactgtt ccttagccct gctctatgga actctccccc 16200
gaattccttg tgccattatt ttatttctgg aatcttcagc cttttagctg agggcaaaag 16260
attgctgatt aggaagcaat atttcccacc tcctgcgcaa aacaagccaa agatcaacag 16320
cagcagcaac atactgagcc ctaaagggca atgacaaatg tggagaatga tacagaggtc 16380
tggttacttc ttagccaatg acacagaatc acaattgaga aaacacagag tttattcatt 16440
cccattgtgc atgccctgga caaaccaagc tgcacctttc gtaacttatc acaatctcat 16500
attgacggaa cactttctac aggtaatgtt tgatttggct gaacacttta gcattgcttc 16560
gtagcaacaa aatgatagct agtaacagaa aaagatccag ggatattacc actgttagtg 16620
aggagaaagg ccttttaatt aattaattaa ttaattaata ggaccaagtg ccatcttttt 16680
ggatcatgcc cttagtggat tattggtagc aaaggttaaa gctcaagctg gttcctttgt 16740
ccccctggca acagttgatt tgcctccctt atctcctgaa gtaccgtaag gactaagagc 16800
caattattac atttggctat gctagcatat gtaaaataga gtttaaaagt ttagattcat 16860
cactcaaaaa ttcatattct ccaaaaccat acagtcactc tgttagcctg tgttccccca 16920
gaaaaaaagt cacaagctta ttattaacat gtgcaatcca ggggcaagag aaaggaactg 16980
aagatgaggc agaaaggaaa agaaagccaa taagaggatg agttatcaaa ctactcgttt 17040
cttaacagca actgattgct taacttcctg ggactgtctc caataagtca aattggcctc 17100

aggttagtcc acctgagtgg gaagaagcgg tgaaagaatt tgtctgtcag tatctgtctc 17160
tcattggtta gaagttcgac ttatggggaa ttaactccct cacatttcct agttggatag 17220
cttgggtacc agaggcatat ggcatccatg ctcagcatga acagggaagc ttcaaggcaa 17280
aagacacata gtgcagctat gagccaaggc aattcaagga tacacccata ggaggctggt 17340
tgacatccac ccagagctaa tcaccaccat gctggaaaaa gacacaggtg aagctgagaa 17400
gaatgaaggt ggtgcatagg aggtatctaa tacagtcact cattttcaaa ctttccatgt 17460
tatgattgca ctgaccactg aggatttcta ttgaaagttt tactgttgtc aaacacgtac 17520
acaaggggaa aggtgtctta cattgtttat gttcctgtgc tgctctagaa acagaaatag 17580
gctcaagagc agagcctgtt tttcttaatt cagcaggtct aagctaacaa gtcctgaaac 17640
atggtacttc ctgttattgg tattgcatag gagaaacaaa gggaaagcac agtaattaga 17700
aaatacaaac aagatggcag gaataagcca aaaatatcag gaaacacaat tattgtgaat 17760
tgggattaaa ctaatctatt aataatgaca actttcagct tggagttaaa aatttaattg 17820
tatactgtta acgaaagtga tacctaaaat aaaattacac tgggaggcca aaatgaaggg 17880
atgtgaaaag aactatcagg taaaaactaa caaaaagaaa ctagcaaagc aatcttaata 17940
tcagacaaaa tagaatccaa gaggaaaatc atttcaaaag acaagagatt ttttttatta 18000
ataaggggaa ttgcatagga gagtaaagaa aatgtgggcc actggaatgc ttagcactaa 18060
tgacatattg gtctttggtc ttcagttacc ttacaggacc ctatttcatt ctcttatgtt 18120
tgatatgtaa ccacctcagc cagcttcaag ttgctttttg gccctaatgg acttcctagc 18180
actataattt cttttttttt aaatgtttta ttttaggttt aggggtacat gtgaaggttt 18240
gttacataga taaacatgtg tcacaggggt ttgttgtaca tattattaca tgacgcagat 18300
attcagctca gtaccaaata gtgatctttt ctgctcctct gcctcatccc accctcctcc 18360
ctcaagtaga ctccagtatc tgttgtttcc ttctttgtgt ttataagttc ttaacactta 18420
gctcccgctt acaagtgaga acctgcagta tttgattttt gttcctacgc tagtttccta 18480
aggatgatag cctccagctc cattcatatt cccacaaaag acataatctc cttcttttct 18540
atggctgcat aatattccat ggtatatatg aaccacattt tctttatcca gtctgtcatt 18600
gatgggcatt taggttgatt ccatgtctgc tattctaaca ctgtaatttc taaagacttc 18660
cagattctac ttttataggt aacctgttaa acagtctagc tctggaagcc aagcaatttc 18720
tagaataact aagcaataga aattacactt caatgcagaa aggcagtatc tacatgagat 18780
tatgaaattg cggttgcttt ttgtgttcac tgaaaaaaat aagtaaaact gtaactttca 18840
gaaaaaatga ttgtacatat agaaaaccca aagcatctaa acaattaaaa taaataagta 18900
tagaaagatt actggataca gagtcaacat acaaatatca attgtatgtc tatataccag 18960
caacgattca aaaatgattt ttataatagc attaaaaatt agacgcttag taataaatgt 19020
gagaaagatg tgcaagaact ctacataaaa aattatgaga cgttattgag aaaaattaag 19080
gaaaacctaa ataaatgaat gaataggcaa tgtttatcat taaaggatac aatatagtaa 19140
atatatcaaa tgtttactaa tggattcaat gcaataccaa agtgccagca ggctttttg 19200
gtggtgggag gtcgggcagg attcataagc taattataaa atgcatatgg aaatgcaaag 19260
agccaaggat agccaagaca gttttgagga agaataaact tgtactactt acactaccag 19320
atgtcaagac ttattatcga gttacattta ttaagacagt gtggtactga cacaaggata 19380
gacaaataga tcagtgaaac acactagagt gctcagaagc acacctgtac atatataaag 19440
gcttgattta tgatagaggt gccagtgcag tagagaagga aattattggt gttttcaata 19500
aaaagtgata ggtcaattag atattcatat ggcatgaagt atgaaacaat aacaatttat 19560
attcataact tgcagaaagc aaaaatttct taaaatacaa aaagtgatca ccataaagga 19620
aaagattgat aaactggact atattaaaac taaggactcc tgttcagcaa aagacactac 19680
ttcgactgaa aagacaagtc acagagtgag acaagatatc tgcaatacag atacctaata 19740
actgaacccc atacagtgat ggtgggaatt taagttcgta caatcatttt agaaaattgc 19800

ttggcagtat ctactagatc tgaacatgtg atccagtaat tacactcata attataagcc 19860
agtaaaaagg catgtttatg tcaccaaaag atatatacaa gaatgttcat tacactatta 19920
tacataagag ccaaaaactg gaaacaaacc aaatatccat taacagtaga atgaataaat 19980
aaaagctgta atagtaatac agtggaatac tacacagcaa tgtaaatgaa ctactgctgt 20040
acaaaacaac atggtttaat ctcacagaca aaatgttaaa tgaaagacac agacgagtac 20100
atattgcgaa cttctgttta taattcaaga actggcaaga actgtttact gtgttagaag 20160
tccaggtaat ggtaacctat aaaaaggaaa aagggtggaa tgattgggag ggggcatctt 20220
ctggggtctt gataatgtgc tatgtattgg tcagtttagt gtttaaacag gctcatttac 20280
tttgtgaaaa cttacactaa aattgtgtgt atttttgaa tatatgttat acattaataa 20340
atagggtttt taaacctgta gttcataatt tagtgaaagt agaatatcca aacatttagt 20400
tttaaaccaa tcaattatag tgctaccatc atttttatgc attattgaga agtttatttt 20460
acctttcttt ccactcttat ttcaaggctc caaaatttct ctccccaacg tatattgggg 20520
gcaacatgaa tgcccccaat gtatatttga cccatacatg agtcagtagt tccatgtact 20580
ttttagaaat gcatgttaaa tgatgctgtt actgtctatt ttgcttcttt tagatgtaac 20640
atgtaacatt aagaatggca gatgcgagca gttttgtaaa aatagtgctg ataacaaggt 20700
ggtttgctcc tgtactgagg gatatcgact tgcagaaaac cagaagtcct gtgaaccagc 20760
aggtcataat ctgaataaga ttttttaaag aaaatctgta tctgaaactt cagcatttta 20820
acaaacctac ataattttaa ttcctacttg aatctgcttc cttttgaaat catagaaaat 20880
atcagtagct tgaattagac caattaattt tctagattgc atcatatttt aaatataact 20940
atgtaatcat ctacaacctg aattctttct gtgtccaatt tgtccaattt ttttctctaa 21000
catttatatc acaaagcaat taatttgtgt gatttctgca tatgtatttg taattcatca 21060
agtcaaatca atgtagtaat actatatcat aaaatataca caaataattg agtgataggc 21120
ttctagtata aggacggtaa gtttgaagca tgattctatc tgggctggct agtttactct 21180
gagaaagtta ttttttattg ttgggtctta agctgagttt acacacttgg tgtcagaatg 21240
attccggcaa tgaactgttt tatgttctgc taggctgatc agcacaatct atatggctgt 21300
gaacaaaaca atgtttccca gtcataccaa ccatgccacc attttaacag ctgattagtg 21360
tattcagaac atctccactc catgttcgta tggctgttat ctaaagatga aagcagtaga 21420
cacttttatt ttttgaaaaa tttaggctct gcagggtcaa ttatatttga taaatgaggg 21480
gctttttga agcaaactag atataatttc ttttgcattt ctaaagcctg atatcttatt 21540
aattggtaca ttaaattgtg caccatttct ctgtaactgt ttcagtacct gtctcagcac 21600
tataccaggc agaagaaata aagaaagaac cagtgccaga tcagcttggt caggagaccc 21660
taatcctgcg gcactagagg aattaaagac acacacacag aaatatagag tatggagtgg 21720
gaaatcaggg gtctcacagc cttcagagct gagagccccg aacagagatt tacccacata 21780
tttattgaca gcaagccagt cataagattt actgaaagta ttccttatgg gaaataaagg 21840
gatgagtctg gctagttatc tgcagcagga acatgtcctt aaggcacaaa tcacttatgc 21900
aattgtctgt ggtttaagaa caccttaag cagttttccg ccctgggtgg gccaggtgtt 21960
ccttgccctc attctggtaa acccacaacc ttccagtgtg gatatcaagg ccatcacgag 22020
catatcacag tgctgcagag attttgttta tggccagttt tggggccagt ttatggccag 22080
atttggaggc ctgttcccaa caaaccagaa gctaggaata tatatcctgc aaataaaatg 22140
aagaatctct aaggcttcag ggcctgccca cttgttcttc tgcctggttc ttcacataca 22200
ctgtctcaaa gctagtctac cttgagagga gcatgaatat gtgtgtgggt gtgtgtctgt 22260
gtattttaac cttaaaaacc taacttccag tatagacaga tggcatacta gctaaaccct 22320
tacaagttct tctatgctat aaaagagaaa cagaattgag aaccacctcc aactattaag 22380
tgttatattt gaatatagcc ttagctttag cagaataagt aggccaaact taaaataagc 22440
ttttctgcct tttcaatgat aaaggtccct tttctgtagc cattgttgat tgtgtacact 22500

tatacataag tattttgaac taatttcctg ttttctcaac cacttgctgt cttcatgata 22560
ctttgtcgca gctggttgct atagaaatgt ctgttacaag gaatgtggct tgaaggaaag 22620
tgataaatga aaatgaaatg tgaagtgact ttgtttgact acaaattccc attctggtag 22680
tccccagtgt atcaatacat tatttttctt tagaaaataa accaacccaa ggaaaaatgg 22740
tgggcaggtc ctggtgaata tggctgtgat aattatatta gcaatctctt tggctaatat 22800
ttgaagccca ataattgaa tcacaatgat ctctccccag aaaatatata aaatgcacct 22860
tggaatctag aaggcctttt agtctgcaaa agaaaccttc ttaatcataa gcagcagaag 22920
tcccatttac caaattggaa agttaaagtt acaaagcatc aatcatcaga cttccattca 22980
gggatggcaa ttgggagtaa gacttttag taaagaaact aaacacaaag tcattagact 23040
ctgtaaaagt cttaccaaat ttgattctgg aacacctatt ctatttccgt aaagatgatg 23100
aattcggagc caaatgttct tttcatgaag gatttgaaaa ctgtccatga aaataacgca 23160
atcaaccttt tagcttgaga ctctattcac tgattagatt tttttaaata ctgatgggcc 23220
tgcttctcag aagtgacaag gatgggcctc aatctcaatt tttgtaatac atgttccatt 23280
tgccaatgag aaatatcagg ttactaattt ttcttctatt tttctagtgc catttccatg 23340
tggaagagtt tctgtttcac aaacttctaa gctcacccgt gctgaggctg tttttcctga 23400
tgtggactat gtaaattcta ctgaagctga aaccattttg gataacatca ctcaaagcac 23460
ccaatcattt aatgacttca ctcgggttgt tggtggagaa gatgccaaac caggtcaatt 23520
cccttggcag gtactttata ctgatggtgt gtcaaaactg gagctcagct ggcaagacac 23580
aggccaggtg ggagactgag gctattttac tagacagacc tattgggatg tgagaagtat 23640
ttaggcaagt ttcagcacta accaatgtga gaaggcctcc agagatgagc agttggtgaa 23700
agagaggctc aaaaccagct accatacagg tcaagaagaa tttggcatta aggaaacagc 23760
atagcaggat tccagacagg caactggtca acaacatgaa ggtctggaag aaaggtcgca 23820
gtactcaggt tcagggcact acttcagctt cagcccttgc aaaaactggt gagagttgga 23880
aagtctttag gctaagaaaa attggattat ttaaaagggg taaagaaagg gactcaagga 23940
ggaaggatta aggcaagaac taggttccaa gaaacagggc atgagagaga gtcttgatct 24000
accactatag ttctcgtggt agcatcagaa tcacctggga acgtagaaat gcaaattctc 24060
ctgctctaca ctagacctac caaatcagaa tatctagggg gtggggccca gcagtctgtg 24120
cgcaaacaag cactgcaggt gattttgatg cacattatag tttgaaaact aggccaggtg 24180
cagtggctca tgccaataat cccagcactt tgggagactg agacgggagg attgcttaaa 24240
cccaggagtt tgagaccagc ctgggcaaca cggcgaaacc ccacctctaa ttaaaaaaaa 24300
tacaaaaatt agctaggtgt gatggctccc acctgtgctc ccagctattc aggaggctga 24360
ggtgggagaa tcacctgagc ctggaaagtc gaggctgcag tgaattgtga tcacaccact 24420
gcacttcagc ctgagtgaca gagtaagacc ctatctcaaa aaacagaaaa agaaaaacac 24480
tggcccaaag gaaatgaact tgttacagaa gccggggttc aaaacaccaa ataatgcact 24540
tgtacctagt ccttcccggg tgctctgcag acatttctcc aagcgtagtc tgcaaacaac 24600
ctacatatgt agaattacct atgcacattt ttcatttaac aaccaagagc tacatttgta 24660
gcaaaatctg ggttgtaact tagcctacag ctgaagccta agagattccg tctgtgagaa 24720
gaaataaccc acctctttgg ccccctccc caggcaggaa gccaggatgg tccttatata 24780
aagttgtgct gtccaatagg taaccactag ccacatatgg ctatttaaat ttaaattaac 24840
tacaattaag agaaattaaa aattcaattc ctcaattgca cctgccaaat tttaagcaca 24900
taacaaccac atgtggctag taactactgt attggagagt gcaagcggag atagaacact 24960
ctattactgc agaaatttct attggatagc acttataata gtttagtgta acttaaaact 25020
ccctagttgc cacagtcatg atttagtagt aatttcatgg atttctctac tgaggttaga 25080
atctctgcca ttagagactg ataaatttaa agtttgcaat tatcaaactg gtgacaattt 25140
aagccagaat caggtaatgt cctcagtttt aacagcattg gaattttctg ggactagctg 25200

tgtatctatc caggattctt gagaatgcct gccatttttc aacataatgg atgtaaggta 25260
ttacacatat acctggggat ggggaggtag gtataattgc acaagcattg tggagaatgg 25320
tatcaaagag tggcagaaca tcacaatcaa ggttttccct ttctttttacc tttgcttttt 25380
aaaaagacaa tatttgctgg acctgatctt ataactcata aatgggacac tgtatgttcc 25440
ttttttacctc ctctgtttct acttaattgc accctatgag gactgcttcc cttacctacc 25500
ataaccccctt ccttcactca tccatatctt tactcttctt cacaactctg taatattgac 25560
cttctttatg aacctttcct ggaacaatcc ctcttaatgc aagcactgtt attatgcctt 25620
caatgtattt aatatccatg tatctattct ctctaatttt gtcattttgt gttctcatgt 25680
attttcattc attatgtgtc caacttccat ggataacatg gttacaacaa aagatcctac 25740
tttatgacaa ttatcttcct tgggtttgtg ggacatagaa cagtgcacag agtaggggat 25800
ccaagaaccc aggagaatat attagctaag aagataactt ccgtttttaa aagtccaaga 25860
ttcaggagat caaaaccatc ctggctaaca tagtgaaacc ccgtctcttc caaaaataca 25920
aaaaattagc ccggcgtggt ggcaggcgcc tatagtccca gctacacggg aggctgaggc 25980
aggagaatgg cgtgaaccgg ggaggcggag ctggcagtga gccgagatcc cgccactgca 26040
ctccagcctg ggcgacagag cgagactccg tctcaaaaaa aaaaaaaaaa aaaaagtcca 26100
agattttaaa aaaaaaaaaa aaaaggatgt ctgctttgtg agtttagcat tgtctccttg 26160
tcattccaga aatgaaatgg caaatacatt taaatcagaa ctaaaaaggg gaacagggta 26220
taaaggctca atttagtcac atcatttccg tttctcaccc acccccttta aaccagatgt 26280
ttgccaatgc attaacaatg cagatgtttc ctgaaagaaa gtttagtaac tcaagcagac 26340
accttatttt cttttcaagc agaaaagact atgagatggt ggttgtggtt gttccgggag 26400
ggagaagata taaatgatac acattatttc aaatcatttc atgacctcac tgcacactta 26460
tagttattgt acctgttgtc tttttgctgt caagcctagc taagatcatt tggaatgttc 26520
aagatcactc atacatgcat gtgcacacat acacatgcac atatgttcac tccctatttc 26580
atccacatga actaagatta ctgatgtgta cagattcaaa gcacttttat tcttttccaa 26640
aggcaagaag ctgagctact ttccagaata gttgtgaaag accctgtcat acttctgcat 26700
tgtttcctcc acaccacctc catccagttc cttatgaatg gttactggtt ttcaaaaata 26760
tgagataaat tgagtgtata aaagtcattt ttagacaaaa tgaaacagga aatgaaagaa 26820
accagaatct ctcctcattt gtggatgggc cagctccacc atgtcatggt taatctgcag 26880
ggaggaaata ctagatttga ttgcagatca gactgcagca aacctgctgt gactaaggca 26940
tcaagagaaa gcaagcaaca gactggggct tcagtggtga aaacattata tatctagctt 27000
tgaaatatga aatactgttt agcagtgtca cctagaaaag agtgtttcaa aatgctgatg 27060
cttcataaga acctttctct tcagagttgg tttcttttat ctttcaaatt agccagggtg 27120
ggaaataaag tgatcacttg gtgaagaaat ctcacaaaga agaacataga gagttcactt 27180
tcatctggag taatgaacag attgaacaaa ctagaaatgg ttagtctgtt aaagaaaagg 27240
tgtaggtgag ctgtttgcaa gagccacaag ggaaagggga agacaacttc tttgtggact 27300
taagggtgaa agttgcaagc aggcaagacg attctgacct ccattaagaa agcccaaacc 27360
aaccaacaac cactgggttg gttacgcagg ttgggcagca ttgggagcaa atgttgattg 27420
aacaaatgtt tgtcggaatt gttgacttaa agagctgttc tgtcactggg gacagcagcg 27480
gctagatagc cccattcagg gagagggcat ttgttcacct ggccagagat cagagcaggc 27540
taagggactg ctgggatcct gtccagcttt gagaccctac agagccatgt tcacctagca 27600
cgtatcccgt ctgcggtcac ggtcatttct taccttattc cagggctttc acctcagctt 27660
gccaggctgg agccaagggc caacgcagcc gcgccttgtt cgcgatggta gcttcccagg 27720
agccccctat ggttccggaa cgcgctgccg gccccatcct gtttgctacc tcctaaagcc 27780
aaaggcactg gcgggccggg ccagcttcta aagtcgcgca aggttagaag gttccggaca 27840
ggaacggcgt gaggccaatg gaaggaggta cttcagtttc cctccagatg cccagcgatg 27900

ggctcagagc tccttgagaa ctcgggaaag gaagcagggt ctctgaagaa atacttcagg 27960
agtagaaaga ggaagctaga gggttaaatg cactacacag gaacagaaat gagtttttct 28020
tagagttagt atatgtctag aggtgtagta aactaaaaca agtcttgaat tgcataccgc 28080
cacgtaggga agaaatgaaa acctttgaat attagtgaaa aaagggaaac tgcaacgcct 28140
gtattactag atagctttca tcaacagctc aaaaccgaca gatttaaaga agcaacaccg 28200
cattttggct ttctaaagct ttaatttggt ttggatccca tgcccatgac cctgccagct 28260
gacaattcta agcatgcgca aactggcccc aaaaattcct cccacatttc cgaagaacta 28320
tttggccctt tatgtgaagt acctggtttt tccattttct gttttaccat aggcctcagt 28380
tcggtgtgtg gcgtatttat tctacattta acaatttgaa gatcattcta ttagattaaa 28440
aaaaaagaat acaatggaag ccaagtgatt aagctttcct tatgcttata ttaagttgta 28500
gcatatgcat ttaccgatag ttaaccgtat taacctacag aaaatgtcca gggaaatggt 28560
ctatttctta ttctattttt gacctaaaga aaatctttaa aatgtcttag cattttcccc 28620
agtctccatc cacttccctc agctttggcc tgaagctatc tttaaaggta ccctgtacaa 28680
gctcttgccc tgtacagcta gctacagaga ttcaatcctt tctgttcgat taggacacat 28740
ctcagtggca gataacatgc aaagttatta tatgtatgaa ccagaacttg tttttcctta 28800
ggggccagga tgttacacta aggtcttaag actatagtaa tatcttcact tgaaaaagcc 28860
ctctattatt cctatctcag atgataaaaa ttcaattaag agaaataaga acgtgacatg 28920
tgtaatcgca cctggctcta caaagctagt ctggacagac atttaaacaa ttatcctcta 28980
agattatttg atgaaatgca tttcaatgac tagttaacca ttaaaaacca aagtgagcat 29040
cccatctgtt cccagtcaaa tgacctagag caaaggacta ggcaaaccac atctgtgggc 29100
atagcaagct gtacatcaca aacaaatgaa tttgctttgt atatgagtga gagcaaacac 29160
tctttattgt acaacttggg tgggtaagta gggagaataa tggttttact gaaatcgcag 29220
gtaacggtta cgttggagtt aaaggttagg aagaaaacca aagggtaaga gctgttgttc 29280
tgggctggca ttgtcaatga agagcataaa ttcagatgtg aatgtatatt ttgtagaagc 29340
atgtgtgttg ttggtttttg tgtatgtgtg agtctgaaag agggaaaaca ggctcccatt 29400
agactatgac taacaaaaat gtttgacaga ttataactca gatgtcttac tcagagcata 29460
tgccttccca ttttccccat tattccccaa catgatgtct ttaagaactt gtccttgacc 29520
gagcagacat ctcatacccc aaatagctaa tattttgata gctatgatcc tgaacggcca 29580
aacattccaa aaccaagtag tttgtaatat ctttaatgca aatatatttt aggccttttc 29640
cttggcaagg atgtttggtc aggggttggc aaaaataatg ctcttcagac ttaaaagaac 29700
acaaccatat ttcttagcca tccaccagaa agtagtagaa cgctccagga agcaagtctt 29760
tgtcaggagt cagactagct acatcataat ctctctgccc aggggctgtg gatgtcatcc 29820
atcctggcct aactagccta ctgagctgag agatgtccaa tttcccccca atacactaac 29880
cagaggagaa ggaccgtgat atcattgcat gtgaattctt aattccaatt gcttaaacaa 29940
atatgttcag ttgtaactat caataccagt atataacagt gttggccaag ttttattgat 30000
gctgacaatc aattggagtt acagccagac acatggtctt atgaccggcg tacttacgca 30060
gggctttgca ctgagacagg tcgtgcatct gaggtttact gctttgcatt tttgttttgt 30120
aactgaagtc tgatgagaca gccagagcat gtgctaccta gggacttgaa tccctgcagc 30180
cccatttcac ttctcaccac cttccggggt ggtttctcga cctcccactc ccctaccacc 30240
tggtgcctta gccagccctg gctctccctc caaacacctg cccaatgagc actgccaccc 30300
catggtgccc agacatgctc tccctcctca tccctaccta gctaccattg ccactccccc 30360
cccccagcgg ggacatgggc ataggagcag ggagagttaa ggttggtcag gtgcacgtgc 30420
cctatgctat cttggaaggg ggcttggcca tgtggcatct ctggaccaag aatgcgccac 30480
agcacatttg gagggtgaat ggtgggggca cacccccttgt ccacctctat ttcaggcatg 30540
gaacacatcc tggcatgaaa gttgcagtcc cttgggaatc acctctccac cttgattgcc 30600

acagtaggcc agtgacaagg gaagattgac acatcatccc tgctggggcc cagtgtcctg 30660
tggctggcag gcaggggatc ctaaggacat gtgggtctta aattgtaggg tgcacttcct 30720
gggcaccttt gagggtctgc actgccccag caaatatccc catgctagaa ggagcaaaat 30780
attaaatggc aaattttaaa aatgtaacaa gatgggttgc aaaagagact acagaggaaa 30840
gcaaaagttt tgtattttag tatcttccat ggcacttttc ttcctagctt ttgaacaagg 30900
ggccccacat ttttatttct cactgagccc cacaaagtat gtagccattc ctgcccggag 30960
tgaggacttt taaaacataa agattatcaa gtcttggaaa ttctgattca gtagatatat 31020
aacaggtctc aaacttaatt atgtaaagaa tattctggag agcttccttt tacccagtcc 31080
cacccaccaa atattctgat aaattaagct tcgattagcc cccagatctg cattttataa 31140
ggatccccag atgattctac tgcaattggt ccacagacca tgcctggacc gaatttgggt 31200
gcttaggagc acaaattctg gagccgggca gacttgagtt tgcttcctag ctttaccaac 31260
tgatctcagg ggagttaatg tttacctcta aactttagct catgcatcta taaataaata 31320
tattaatatc atgtcataag gatattatgt tgtattaaat gtctttaaaa caccacaatg 31380
attagcccaa agtaaacact caataaatgt tcaaaaattt aggaaaattg ttaagactgg 31440
gttgtatgca cactggtgtt tattatatta tgtagttttt tctgtatttt tacaacattt 31500
cagaattaaa agcaacagct agaaaaagag ggaaatggcc gggtgcagtc gtcacgcctg 31560
taatcccagc actttgggag gccaaggcgg gcggatcacg aggtcgagag atcgagacca 31620
tcctggccaa catggtgaaa ccccatctct actaaaaata caaaaattaa ctgggcatgg 31680
tggcatgcgc ctgtagtccc aggagaattg cttgaacctg ggaggcggag gttgcagtga 31740
gccaagatct caccactgct ctccagcctg gtgacagggc aagactccgt caaaaaaaaa 31800
aaagagaggg agagccagag tatgaaaaag gaagtcagag ccctttaatg agtcagcttt 31860
gtaggtctcc aggtaggagg ctagtgcttc agtgtctagg acatagtagg tgttcagtaa 31920
attaaattca ggacaaaaag aacatgcccc aaggaccatc tgatatccac ttaaagtgat 31980
ggactacctc gtttcccttg tttatgaatg ggttcatgcc taagactgtg tgcactttaa 32040
tacaagggca gtcgttcaga actagtcagg tcctgaaaag gatttaccaa atgttgagtg 32100
tgccctctag tgttcacact tcccagcttt cttcctataa aggtggatca aggcacttgc 32160
ttacaactgg aactgaaatc ctccaagtcg atctagacat tgagatggag aaaatattca 32220
ttgtcgactg taattatgca acgaatatcc agttgagata atggacttgc ctcttatcta 32280
ataataccca ggctcaatgc gtcactgctt tgtccacttt gcccaaaatt caagcacagc 32340
taagttgata ttttaggaca aaggcagctt actatccagc cagaggggag tagaatatgg 32400
ttaagagaga gtggaaagaa tgaatgagcc ctgctattcc tcactgcctg gatggctata 32460
agcacagccc ttatggaggc cttaggtctt gcttcacaat attccagttt gaaaagggtt 32520
tgaaaagacc tcctagaaaa atcagtagtt tttctctttt gagtaacatg tagcaaaaaa 32580
aatttcatca tgtaggtaca gggaacaccc tagtaactat taatctcaag gagtcaagcc 32640
agtgtgtttc ctaatgtatc tgctgtatcc ccatgaagca aattttgcca tcagagaaac 32700
tgactcatgg ggaaaaaatc caaggacctc aaatcaccaa aagaagccat tcctcagatt 32760
tgcctaagct taagcttccc tgtctctcat tgtgtgttgc tttcaatgca gttacataaa 32820
tggctttttt gtttatgcac caaaaacact aattcatctg caaagctcac atttccagaa 32880
acattccatt tctgccagca cctagaagcc aatattttgc ctattcctgt aaccagcaca 32940
catatttatt tttttctaga tcaaatgtat tatgcagtaa gagtcttaat tttgttttca 33000
caggttgttt tgaatggtaa agttgatgca ttctgtggag gctctatcgt taatgaaaaa 33060
tggattgtaa ctgctgccca ctgtgttgaa actggtgtta aaattacagt tgtcgcaggt 33120
aaatacacag aaagaataat aatctgcagc accactagct ctttaatatg attggtacac 33180
catattttac taaggtctaa taaaattgtt gttgaataaa ttgggctaaa ggcagaaggg 33240
tcataatttc agaacccacg tcgcaccgtc ctccaagcat ccatagttct tttgatatac 33300

ccctattatc actcatttca gtgaggtaca attagttctt gatgtagcca tttccatacc 33360
agaaggcctt cccaaaaatc agtgtcatgt caccgatcct tttatctctg gtgcttggca 33420
caacctgtag caggtcctca gaaaacaaac atttgaatta atggccaaat gagtttgtgc 33480
tcaaaaaagg ggtgaggata cttgaaattt ggaaaatcta ggataattca tgactagtgg 33540
attcattatc accaatgaaa ggcttataac agcatgagtg aacagaacca tctctatgat 33600
agtcctgaat ggctttttgg tctgaaaaat atgcattggc tctcattaca tttaaccaaa 33660
attatcacaa tataagaatg agatctttaa cattgccaat taggtcagtg gtcccaagta 33720
gtcacttaga aaatctgtgt atgtgaaata ctgtttgtga cttaaaatga aatttatttt 33780
taataggtga acataatatt gaggagacag aacatacaga gcaaaagcga aatgtgattc 33840
gaattattcc tcaccacaac tacaatgcag ctattaataa gtacaaccat gacattgccc 33900
ttctggaact ggacgaaccc ttagtgctaa acagctacgt tacacctatt tgcattgctg 33960
acaaggaata cacgaacatc ttcctcaaat ttggatctgg ctatgtaagt ggctggggaa 34020
gagtcttcca caaagggaga tcagctttag ttcttcagta ccttagagtt ccacttgttg 34080
accgagccac atgtcttcga tctacaaagt tcaccatcta taacaacatg ttctgtgctg 34140
gcttccatga aggaggtaga gattcatgtc aaggagatag tgggggaccc catgttactg 34200
aagtggaagg gaccagtttc ttaactggaa ttattagctg gggtgaagag tgtgcaatga 34260
aaggcaaata tggaatatat accaaggtat cccggtatgt caactggatt aaggaaaaaa 34320
caaagctcac ttaatgaaag atggatttcc aaggttaatt cattggaatt gaaaattaac 34380
agggcctctc actaactaat cactttccca tcttttgtta gatttgaata tatacattct 34440
atgatcattg ctttttctct ttacagggga gaatttcata ttttacctga gcaaattgat 34500
tagaaaatgg aaccactaga ggaatataat gtgttaggaa attacagtca tttctaaggg 34560
cccagccctt gacaaaattg tgaagttaaa ttctccactc tgtccatcag atactatggt 34620
tctccactat ggcaactaac tcactcaatt ttccctcctt agcagcattc catcttcccg 34680
atcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga 34740
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta 34800
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc 34860
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc 34920
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg 34980
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc 35040
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag 35100
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat 35160
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa 35220
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg 35280
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct 35340
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac 35400
agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa 35460
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca 35520
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa 35580
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct 35640
tctatcttga atcttctaga gagttgctga ccaactgacg tatgtttccc tttgtgaatt 35700
aataaactgg tgttctggtt cataccttgg ctttttgtgg attccattga tgtgaatcag 35760
tcaccctgta tttgatgatg catgggacta ctgacaaaat cactctgacc ctgccaagct 35820
gctgccttct cctgccccaa cctcaccccc agccaggcct cactcttgct agttccttta 35880
gttcttttag tcaatatatt tttgtcttcg catataagta taaataaaca tatttttaaa 35940
tttcttggct gggcccagtg gctcacgcct ataatcccag cacttctgga ggccaaggtg 36000

ggcggatcac ctgaggttag gagtttcagg ccagcctggc caacatggtg aaaccctgtc 36060
tctactaaaa atagaacaat tagctgggct tggtaatgtg cacctataat cccagctact 36120
ggggaggctg aggcaggaga atcacttgag cctggggagc aggggtgcg ggaggttgca 36180
gtgagacaag atcgcaccag tgcactcccc atcctgggtg acagagtgag actctgtctc 36240
aaagaaaata aataaataaa tacatttctt gaggcgtttc ttgttaaatc attcatggag 36300
aggcatccca aacaccacat tcaacaaaac actctgaaaa atgttttcaa atgcaatata 36360
acacagcaga gatttgatgc tctgttatcc agttttcata taaggctgtg tgagctgtgt 36420
cccagagagg acagtggtct gaatccacct gagacagaat tgggtctaac taactgtgag 36480
tatggccttc aataagtcac tctccatttg ggaatttgat ttctccactt gtataatgag 36540
agtatttgac aggatgctct cccaaatccc ttgcaatttt gttagtctgt gatttcatgt 36600
ttttatttt attccttcat ccaacaaata gtcaaggagt aattgctgtg tgccaaatac 36660
caacagtatt cattaaattg taattcagat tttatatata tataaataat gtataatgtg 36720
tataaattgc tttgtgagtg cctactacac tgctagacag tagttgctca ataacttgtt 36780
agctgaatca gaatccatgt ttatcccaga gtagcaatta gtcttgcatc gagtatcgtg 36840
aaagaaggcc acacttaaat aagaataatg cctggggttt aggttttatg aaaaaatgaa 36900
aggaaattag ttctgctttt gttgactaaa ggaagggaag agagaagaga cactataatt 36960
gtctgcctca gatttaagga ggaggctaat tcatgcatta aacacgttac ttcaaatttg 37020
aatgaccaaa ggtctgtagc ctcagcactt caaaattggt aaaagtaaga cactctggcc 37080
ttgtttccat agagaccacc ccttacaaag gcaccaatgg gaaactggcc tcaggactcc 37140
tgttattggt cttctctgtg gcagagaaag gagctcttgg acccataaat ctctgagcca 37200
cagttctttt tgccatgggc tcaaaaatga ttgaattcat catgagccac ctgtggcata 37260
ttgccacact aaacatgtgg ggcctttaag ctcactaaga gccaatgtct tcagagccag 37320
ccctggcttg attctaccta gggcatttgc agttgccata taagaatcat tagtgctttc 37380
aaaattactg tagatacttt gcctaaatag actaaaacat gctgccgtca tattggaagt 37440
gacagattaa aatagaactc ttgccaagtg aaggaaagtg tgctaatata atgcagtcat 37500
tttaacttgc tgtttaagtg tgattgtttt tagttctttt gaatattatt tgttttatac 37560
tgacaggaac gaagtactgt ccaattttct ctgccaagga aaaaagaaaa ggtgttcttc 37620
cttacttacc tgaaccaaaa cagaccagtt tacaaaattg cctaattata attgctaaac 37680
aagttccgaa tgcttacagt ctaatccaag aatgtcagag ctgcaagggc ccttaaacac 37740
catccaatcc actccactca tttagcagat gaagagattg agggcaacat aaggccaggc 37800
ccaagataac acaatgacag ccaggactag agctcaagtc tcccaccctg cactttgaaa 37860
gaataatgct ttcaactgga gtacattaac tctactgtct atatttttag ggcagctggg 37920
gcattctgca ttggtggcaa tcctctcaac aaccctggga ctgaaaactg cctggaattc 37980
ttactaacaa ttctctaatt gaccaaaagg tgacgaaatc aaggagacca ataaggtagc 38040
cttggaaagc aagagtggc 38059

<210> 5
<211> 29
<212> PRT
<213> Homo sapiens

<400> 5
Met Gln Arg Val Asn Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr
1 5 10 15

Ile Cys Leu Leu Gly Tyr Leu Leu Ser Ala Glu Cys Thr
20 25

<210> 6
<211> 55
<212> PRT
<213> Homo sapiens

<400> 6
Val Phe Leu Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys
1 5 10 15

Arg Tyr Asn Ser Gly Lys Leu Glu Glu Phe Val Gln Gly Asn Leu Glu
20 25 30

Arg Glu Cys Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val
35 40 45

Phe Glu Asn Thr Glu Arg Thr
50 55

<210> 7
<211> 8
<212> PRT
<213> Homo sapiens

<400> 7
Thr Glu Phe Trp Lys Gln Tyr Val
1 5

<210> 8
<211> 38
<212> PRT
<213> Homo sapiens

<400> 8
Asp Gly Asp Gln Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly Ser Cys
1 5 10 15

Lys Asp Asp Ile Asn Ser Tyr Glu Cys Trp Cys Pro Phe Gly Phe Glu
20 25 30

Gly Lys Asn Cys Glu Leu
35

<210> 9
<211> 43
<212> PRT
<213> Homo sapiens

<400> 9
Asp Val Thr Cys Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe Cys Lys
1 5 10 15

Asn Ser Ala Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly Tyr Arg
20 25 30

Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala
35 40

<210> 10
<211> 68
<212> PRT
<213> Homo sapiens

<400> 10
Val Pro Phe Pro Cys Gly Arg Val Ser Val Ser Gln Thr Ser Lys Leu
1 5 10 15

Thr Arg Ala Glu Ala Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr
20 25 30

Glu Ala Glu Thr Ile Leu Asp Asn Ile Thr Gln Ser Thr Gln Ser Phe
35 40 45

Asn Asp Phe Thr Arg Val Val Gly Gly Glu Asp Ala Lys Pro Gly Gln
50 55 60

Phe Pro Trp Gln
65

<210> 11
<211> 38
<212> PRT
<213> Homo sapiens

<400> 11
Val Val Leu Asn Gly Lys Val Asp Ala Phe Cys Gly Gly Ser Ile Val
1 5 10 15

Asn Glu Lys Trp Ile Val Thr Ala Ala His Cys Val Glu Thr Gly Val
20 25 30

Lys Ile Thr Val Val Ala
35

<210> 12
<211> 182
<212> PRT
<213> Homo sapiens

<400> 12
Gly Glu His Asn Ile Glu Glu Thr Glu His Thr Glu Gln Lys Arg Asn
1 5 10 15

Val Ile Arg Ile Ile Pro His His Asn Tyr Asn Ala Ala Ile Asn Lys
20 25 30

Tyr Asn His Asp Ile Ala Leu Leu Glu Leu Asp Glu Pro Leu Val Leu
35 40 45

Asn Ser Tyr Val Thr Pro Ile Cys Ile Ala Asp Lys Glu Tyr Thr Asn
50 55 60

Ile Phe Leu Lys Phe Gly Ser Gly Tyr Val Ser Gly Trp Gly Arg Val
65 70 75 80

Phe His Lys Gly Arg Ser Ala Leu Val Leu Gln Tyr Leu Arg Val Pro
85 90 95

Leu Val Asp Arg Ala Thr Cys Leu Arg Ser Thr Lys Phe Thr Ile Tyr
100 105 110

Asn Asn Met Phe Cys Ala Gly Phe His Glu Gly Gly Arg Asp Ser Cys
115 120 125

Gln Gly Asp Ser Gly Gly Pro His Val Thr Glu Val Glu Gly Thr Ser
130 135 140

Phe Leu Thr Gly Ile Ile Ser Trp Gly Glu Glu Cys Ala Met Lys Gly
145 150 155 160

Lys Tyr Gly Ile Tyr Thr Lys Val Ser Arg Tyr Val Asn Trp Ile Lys
165 170 175

Glu Lys Thr Lys Leu Thr
180

<210> 13
<211> 2410
<212> DNA
<213> Mus musculus

<400> 13
gaattccgtg gatgtgcttt aaaaccacac ctaacgtttg agcacaagtc tcacgaactg 60
gcgctacaac ttcatcagaa acgaagtctc caaatctgtc caacgcaaaa acacaaagga 120
gtctaatgac taagtcttcc aaccacaact gtctgctgcg cccggaaaac aagccggggc 180
tctggggacc cggggctcag gccgcctcgc tccggcctag ccccgccacc ttagttgtgt 240
catcccccgg gcatgctgag catcccccgg cggctccggc acagacgccc ggacctcagg 300
tctctgcctc cgcgcggggg cccggccctg tggccggagg gagcggccgg atggagcgga 360
ggatgaaagg cggatacttg gaccagcgag tgccctacac cttctgcagc aaatctcccg 420
gaaatgggag cttgggcgaa gcgctgatgg tcccgcaggg aaagctcatg gacccgggct 480
ccctgccgcc ttccgactca gaagatctct tccaggacct cagtcacttc caagagacgt 540
ggctcgcaga agctcaggta ccggacagtg atgagcagtt tgttcctgat ttccattcag 600
aaaacttagc tttccatagc cccaccacca ggatcaagaa ggaaccccag agtccccgca 660
cagaccccgc cctgtcctgc agcaggaagc caccactccc ctaccaccat ggagagcagt 720
gcctttactc cagacaaatc gccatcaagt cccccgctcc cggtgcccct ggacagtcgc 780
ccctgcagcc cttttccagg gcagaacagc agcagagcct cctgagagcc tccagctctt 840
cccagtccca ccctggccac gggtaccttg gtgagcacag ctccgtcttc cagcagcccg 900
tggacatgtg ccactccttc acatctcctc agggaggggg ccgggaacct ctcccagccc 960
cctatcaaca ccaactgtcg gagccctgcc caccctaccc ccagcagaac ttcaagcagg 1020
agtaccatga ccccctgtac gaacaggctg gccagcccgc ttcaagccag ggtggggtca 1080
gtgggcacag gtacccaggg gcgggggtgg tgatcaaaca ggagcgcaca gacttcgcct 1140
acgactcaga tgtccctgga tgtgcatcaa tgtacctcca cccagagggc ttctctggac 1200
cctctccagg tgatggagtg atgggttatg gctatgaaaa atcccttcga ccattcccag 1260
atgatgtctg cattgtccct aaaaaatttg aaggagacat caagcaggaa gggattggag 1320
ctttccggga ggggccaccc taccagcgcc ggggtgcctt acaactgtgg cagtttctgg 1380
tggccctgct ggatgaccca acaaatgctc atttcattgc ttggacaggc cggggaatgg 1440
agtttaaact aattgaacct gaagaggttg ccaggctctg gggtatccag aagaaccggc 1500
cagccatgaa ttatgacaag ctgagccgct cgctgcgata ctattatgag aaaggcatca 1560
tgcagaaggt ggctggcgaa cgctacgtgt acaagtttgt gtgcgagccg gaggccctgt 1620

tctctctggc cttcccagat aatcaacgtc cagctctgaa ggctgagttt gaccggccag 1680
tcagtgagga ggacacagtc cctttgtccc acttggatga gagtcctgcc tacctcccag 1740
aactcactgg ccccgctccg cccttcggcc acagaggtgg atattcttac taggcaccag 1800
tggcttcccc ttgacatggt ggggttgctc agtgtatata tcaactgatt tggtattggt 1860
gaaggccctc tttctgatgc ctgtagaagt ctctggggtc agagctccac tatcccatct 1920
gatactcctg gccagactca gctgctaacc agagtctgcg ggaaagacag tggaggcagg 1980
ccaaatctaa aggcagtagc tgaagttcgc tgtggctcac ctgtaccttc agttcagctt 2040
ggcctctgcc taggtcttgc tcagaggcca agttcctcac ccccaccaca gagatccagt 2100
gttctattct ggggacatac agggacttcc cttgtttatt atggcaacag ggccaagggg 2160
attctcagaa caccctgtgt ctcccctctc ccaacccccc atgggagaca aagttctgcc 2220
tggcttctgc cctgaacagg ggggtcctgt gttcttggtg ctgtgctctg ggaggcagga 2280
gcatgtgggc ggcagctggg gggggggtgtg gaagtagaga tggctctctg ccctaggcct 2340
acccaggcct aattccacct ttgcctctta tgccagacct taataaagcc tctgcttctc 2400
cccggaattc 2410

<210> 14
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 14
taacaggatc cggcctctca ctaactaatc ac 32

<210> 15
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 15
caactggatc caagattcaa gatagaagga t 31

<210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 16
ggacaggatc ccccaaactt ttcaggcac 29

<210> 17
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 17
caagcatgca tctagtgtta gtggaagag 29

<210> 18
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 18
caagcatgca aatattaact caaaatgga 29

<210> 19
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 19
caagcatgct gttgtttttt gttttaac 28

<210> 20
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 20
caagcatgca gccattcagt cgaggaagg 29

<210> 21
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 21
caagcatgcg atcccttcct tatacct 27

<210> 22
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 22
taagcttaac ctttgctagc agattgt 27

<210> 23
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 23
cttggtacca gccattcagt cgaggaagg 29

<210> 24
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 24
cttggtacca tatgaatcct ttcatagat 29

<210> 25
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 25
ctgtgggaac acacagattt tgg 23

<210> 26
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 26
ggaataattc gaatcacat 19

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 27
ccaatctgct cacacaggat 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 28
ccttgaggct gtccaagtga 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 29
atggttaact gacttacgaa 20

<210> 30
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 30
gctccatttt gagttaatat ttgtgt 26

<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 31
ttcagtcgag gaaggatagg gt 22

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 32
ttcagtcggt tggtgatagg gt 22

<210> 33
<211> 11
<212> DNA
<213> Homo sapiens

<400> 33
tcgaggaagg a 11

<210> 34
<211> 15
<212> DNA
<213> Homo sapiens

<400> 34
agtcgaggaa ggata 15

<210> 35
<211> 19
<212> DNA
<213> Homo sapiens

<400> 35
tcagtcgagg aaggatagg 19

<210> 36
<211> 23
<212> DNA
<213> Homo sapiens

<400> 36
attcagtcga ggaaggatag ggt 23

<210> 37
<211> 27
<212> DNA
<213> Homo sapiens

<400> 37
ccattcagtc gaggaaggat agggtgg 27

<210> 38
<211> 30
<212> DNA
<213> Homo sapiens

<400> 38
gccattcagt cgaggaagga tagggtggta 30

<210> 39
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 39
gaggatg 7

<210> 40
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 40
caggaag 7

<210> 41
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 41
caggatg 7

<210> 42
<211> 12222
<212> DNA
<213> Homo sapiens

<400> 42

gaattccagg ttggaggggc ggcaacctcc tgccagcctt caggccactc tcctgtgcct 60
gccagaagag acagagcttg aggagagctt gaggagagca ggaaaggtgg aacattgctg 120
ctgctgctca ctcagttcca caggtgggag gaacagcagg gcttagagtg ggggtcattg 180
tgcagatggg aaaacaaagg cccagagagg ggaagaaatg cctaggagct accgagggca 240
ggcgacctca accacagccc agtgctggag ctgtgagtgg atgtagagca gcggaatatc 300
cattcagcca gctcagggga aggacagggg ccctgaagcc aggggatgga gctgcaggga 360
agggagctca gagagaaggg gaggggagtc tgagctcagt ttcccgctgc ctgaaaggag 420
ggtggtacct actcccttca cagggtaact gaatgagaga ctgcctggag gaaagctctt 480
caagtgtggc ccaccccacc ccagtgacac cagcccctga cacgggggag ggagggcagc 540
atcaggaggg gctttctggg cacacccagt acccgtctct gagctttcct tgaactgttg 600
cattttaatc ctcacagcag ctcaacaagg tacataccgt caccatcccc attttacaga 660
tagggaaatt gaggctcgga gcggttaaac aactcacctg aggcctcaca gccagtaagt 720
gggttccctg gtctgaatgt gtgtgctgga ggatcctgtg ggtcactcgc ctggtagagc 780
cccaaggtgg aggcataaat gggactggtg aatgacagaa ggggcaaaaa tgcactcatc 840
cattcactct gcaagtatct acggcacgta cgccagctcc caagcaggtt tgcgggttgc 900
acagcggagc gatgcaatct gatttaggct tttaaaggat tgcaatcaag tgggacccac 960
tagcctcaac cctgtacctc ccctccctc caccccagc agtctccaaa ggcctccaac 1020
aaccccagag tgggggccat gtatccaaag aaactccaag ctgtatacgg atcacactgg 1080
ttttccagga gcaaaaacag aaacagcctg aggctggtca aaattgaacc tcctcctgct 1140
ctgagcagcc taggggggcag actaagcaga gggctgtgca gacccacata aagagcctac 1200
tgtgtgccag gcacttcacc cgaggcactt cacaagcatg cttgggaatg aaacttccaa 1260
ctctttggga tgcaggtgaa acagttcctg gttcagagag gtgaagcggc ctgcctgagg 1320
cagcacagct cttctttaca gatgtgcttc cccacctcta ccctgtctca cggcccccca 1380
tgccagcctg acggttgtgt ctgcctcagt catgctccat ttttccatcg ggaccatcaa 1440
gagggtgttt gtgtctaagg ctgactgggt aactttggat gagcggtctc tccgctccga 1500
gcctgtttcc tcatctgtca aacgggctct aacccactct gatctcccag ggcggcagta 1560
agtcttcagc atcaggcatt ttggggtgac tcagtaaatg gtagatcttg ctaccagtgg 1620
aacagccact aaggattctg cagtgagagc agagggccag ctaagtggta ctctcccaga 1680
gactgtctga ctcacgccac cccctccacc ttggacacag gacgctgtgg tttctgagcc 1740
aggtacaatg actcctttcg gtaagtgcag tggaagctgt acactgccca ggcaaagcgt 1800
ccgggcagcg taggcgggcg actcagatcc cagccagtgg acttagcccc tgtttgctcc 1860
tccgataact ggggtgacct tggttaatat tcaccagcag cctcccccgt tgcccctctg 1920
gatccactgc ttaaatacgg acgaggacag ggccctgtct cctcagcttc aggcaccacc 1980
actgacctgg gacagtgaat cgtaagtatg cctttcactg cgaggggttc tggagaggct 2040
tccgagctcc ccatggccca ggcaggcagc aggtctgggg caggaggggg gttgtggagt 2100
gggtatccgc ctgctgaggt gcagggcaga tggagaggct gcagctgagc tcctattttc 2160
ataataacag cagccatgag ggttgtgtcc tgtttcccag tcctgcccgg tccccctcg 2220
gtacctcctg gtggatacac tggttcctgt aagcagaagt ggatgagggt gtctaggtct 2280
gcagtcctgg caccccagga tgggggacac cagccaagat acagcaacag caacaaagcg 2340
cagccatttc tttctgtttg cacagctcct ctgtctgtcg ggggctcctg tctgttgtct 2400
cctataagcc tcaccacctc tcctactgct tgggcatgca tctttctccc cttctataga 2460
tgaggaggtt aaggttcaga gaggggtggg gaggaacgcc ggctcacatt ctccatcccc 2520
tccagatatg accaggaaca gacctgtgcc agcctcagcc ttacatcaaa atgggcctcc 2580
ccatgcaccg tggacctctg ggccctcctg tcccagtgga ggacaggaag ctgtgagggg 2640

cactgtcacc cagggctcaa gctggcattc ctgaataatc gctctgcacc aggccacggc 2700
taagctcagt gcgtgattaa gcctcataac cctccaaggc agttactagt gtgattccca 2760
ttttacagat gaggaagatg gggacagaga ggtgaataac tggccccaaa tcacacacca 2820
tccataattc gggctcaggc acctggctcc agtccccaaa ctcttgaacc tggccctagt 2880
gtcactgttt ctcttgggtc tcaggcgctg gatggggaac aggaaacctg ggctgaactt 2940
gaggcctctc tgatgctcgg tgacttcaga cagttgctca acctctctgt tctcttgggc 3000
aaaacatgat aacctttgac ttctgtcccc tcccctcacc ccacccgacc ttgatctctg 3060
aagtgttgga aggatttaat ttttcctgca ctgagttttg gagacaggtc aaaaagatga 3120
ccaaggccaa ggtggccagt ttcctataga acgcctctaa aagacctgca gcaatagcag 3180
caagaactgg tattctcgag aacttgctgc gcagcaggca cttcttggca ttttatgtgt 3240
atttaatttc acaatagctc tatgacaaag tccacctttc tcatctccag gaaactgagg 3300
ttcagagagg ttaagtaact tgtccaaggt cacacagcta atagcaagtt gacgtggagc 3360
aatctggcct cagagccttt aattttagcc acagactgat gctcccctct tcatttagcc 3420
aggctgcctc tgaagttttc tgattcaaga cttctggctt cagctttgta cacagagatg 3480
attcaatgtc aggttttgga gcgaaatctg tttaatccca gacaaaacat ttaggattac 3540
atctcagttt tgtaagcaag tagctctgtg atttttagtg agttatttaa tgctctttgg 3600
ggctcaattt ttctatctat aaaatagggc taataatttg caccttatag ggtaagcttt 3660
gaggacagat tagatgatac ggtgcctgta aaacaccagg tgttagtaag tgtggcaatg 3720
atggtgacgc tgaggctgtg tttgcttagc atagggttag gcagctggca ggcagtaaac 3780
agttggataa tttaatggaa aatttgccaa actcagatgc tgttcactgc tgagcaggag 3840
ccccttcctg ctgaaatggt cctggggagt gcagcaggct ctccgggaag aaatctacca 3900
tctctcgggc aggagctcaa cctgtgtgca ggtacaggga gggcttcctc acctggtgcc 3960
cactcatgca ttacgtcagt tattcctcat ccctgtccaa aggattcttt tctccattgt 4020
acagctatga agctagtgct caaagaagtg aagtcattta ccccaggccc cctgccagta 4080
agtgacaggg cctggtcaca cttgggttta tttattgccc agttcaacag gttgtttgac 4140
cataggcgag attctcttcc ctgcaccctg ccgggttgct cttggtccct tattttatgc 4200
tcctgggtag aaatggtgcg agattaggca gggagtggac gcttccctgt ccctggcccc 4260
gcaaagagtg ctcccacctg ccccgatccc agaaatgtca ccatgaagcc ttcattcttt 4320
tggtttaaag cttggcctca gtgtccgtac accatggggt ccttggccag atggcgactt 4380
tctcctctcc agtcgccctc ccaggcacta gcttttagga gtgcagggtg ctgcctctga 4440
tagaagggcc aggagagagc aggttttgga gacctgatgt tataaggaac agcttgggag 4500
gcataatgaa cccaacatga tgcttgagac caatgtcaca gcccaattct gacattcatc 4560
atctgagatc tgaggacaca gctgtctcag ttcatgatct gagtgctggg aaagccaaga 4620
cttgttccag ctttgtcact gacttgctgt atagcctcaa caaggccctg accctctctg 4680
ggcttcaaac tcttcactgt gaaaggagga aaccagagta ggtgatgtga caccaggaaa 4740
gatggatggg tgtgggggaa tgtgctcctc ccagctgtca ccccctcgcc accctccctg 4800
caccagcctc tccacctcct ttgagcccag aattcccctg tctaggaggg cacctgtctc 4860
gtgcctagcc atgggaattc tccatctgtt ttgctacatt gaacccagat gccattctaa 4920
ccaagaatcc tggctgggtg caggggctct cgcctgtaac cccagcactt tgggaggcca 4980
aggcaggcgg atcaagaggt caggagttca agacctgcct ggccaacacg gtgaaacctc 5040
agctctacta aaaatacaaa aattagccag gcgtggtggc acacgcctgt aatcccagct 5100
atttgggaag ctgagacaga agaatttctt gaacccggga ggtggaggtt tcagtgagcc 5160
gagatcacgc cactgcactc caccctggcg gataaagcga gactctgtct caaaaaaaac 5220
ccaaaaacct atgttagtgt acagagggcc ccagtgaagt cttctcccag ccccactttg 5280
cacaactggg gagagtgagg ccccaggacc agaggattct tgctaaaggc caagtggata 5340

gtgatggccc tgccaggcta gaagccacaa cctctggccc tgaggccact cagcatattt 5400
agtgtcccca ccctgcagag gcccaactcc ctcctgacca ctgagccctg taatgatggg 5460
ggaatttcca taagccatga aggactgcac aaagttcagt tgggagtgaa agagaaatta 5520
aagggagatg gaaatataca gcactaattt tagcaccgtc ttcagttcta acaacactag 5580
ctagctgaag aaaatacaaa catgtattat gtaatgtgtg gtctgttcca tttggattac 5640
ttagaggcac gagggccaag gagaaaggtg gtggagagaa accagctttg cacttcattt 5700
gttgctttat tggaaggaaa cttttaaaag tccaaggggg ttgaagaatc tcaatatttg 5760
ttatttccag ctttttttct ccagtttttc atttcccaaa ttcaaggaca ccttttttctt 5820
tgtattttgt taagatgatg gttttggttt tgtgactagt agttaacaat gtggctgccg 5880
ggcatattct cctcagctag gacctcagtt ttcccatctg tgaagacggc aggttctacc 5940
taggggctg caggcaggtg gtccgaagcc tgggcatatc tggagtagaa ggatcactgt 6000
ggggcagggc aggttctgtg ttgctgtgga tgacgttgac tttgaccatt gctcggcaga 6060
gcctgctctc gctggttcag ccacaggccc caccactccc tattgtctca gccccgggta 6120
tgaaacatgt attcctcact ggcctatcac ctgaagcctt tgaatttgca acacctgcca 6180
acccctccct caaaagagtt gccctctcta gatccttttg atgtaaggtt tggtgttgag 6240
acttatttca ctaaattctc atacataaac atcactttat gtatgaggca aaatgaggac 6300
cagggagatg aatgacttgt cctggctcat acacctggaa agtgacagag tcagattaga 6360
tcctaggtct atctgaagtt aaaagaggtg tcttttcact tcccacctcc tccatctact 6420
ttaaagcagc acaaacccct gctttcaagg agagatgagc gtctctaaag cccctgacag 6480
caagagccca gaactgggac accattagtg acccagacgg caggtaagct gactgcagga 6540
gcatcagcct attcttgtgt ctgggaccac agagcattgt ggggacagcc ccgtctcttg 6600
ggaaaaaaac cctaagggct gaggatcctt gtgagtgttg ggtgggaaca gctcccagga 6660
ggtttaatca cagcccctcc atgctctcta gctgttgcca ttgtgcaaga tgcatttccc 6720
ttctgtgcag cagtttccct ggccactaaa tagtgggatt agatagaagc cctccaaggg 6780
ctccagcttg acatgattct tgattctgat ctgacccgat tctgataatc gtgggcaggc 6840
ccattcctct tcttgtgcct cattttcttc ttttgtaaaa caatggctgt accatttgca 6900
tcttagggtc attgcagatg aaagtgttgc tgtccagagc ctgggtgcag gacctagatg 6960
taggattctg gttctgctac ttcctcagtg acattgaata gctgacctaa tctctctggc 7020
tttggtttct tcatctgtaa aagaaggata ttagcattag cacctcacgg gattgttaca 7080
agaaagcaat gaattaacac atgtgagcac ggagaacagt gcttggcata tggtaagcac 7140
tacgtacatt ttgctattct tctgattctt tcagtgttac tgatgtcggc aagtacttgg 7200
cacaggctgg tttaataatc cctaggcact ttcacgtggt gtcaatccct gatcactggg 7260
agtcatcatg tgccttgact cgggcctggc ccccccatct ctgtcttgca ggacaatgcc 7320
gtcttctgtc tcgtggggca tcctcctgct ggcaggcctg tgctgcctgg tccctgtctc 7380
cctggctgag gatccccagg gagatgctgc ccagaagaca gatacatccc accatgatca 7440
ggatcaccca accttcaaca agatcacccc caacctggct gagttcgcct tcagcctata 7500
ccgccagctg gcacaccagt ccaacagcac caatatcttc ttctccccag tgagcatcgc 7560
tacagccttt gcaatgctct ccctggggac caaggctgac actcacgatg aaatcctgga 7620
gggcctgaat ttcaacctca cggagattcc ggaggctcag atccatgaag gcttccagga 7680
actcctccgt accctcaacc agccagacag ccagctccag ctgaccaccg gcaatggcct 7740
gttcctcagc gagggcctga agctagtgga taagtttttg gaggatgtta aaaagttgta 7800
ccactcagaa gccttcactg tcaacttcgg ggacaccgaa gaggccaaga aacagatcaa 7860
cgattacgtg gagaagggta ctcaagggaa aattgtggat ttggtcaagg agcttgacag 7920
agacacagtt tttgctctgg tgaattacat cttctttaaa ggtaaggttg ctcaaccagc 7980
ctgagctgtt tcccatagaa acaagcaaaa atatttctca aaccatcagt tcttgaactc 8040

tccttggcaa tgcattatgg gccatagcaa tgcttttcag cgtggattct tcagttttct 8100
acacacaaac actaaaatgt tttccatcat tgagtaattt gaggaaataa tagattaaac 8160
tgtcaaaact actgacgctc tgcagaactt ttcagagcct ttaatgtcct tgtgtatact 8220
gtatatgtag aatatataat gcttagaact atagaacaaa ttgtaataca ctgcataaag 8280
ggatagtttc atggaacata ctttacacga ctctagtgtc ccagaatcag tatcagtttt 8340
gcaatctgaa agacctgggt tcaaatcctg cctctaacac aattagcttt tgacaaaaac 8400
aatgcattct acctctttga ggtgctaatt tctcatctta gcatggacaa aataccattc 8460
ttgctgtcag gttttttag gattaaacaa atgacaaaga ctgtggggat ggtgtgtggc 8520
atacagcagg tgatggactc ttctgtatct caggctgcct tcctgccccc gaggggttaa 8580
aatgccaggg tcctgggggc cccagggcat tctaagccag ctcccactgt cccaggaaaa 8640
cagcataggg gaggggaggt gggaggcaag gccaggggct gcttcctcca ctctgaggct 8700
cccttgctct tgaggcaaag gagggcagtg gaggcaagcc aggctgcagt cagcacagct 8760
aaagtcctgg ctctgctgtg gccttagtgg gggcccaggt ccctctccag ccccagtctc 8820
ctccttctgt ccaatgagaa agctgggatc aggggtccct gaggcccctg tccactctgc 8880
atgcctcgat ggtgaagctc tgttggtatg gcagagggga ggctgctcag gcatctgcat 8940
ttcccctgcc aatctagagg atgaggaaag ctctcaggaa tagtaagcag aatgtttgcc 9000
ctggatgaat aactgagctg ccaattaaca aggggcaggg agccttagac agaaggtacc 9060
aaatatgcct gatgctccaa cattttattt gtaatatcca agacaccctc aaataaacat 9120
atgattccaa taaaaatgca cagccacgat ggcatctctt agcctgacat cgccacgatg 9180
tagaaattct gcatcttcct ctagttttga attatcccca cacaatcttt ttcggcagct 9240
tggatggtca gtttcagcac cttttacaga tgatgaagct gagcctcgag ggatgtgtgt 9300
cgtcaagggg gctcagggct tctcagggag gggactcatg gtttcttatt ctgctacact 9360
cttccaaacc ttcactcacc cctggtgatg cccaccttcc cctctctcca ggcaaatggg 9420
agagaccctt tgaagtcaag gacaccgagg aagaggactt ccacgtggac caggtgacca 9480
ccgtgaaggt gcctatgatg aagcgtttag gcatgtttaa catccagcac tgtaagaagc 9540
tgtccagctg ggtgctgctg atgaaatacc tgggcaatgc caccgccatc ttcttcctgc 9600
ctgatgaggg gaaactacag cacctggtaa atgaactcac ccacgatatc atcaccaagt 9660
tcctggaaaa tgaagacaga aggtgattcc ccaacctgag ggtgaccaag aagctgccca 9720
cacctcttag ccatgttggg actgaggccc atcaggactg gccagagggc tgaggagggt 9780
gaaccccaca tccctgggtc actgctactc tgtataaact tggcttccag aatgaggcca 9840
ccactgagtt caggcagcgc cgtccatgct ccatgaggag aacagtaccc agggtgagga 9900
ggtaaaggtc tcgtccctgg gaacttccca ctccagtgtg gacactgtcc cttcccaata 9960
tccagtgccc aaggcaggga cagcagcacc accacacgtt ctggcagaac caaaaaggaa 10020
cagatgggct tcctggcaaa ggcagcagtg gagtgtggag ttcaagggta gaatgtccct 10080
ggggggacgg gggaagagcc tgtgtggcaa ggcccagaaa agcaaggttc ggaattggaa 10140
cagccaggcc atgttcgcag aaggcttgcg tttctctgtc actttatcgg tgctgttaga 10200
ttgggtgtcc tgtagtaagt gatacttaaa catgagccac acattagtgt atgtgtgtgc 10260
attcgtgatt atgcccatgc cctgctgatc tagttcgttt tgtacactgt aaaaccaaga 10320
tgaaaataca aaaggtgtcg ggttcataat aggaatcgag gctggaattt ctctgttcca 10380
tgccagcacc tcctgaggtc tctgctccag gggttgagaa agaacaaaga ggctgagagg 10440
gtaacggatc agagagccca gagccagctg ccgctcacac cagaccctgc tcagggtggc 10500
attgtctccc catggaaaac cagagaggag cactcagcct ggtgtggtca ctcttctctt 10560
atccactaaa cggttgtcac tgggcactgc caccagcccc gtgtttctct gggtgtaggg 10620
ccctggggat gttacaggct gggggccagg tgacccaaca ctacagggca agatgagaca 10680
ggcttccagg acacctagaa tatcagagga ggtggcattt caagcttttg tgattcattc 10740

gatgttaaca ttctttgact caatgtagaa gagctaaaag tagaacaaac caaagccgag 10800
ttcccatctt agtgtgggtg gaggacacag gagtaagtgg cagaaataat cagaaaagaa 10860
aacacttgca ctgtggtggg tcccagaaga acaagaggaa tgctgtgcca tgccttgaat 10920
ttcttttctg cacgacaggt ctgccagctt acatttaccc aaactgtcca ttactggaac 10980
ctatgatctg aagagcgtcc tgggtcaact gggcatcact aaggtcttca gcaatggggc 11040
tgacctctcc ggggtcacag aggaggcacc cctgaagctc tccaaggtga gatcaccctg 11100
acgaccttgt tgcaccatgg tatctgtagg gaagaatgtg tgggggctgc agcactgtcc 11160
tgaggctgag gaaggggccg agggaaacaa atgaagaccc aggctgagct cctgaagatg 11220
cccgtgattc actgacacgg gacggtgggc aaacagcaaa gccaggcagg ggctgctgtg 11280
cagctggcac tttcggggcc tcccttgagg ttgtgtcact gaccctgaat ttcaactttg 11340
cccaagacct tctagacatt gggccttgat ttatccatac tgacacagaa aggtttgggc 11400
taagttgttt caaaggaatt tctgactcct tcgatctgtg agatttggtg tctgaattaa 11460
tgaatgattt cagctaaagt gacacttatt ttggaaaact aaaggcgacc aatgaacaac 11520
ctgcagttcc atgaatggct gcattatctt ggggtctggg cactgtgaag gtcactgcca 11580
gggtccgtgt cctcaaggag cttcaagccg tgtactagaa aggagagagc cctggaggca 11640
gacgtggagt gacgatgctc ttccctgttc tgagttgtgg gtgcacctga gcagggggag 11700
aggcgcttgt caggaagatg gacagagggg agccagcccc atcagccaaa gccttgagga 11760
ggagcaaggc ctatgtgaca gggagggaga ggatgtgcag ggccagggcc gtccaggggg 11820
agtgagcgct tcctgggagg tgtccacgtg agccttgctc gaggcctggg atcagcctta 11880
caacgtgtct ctgcttctct cccctccagg ccgtgcataa ggctgtgctg accatcgacg 11940
agaaagggac tgaagctgct ggggccatgt ttttagaggc catacccatg tctatccccc 12000
ccgaggtcaa gttcaacaaa ccctttgtct tcttaatgat tgaacaaaat accaagtctc 12060
ccctcttcat gggaaaagtg gtgaatccca cccaaaaata actgcctctc gctcctcaac 12120
ccctcccctc catccctggc cccctccctg gatgacatta aagaagggtt gagctggtcc 12180
ctgcctgcat gtgatctgta aatccctggg atgttttctc tg 12222

<210> 43
<211> 1599
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 43
caccagcatc atctcctcca attcatccag ctactctgcc catgaagata atagttttca 60
ggcggattgc ctcagatcac actatctcca cttgcccagc cctgtggaag attagcggcc 120
atgtattcca atgtgatagg aactgtaacc tctggaaaaa ggaaggttta tcttttgtcc 180
ttgctgctca ttggcttctg ggactgcgtg acctgtcacg ggagccctgt ggacatctgc 240
acagccaagc cgcgggacat tcccatgaat cccatgtgca tttaccgctc cccggagaag 300
aaggcaactg aggatgaggg ctcagaacag aagatcccgg aggccaccaa ccggcgtgtc 360
tgggaactgt ccaaggccaa ttcccgcttt gctaccactt tctatcagca cctggcagat 420
tccaagaatg acaatgataa cattttcctg tcacccctga gtatctccac ggcttttgct 480
atgaccaagc tgggtgcctg taatgacacc ctccagcaac tgatggaggt atttaagttt 540
gacaccatat ctgagaaaac atctgatcag atccacttct tctttgccaa actgaactgc 600

cgactctatc gaaaagccaa caaatcctcc aagttagtat cagccaatcg ccttttttgga 660
gacaaatccc ttaccttcaa tgagacctac caggacatca gtgagttggt atatggagcc 720
aagctccagc ccctggactt caaggaaaat gcagagcaat ccagagcggc catcaacaaa 780
tgggtgtcca ataagaccga aggccgaatc accgatgtca ttccctcgga agccatcaat 840
gagctcactg ttctggtgct ggttaacacc atttacttca agggcctgtg gaagtcaaag 900
ttcagccctg agaacacaag gaaggaactg ttctacaagg ctgatggaga gtcgtgttca 960
gcatctatga tgtaccagga aggcaagttc cgttatcggc gcgtggctga aggcacccag 1020
gtgcttgagt tgcccttcaa aggtgatgac atcaccatgg tcctcatctt gcccaagcct 1080
gagaagagcc tggccaaggt ggagaaggaa ctcaccccag aggtgctgca ggagtggctg 1140
gatgaattgg aggagatgat gctggtggtt cacatgcccc gcttccgcat tgaggacggc 1200
ttcagtttga aggagcagct gcaagacatg ggccttgtcg atctgttcag ccctgaaaag 1260
tccaaactcc caggtattgt tgcagaaggc cgagatgacc tctatgtctc agatgcattc 1320
cataaggcat ttcttgaggt aaatgaagaa ggcagtgaag cagctgcaag taccgctgtt 1380
gtgattgctg gccgttcgct aaaccccaac agggtgactt tcaaggccaa caggcccttc 1440
ctggttttta taagagaagt tcctctgaac actattatct tcatgggcag agtagccaac 1500
ccttgtgtta agtaaaatgt tcttattctt tgcacctctt cctatttttg gtttgtgaac 1560
agaagtaaaa ataaatacaa actacttcca tctcacatt 1599

<210> 44
<211> 23
<212> DNA
<213> T7 virus

<400> 44
taatacgact cactataggg cga 23

<210> 45
<211> 24
<212> DNA
<213> T3 virus

<400> 45
ttattaaccc tcactaaagg gaag 24

<210> 46
<211> 23
<212> DNA
<213> SP6 virus

<400> 46
atttaggtga cactatagaa tac 23

<210> 47
<211> 555
<212> PRT
<213> Mus musculus

<400> 47

```
Met Thr Lys Ser Ser Asn His Asn Cys Leu Leu Arg Pro Glu Asn Lys
  1               5                  10                  15

Pro Gly Leu Trp Gly Pro Gly Ala Gln Ala Ala Ser Leu Arg Pro Ser
             20                  25                  30

Pro Ala Thr Leu Val Val Ser Ser Pro Gly His Ala Glu His Pro Pro
         35                  40                  45

Ala Ala Pro Ala Gln Thr Pro Gly Pro Gln Val Ser Ala Ser Ala Arg
     50                  55                  60

Gly Pro Gly Pro Val Ala Gly Gly Ser Gly Arg Met Glu Arg Arg Met
 65                  70                  75                  80

Lys Gly Gly Tyr Leu Asp Gln Arg Val Pro Tyr Thr Phe Cys Ser Lys
                 85                  90                  95

Ser Pro Gly Asn Gly Ser Leu Gly Glu Ala Leu Met Val Pro Gln Gly
            100                 105                 110

Lys Leu Met Asp Pro Gly Ser Leu Pro Pro Ser Asp Ser Glu Asp Leu
        115                 120                 125

Phe Gln Asp Leu Ser His Phe Gln Glu Thr Trp Leu Ala Glu Ala Gln
    130                 135                 140

Val Pro Asp Ser Asp Glu Gln Phe Val Pro Asp Phe His Ser Glu Asn
145                 150                 155                 160

Leu Ala Phe His Ser Pro Thr Thr Arg Ile Lys Lys Glu Pro Gln Ser
                165                 170                 175

Pro Arg Thr Asp Pro Ala Leu Ser Cys Ser Arg Lys Pro Pro Leu Pro
            180                 185                 190

Tyr His His Gly Glu Gln Cys Leu Tyr Ser Arg Gln Ile Ala Ile Lys
        195                 200                 205
```

```
Ser Pro Ala Pro Gly Ala Pro Gly Gln Ser Pro Leu Gln Pro Phe Ser
    210                 215                 220

Arg Ala Glu Gln Gln Gln Ser Leu Leu Arg Ala Ser Ser Ser Ser Gln
225                 230                 235                 240

Ser His Pro Gly His Gly Tyr Leu Gly Glu His Ser Ser Val Phe Gln
                245                 250                 255

Gln Pro Val Asp Met Cys His Ser Phe Thr Ser Pro Gln Gly Gly Gly
            260                 265                 270

Arg Glu Pro Leu Pro Ala Pro Tyr Gln His Gln Leu Ser Glu Pro Cys
        275                 280                 285

Pro Pro Tyr Pro Gln Gln Asn Phe Lys Gln Glu Tyr His Asp Pro Leu
    290                 295                 300

Tyr Glu Gln Ala Gly Gln Pro Ala Ser Ser Gln Gly Gly Val Ser Gly
305                 310                 315                 320

His Arg Tyr Pro Gly Ala Gly Val Val Ile Lys Gln Glu Arg Thr Asp
                325                 330                 335

Phe Ala Tyr Asp Ser Asp Val Pro Gly Cys Ala Ser Met Tyr Leu His
            340                 345                 350

Pro Glu Gly Phe Ser Gly Pro Ser Pro Gly Asp Gly Val Met Gly Tyr
        355                 360                 365

Gly Tyr Glu Lys Ser Leu Arg Pro Phe Pro Asp Asp Val Cys Ile Val
    370                 375                 380

Pro Lys Lys Phe Glu Gly Asp Ile Lys Gln Glu Gly Ile Gly Ala Phe
385                 390                 395                 400

Arg Glu Gly Pro Pro Tyr Gln Arg Arg Gly Ala Leu Gln Leu Trp Gln
                405                 410                 415

Phe Leu Val Ala Leu Leu Asp Asp Pro Thr Asn Ala His Phe Ile Ala
            420                 425                 430

Trp Thr Gly Arg Gly Met Glu Phe Lys Leu Ile Glu Pro Glu Glu Val
        435                 440                 445
```

Ala Arg Leu Trp Gly Ile Gln Lys Asn Arg Pro Ala Met Asn Tyr Asp
450 455 460

Lys Leu Ser Arg Ser Leu Arg Tyr Tyr Tyr Glu Lys Gly Ile Met Gln
465 470 475 480

Lys Val Ala Gly Glu Arg Tyr Val Tyr Lys Phe Val Cys Glu Pro Glu
485 490 495

Ala Leu Phe Ser Leu Ala Phe Pro Asp Asn Gln Arg Pro Ala Leu Lys
500 505 510

Ala Glu Phe Asp Arg Pro Val Ser Glu Glu Asp Thr Val Pro Leu Ser
515 520 525

His Leu Asp Glu Ser Pro Ala Tyr Leu Pro Glu Leu Thr Gly Pro Ala
530 535 540

Pro Pro Phe Gly His Arg Gly Gly Tyr Ser Tyr
545 550 555

<210> 48
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 48
cccggaag 8

<210> 49
<211> 1843
<212> DNA
<213> Homo sapiens

<400> 49
ctgcaggggg gggggggggg gggggctgtc atggcggcag gacggcgaac ttgcagtatc 60
tccacgaccc gcccctacag gtgccagtgc ctccagaatg tggcagctca caagcctcct 120
gctgttcgtg gccacctggg gaatttccgg cacaccagct cctcttgact cagtgttctc 180
cagcagcgag cgtgcccacc aggtgctgcg gatccgcaaa cgtgccaact ccttcctgga 240
ggagctccgt cacagcagcc tggagcggga gtgcatagag gagatctgtg acttcgagga 300
ggccaaggaa attttccaaa atgtggatga cacactggcc ttctggtcca agcacgtcga 360

cggtgaccag tgcttggtct tgcccttgga gcacccgtgc gccagcctgt gctgcgggca 420
cggcacgtgc atcgacggca tcggcagctt cagctgcgac tgccgcagcg gctgggaggg 480
ccgcttctgc cagcgcgagg tgagcttcct caattgctcg ctggacaacg gcggctgcac 540
gcattactgc ctagaggagg tgggctggcg gcgctgtagc tgtgcgcctg gctacaagct 600
gggggacgac ctcctgcagt gtcaccccgc agtgaagttc ccttgtggga ggccctggaa 660
gcggatggag aagaagcgca gtcacctgaa acgagacaca gaagaccaag aagaccaagt 720
agatccgcgg ctcattgatg ggaagatgac caggcgggga gacagcccct ggcaggtggt 780
cctgctggac tcaaagaaga agctggcctg cggggcagtg ctcatccacc cctcctgggt 840
gctgacagcg gcccactgca tggatgagtc caagaagctc cttgtcaggc ttggagagta 900
tgacctgcgg cgctgggaga agtgggagct ggacctggac atcaaggagg tcttcgtcca 960
ccccaactac agcaagagca ccaccgacaa tgacatcgca ctgctgcacc tggcccagcc 1020
cgccaccctc tcgcagacca tagtgcccat ctgcctcccg gacagcggcc ttgcagagcg 1080
cgagctcaat caggccggcc aggagaccct cgtgacgggc tggggctacc acagcagccg 1140
agagaaggag gccaagagaa accgcacctt cgtcctcaac ttcatcaaga ttcccgtggt 1200
cccgcacaat gagtgcagcg aggtcatgag caacatggtg tctgagaaca tgctgtgtgc 1260
gggcatcctc ggggaccggc aggatgcctg cgagggcgac agtgggggggc ccatggtcgc 1320
ctccttccac ggcacctggt tcctggtggg cctggtgagc tggggtgagg gctgtgggct 1380
ccttcacaac tacggcgttt acaccaaagt cagccgctac ctcgactgga tccatgggca 1440
catcagagac aaggaagccc cccagaagag ctgggcacct tagcgaccct ccctgcaggg 1500
ctgggctttt gcatggcaat ggatgggaca ttaaagggac atgtaacaag cacaccggcc 1560
tgctgttctg tccttccatc cctcttttgg gctcttctgg agggaagtaa catttactga 1620
gcacctgttg tatgtcacat gccttatgaa tagaatctta actcctagag caactctgtg 1680
gggtggggag gagcagatcc aagttttgcg gggtctaaag ctgtgtgtgt tgagggggat 1740
actctgttta tgaaaaagaa taaaaaacac aaccacgaaa aaaaaaaaaa aaaaaaaaaa 1800
aaaaaaaaaa aaaaaaaccc ccccccgccc ccccccccctg cag 1843

<210> 50
<211> 11725
<212> DNA
<213> Homo sapiens

<400> 50
agtgaatctg ggcgagtaac acaaaacttg agtgtcctta cctgaaaaat agaggttaga 60
gggatgctat gtgccattgt gtgtgtgtgt tgggggtggg gattgggggt gatttgtgag 120
caattggagg tgagggtgga gcccagtgcc cagcacctat gcactgggga cccaaaaagg 180
agcatcttct catgatttta tgtatcagaa attgggatgg catgtcattg ggacagcgtc 240
ttttttcttg tatggtggca cataaataca tgtgtcttat aattaatggt attttagatt 300
tgacgaaata tggaatatta cctgttgtgc tgatcttggg caaactataa tatctctggg 360
caaaaatgtc cccatctgaa aaacagggac aacgttcctc cctcagccag ccactatggg 420
gctaaaatga gaccacatct gtcaagggtt ttgccctcac ctccctccct gctggatggc 480
atccttggta ggcagaggtg ggcttcgggc agaacaagcc gtgctgagct aggaccagga 540
gtgctagtgc cactgtttgt ctatggagag ggaggcctca gtgctgaggg ccaagcaaat 600
atttgtggtt atggattaac tcgaactcca ggctgtcatg gcggcaggac ggcgaacttg 660
cagtatctcc acgacccgcc cctgtgagtc cccctccagg caggtctatg aggggtgtgg 720
agggagggct gcccccggga gaagagagct aggtggtgat gagggctgaa tcctccagcc 780

agggtgctca acaagcctga gcttggggta aaaggacaca aggccctcca caggccaggc 840
ctggcagcca cagtctcagg tccctttgcc atgcgcctcc ctctttccag gccaagggtc 900
cccaggccca gggccattcc aacagacagt ttggagccca ggaccctcca ttctccccac 960
cccacttcca cctttggggg tgtcggattt gaacaaatct cagaagcggc ctcagaggga 1020
gtcggcaaga atggagagca gggtccggta gggtgtgcag aggccacgtg gcctatccac 1080
tggggagggt tccttgatct ctggccacca gggctatctc tgtggccttt tggagcaacc 1140
tggtggtttg gggcaggggt tgaatttcca ggcctaaaac cacacaggcc tggccttgag 1200
tcctggctct gcgagtaatg catggatgta aacatggaga cccaggacct tgcctcagtc 1260
ttccgagtct ggtgcctgca gtgtactgat ggtgtgagac cctactcctg gaggatgggg 1320
gacagaatct gatcgatccc ctgggttggt gacttccctg tgcaatcaac ggagaccagc 1380
aagggttgga tttttaataa accacttaac tcctccgagt ctcagtttcc ccctctatga 1440
aatggggttg acagcattaa taactacctc ttgggtggtt gtgagcctta actgaagtca 1500
taatatctca tgtttactga gcatgagcta tgtgcaaagc ctgttttgag agctttatgt 1560
ggactaactc ctttaattct cacaacaccc tttaaggcac agatacacca cgttattcca 1620
tccattttac aaatgaggaa actgaggcat ggagcagtta agcatcttgc ccaacattgc 1680
cctccagtaa gtgctggagc tggaatttgc accgtgcagt ctggcttcat ggcctgccct 1740
gtgaatcctg taaaaattgt ttgaaagaca ccatgagtgt ccaatcaacg ttagctaata 1800
ttctcagccc agtcatcaga ccggcagagg cagccacccc actgtcccca gggaggacac 1860
aaacatcctg gcaccctctc cactgcattc tggagctgct ttctaggcag gcagtgtgag 1920
ctcagcccca cgtagagcgg gcagccgagg ccttctgagg ctatgtctct agcgaacaag 1980
gaccctcaat tccagcttcc gcctgacggc cagcacacag ggacagccct ttcattccgc 2040
ttccacctgg gggtgcaggc agagcagcag cgggggtagc actgcccgga gctcagaagt 2100
cctcctcaga caggtgccag tgcctccaga atgtggcagc tcacaagcct cctgctgttc 2160
gtggccacct ggggaatttc cggcacacca gctcctcttg gtaaggccac cccaccccta 2220
ccccgggacc cttgtggcct ctacaaggcc ctggtggcat ctgcccaggc cttcacagct 2280
tccaccatct ctctgagccc tgggtgaggt gaggggcaga tgggaatggc aggaatcaac 2340
tgacaagtcc caggtaggcc agctgccaga gtgccacaca ggggctgcca gggcaggcat 2400
gcgtgatggc agggagcccc gcgatgacct cctaaagctc cctcctccac acggggatgg 2460
tcacagagtc ccctgggcct tccctctcca cccactcact ccctcaactg tgaagacccc 2520
aggcccaggc taccgtccac actatccagc acagcctccc ctactcaaat gcacactggc 2580
ctcatggctg ccctgcccca acccctttcc tggtctccac agccaacggg aggaggccat 2640
gattcttggg gaggtccgca ggcacatggg cccctaaagc cacaccaggc tgttggtttc 2700
atttgtgcct ttatagagct gtttatctgc ttgggacctg cacctccacc ctttcccaag 2760
gtgccctcag ctcaggcata ccctcctcta ggatgccttt tcccccatcc cttcttgctc 2820
acacccccaa cttgatctct ccctcctaac tgtgccctgc accaagacag acacttcaca 2880
gagcccagga cacacctggg gacccttcct gggtgatagg tctgtctatc ctccaggtgt 2940
ccctgcccaa ggggagaagc atggggaata cttggttggg ggaggaaagg aagactgggg 3000
ggatgtgtca agatggggct gcatgtggtg tactggcaga agagtgagag gatttaactt 3060
ggcagccttt acagcagcag ccagggcttg agtacttatc tctgggccag gctgtattgg 3120
atgttttaca tgacggtctc atccccatgt ttttggatga gtaaattgaa ccttagaaag 3180
gtaaagacac tggctcaagg tcacacagag atcggggtgg ggttcacagg gaggcctgtc 3240
catctcagag caaggcttcg tcctccaact gccatctgct tcctggggag gaaaagagca 3300
gaggacccct gcgccaagcc atgacctaga attagaatga gtcttgaggg ggcggagaca 3360
agaccttccc aggctctccc agctctgctt cctcagaccc cctcatggcc ccagcccctc 3420
ttaggccccc caccaaggtg agctcccctc cctccaaaac cagactcagt gttctccagc 3480

agcgagcgtg cccaccaggt gctgcggatc cgcaaacgtg ccaactcctt cctggaggag 3540
ctccgtcaca gcagcctgga gcgggagtgc atagaggaga tctgtgactt cgaggaggcc 3600
aaggaaattt tccaaaatgt ggatgacaca gtaaggccac catgggtcca gaggatgagg 3660
ctcaggggcg agctggtaac cagcaggggc ctcgaggagc aggtggggac tcaatgctga 3720
ggccctctta ggagttgtgg gggtggctga gtggagcgat taggatgctg gccctatgat 3780
gtcggccagg cacatgtgac tgcaagaaac agaattcagg aagaagctcc aggaaagagt 3840
gtggggtgac cctaggtggg gactcccaca gccacagtgt aggtggttca gtccaccctc 3900
cagccactgc tgagcaccac tgcctccccg tcccacctca caaagagggg acctaaagac 3960
caccctgctt ccacccatgc ctctgctgat cagggtgtgt gtgtgaccga aactcacttc 4020
tgtccacata aaatcgctca ctctgtgcct cacatcaaag ggagaaaatc tgattgttca 4080
gggggtcgga agacagggtc tgtgtcctat ttgtctaagg gtcagagtcc tttggagccc 4140
ccagagtcct gtggacgtgg ccctaggtag tagggtgagc ttggtaacgg ggctggcttc 4200
ctgagacaag gctcagaccc gctctgtccc tggggatcgc ttcagccacc aggacctgaa 4260
aattgtgcac gcctgggccc ccttccaagg catccaggga tgctttccag tggaggcttt 4320
cagggcagga gaccctctgg cctgcaccct ctcttgccct cagcctccac ctccttgact 4380
ggacccccat ctggacctcc atccccacca cctctttccc cagtggcctc cctggcagac 4440
accacagtga ctttctgcag gcacatatct gatcacatca agtccccacc gtgctcccac 4500
ctcacccatg gtctctcagc cccagcagcc ttggctggcc tctctgatgg agcaggcatc 4560
aggcacaggc cgtgggtctc aacgtgggct gggtggtcct ggaccagcag cagccgccgc 4620
agcagcaacc ctggtacctg gttaggaacg cagaccctct gcccccatcc tcccaactct 4680
gaaaaacact ggcttaggga aaggcgcgat gctcaggggt cccccaaagc ccgcaggcag 4740
agggagtgat gggactggaa ggaggccgag tgacttggtg agggattcgg gtcccttgca 4800
tgcagaggct gctgtgggag cggacagtcg cgagagcagc actgcagctg catggggaga 4860
gggtgttgct ccagggacgt gggatggagg ctgggcgcgg gcgggtggcg ctggagggcg 4920
ggggaggggc agggagcacc agctcctagc agccaacgac catcgggcgt cgatccctgt 4980
ttgtctggaa gccctcccct cccctgcccg ctcacccgct gccctgcccc acccgggcgc 5040
gcccctccgc acaccggctg caggagcctg acgctgcccg ctctctccgc agctggcctt 5100
ctggtccaag cacgtcggtg agtgcgttct agatccccgg ctggactacc ggcgcccgcg 5160
cccctcggga tctctggccg ctgacccccc accccgcctt gtgtcgcaga cggtgaccag 5220
tgcttggtct tgcccttgga gcacccgtgc gccagcctgt gctgcgggca cggcacgtgc 5280
atcgacggca tcggcagctt cagctgcgac tgccgcagcg gctgggaggg ccgcttctgc 5340
cagcgcggtg aggggagag gtggatgctg gcgggcggcg gggcggggct ggggccgggt 5400
tgggggcgcg gcaccagcac cagctgcccg cgccctcccc tgcccgcaga ggtgagcttc 5460
ctcaattgct ctctggacaa cggcggctgc acgcattact gcctagagga ggtgggctgg 5520
cggcgctgta gctgtgcgcc tggctacaag ctgggggacg acctcctgca gtgtcacccc 5580
gcaggtgaga agcccccaat acatcgccca ggaatcacgc tgggtgcggg gtgggcaggc 5640
ccctgacggg cgcggcgcgg ggggctcagg agggtttcta gggagggagc gaggaacaga 5700
gttgagcctt ggggcagcgg cagacgcgcc caacaccggg gccactgtta gcgcaatcag 5760
cccgggagct gggcgcgccc tccgctttcc ctgcttcctt tcttcctggc gtccccgctt 5820
cctccgggcg cccctgcgac ctggggccac ctcctggagc gcaagcccag tggtggctcc 5880
gctccccagt ctgagcgtat ctggggcgag gcgtgcagcg tcctcctcca tgtagcctgg 5940
ctgcgttttt ctctgacgtt gtccggcgtg catcgcattt ccctctttac ccccttgctt 6000
ccttgaggag agaacagaat cccgattctg ccttcttcta tattttcctt tttatgcatt 6060
ttaatcaaat ttatatatgt atgaaacttt aaaaatcaga gttttacaac tcttacactt 6120
tcagcatgct gttccttggc atgggtcctt ttttcattca ttttcataaa aggtggaccc 6180

ttttaatgtg gaaattccta tcttctgcct ctagggcatt tatcacttat ttcttctaca 6240
atctcccctt tacttcctct attttctctt tctggacctc ccattattca gacctctttc 6300
ctctagtttt attgtctctt ctatttccca tctctttgac tttgtgtttt ctttcaggga 6360
actttctttt ttttcttttt ttttgagatg gagtttcact cttgttgtcc caggctggag 6420
tgcaatgacg tgatctcagc tcaccacaac ctccgcctcc tggattcaag cgattctcct 6480
gccgcagcct cccgagtagc tgggattaca ggcatgcgcc accacgccca gctaattttg 6540
tgtttttagt agagaagggg tttctccgtg ttggtcaagc tggtcttgaa ctcctgacct 6600
caggtgatcc acctgccttg gcctcctaaa gtgctgggat tacaggcgtg agccaccgcg 6660
cccagcctct ttcagggaac tttctacaac tttataattc aattcttctg cagaaaaaaa 6720
tttttggcca ggctcagtag ctcagaccaa taattccagc actttgagag gctgaggtgg 6780
gaggattgct tgagcttggg agtttgagac tagcctgggc aacacagtga gaccctgtct 6840
ctatttttaa aaaaagtaaa aaaagatcta aaaatttaac tttttatttt gaaataatta 6900
gatatttcca ggaagctgca aagaaatgcc tggtgggcct gttggctgtg ggtttcctgc 6960
aaggccgtgg gaaggccctg tcattggcag aaccccagat cgtgagggct ttccttttag 7020
gctgctttct aagaggactc ctccaagctc ttggaggatg gaagacgctc acccatggtg 7080
ttcggcccct cagagcaggg tggggcaggg gagctggtgc ctgtgcaggc tgtggacatt 7140
tgcatgactc cctgtggtca gctaagagca ccactccttc ctgaagcggg gcctgaagtc 7200
cctagtcaga gcctctggtt caccttctgc aggcagggag aggggagtca agtcagtgag 7260
gagggctttc gcagtttctc ttacaaactc tcaacatgcc ctcccacctg cactgccttc 7320
ctggaagccc cacagcctcc tatggttccg tggtccagtc cttcagcttc tgggcgcccc 7380
catcacgggc tgagattttt gctttccagt ctgccaagtc agttactgtg tccatccatc 7440
tgctgtcagc ttctggaatt gttgctgttg tgccctttcc attcttttgt tatgatgcag 7500
ctcccctgct gacgacgtcc cattgctctt ttaagtctag atatctggac tgggcattca 7560
aggcccattt tgagcagagt cgggctgacc tttcagccct cagttctcca tggagtatgc 7620
gctctcttct tggcagggag gcctcacaaa catgccatgc ctattgtagc agctctccaa 7680
gaatgctcac ctccttctcc ctgtaattcc tttcctctgt gaggagctca gcagcatccc 7740
attatgagac cttactaatc ccagggatca cccccaacag ccctggggta caatgagctt 7800
ttaagaagtt taaccaccta tgtaaggaga cacaggcagt gggcgatgct gcctggcctg 7860
actcttgcca ttgggtggta ctgtttgttg actgactgac tgactgactg gaggggttt 7920
gtaatttgta tctcagggat taccccccaac agccctgggg tacaatgagc cttcaagaag 7980
tttaacaacc tatgtaagga cacacagcca gtgggtgatg ctgcctggtc tgactcttgc 8040
cattcagtgg cactgtttgt tgactgactg actgactgac tggctgactg gaggggttc 8100
atagctaata ttaatggagt ggtctaagta tcattggttc cttgaaccct gcactgtggc 8160
aaagtggccc acaggctgga ggaggaccaa gacaggaggg cagtctcggg aggagtgcct 8220
ggcaggcccc tcaccacctc tgcctacctc agtgaagttc ccttgtggga ggccctggaa 8280
gcggatggag aagaagcgca gtcacctgaa acgagacaca gaagaccaag aagaccaagt 8340
agatccgcgg ctcattgatg ggaagatgac caggcgggga gacagcccct ggcaggtggg 8400
aggcgaggca gcaccggctc gtcacgtgct gggtccggga tcactgagtc catcctggca 8460
gctatgctca gggtgcagaa accgagaggg aagcgctgcc attgcgtttg ggggatgatg 8520
aaggtggggg atgcttcagg gaaagatgga cgcaacctga ggggagagga gcagccaggg 8580
tgggtgaggg gaggggcatg ggggcatgga ggggtctgca ggagggaggg ttacagtttc 8640
taaaaagagc tggaaagaca ctgctctgct ggcgggattt taggcagaag ccctgctgat 8700
gggagagggc taggagggag ggccgggcct gagtacccct ccagcctcca catgggaact 8760
gacacttact gggttcccct ctctgccagg catgggggag ataggaacca acaagtggga 8820
gtatttgccc tggggactca gactctgcaa gggtcaggac cccaaagacc cggcagccca 8880

gtgggaccac agccaggacg gcccttcaag ataggggctg agggaggcca aggggaacat 8940
ccaggcagcc tgggggccac aaagtcttcc tggaagacac aaggcctgcc aagcctctaa 9000
ggatgagagg agctcgctgg gcgatgttgg tgtggctgag ggtgactgaa acagtatgaa 9060
cagtgcagga acagcatggg caaaggcagg aagacaccct gggacaggct gacactgtaa 9120
aatgggcaaa aatagaaaac gccagaaagg cctaagccta tgcccatatg accagggaac 9180
ccaggaaagt gcatatgaaa cccaggtgcc ctggactgga ggctgtcagg aggcagccct 9240
gtgatgtcat catcccaccc cattccaggt ggtcctgctg gactcaaaga agaagctggc 9300
ctgcggggca gtgctcatcc acccctcctg ggtgctgaca gcggcccact gcatggatga 9360
gtccaagaag ctccttgtca ggcttggtat gggctggagc caggcagaag ggggctgcca 9420
gaggcctggg taggggacc aggcaggctg ttcaggtttg ggggaccccg ctccccaggt 9480
gcttaagcaa gaggcttctt gagctccaca gaaggtgttt gggggaaga ggcctatgtg 9540
cccccaccct gcccacccat gtacacccag tattttgcag taggggttc tctggtgccc 9600
tcttcgaatc tgggcacagg tacctgcaca cacatgtttg tgaggggcta cacagacctt 9660
cacctctcca ctcccactca tgaggagcag gctgtgtggg cctcagcacc cttgggtgca 9720
gagaccagca aggcctggcc tcagggctgt gcctcccaca gactgacagg gatggagctg 9780
tacagaggga gccctagcat ctgccaaagc cacaagctgc ttccctagca ggctgggggc 9840
tcctatgcat tggccccgat ctatggcaat ttctggaggg ggggtctggc tcaactcttt 9900
atgccaaaaa gaaggcaaag catattgaga aaggccaaat tcacatttcc tacagcataa 9960
tctatgccag tggccccgtg gggcttggct tagaattccc aggtgctctt cccagggaac 10020
catcagtctg gactgagagg accttctctc tcaggtggga cccggccctg tcctccctgg 10080
cagtgccgtg ttctgggggt cctcctctct gggtctcact gcccctgggg tctctccagc 10140
tacctttgct ccatgttcct ttgtggctct ggtctgtgtc tggggtttcc aggggtctcg 10200
ggcttccctg ctgcccattc cttctctggt ctcacggctc cgtgactcct gaaaaccaac 10260
cagcatccta ccccttttgga ttgacacctg ttggccactc cttctggcag gaaaagtcac 10320
cgttgatagg gttccacggc atagacaggt ggctccgcgc cagtgcctgg gacgtgtggg 10380
tgcacagtct ccgggtgaac cttcttcagg ccctctccca ggcctgcagg ggcacagcag 10440
tgggtgggcc tcaggaaagt gccactgggg agaggctccc cgcagcccac tctgactgtg 10500
ccctctgccc tgcaggagag tatgacctgc ggcgctggga gaagtgggag ctggacctgg 10560
acatcaagga ggtcttcgtc caccccaact acagcaagag caccaccgac aatgacatcg 10620
cactgctgca cctggcccag cccgccaccc tctcgcagac catagtgccc atctgcctcc 10680
cggacagcgg ccttgcagag cgcgagctca atcaggccgg ccaggagacc ctcgtgacgg 10740
gctggggcta ccacagcagc cgagagaagg aggccaagag aaaccgcacc ttcgtcctca 10800
acttcatcaa gattcccgtg gtcccgcaca atgagtgcag cgaggtcatg agcaacatgg 10860
tgtctgagaa catgctgtgt gcgggcatcc tcggggaccg gcaggatgcc tgcgagggcg 10920
acagtggggg gcccatggtc gcctccttcc acggcacctg gttcctggtg ggcctggtga 10980
gctggggtga gggctgtggg ctccttcaca actacggcgt ttacaccaaa gtcagccgct 11040
acctcgactg gatccatggg cacatcagag acaaggaagc cccccagaag agctgggcac 11100
cttagcgacc ctccctgcag ggctgggctt ttgcatggca atggatggga cattaaaggg 11160
acatgtaaca agcacaccgg cctgctgttc tgtccttcca tccctctttt gggctcttct 11220
ggagggaagt aacatttact gagcacctgt tgtatgtcac atgccttatg aatagaatct 11280
taactcctag agcaactctg tggggtgggg aggagcagat ccaagttttg cggggtctaa 11340
agctgtgtgt gttgaggggg atactctgtt tatgaaaaag aataaaaaac acaaccacga 11400
agccactaga gccttttcca gggctttggg aagagcctgt gcaagccggg gatgctgaag 11460
gtgaggcttg accagctttc cagctagccc agctatgagg tagacatgtt tagctcatat 11520
cacagaggag gaaactgagg ggtctgaaag gtttacatgg tggagccagg attcaaatct 11580

aggtctgact ccaaaaccca ggtgcttttt tctgttctcc actgtcctgg aggacagctg 11640
tttcgacggt gctcagtgtg gaggccacta ttagctctgt agggaagcag ccagagaccc 11700
agaaagtgtt ggttcagccc agaat 11725

<210> 51
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 51
ttattttata tatataatat atatataaaa ta 32

<210> 52
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 52
tataatata 9

<210> 53
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 53
caatataaat atatag 16

<210> 54
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 54
tgtgtgtgta tgcgtgtgtg tagacacaca cgcatacaca cata 44

<210> 55
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 55
ttattttata tatataatat atatataaaa tatataatat a 41

<210> 56
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 56
tataatatac aatataaata tatag 25

<210> 57
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 57
caatataaat atatagtgtg tgtgtatgcg tgtgtgtaga cacacacgca tacacacata 60

<210> 58
<211> 101
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 58
ttattttata tatataatat atatataaaa tatataatat acaatataaa tatatagtgt 60
gtgtgtatgc gtgtgtgtag acacacacgc atacacacat a 101

<210> 59
<211> 723
<212> DNA
<213> Homo sapiens

<400> 59
tttaggaaaa ttgttaagac tgggttgtat gcacactggt gtttattata ttatgtagtt 60
ttttctgtat ttttacaaca tttcagaatt aaaagcaaca gctagaaaaa gagggaaatg 120
gccgggtgca gtcgtcacgc ctgtaatccc agcactttgg gaggccaagg cgggcggatc 180
acgaggtcga gagatcgaga ccatcctggc caacatggtg aaaccccatc tctactaaaa 240
atacaaaaat taactgggca tggtggcatg cgcctgtagt cccaggagaa ttgcttgaac 300
ctgggaggcg gaggttgcag tgagccaaga tctcaccact gctctccagc ctggtgacag 360
ggcaagactc cgtcaaaaaa aaaaaagaga gggagagcca gagtatgaaa aaggaagtca 420
gagcccttta atgagtcagc tttgtaggtc tccaggtagg aggctagtgc ttcagtgtct 480
aggacatagt aggtgttcag taaattaaat tcaggacaaa aagaacatgc cccaaggacc 540
atctgatatc cacttaaagt gatggactac ctcgtttccc ttgtttatga atgggttcat 600
gcctaagact gtgtgcactt taatacaagg gcagtcgttc agaactagtc aggtcctgaa 660
aaggatttac caaatgttga gtgtgccctc tagtgttcac acttcccagc tttcttccta 720
taa 723

<210> 60
<211> 447
<212> DNA
<213> Homo sapiens

<400> 60
aatatccagt tgagataatg gacttgcctc ttatctaata atacccaggc tcaatgcgtc 60
actgctttgt ccactttgcc caaaattcaa gcacagctaa gttgatattt taggacaaag 120
gcagcttact atccagccag aggggagtag aatatggtta agagagagtg gaaagaatga 180
atgagccctg ctattcctca ctgcctggat ggctataagc acagccctta tggaggcctt 240
aggtcttgct tcacaatatt ccagtttgaa aagggtttga aaagacctcc tagaaaaatc 300
agtagttttt ctcttttgag taacatgtag caaaaaaaat ttcatcatgt aggtacaggg 360
aacaccctag taactattaa tctcaaggag tcaagccagt gtgtttccta atgtatctgc 420
tgtatcccca tgaagcaaat tttgcca 447

<210> 61
<211> 103
<212> DNA
<213> Homo sapiens

<400> 61
aggtggatca aggcacttgc ttacaactgg aactgaaatc ctccaagtcg atctagacat 60
tgagatggag aaaatattca ttgtcgactg taattatgca acg 103

<210> 62
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 62
gtggaag 7

<210> 63
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 63
gtggatg 7

<210> 64
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 64
ctggaag 7

<210> 65
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 65
ctggatg 7

<210> 66
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 66
acccattcag tcgaggaagg atagggtggt at 32

<210> 67
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 67
agccattgag tcgaggaagg atagggtggt at 32

<210> 68
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 68
agccattcag acgaggaagg atagggtggt at 32

<210> 69
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 69
agccattcag tcgaggaagg atagggtggt tt 32

<210> 70
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 70
agccattcag tcgaggatcc caagggtggt at 32

<210> 71
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 71
agccattcag tcgaggaagg atagggccta at 32

<210> 72
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 72
agaccattca gtcgaggaag gatagggtgg tat 33

<210> 73
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 73
agccattcag tcgaggaagg atagcggtgg tat 33

<210> 74
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 74
agccattcag tcgaggaagg ataat 25

<210> 75
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 75
agccattcga ggaaggatag ggtggtat 28

<210> 76
<211> 1273
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 76
ggcctctgac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttacctttte caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggagcat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660

aacataggga tgaagtaagg tgcctgaaaa gtttggggga aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatca tgtctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
aagttgtcct tttctggttt cgtgttcacc atggaacatt ttgattatag ttaatccttc 1260
tatcttgaat ctt 1273

<210> 77
<211> 1273
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 77
ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaaattt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttacctttc caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggagcat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660
aacataggga tgaagtaagg tgcctgaaaa gtttggggga aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatca tgtctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
aagttgtcct tttctggttt cgtgttcacc atggaacatt ttgattatag ttaatccttc 1260
tatcttgaat ctt 1273

<210> 78
<211> 1273
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 78
ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttacctttte caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggacgat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660
aacataggga tgaagtaagg tgcctgaaaa gtttgggggа aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatca tgtctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
aagttgtcct tttctggttt cgtgttcacc atggaacatt ttgattatag ttaatccttc 1260
tatcttgaat ctt 1273

<210> 79
<211> 1273
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 79
ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240

tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttaccttttc caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggagcat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660
aacataggga tgaagtaagg tgcctgaaaa gtttgggggа aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatgt actctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
aagttgtcct tttctggttt cgtgttcacc atggaacatt ttgattatag ttaatccttc 1260
tatcttgaat ctt 1273

<210> 80
<211> 1275
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 80
ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
ttcttctttg cttctccaac caaaacatca atgtttatta gttctgtata cagtacagga 360
tctttggtct actctatcac aaggccagta ccacactcat gaagaaagaa cacaggagta 420
gctgagaggc taaaactcat caaaaacact actccttttc ctctacccta ttcctcaatc 480
ttttaccttt tccaaatccc aatccccaaa tcagtttttc tctttcttac tccctctctc 540
ccttttaccc tccatggtcg ttaaaggaga gatggggagc atcattctgt tatacttctg 600
tacacagtta tacatgtcta tcaaacccag acttgcttcc atagtggaga cttgcttttc 660
agaacatagg gatgaagtaa ggtgcctgaa aagtttgggg gaaaagtttc tttcagagag 720
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat 780
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa 840
taagccattc taagagcttg tatggttatg gaggtctgac taggcatgat ttcacgaagg 900
caagattggc atatcattgt aactaaaaaa gctgacattg acccagacat attgtactct 960
ttctaaaaat aataataata atgctaacag aaagaagaga accgttcgtt tgcaatctac 1020

agctagtaga gactttgagg aagaattcaa cagtgtgtct tcagcagtgt tcagagccaa 1080
gcaagaagtt gaagttgcct agaccagagg acataagtat catgtctcct ttaactagca 1140
taccccgaag tggagaaggg tgcagcaggc tcaaaggcat aagtcattcc aatcagccaa 1200
ctaagttgtc cttttctggt ttcgtgttca ccatggaaca ttttgattat agttaatcct 1260
tctatcttga atctt 1275

<210> 81
<211> 1276
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 81
ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttacctttc caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggagcat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660
aacataggga tgaagtaagg tgcctgaaaa gtttggggga aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatca tgtctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
gctaagttgt ccttttctgg tttcgtgttc accatggaac attttgatta tagttaatcc 1260
ttctatcttg aatctt 1276

<210> 82
<211> 1272
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 82
ggcctctcac taactaatca ctttcccatc ttttgttaga tttgaatata tacattctat 60
gatcattgct ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta 120
gaaaatggaa ccactagagg aatataatgt gttaggaaat tacagtcatt tctaagggcc 180
cagcccttga caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc 240
tccactatgg caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat 300
cttctttgct tctccaacca aaacatcaat gtttattagt tctgtataca gtacaggatc 360
tttggtctac tctatcacaa ggccagtacc acactcatga agaaagaaca caggagtagc 420
tgagaggcta aaactcatca aaaacactac tccttttcct ctaccctatt cctcaatctt 480
ttacctttc caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc 540
ttttaccctc catggtcgtt aaaggagaga tggggagcat cattctgtta tacttctgta 600
cacagttata catgtctatc aaacccagac ttgcttccat agtggagact tgcttttcag 660
aacataggga tgaagtaagg tgcctgaaaa gtttgggggа aaagtttctt tcagagagtt 720
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 780
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 840
agccattcta agagcttgta tggttatgga ggtctgacta ggcatgattt cacgaaggca 900
agattggcat atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt 960
ctaaaaataa taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag 1020
ctagtagaga ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc 1080
aagaagttga agttgcctag accagaggac ataagtatca tgtctccttt aactagcata 1140
ccccgaagtg gagaagggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact 1200
aagttgtcct tttctggttt cgtgttcacc atggaacatt ttgattatag ttatccttct 1260
atcttgaatc tt 1272

<210> 83
<211> 1272
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 83
gcctctcact aactaatcac tttcccatct tttgttagat ttgaatatat acattctatg 60
atcattgctt tttctcttta caggggagaa tttcatattt tacctgagca aattgattag 120
aaaatggaac cactagagga atataatgtg ttaggaaatt acagtcattt ctaagggccc 180
agcccttgac aaaattgtga agttaaattc tccactctgt ccatcagata ctatggttct 240
ccactatggc aactaactca ctcaattttc cctccttagc agcattccat cttcccgatc 300
ttctttgctt ctccaaccaa aacatcaatg tttattagtt ctgtatacag tacaggatct 360
ttggtctact ctatcacaag gccagtacca cactcatgaa gaaagaacac aggagtagct 420
gagaggctaa aactcatcaa aaacactact cctttttcctc taccctattc ctcaatcttt 480
tacctttcc aaatcccaat ccccaaatca gtttttctct ttcttactcc ctctctccct 540

tttaccctcc atggtcgtta aaggagagat ggggagcatc attctgttat acttctgtac 600
acagttatac atgtctatca aacccagact tgcttccata gtggagactt gcttttcaga 660
acatagggat gaagtaaggt gcctgaaaag tttgggggaa aagtttcttt cagagagtta 720
agttatttta tatatataat atatatataa aatatataat atacaatata aatatatagt 780
gtgtgtgtgt atgcgtgtgt gtagacacac acgcatacac acatataatg gaagcaataa 840
gccattctaa gagcttgtat ggttatggag gtctgactag gcatgatttc acgaaggcaa 900
gattggcata tcattgtaac taaaaaagct gacattgacc cagacatatt gtactctttc 960
taaaaataat aataataatg ctaacagaaa gaagagaacc gttcgtttgc aatctacagc 1020
tagtagagac tttgaggaag aattcaacag tgtgtcttca gcagtgttca gagccaagca 1080
agaagttgaa gttgcctaga ccagaggaca taagtatcat gtctccttta actagcatac 1140
cccgaagtgg agaagggtgc agcaggctca aaggcataag tcattccaat cagccaacta 1200
agttgtcctt ttctggtttc gtgttcacca tggaacattt tgattatagt taatccttct 1260
atcttgaatc tt 1272

<210> 84
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 84
gcggaag 7

<210> 85
<211> 1463
<212> DNA
<213> Homo sapiens

<400> 85
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgatagac 660
tgcaggacac aggcaaaggt gctgagctgg acccttttatt tctgcccttc tcccttctgg 720
cacccggcc aggaaattgc tgcagccttt ctggaatccc gttcattttt cttactggtc 780
cacaaaaggg gccaaatgga agcagcaaga cctgagttca aattaaatct gccaactacc 840

agctcagtga atctgggcga gtaacacaaa acttgagtgt ccttacctga aaaatagagg 900
ttagagggat gctatgtgcc attgtgtgtg tgtgttgggg gtggggattg ggggtgattt 960
gtgagcaatt ggaggtgagg gtggagccca gtgcccagca cctatgcact ggggacccaa 1020
aaaggagcat cttctcatga ttttatgtat cagaaattgg gatggcatgt cattgggaca 1080
gcgtcttttt tcttgtatgg tggcacataa atacatgtgt cttataatta atggtatttt 1140
agatttgacg aaatatggaa tattacctgt tgtgctgatc ttgggcaaac tataatatct 1200
ctgggcaaaa atgtccccat ctgaaaaaca gggacaacgt tcctccctca gccagccact 1260
atggggctaa aatgagacca catctgtcaa gggttttgcc ctcacctccc tccctgctgg 1320
atggcatcct tggtaggcag aggtgggctt cgggcagaac aagccgtgct gagctaggac 1380
caggagtgct agtgccactg tttgtctatg gagagggagg cctcagtgct gagggccaag 1440
caaatatttg tggttatgga tta 1463

<210> 86
<211> 83
<212> DNA
<213> Homo sapiens

<400> 86
caggagtgct agtgccactg tttgtctatg gagagggagg cctcagtgct gagggccaag 60
caaatatttg tggttatgga tta 83

<210> 87
<211> 614
<212> DNA
<213> Homo sapiens

<400> 87
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gcccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggt 614

<210> 88
<211> 661
<212> DNA
<213> Homo sapiens

<400> 88
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgatagac 660
t 661

<210> 89
<211> 7
<212> DNA
<213> Homo sapiens

<400> 89
gaggaaa 7

<210> 90
<211> 7
<212> DNA
<213> Homo sapiens

<400> 90
caggaag 7

<210> 91
<211> 102
<212> DNA
<213> Homo sapiens

<400> 91
tattttatat atataatata tatataaaat atataatata caatataaat atatagtgtg 60
tgtgtgtatg cgtgtgtgta gacacacacg catacacaca ta 102

<210> 92
<211> 1380
<212> DNA
<213> Homo sapiens

<400> 92
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgatagac 660
tgcaggacac aggcaaaggt gctgagctgg acccttttatt tctgcccttc tcccttctgg 720
caccccggcc aggaaattgc tgcagccttt ctggaatccc gttcattttt cttactggtc 780
cacaaaaggg gccaaatgga agcagcaaga cctgagttca aattaaatct gccaactacc 840
agctcagtga atctgggcga gtaacacaaa acttgagtgt ccttacctga aaaatagagg 900
ttagagggat gctatgtgcc attgtgtgtg tgtgttgggg gtggggattg ggggtgattt 960
gtgagcaatt ggaggtgagg gtggagccca gtgcccagca cctatgcact ggggacccaa 1020
aaaggagcat cttctcatga ttttatgtat cagaaattgg gatggcatgt cattgggaca 1080
gcgtcttttt tcttgtatgg tggcacataa atacatgtgt cttataatta atggtatttt 1140
agatttgacg aaatatggaa tattacctgt tgtgctgatc ttgggcaaac tataatatct 1200
ctgggcaaaa atgtccccat ctgaaaaaca gggacaacgt tcctccctca gccagccact 1260
atggggctaa aatgagacca catctgtcaa gggttttgcc ctcacctccc tccctgctgg 1320
atggcatcct tggtaggcag aggtgggctt cgggcagaac aagccgtgct gagctaggac 1380

<210> 93
<211> 154
<212> DNA
<213> Homo sapiens

<400> 93
ttgggggaaa agtttctttc agagagttaa gttatttttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaataag ccat 154

<210> 94
<211> 153
<212> DNA
<213> Homo sapiens

<400> 94
tgggggaaaa gtttctttca gagagttaag ttattttata tatataatat atatataaaa 60
tatataatat acaatataaa tatatagtgt gtgtgtgtat gcgtgtgtgt agacacacac 120
gcatacacac atataatgga agcaataagc cat 153

<210> 95
<211> 152
<212> DNA
<213> Homo sapiens

<400> 95
ggggggaaaag tttctttcag agagttaagt tattttatat atataatata tatataaaat 60
atataatata caatataaat atatagtgtg tgtgtgtatg cgtgtgtgta gacacacacg 120
catacacaca tataatggaa gcaataagcc at 152

<210> 96
<211> 151
<212> DNA
<213> Homo sapiens

<400> 96
ggggaaaagt ttctttcaga gagttaagtt attttatata tataatatat atataaaata 60
tataatatac aatataaata tatagtgtgt gtgtgtatgc gtgtgtgtag acacacacgc 120
atacacacat ataatggaag caataagcca t 151

<210> 97
<211> 150
<212> DNA
<213> Homo sapiens

<400> 97
gggaaaagtt tctttcagag agttaagtta ttttatatat ataatatata tataaaatat 60
ataatataca atataaatat atagtgtgtg tgtgtatgcg tgtgtgtaga cacacacgca 120
tacacacata taatggaagc aataagccat 150

<210> 98
<211> 149
<212> DNA
<213> Homo sapiens

<400> 98
ggaaaagttt ctttcagaga gttaagttat tttatatata taatatatat ataaaatata 60
taatatacaa tataaatata tagtgtgtgt gtgtatgcgt gtgtgtagac acacacgcat 120
acacacatat aatggaagca ataagccat 149

<210> 99
<211> 148
<212> DNA
<213> Homo sapiens

<400> 99
gaaaagtttc tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat 60
aatatacaat ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata 120
cacacatata atggaagcaa taagccat 148

<210> 100
<211> 147
<212> DNA
<213> Homo sapiens

<400> 100
aaaagtttct ttcagagagt taagttattt tatatatata atatatatat aaaatatata 60
atatacaata taaatatata gtgtgtgtgt gtatgcgtgt gtgtagacac acacgcatac 120
acacatataa tggaagcaat aagccat 147

<210> 101
<211> 146
<212> DNA
<213> Homo sapiens

<400> 101
aaagtttctt tcagagagtt aagttatttt atatatataa tatatatata aaatatataa 60
tatacaatat aaatatatag tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca 120
cacatataat ggaagcaata agccat 146

<210> 102
<211> 145
<212> DNA
<213> Homo sapiens

<400> 102
aagtttcttt cagagagtta agttatttta tatatataat atatatataa aatatataat 60
atacaatata aatatatagt gtgtgtgtgt atgcgtgtgt gtagacacac acgcatacac 120
acatataatg gaagcaataa gccat 145

<210> 103
<211> 144
<212> DNA
<213> Homo sapiens

<400> 103
agtttctttc agagagttaa gttattttat atatataata tatatataaa atatataata 60
tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca cgcatacaca 120
catataatgg aagcaataag ccat 144

<210> 104
<211> 143
<212> DNA
<213> Homo sapiens

<400> 104
gtttctttca gagagttaag ttattttata tatataatat atatataaaa tatataatat 60
acaatataaa tatatagtgt gtgtgtgtat gcgtgtgtgt agacacacac gcatacacac 120
atataatgga agcaataagc cat 143

<210> 105
<211> 142
<212> DNA
<213> Homo sapiens

<400> 105
tttctttcag agagttaagt tattttatat atataatata tatataaaat atataatata 60
caatataaat atatagtgtg tgtgtgtatg cgtgtgtgta gacacacacg catacacaca 120
tataatggaa gcaataagcc at 142

<210> 106
<211> 141
<212> DNA
<213> Homo sapiens

<400> 106
ttctttcaga gagttaagtt attttatata tataatatat atataaaata tataatatac 60
aatataaata tatagtgtgt gtgtgtatgc gtgtgtgtag acacacacgc atacacacat 120
ataatggaag caataagcca t 141

<210> 107
<211> 140
<212> DNA
<213> Homo sapiens

<400> 107
tctttcagag agttaagtta ttttatatat ataatatata tataaaatat ataatataca 60
atataaatat atagtgtgtg tgtgtatgcg tgtgtgtaga cacacacgca tacacacata 120
taatggaagc aataagccat 140

<210> 108
<211> 139
<212> DNA
<213> Homo sapiens

<400> 108
ctttcagaga gttaagttat tttatatata taatatatat ataaaatata taatatacaa 60
tataaatata tagtgtgtgt gtgtatgcgt gtgtgtagac acacacgcat acacacatat 120
aatggaagca ataagccat 139

<210> 109
<211> 138
<212> DNA
<213> Homo sapiens

<400> 109
tttcagagag ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat 60
ataaatatat agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata 120
atggaagcaa taagccat 138

<210> 110
<211> 137
<212> DNA
<213> Homo sapiens

<400> 110
ttcagagagt taagttattt tatatatata atatatatat aaaatatata atatacaata 60
taaatatata gtgtgtgtgt gtatgcgtgt gtgtagacac acacgcatac acacatataa 120
tggaagcaat aagccat 137

<210> 111
<211> 136
<212> DNA
<213> Homo sapiens

<400> 111
tcagagagtt aagttatttt atatatataa tatatatata aaatatataa tatacaatat 60
aaatatatag tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat 120
ggaagcaata agccat 136

<210> 112
<211> 135
<212> DNA
<213> Homo sapiens

<400> 112
cagagagtta agttatttta tatatataat atatatataa aatatataat atacaatata 60
aatatatagt gtgtgtgtgt atgcgtgtgt gtagacacac acgcatacac acatataatg 120
gaagcaataa gccat 135

<210> 113
<211> 134
<212> DNA
<213> Homo sapiens

<400> 113
agagagttaa gttattttat atatataata tatatataaa atatataata tacaatataa 60
atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca cgcatacaca catataatgg 120
aagcaataag ccat 134

<210> 114
<211> 133
<212> DNA
<213> Homo sapiens

<400> 114
gagagttaag ttattttata tatataatat atatataaaa tatataatat acaatataaa 60
tatatagtgt gtgtgtgtat gcgtgtgtgt agacacacac gcatacacac atataatgga 120
agcaataagc cat 133

<210> 115
<211> 132
<212> DNA
<213> Homo sapiens

<400> 115
agagttaagt tattttatat atataatata tatataaaat atataatata caatataaat 60
atatagtgtg tgtgtgtatg cgtgtgtgta gacacacacg catacacaca tataatggaa 120
gcaataagcc at 132

<210> 116
<211> 131
<212> DNA
<213> Homo sapiens

<400> 116
gagttaagtt attttatata tataatatat atataaaata tataatatac aatataaata 60
tatagtgtgt gtgtgtatgc gtgtgtgtag acacacacgc atacacacat ataatggaag 120
caataagcca t 131

<210> 117
<211> 130
<212> DNA
<213> Homo sapiens

<400> 117
agttaagtta ttttatatat ataatatata tataaaatat ataatataca atataaatat 60
atagtgtgtg tgtgtatgcg tgtgtgtaga cacacacgca tacacacata taatggaagc 120
aataagccat 130

<210> 118
<211> 129
<212> DNA
<213> Homo sapiens

<400> 118
gttaagttat tttatatata taatatatat ataaaatata taatatacaa tataaatata 60
tagtgtgtgt gtgtatgcgt gtgtgtagac acacacgcat acacacatat aatggaagca 120
ataagccat 129

<210> 119
<211> 128
<212> DNA
<213> Homo sapiens

<400> 119
ttaagttatt ttatatatat aatatatata taaaatatat aatatacaat ataaatatat 60
agtgtgtgtg tgtatgcgtg tgtgtagaca cacacgcata cacacatata atggaagcaa 120
taagccat 128

<210> 120
<211> 127
<212> DNA
<213> Homo sapiens

<400> 120
taagttattt tatatatata atatatatat aaaatatata atatacaata taaatatata 60
gtgtgtgtgt gtatgcgtgt gtgtagacac acacgcatac acacatataa tggaagcaat 120
aagccat 127

<210> 121
<211> 126
<212> DNA
<213> Homo sapiens

<400> 121
aagttatttt atatatataa tatatatata aaatatataa tatacaatat aaatatatag 60
tgtgtgtgtg tatgcgtgtg tgtagacaca cacgcataca cacatataat ggaagcaata 120
agccat 126

<210> 122
<211> 125
<212> DNA
<213> Homo sapiens

<400> 122
agttatttta tatatataat atatatataa aatatataat atacaatata aatatatagt 60
gtgtgtgtgt atgcgtgtgt gtagacacac acgcatacac acatataatg gaagcaataa 120
gccat 125

<210> 123
<211> 124
<212> DNA
<213> Homo sapiens

<400> 123
gttattttat atatataata tatatataaa atatataata tacaatataa atatatagtg 60
tgtgtgtgta tgcgtgtgtg tagacacaca cgcatacaca catataatgg aagcaataag 120
ccat 124

<210> 124
<211> 123
<212> DNA
<213> Homo sapiens

<400> 124
ttattttata tatataatat atatataaaa tatataatat acaatataaa tatatagtgt 60
gtgtgtgtat gcgtgtgtgt agacacacac gcatacacac atataatgga agcaataagc 120
cat 123

<210> 125
<211> 153
<212> DNA
<213> Homo sapiens

<400> 125
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaataag cca 153

<210> 126
<211> 152
<212> DNA
<213> Homo sapiens

<400> 126
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaataag cc 152

<210> 127
<211> 151
<212> DNA
<213> Homo sapiens

<400> 127
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaataag c 151

<210> 128
<211> 150
<212> DNA
<213> Homo sapiens

<400> 128
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaataag 150

<210> 129
<211> 149
<212> DNA
<213> Homo sapiens

<400> 129
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaataa 149

<210> 130
<211> 148
<212> DNA
<213> Homo sapiens

<400> 130
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaata 148

<210> 131
<211> 147
<212> DNA
<213> Homo sapiens

<400> 131
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaat 147

<210> 132
<211> 146
<212> DNA
<213> Homo sapiens

<400> 132
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagcaa 146

<210> 133
<211> 145
<212> DNA
<213> Homo sapiens

<400> 133
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagca 145

<210> 134
<211> 144
<212> DNA
<213> Homo sapiens

<400> 134
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aagc 144

<210> 135
<211> 143
<212> DNA
<213> Homo sapiens

<400> 135
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aag 143

<210> 136
<211> 142
<212> DNA
<213> Homo sapiens

<400> 136
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg aa 142

<210> 137
<211> 141
<212> DNA
<213> Homo sapiens

<400> 137
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg a 141

<210> 138
<211> 140
<212> DNA
<213> Homo sapiens

<400> 138
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatgg 140

<210> 139
<211> 139
<212> DNA
<213> Homo sapiens

<400> 139
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataatg 139

<210> 140
<211> 138
<212> DNA
<213> Homo sapiens

<400> 140
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataat 138

<210> 141
<211> 137
<212> DNA
<213> Homo sapiens

<400> 141
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catataa 137

<210> 142
<211> 136
<212> DNA
<213> Homo sapiens

<400> 142
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catata 136

<210> 143
<211> 135
<212> DNA
<213> Homo sapiens

<400> 143
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca catat 135

<210> 144
<211> 134
<212> DNA
<213> Homo sapiens

<400> 144
ttgggggaaa agtttctttc agagagttaa gttattttat atatataata tatatataaa 60
atatataata tacaatataa atatatagtg tgtgtgtgta tgcgtgtgtg tagacacaca 120
cgcatacaca cata 134

<210> 145
<211> 659
<212> DNA
<213> Homo sapiens

<400> 145
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gcccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgataga 659

<210> 146
<211> 658
<212> DNA
<213> Homo sapiens

<400> 146
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gcccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgatag 658

<210> 147
<211> 657
<212> DNA
<213> Homo sapiens

<400> 147
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgata 657

<210> 148
<211> 656
<212> DNA
<213> Homo sapiens

<400> 148
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgat 656

<210> 149
<211> 655
<212> DNA
<213> Homo sapiens

<400> 149
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480

cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctga 655

<210> 150
<211> 654
<212> DNA
<213> Homo sapiens

<400> 150
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctg 654

<210> 151
<211> 653
<212> DNA
<213> Homo sapiens

<400> 151
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gct 653

<210> 152
<211> 652
<212> DNA
<213> Homo sapiens

<400> 152
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gc 652

<210> 153
<211> 651
<212> DNA
<213> Homo sapiens

<400> 153
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat g 651

<210> 154
<211> 650
<212> DNA
<213> Homo sapiens

<400> 154
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480

cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat 650

<210> 155
<211> 649
<212> DNA
<213> Homo sapiens

<400> 155
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaa 649

<210> 156
<211> 648
<212> DNA
<213> Homo sapiens

<400> 156
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataa 648

<210> 157
<211> 647
<212> DNA
<213> Homo sapiens

<400> 157
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaata 647

<210> 158
<211> 646
<212> DNA
<213> Homo sapiens

<400> 158
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaat 646

<210> 159
<211> 645
<212> DNA
<213> Homo sapiens

<400> 159
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480

cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaa 645

<210> 160
<211> 644
<212> DNA
<213> Homo sapiens

<400> 160
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg ctta 644

<210> 161
<211> 643
<212> DNA
<213> Homo sapiens

<400> 161
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg ctt 643

<210> 162
<211> 642
<212> DNA
<213> Homo sapiens

<400> 162
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg ct 642

<210> 163
<211> 641
<212> DNA
<213> Homo sapiens

<400> 163
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg c 641

<210> 164
<211> 640
<212> DNA
<213> Homo sapiens

<400> 164
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480

cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagacg 640

<210> 165
<211> 639
<212> DNA
<213> Homo sapiens

<400> 165
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gcccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaagac 639

<210> 166
<211> 638
<212> DNA
<213> Homo sapiens

<400> 166
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gcccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaaga 638

<210> 167
<211> 637
<212> DNA
<213> Homo sapiens

<400> 167
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tggtgcagcc cggttcggag caggaag 637

<210> 168
<211> 650
<212> DNA
<213> Homo sapiens

<400> 168
agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta gagtgttaga 60
gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg gtgtggtgcc 120
tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt aaagaaactt 180
caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag ccaggatgtg 240
ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc tctaggtgtc 300
cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt cctctgcttt 360
aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt acttatggtg 420
tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga cttccctgtg 480
caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc agacttggag 540
aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg ggggcatctc 600
tggtgcagcc cggttcggag caggaagacg cttaataaat gctgatagac 650

<210> 169
<211> 640
<212> DNA
<213> Homo sapiens

<400> 169
atgtgtacct gcccctgggc aaggtgggcc tgacttgtta gagtgttaga gttttaccct 60
gttcctctag gagggcctgg taccaccaca gcccagcatg gtgtggtgcc tcagcaggag 120
gcatctggtt acaatcaaca caagctgttc cagccaattt aaagaaactt caggaggaat 180
agggttttag gagggcatgg ggaccctcct gcacccgaag ccaggatgtg ccaccaatca 240
taaggaggca ggggcctcct tccgctgctc cctgggactc tctaggtgtc cgtggcctca 300
gccccctct gcacacctgc atcttccttc tcatcagctt cctctgcttt aagcgtaaac 360
atggatgccc aggacctggc ctcaatcttc cgagtctggt acttatggtg tactgacagt 420
gtgagaccct actcctctga tcaatcccct gggttggtga cttccctgtg caatcaatgg 480

aagccagcga ggcagggtca catgccccgt ttagaggtgc agacttggag aaggaacgtg 540
ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg ggggcatctc tggtgcagcc 600
cggttcggag caggaagacg cttaataaat gctgatagac 640

<210> 170
<211> 610
<212> DNA
<213> Homo sapiens

<400> 170
tgacttgtta gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca 60
gcccagcatg gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc 120
cagccaattt aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct 180
gcacccgaag ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc 240
cctgggactc tctaggtgtc cgtggcctca gccccccctct gcacacctgc atcttccttc 300
tcatcagctt cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc 360
cgagtctggt acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct 420
gggttggtga cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt 480
ttagaggtgc agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag 540
ggaggaaagg ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat 600
gctgatagac 610

<210> 171
<211> 300
<212> DNA
<213> Homo sapiens

<400> 171
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 60
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 120
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 180
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 240
ggggcatctc tggtgcagcc cggttcggag caggaagacg cttaataaat gctgatagac 300

<210> 172
<211> 100
<212> DNA
<213> Homo sapiens

<400> 172
ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg ggggcatctc tggtgcagcc 60
cggttcggag caggaagacg cttaataaat gctgatagac 100

<210> 173
<211> 71
<212> DNA
<213> Homo sapiens

<400> 173
gggaggaaag gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa 60
tgctgataga c 71

<210> 174
<211> 613
<212> DNA
<213> Homo sapiens

<400> 174
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tgg 613

<210> 175
<211> 612
<212> DNA
<213> Homo sapiens

<400> 175
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc tg 612

<210> 176
<211> 611
<212> DNA
<213> Homo sapiens

<400> 176
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc t 611

<210> 177
<211> 610
<212> DNA
<213> Homo sapiens

<400> 177
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatctc 610

<210> 178
<211> 609
<212> DNA
<213> Homo sapiens

<400> 178
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180

aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatct 609

<210> 179
<211> 608
<212> DNA
<213> Homo sapiens

<400> 179
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcatc 608

<210> 180
<211> 607
<212> DNA
<213> Homo sapiens

<400> 180
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggcat 607

<210> 181
<211> 606
<212> DNA
<213> Homo sapiens

<400> 181
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggca 606

<210> 182
<211> 605
<212> DNA
<213> Homo sapiens

<400> 182
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggggc 605

<210> 183
<211> 604
<212> DNA
<213> Homo sapiens

<400> 183
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180

aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
gggg 604

<210> 184
<211> 603
<212> DNA
<213> Homo sapiens

<400> 184
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
ggg 603

<210> 185
<211> 602
<212> DNA
<213> Homo sapiens

<400> 185
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatccccc gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
gg 602

<210> 186
<211> 601
<212> DNA
<213> Homo sapiens

<400> 186
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600
g 601

<210> 187
<211> 600
<212> DNA
<213> Homo sapiens

<400> 187
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaagg 600

<210> 188
<211> 599
<212> DNA
<213> Homo sapiens

<400> 188
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240

ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaag 599

<210> 189
<211> 598
<212> DNA
<213> Homo sapiens

<400> 189
gaattctgta agcatttcct atgtgtacct gcccctgggc aaggtgggcc tgacttgtta 60
gagtgttaga gttttaccct gttcctctag gagggcctgg taccaccaca gcccagcatg 120
gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca caagctgttc cagccaattt 180
aaagaaactt caggaggaat agggttttag gagggcatgg ggaccctcct gcacccgaag 240
ccaggatgtg ccaccaatca taaggaggca ggggcctcct tccgctgctc cctgggactc 300
tctaggtgtc cgtggcctca gccccccctct gcacacctgc atcttccttc tcatcagctt 360
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 420
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 480
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 540
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaa 598

<210> 190
<211> 498
<212> DNA
<213> Homo sapiens

<400> 190
taccaccaca gcccagcatg gtgtggtgcc tcagcaggag gcatctggtt acaatcaaca 60
caagctgttc cagccaattt aaagaaactt caggaggaat agggttttag gagggcatgg 120
ggaccctcct gcacccgaag ccaggatgtg ccaccaatca taaggaggca ggggcctcct 180
tccgctgctc cctgggactc tctaggtgtc cgtggcctca gccccccctct gcacacctgc 240
atcttccttc tcatcagctt cctctgcttt aagcgtaaac atggatgccc aggacctggc 300
ctcaatcttc cgagtctggt acttatggtg tactgacagt gtgagaccct actcctctga 360
tcaatcccct gggttggtga cttccctgtg caatcaatgg aagccagcga ggcagggtca 420
catgccccgt ttagaggtgc agacttggag aaggaacgtg ggcaagtctt cccaggaaca 480
ggtagggcag ggaggaaa 498

<210> 191
<211> 398
<212> DNA
<213> Homo sapiens

<400> 191
agggttttag gagggcatgg ggaccctcct gcacccgaag ccaggatgtg ccaccaatca 60
taaggaggca ggggcctcct tccgctgctc cctgggactc tctaggtgtc cgtggcctca 120
gccccctct gcacacctgc atcttccttc tcatcagctt cctctgcttt aagcgtaaac 180
atggatgccc aggacctggc ctcaatcttc cgagtctggt acttatggtg tactgacagt 240
gtgagaccct actcctctga tcaatcccct gggttggtga cttccctgtg caatcaatgg 300
aagccagcga ggcagggtca catgccccgt ttagaggtgc agacttggag aaggaacgtg 360
ggcaagtctt cccaggaaca ggtagggcag ggaggaaa 398

<210> 192
<211> 298
<212> DNA
<213> Homo sapiens

<400> 192
tctaggtgtc cgtggcctca gccccctct gcacacctgc atcttccttc tcatcagctt 60
cctctgcttt aagcgtaaac atggatgccc aggacctggc ctcaatcttc cgagtctggt 120
acttatggtg tactgacagt gtgagaccct actcctctga tcaatcccct gggttggtga 180
cttccctgtg caatcaatgg aagccagcga ggcagggtca catgccccgt ttagaggtgc 240
agacttggag aaggaacgtg ggcaagtctt cccaggaaca ggtagggcag ggaggaaa 298

<210> 193
<211> 198
<212> DNA
<213> Homo sapiens

<400> 193
ctcaatcttc cgagtctggt acttatggtg tactgacagt gtgagaccct actcctctga 60
tcaatcccct gggttggtga cttccctgtg caatcaatgg aagccagcga ggcagggtca 120
catgccccgt ttagaggtgc agacttggag aaggaacgtg ggcaagtctt cccaggaaca 180
ggtagggcag ggaggaaa 198

<210> 194
<211> 98
<212> DNA
<213> Homo sapiens

<400> 194
aagccagcga ggcagggtca catgccccgt ttagaggtgc agacttggag aaggaacgtg 60
ggcaagtctt cccaggaaca ggtagggcag ggaggaaa 98

<210> 195
<211> 8
<212> DNA
<213> Homo sapiens

<400> 195
ggaggaaa 8

<210> 196
<211> 781
<212> DNA
<213> Homo sapiens

<400> 196
ggggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gacccttttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180
ccacaaaagg ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac 240
cagctcagtg aatctgggcg agtaacacaa aacttgagtg tccttacctg aaaaatagag 300
gttagaggga tgctatgtgc cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt 360
tgtgagcaat tggaggtgag ggtggagccc agtgcccagc acctatgcac tggggaccca 420
aaaaggagca tcttctcatg attttatgta tcagaaattg ggatggcatg tcattgggac 480
agcgtctttt ttcttgtatg gtggcacata aatacatgtg tcttataatt aatggtattt 540
tagatttgac gaaatatgga atattacctg ttgtgctgat cttgggcaaa ctataatatc 600
tctgggcaaa aatgtcccca tctgaaaaac agggacaacg ttcctccctc agccagccac 660
tatggggcta aaatgagacc acatctgtca agggttttgc cctcacctcc ctccctgctg 720
gatggcatcc ttggtaggca gaggtgggct tcgggcagaa caagccgtgc tgagctagga 780
c 781

<210> 197
<211> 771
<212> DNA
<213> Homo sapiens

<400> 197
ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga ctgcaggaca 60
caggcaaagg tgctgagctg gacccttttat ttctgccctt ctcccttctg gcaccccggc 120
caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt ccacaaaagg 180
ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac agctcagtg 240
aatctgggcg agtaacacaa aacttgagtg tccttacctg aaaaatagag gttagaggga 300
tgctatgtgc cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt tgtgagcaat 360
tggaggtgag ggtggagccc agtgcccagc acctatgcac tggggaccca aaaaggagca 420
tcttctcatg attttatgta tcagaaattg ggatggcatg tcattgggac agcgtctttt 480
ttcttgtatg gtggcacata aatacatgtg tcttataatt aatggtattt tagatttgac 540
gaaatatgga atattacctg ttgtgctgat cttgggcaaa ctataatatc tctgggcaaa 600
aatgtcccca tctgaaaaac agggacaacg ttcctccctc agccagccac tatggggcta 660
aaatgagacc acatctgtca agggttttgc cctcacctcc ctccctgctg gatggcatcc 720
ttggtaggca gaggtgggct tcgggcagaa caagccgtgc tgagctagga c 771

<210> 198
<211> 761
<212> DNA
<213> Homo sapiens

<400> 198
ccggttcgga gcaggaagac gcttaataaa tgctgataga ctgcaggaca caggcaaagg 60
tgctgagctg gaccctttat ttctgccctt ctcccttctg gcaccccggc caggaaattg 120
ctgcagcctt tctggaatcc cgttcatttt tcttactggt ccacaaaagg ggccaaatgg 180
aagcagcaag acctgagttc aaattaaatc tgccaactac cagctcagtg aatctgggcg 240
agtaacacaa aacttgagtg tccttacctg aaaaatagag gttagaggga tgctatgtgc 300
cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt tgtgagcaat tggaggtgag 360
ggtggagccc agtgcccagc acctatgcac tggggaccca aaaaggagca tcttctcatg 420
attttatgta tcagaaattg ggatggcatg tcattgggac agcgtctttt ttcttgtatg 480
gtggcacata aatacatgtg tcttataatt aatggtattt tagatttgac gaaatatgga 540
atattacctg ttgtgctgat cttgggcaaa ctataatatc tctgggcaaa aatgtcccca 600
tctgaaaaac agggacaacg ttcctccctc agccagccac tatggggcta aaatgagacc 660
acatctgtca agggttttgc cctcacctcc ctccctgctg gatggcatcc ttggtaggca 720
gaggtgggct tcgggcagaa caagccgtgc tgagctagga c 761

<210> 199
<211> 751
<212> DNA
<213> Homo sapiens

<400> 199
gcaggaagac gcttaataaa tgctgataga ctgcaggaca caggcaaagg tgctgagctg 60
gaccctttat ttctgccctt ctcccttctg gcaccccggc caggaaattg ctgcagcctt 120
tctggaatcc cgttcatttt tcttactggt ccacaaaagg ggccaaatgg aagcagcaag 180
acctgagttc aaattaaatc tgccaactac cagctcagtg aatctgggcg agtaacacaa 240
aacttgagtg tccttacctg aaaaatagag gttagaggga tgctatgtgc cattgtgtgt 300
gtgtgttggg ggtggggatt gggggtgatt tgtgagcaat tggaggtgag ggtggagccc 360
agtgcccagc acctatgcac tggggaccca aaaaggagca tcttctcatg attttatgta 420
tcagaaattg ggatggcatg tcattgggac agcgtctttt ttcttgtatg gtggcacata 480
aatacatgtg tcttataatt aatggtattt tagatttgac gaaatatgga atattacctg 540
ttgtgctgat cttgggcaaa ctataatatc tctgggcaaa aatgtcccca tctgaaaaac 600
agggacaacg ttcctccctc agccagccac tatggggcta aaatgagacc acatctgtca 660
agggttttgc cctcacctcc ctccctgctg gatggcatcc ttggtaggca gaggtgggct 720
tcgggcagaa caagccgtgc tgagctagga c 751

<210> 200
<211> 750
<212> DNA
<213> Homo sapiens

<400> 200
caggaagacg cttaataaat gctgatagac tgcaggacac aggcaaaggt gctgagctgg 60
acccttttatt tctgcccttc tcccttctgg caccccggcc aggaaattgc tgcagccttt 120
ctggaatccc gttcattttt cttactggtc cacaaaaggg gccaaatgga agcagcaaga 180
cctgagttca aattaaatct gccaactacc agctcagtga atctgggcga gtaacacaaa 240
acttgagtgt ccttacctga aaaatagagg ttagagggat gctatgtgcc attgtgtgtg 300
tgtgttgggg gtggggattg ggggtgattt gtgagcaatt ggaggtgagg gtggagccca 360
gtgcccagca cctatgcact ggggacccaa aaaggagcat cttctcatga ttttatgtat 420
cagaaattgg gatggcatgt cattgggaca gcgtcttttt tcttgtatgg tggcacataa 480
atacatgtgt cttataatta atggtatttt agatttgacg aaatatggaa tattacctgt 540
tgtgctgatc ttgggcaaac tataatatct ctgggcaaaa atgtccccat ctgaaaaaca 600
gggacaacgt tcctccctca gccagccact atggggctaa aatgagacca catctgtcaa 660
gggttttgcc ctcacctccc tccctgctgg atggcatcct tggtaggcag aggtgggctt 720
cgggcagaac aagccgtgct gagctaggac 750

<210> 201
<211> 681
<212> DNA
<213> Homo sapiens

<400> 201
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gaccctttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180
ccacaaaagg ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac 240
cagctcagtg aatctgggcg agtaacacaa aacttgagtg tccttacctg aaaaatagag 300
gttagaggga tgctatgtgc cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt 360
tgtgagcaat tggaggtgag ggtggagccc agtgcccagc acctatgcac tggggaccca 420
aaaaggagca tcttctcatg attttatgta tcagaaattg ggatggcatg tcattgggac 480
agcgtctttt ttcttgtatg gtggcacata aatacatgtg tcttataatt aatggtattt 540
tagatttgac gaaatatgga atattacctg ttgtgctgat cttgggcaaa ctataatatc 600
tctgggcaaa aatgtcccca tctgaaaaac agggacaacg ttcctccctc agccagccac 660
tatggggcta aaatgagacc a 681

<210> 202
<211> 581
<212> DNA
<213> Homo sapiens

<400> 202
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gaccctttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180
ccacaaaagg ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac 240
cagctcagtg aatctgggcg agtaacacaa aacttgagtg tccttacctg aaaaatagag 300

gttagaggga tgctatgtgc cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt 360
tgtgagcaat tggaggtgag ggtggagccc agtgcccagc acctatgcac tggggaccca 420
aaaaggagca tcttctcatg attttatgta tcagaaattg ggatggcatg tcattgggac 480
agcgtctttt ttcttgtatg gtggcacata aatacatgtg tcttataatt aatggtattt 540
tagatttgac gaaatatgga atattacctg ttgtgctgat c 581

<210> 203
<211> 481
<212> DNA
<213> Homo sapiens

<400> 203
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gaccctttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180
ccacaaaagg ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac 240
cagctcagtg aatctgggcg agtaacacaa aacttgagtg tccttacctg aaaaatagag 300
gttagaggga tgctatgtgc cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt 360
tgtgagcaat tggaggtgag ggtggagccc agtgcccagc acctatgcac tggggaccca 420
aaaaggagca tcttctcatg attttatgta tcagaaattg ggatggcatg tcattgggac 480
a 481

<210> 204
<211> 381
<212> DNA
<213> Homo sapiens

<400> 204
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gaccctttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180
ccacaaaagg ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac 240
cagctcagtg aatctgggcg agtaacacaa aacttgagtg tccttacctg aaaaatagag 300
gttagaggga tgctatgtgc cattgtgtgt gtgtgttggg ggtggggatt gggggtgatt 360
tgtgagcaat tggaggtgag g 381

<210> 205
<211> 281
<212> DNA
<213> Homo sapiens

<400> 205
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gaccctttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180

ccacaaaagg ggccaaatgg aagcagcaag acctgagttc aaattaaatc tgccaactac 240
cagctcagtg aatctgggcg agtaacacaa aacttgagtg t 281

<210> 206
<211> 181
<212> DNA
<213> Homo sapiens

<400> 206
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg tgctgagctg gacccttttat ttctgccctt ctcccttctg 120
gcaccccggc caggaaattg ctgcagcctt tctggaatcc cgttcatttt tcttactggt 180
c 181

<210> 207
<211> 81
<212> DNA
<213> Homo sapiens

<400> 207
gggggcatct ctggtgcagc ccggttcgga gcaggaagac gcttaataaa tgctgataga 60
ctgcaggaca caggcaaagg t 81

<210> 208
<211> 38
<212> DNA
<213> Homo sapiens

<400> 208
gggggcatct ctggtgcagc ccggttcgga gcaggaag 38